



# ESCMID Global

European Congress of Clinical Microbiology & Infectious Diseases

## Preliminary Programme

**Vienna, Austria**

**11-15 April 2025**



<http://www.escmid.org/congress-events/escmid-global>

# ESCMID Global 2025 - Programme

Friday, 11 April 2025

SP1		08:30 – 10:30	Hall 0
CLN		Special Session	
Antimicrobial Stewardship in Different Scenarios			
Chairs	Murat Akova (Ankara, Türkiye) Andre Fuchs (Augsburg, Germany) Maddalena Giannella (Bologna, Italy) Angela Huttner (Geneva, Switzerland) Benedikt Huttner (Geneva, Switzerland) Jose Ramon Pano-Pardo (Zaragoza, Spain) Galadriel Pellejero-Sagastizábal (Zaragoza, Spain) Holger Rohde (Hamburg, Germany) Oana Sandulescu (Bucharest, Romania) Jeroen Schouten (Nijmegen, Netherlands) Valentijn Schweitzer (Utrecht, Netherlands) Thomas Tängdén (Uppsala, Sweden) Suzanne Van Asten (Nijmegen, Netherlands) Dafna Yahav (Ramat-Gan, Israel)		
Co-organised with: ESCMID Education Subcommittee			
EW001		08:30 – 10:30	Hall 2
CLN IPC		Educational Session	
Surgical site infections: principles and practice in the era of multidrug resistance			
Chairs	Gabriel Birgand (Nantes, France) Efthymia Giannitsioti (Athens, Greece)		
W0001	08:30	Evolving antimicrobial resistance: do we need a change in surgical antimicrobial prophylaxis? Camilla Rodrigues (Mumbai, India)	
W0002	08:50	Role of decolonisation and bowel decontamination in regions of overwhelming multidrug resistancePrasannakumar Palanikumar (Vellore, India)	
W0003	09:10	Screening for MDR GNR coloniSation: is there evidence for prophylaxisElisabeth Presterl (Vienna, Austria)	
W0004	09:30	Perioperative prophylaxis in special populations in the era of MDRDivyashree Shanthamurthy (Mumbai, India)	
EW002		08:30 – 10:30	Hall 3
ANT		Educational Session	
Demystifying pharmacokinetics and population pharmacokinetics: a toolkit for non-experts			
Chairs	Shampa Das (Liverpool, United Kingdom) João Paulo Telles (Sao Paulo, Brazil)		
W0005	08:30	Pharmacokinetics 101: navigating the basics for optimal dosingLinda Aulin (Leiden, Netherlands)	
W0006	08:50	The ABCs of population pharmacokinetic modelsErwin Dreesen (Leuven, Belgium)	
W0007	09:10	Looking into the crystal ball: exploring the fabulous world of PK-PD simulationsVincent Aranzana-Climent (Poitiers, France)	
W0008	09:30	Decoding population pharmacokinetic papers: Interpreting, comparing and discussing resultsIris K. Minichmayr (Vienna, Austria)	
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)			
EW003		08:30 – 10:30	Hall 5
DX		Educational Session	

Challenges in Identification and relevance of slow-growing pathogens		
Chairs	Kerrie Davies (Leeds, United Kingdom) Yann Dumont (Nancy, France)	
W0009	08:30	Sampling and culturing anaerobes Hugo Cruz (Porto, Portugal)
W0010	08:50	I have an anaerobe: what is it and does it matter? Kathleen Boiten (Groningen, Netherlands)
W0011	09:10	Actinomyces in clinical samples: when is it worth the trouble? Eija Inkeri Könönen (Turku, Finland)
W0012	09:30	Nocardiosis: when to test and how to manage results? David Lebeaux (Paris, France)
Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI), ESCMID Study Group for Clostridioides difficile (ESGCD)		
EW004		
	08:30 – 10:30	Hall 6
	Educational Session	
	CLN DX IPC	
A hard nut to crack in HIV		
Chairs	Yoav Keynan (Winnipeg, Canada) Justyna Kowalska (Warsaw, Poland)	
W0013	08:30	Viral reservoir: what a physician should know Ivailo Alexiev (Sofia, Bulgaria)
W0014	08:50	Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians Jose Arribas (Madrid, Spain)
W0015	09:10	Chronic vascular and pulmonary disease and HIV: what can we do about it? Susanne Dam Poulsen (Copenhagen, Denmark)
W0016	09:30	Opportunistic infections: most common and most deadly Milena Stevanovikj (Sopje, North Macedonia, Republic of)
Co-organised with: Euroguidelines in Central and Eastern Europe Network Group		
EW005		
	08:30 – 10:30	Hall 8
	Educational Session	
	DX	
Diagnostic parasitology in the XXIst century: is microscopy "+" still useful?		
Chairs	Miriam José Álvarez-Martínez (Barcelona, Spain) Caroline Rönnberg (Stockholm, Sweden)	
W0017	08:30	Artificial Intelligence for the diagnosis of parasitic infections Bobbi Pritt (Rochester, United States)
W0018	08:50	Histopathology of parasitic infections Richard Bradbury (Townsville, Australia)
W0019	09:10	Molecular diagnosis vs. microscopy in the diagnosis of parasitic infections Sitara Sr Ajampur (Vellore, India)
W0020	09:30	Paleoparasitology: what diagnostic tools? Ayman El-Badry (Cairo, Egypt)
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)		
EW006		
	08:30 – 10:30	Hall 9
	Educational Session	
	PRO PHEI	
Vaccine hesitancy: from issues to solutions through developing communication skills		
Chairs	Monia Chemais (Soignies, Belgium) Petar Velikov (Sofia, Bulgaria)	
W0021	08:30	Vaccine hesitancy and its consequences Noni Macdonald (Halifax, Canada)
W0022	08:50	Why are patients and parents hesitant about vaccination? Eve Dube (Quebec City, Canada)
W0023	09:10	Using social media to deal with vaccine hesitancy Muge Cevik (St Andrews, United Kingdom)

# ESCMID Global 2025 - Programme

W0024	09:30	Strengthening vaccine confidence in patients and parents <i>Tba</i>	
Co-organised with: ESCMID Vaccine Study Group (EVASG)			
SP2	11:00 – 12:00	Hall 0	
	Special Session		
Principles of systematic reviews (with and without meta-analysis)			
Chairs	Chiara Iaria (Palermo, Italy) Miranda Langendam (Amsterdam, Netherlands) Blin Nagavci (Gjakove, Kosovo) Mical Paul (Haifa, Israel) Luigia Scudeller (Pavia, Italy)		
Co-organised with: ESCMID Education Subcommittee			
ME007	11:00 – 12:00	Hall 2	
	Meet-the-Expert		
How to interpret resistance patterns from antibiograms			
M0025	11:00	Tommaso Giani (Florence, Italy)	
M0026	11:12	Diaz Lorena (Santiago, Chile)	
ME008	11:00 – 12:00	Hall 3	
	Meet-the-Expert		
Children are not just small adults: Interactive paediatric cases			
M0027	11:00	Julie Toubiana (Paris, France)	
M0028	11:12	Sanjay Patel (Winchester, United Kingdom)	
ME009	11:00 – 12:00	Hall 5	
	Meet-the-Expert		
How to practise WHO Guidelines for the prevention of bloodstream infections and other intravascular catheter infections			
M0029	11:00	Kushlani Jayatileke (Battaramulla, Sri Lanka)	
M0030	11:12	Walter Zingg (Zurich, Switzerland)	
ME010	11:00 – 12:00	Hall 6	
	Meet-the-Expert		
Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional experience			
M0031	11:00	Ecaterina Noroc (Chisinau, Moldova, Republic of)	
M0032	11:12	Fakhriddin Nizamov (Almaty, Kazakhstan)	
Co-organised with: Euroguidelines in Central and Eastern Europe Network Group, United Nations International Children's Emergency Fund (UNICEF)			
ME011	11:00 – 12:00	Hall 8	
	Meet-the-Expert		
Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare			
M0033	11:00	Jaime Esteban (Madrid, Spain)	
M0034	11:12	Philippe Morand (Paris, France)	

Co-organised with: ESCMID Study Group for Implant-associated Infections (ESGII), ESCMID Study Group for Mycobacterial Infections (ESGMYC)			
ME012	11:00 – 12:00	Hall 9	
	Meet-the-Expert		
How to understand infectious disease risks in changing climates			
M0035	11:00	Kimberly Fornace (Singapore, Singapore)	
M0036	11:12	Rachel Lowe (Barcelona, Spain)	
SP3	13:30 – 14:30	Hall 0	
	Special Session		
Top five mistakes in Infection prevention and control			
Chairs	Maeve Doyle (Waterford, Ireland) Barbara Juliane Holzknecht (Copenhagen, Denmark) David Ong (Zoetermeer, Netherlands) Arjana Tambic Andrasevic (Zagreb, Croatia)		
Co-organised with: ESCMID Education Subcommittee			
ME013	13:30 – 14:30	Hall 2	
	Meet-the-Expert		
Orthopaedic implant infections: new approaches for improved outcomes			
M0037	13:30	Marjan Wouthuyzen-Bakker (Groningen, Netherlands)	
M0038	13:42	Trisha Peel (Melbourne, Australia)	
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGII), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)			
ME014	13:30 – 14:30	Hall 3	
	Meet-the-Expert		
Timing of antimicrobials in sepsis and septic shock - the sooner the better?			
M0039	13:30	Laura Evans (Seattle, United States)	
M0040	13:42	Evangelos Giamarellos-Bourboulis (Athens, Greece)	
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)			
ME015	13:30 – 14:30	Hall 5	
	Meet-the-Expert		
PrEP in Europe: Current gaps and solutions			
M0041	13:30	Teymur Noori (Stockholm, Sweden)	
M0042	13:42	Milosz Parczewski (Szczecin, Poland)	
Co-organised with: European AIDS Clinical Society (EACS)			
ME016	13:30 – 14:30	Hall 6	
	Meet-the-Expert		
Short regimens for treating drug-susceptible and drug-resistant tuberculosis: Insights from guidelines			





ESCMID Global 2025 - Programme

(Münster, Germany)

Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Veterinary Microbiology (ESGVM)

EW026	16:15 – 18:15	Hall 3
Educational Session		
AMR		
New insights into antifungal agents and resistance		
ChairsAnuradha Chowdhary (New Delhi, India)Jon Salmanton-García (Cologne, Germany)		
W0065	16:15	Emerging resistance in <i>Candida tropicalis</i> Sharon Chen (Sydney, Australia)
W0066	16:35	Mechanisms of resistance in <i>Candida glabrata</i> David Perlin (Nutley, United States)
W0067	16:55	Surveillance of resistance in <i>Aspergillus</i> speciesMaiken Cavling Arendrup (Copenhagen, Denmark)
W0068	17:15	Environmental surveillance for antifungal resistanceEveline Snelders (Wageningen, Netherlands)

EW027	16:15 – 18:15	Hall 5
Educational Session		
ANTCLNTRN		
Going Viral! Phage Therapy Clinical rounds		
ChairsGregory German (Maple, Canada)Ameneh Khatami (Sydney, Australia)		
W0069	16:15	Clinical cases and lessons from the STAMP protocolHolly Sinclair (Nsw, Australia)
W0070	16:35	Difficult cases treated with phagesGhady Haidar (Pittsburgh, United States)
W0071	16:55	Challenging osteoarticular cases treated with phagesTristan Ferry (Lyon, France)
W0072	17:15	Treating urinary tract infections with phages: dream or reality?Saima Aslam (San Diego, United States)
Co-organised with: ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA)		

EW028	16:15 – 18:15	Hall 6
Educational Session		
CLNVAX		
Addressing infection challenges in Immunocompromised patients: a case-based exploration		
ChairsMaddalena Giannella (Bologna, Italy)Asma Nasim (Karachi, Pakistan)		
W0073	16:15	Challenges in managing gastrointestinal infections in patients with primary immunodeficiencyEffrossyni Gkrania-Klotsas (Cambridge, United Kingdom)
W0074	16:35	Respiratory infections in patients receiving CAR-T cells or bispecific monoclonal antibodiesGemma Reynolds (Heidelberg, Australia)
W0075	16:55	Mycobacterial infections in patients with HIV infectionGraeme Ayton Meintjes (Observatory, South Africa)
W0076	17:15	Breakthrough fungal infections in haematopoietic cancer and in stem cell transplantationDimitrios P. Kontoyiannis (Houston, Tx, United States)
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)		

EW029	16:15 – 18:15	Hall 8
Educational Session		
TRN		
Impact of diabetes on infectious diseases: what should we know?		

Chairs		Mark G. J. De Boer (Leiden, Netherlands) Suzanne Van Asten (Nijmegen, Netherlands)
W0077	16:15	The impact of diabetes and host-pathogen interaction and gut microbiomeReinout Van Crevel (Nijmegen, Netherlands)
W0078	16:35	Diabetes and invasive fungal infectionsJochem Buil (Nijmegen, Netherlands)
W0079	16:55	Viral infections and diabetes: is there a connection?Malin Flodström-Tullberg (Stockholm, Sweden)
W0080	17:15	Pathogenesis of diabetic wound infectionTba

EW030	16:15 – 18:15	Hall 9
Educational Session		
DXIPC		
Primer on infection prevention and control: the crucial support by clinical microbiology		
ChairsNico Tom Muters (Bonn, Germany) Margreet C. Vos (Rotterdam, Netherlands)		
W0081	16:15	Microbial fundamentals: building blocks of infection prevention and controlLaurence Armand-Lefevre (Paris, France)
W0082	16:35	Optimising environmental sampling in infection control: rational use of the microbiology laboratoryJohn E. Coia (Esbjerg, Denmark)
W0083	16:55	The crucial role of molecular typing in infection controlStefanie Kampmeier (Würzburg, Germany)
W0084	17:15	How can we link diagnostic and antibiotic stewardship?Constantinos Tsioutis (Nicosia, Cyprus)
Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee		

Saturday, 12 April 2025

SY036	08:30 – 10:30	Hall 15
2-hour Symposium		
ANT		
The quality of antibiotics used in the communities of LMICs		
ChairsThi Thuy Nga Do (Ha Noi, Vietnam) Christina Obiero (Kilifi, Kenya)		
S0105	08:30	The quality of antibiotics and their potential impact on patient outcome and AMRPaul Newton (Oxford, United Kingdom)
S0106	09:00	Community antibiotic access and use in Sub-Saharan AfricaSamuel Afari-Asiedu (Kintampo, Ghana)
S0107	09:30	Encountered challenges and reflections on conducting multi-country medicine quality studiesNoudy Sengxeu (Vientiane Capital, Lao People's democratic republic)
S0108	10:00	Confusion in appearance of common used antibiotics in LMICsHeiman Wertheim (Nijmegen, Netherlands)

SY031	08:30 – 10:30	Hall 6
2-hour Symposium		
CLNVAX		
To screen or not to screen prior to transplant?		
ChairsLaura Alicia Barcan (Buenos Aires, Argentina) Oscar Len (Barcelona, Spain)		
S0085	08:30	HHV-8 ScreeningAlessandra Mularoni (Palermo, Italy)
S0086	09:00	TB screening and prevention in endemic regionsRubina Naqvi (Karachi, Pakistan)

ESCMID Global 2025 - Programme

S0087	09:30	Screening for and prevention of chagas in immunocompromised hosts <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i>
S0088	10:00	Screening of lung donors for Mollicutes <i>Michael G Ison (Derwood (MD), United States)</i>
EF003	08:30 – 09:30	Arena 1
	ePoster Flash Session	
	CLN VAX	
On the frontiers of vaccine driven prevention		
Chair	<i>Maria Ganczak (Zielona Gora, Poland)</i>	
E0021	Changes in dose interval can impact T cell responses but not antibody levels in individuals receiving the modified vaccinia Ankara Mpox vaccine <i>J. Parsons* (Liverpool, United Kingdom), K. Subramaniam, L. Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P. Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M. Carroll</i>	
E0022	A phase 1 study with an innovative approach for an HIV-1 prophylactic vaccine <i>P. Garbes* (Newark, United States), C. Chang, H. Wraight, R. Norton, S. Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall, S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M. Giffear, K. Damjanoska, J. Li</i>	
E0023	A Pragmatic Randomized Trial to Evaluate Bivalent RSV Prefusion F Protein–based Vaccine Effectiveness for Preventing RSV Hospitalizations in Older Adults (DAN-RSV): Rationale & Trial Design <i>M. Lassen* (Copenhagen, Denmark), S. Christensen, N. Johansen, K. Skaarup, D. Modin, B. Claggett, C. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen</i>	
E0024	Six-month Immunogenicity of mRNA-1345 RSV Vaccine in Adults Aged ≥60 Years <i>M. Desai* (Cambridge, United States), E. Comstock, L. Lan, A. Kapoor, F. She, C. Reuter, J. Goswami, F. Priddy, R. Das</i>	
E0025	Comparative Immune Responses to Homologous and Heterologous SARS-CoV-2 Vaccination Using DNA and Protein Platforms <i>S. Prieto Martin Gil* (Madrid, Spain), S. Prieto Martín Gil, M. López Siles, J.A. Infantes Lorenzo, E. Lorente, D. Fouteris, B. Cano Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato, A. Pérez, M.J. McConnell</i>	
E0026	Quantitative correlates of protection against SARS-CoV-2 variants using individual-level reconstructed antibody kinetics <i>T. Russell* (London, United Kingdom), E.C. Wall, A.J. Kucharski, J. Hellewell, O. Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D. Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr</i>	
E0027	Effectiveness of the 2023-24 seasonal influenza vaccine in UK healthcare workers: results from the SIREN prospective cohort study <i>L. Mcgeoch* (London, United Kingdom), S. Foulkes, H. Whitaker, K. Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall</i>	
E0028	Immunogenicity and safety of second COVID-19 booster and Influenza vaccination coadministration <i>I. Wagenhäuser* (Würzburg, Germany), J. Reusch, J. Mees, A. Gabel, N. Petri, M. Krone</i>	
E0029	The degree of immunization against the Measles virus of the infant population in Sibiu county, Romania <i>S. Cristea* (Sibiu, Romania), C. Grigore</i>	
EF004	08:30 – 09:30	Arena 3
	ePoster Flash Session	
	ANT	
Pharmacology from bench to the bedside		
Chair	<i>Alina Karoline Nussbaumer-Pröll (Wien, Österreich, Austria)</i>	
E0030	<i>Enterococcus faecalis</i> impairs <i>Escherichia coli</i>	

		response to antibiotics in a dual-species intracellular infection model <i>F. Van Bambeke* (Brussels, Belgium), G. Wang</i>
E0031		In vitro investigations of ceftazidime-avibactam and fosfomycin against carbapenemase-producing <i>Enterobacterales</i> clinical isolates <i>M. Martens* (Hamburg, Germany), F.M. Docobo-Perez, C. Sauco Carballo, J. Rodriguez-Baño, S. Marchand, L. Keomany, I. Portillo-Calderon, M. Gianella, S. Ambretti, B. Secci, S.G. Wicha</i>
E0032		<i>In vivo</i> activity and PK of the novel siderophore-cephalosporin AR-2126 in a lethal lung infection model in mice infected with a carbapenem-resistant <i>Pseudomonas aeruginosa</i> following subcutaneous administration <i>W. Wicha* (Bruck An Der Leitha, Austria), S. Paukner</i>
E0033		Synergistic Potency Unveiled: [β]-Lactam and [β]-Lactamase Inhibitor Combination against <i>Mycobacterium abscessus</i> with Dual Action of [β]-Lactamase Inhibition and Multi-Target Receptor Inactivation <i>E. Shin* (Cleveland, United States), K.M. Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J. Rubin, J.B. Bulitta, K. Barry, R.A. Bonomo</i>
E0034		Pharmacokinetic/pharmacodynamic evaluation of benzoxaborole MRX-5 in mouse pneumonia model with <i>Mycobacterium abscessus</i> infection <i>W. Wang* (Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q. Dai, G. Lamichhane</i>
E0035		Pharmacokinetic/pharmacodynamic modelling of immune response and meropenem activity in immunocompetent and neutropenic mouse lung infection models <i>R. Saporta* (Uppsala, Sweden), N. Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I. Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg</i>
E0036		Implementation of a model-based nomogram for amoxicillin precision dosing in patients suspected of infective endocarditis: preliminary results of the NOMOBA-AMX multicentre study <i>P. Le Turnier* (Cayenne, French Guiana), S. Jamard, A. Lorleac'h, C. Deschanvres, F. Andry, A. Coste, P. Danneels, T. Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R. Lamberet, A. Le Bot, M. Maillet, P. Petitgas, V. Rabier, S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M. Grégoire, A.G. Leroy, M. Wargny, R. Bellouard</i>
E0037		No time to waste: hospital-wide assessment of IV-vial and line residuals and impact on target attainment. <i>D. Vanneste* (Leuven, Belgium), M. Gijssen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters, S. Desmet, E. Dreesen, I. Spriet</i>
E0038		Population pharmacokinetic modelling of colistin in critically-ill patients on sustained low-efficiency dialysis: Implications for dose selection <i>D. Fuhs* (Parkville, Australia), A. Boonyasiri, T. Naorungroj, L. Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T. Visanu, C. Landersdorfer</i>
SY034	08:30 – 10:30	Hall 10
	2-hour Symposium	
	IPC	
Endoscopy: infection risks and mitigation		
Chairs	<i>Elisabeth Prestler (Vienna, Austria)</i> <i>Gordon Ramage (Glasgow, United Kingdom)</i>	
S0097	08:30	Should we be concerned about infection from contaminated endoscopes? <i>Claire Aumeran (Clermont-Ferrand, France)</i>
S0098	09:00	Prevention of multidrug-resistant infections from contaminated duodenoscopes <i>Margreet C. Vos (Rotterdam, Netherlands)</i>
S0099	09:30	Understanding the causes of medical device contamination: it is all biofilm! <i>Roberto Rusconi (Milan, Italy)</i>
S0100	10:00	Does the European medical Device Regulation bring us safer duodenoscopes? <i>Markus Hell (Salzburg, Austria)</i>
Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study Group for Nosocomial Infections (ESGNI)		



ESCMID Global 2025 - Programme

OS002	08:30 – 10:30	Hall 11
	2-hour Oral Session	
	<div>DX</div>	
Translating metagenomics into clinical practice		
Chairs	Benjamin Peter Howden (Parkville (Victoria), Australia) Paula Mölling (Örebro, Sweden)	
00011	Nanopore metagenomic sequencing for rapid bloodstream infection diagnostics evaluated in a prospective observational studyH.L. Nielsen* (Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B. Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen	
00012	Interpretative Criteria for Adjudicating Clinical Significance to Next-Generation Sequencing Results from Bronchial-alveolar Lavage and Bronchial Wash.J. Alexander* (Orlando, United States), A. Charles	
00013	Implementing same-day respiratory metagenomic diagnostics in paediatric intensive careR. Hammond* (London, United Kingdom), A. Kopeck, J. Brown, J. Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B. Snell, J. Breuer	
00014	Detection of pathogenic microorganisms using metagenomic next-generation sequencing in ICU patients with ongoing antibiotic therapy T. Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, A. Dervishi, P. Kawaletz, H. Stäudle	
00015	Analysis of metagenomic pathogen detection compared to conventional diagnostics: clinical usage and relevance for patient outcomesE. Siegel* (Mainz, Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C. Hamm, D. Teschner, O. Kriege, D. Grimm, I. Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. Hagge, S. Vieira-Silva, T. Sparwasser	
00016	Same-day pan-microbial metagenomics for personalized therapy and pathogen surveillance on the intensive care unit: a single-centre prospective studyL.B. Snell* (London, United Kingdom), A. Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D. Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W. Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J. Whitehorn, G. Nebbia	
00017	Evaluation of the diagnostic efficacy of targeted next-generation sequencing in the detection of pathogens in bronchoalveolar lavage fluid from patients with lower respiratory tract infections in ICUB. Ran* (Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. Zhang, J. Hao, L. Jin, Z. Huang	
00018	Prognostic and diagnostic value of Next-generation sequencing in female reproductive tract infection and HPV persistenceC. Peng* (Shiyan, China), S. Qi, C. Jiachang, P. Chunyan, W. Taiquan, X. Xianru, Y. Jianying, Y. Qirong, Z. Pengyuan, L. Jun	
00019	A promising approach to rapid, non-culture diagnosis of invasive fungal infections (IFIs) by targeted next-generation sequencing (tNGS)M.H. Nguyen* (Pittsburgh, United States), H. Badrane, B.A. Stevens, S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. Hao, E. Driscoll, W. Maynard, C. Clancy	
00020	Implementation of Clinical Metagenomics in France: Insights from a Five-Years StudyM. Dutkiewicz* (Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Caméléna, J. Le Goff, M. Salmona	

SY035	08:30 – 10:30	Hall 12
	2-hour Symposium	
	<div>PHEI</div>	
Barriers to TB/HIV elimination in low- and high-incidence settings		
Chair	Daria Podlekareva (Copenhagen, Denmark)	
S0101	08:30	HIV and TB epidemic: the storm hasn't subsided yet Tetiana Koval (Poltava, Ukraine)
S0102	09:00	Approaches for latent and active TB screening in

		people living with HIVRaimonda Matulionyte (Vilnius, Lithuania)
S0103	09:30	Integration of HIV and TB care to improve patient outcome in resource-limited settingsAkaki Abutidze (Tbilisi, Georgia)
S0104	10:00	How researchers can influence policy and practice in HIV/TB careJens D. Lundgren (Copenhagen, Denmark)

Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), Euroguidelines in Central and Eastern Europe Network Group

EW041	08:30 – 10:30	Hall 13
	Educational Session	
	<div>CLN DX VAX</div>	
RSV infections: diagnosis, surveillance and treatment in the advent of vaccines		
Chair	Monika Redlberger-Fritz (Vienna, Austria)	
W0126	08:30	Costs of RSV infection, compared to other respiratory virusesBarbara Rath (Besançon, France)
W0127	08:50	Virology and host interactions of RSV
W0128	09:10	RSV surveillance in the EU/EEA in the vaccine eraEeva Broberg (Solna, Sweden)
W0129	09:30	RSV fusion inhibitors and monoclonals: current status and future developmentsPeter Openshaw (London, United Kingdom)

Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Society for Influenza and other Respiratory Viruses (ISIRV)

EW042	08:30 – 10:30	Hall 14
	Educational Session	
	<div>CLN</div>	
Traumatic wound infections: diagnosis and treatment options		
Chairs	Amparo Fernández-Rodríguez (Madrid, Spain) Veroniek Saegeman (Sint-Niklaas, Belgium)	
W0130	08:30	Multidrug-resistant infections after trauma in warzoneShehan Hettiaratchy (Hampton, United Kingdom)
W0131	08:50	Fungal infections during natural disastersAnuradha Chowdhary (New Delhi, India)
W0132	09:10	Bacteriophage therapy for multidrug-resistant wound infections in traumaTristan Ferry (Lyon, France)
W0133	09:30	Infection of burn woundsNur Benzonana (Istanbul, Türkiye)

Co-organised with: ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades Infecciosas Microbiología Clínica), International Society of Antimicrobial Chemotherapy (ISAC)

SY037	08:30 – 10:30	Hall 16
	2-hour Symposium	
	<div>CLN DX</div>	
Unveiling the challenges: nosocomial infections in ECMO-supported patients		
Chairs	Antonios Katsounas (Bochum, Germany) Jordi Riera (Barcelona, Spain)	

S0109	08:30	Source of infection and pathogensChristian Eckmann (Hannover, Germany)
S0110	09:00	Prophylaxis and empiric treatmentGiacomo Grasselli (Besana In Brianza, Italy)
S0111	09:30	Diagnostic criteria and definitionsGraeme Maclaren (Singapore, Singapore)
S0112	10:00	Microbial filmsMarta Hernández-Meneses (Barcelona, Spain)

Co-organised with: European Extracorporeal Life Support Organization (EuroELSO)

ESCMID Global 2025 - Programme

EW039		08:30 – 10:30	Hall 2
		Educational Session	
		CLN DX	
Are urinary tract infections still the same?			
Chairs		Suzanne Geerlings (Amsterdam, Netherlands) Agnes Maria Sonnevend (Pécs, Hungary)	
W0118	08:30	Update on paediatric UTI	Michael Buettcher (Luzern, Switzerland)
W0119	08:50	Diagnosis and treatment of UTI in the era of antimicrobial resistance	Jennifer Kranz (Aachen, Germany)
W0120	09:10	Can UTI be prevented?	Chris Harding (Newcastle Upon Tyne, United Kingdom)
W0121	09:30	Fungal and parasitic infections of the urinary tract	Gladys Mbwangi (Mwanza, Tanzania, United republic of)
EW040		08:30 – 10:30	Hall 3
		Educational Session	
		ANT CLN	
OPAT: from aged wine to new vintage			
Chairs		Birgit Koch (Rotterdam, Netherlands) Sonia Luque (Barcelona, Spain)	
W0122	08:30	OPAT: principles, practice and checklists	Charlotte Quintens (Leuven, Belgium)
W0123	08:50	COPAT: complex outpatient parenteral antimicrobial therapy	Ronald Andrew Seaton (Glasgow, United Kingdom)
W0124	09:10	Antimicrobial stability and other challenges for OPAT practice?	Mark Gilchrist (London, United Kingdom)
W0125	09:30	New OPAT safety and efficacy data to guide practice	Matthew Rawlins (Murdoch, Australia)
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), Society of Infectious Diseases Pharmacists (SIDP)			
EW038		08:30 – 11:30	Hall 4
		Educational Session	
		AMR DX	
EUCAST Educational Workshop			
Chairs		Marlene Amara (Le Chesnay Cedex, France) Alasdair P. Macgowan (Bristol, United Kingdom)	
W0113	08:30	EUCAST update	Sören G. Gatermann (Bochum, Germany)
W0114	08:50	Setting clinical breakpoints, assessing evidence	Anouk Edwina Muller (The Hague, Netherlands)
W0115	09:10	Benzylpenicillin susceptibility testing of <i>S. pneumoniae</i> by disk diffusion	Gunnar Kahlmeter (Tävelsås, Sweden)
W0116	09:30	What to do when there are no breakpoints	Barbara Juliane Holzknecht (Copenhagen, Denmark)
W0117	09:50	Detection of resistance mechanisms	Christian Giske (Stockholm, Sweden)
Co-organised with: EUCAST Steering Committee			
OS001		08:30 – 10:30	Hall 5
		2-hour Oral Session	
		AMR PHEI TRN	
One Health means resistance everywhere			
Chairs		Alessandra Carattoli (Rome, Italy) Prasannakumar Palanikumar (Vellore, India)	

O0001	Decoding the role of <i>bla</i> <sub>CE</sub> -carrying plasmids on wings: A holistic view using the One Health approach S.A. Martínez-Álvarez* (Logrono, Spain), P. Châtre, T. Cardona-Cabrera, P. François, U. Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C. Torres		
O0002	A novel isolation room model leveraging culture-independent Hi-C metagenomics for tracking antimicrobial resistance transmission between patients and hospital environmental reservoirs V. Koh* (Singapore, Singapore), R. Cabrera, J. Chua, J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M. Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng		
O0003	Deciphering the pathogenic potentials and epidemiological identities of <i>Staphylococcus pseudintermedius</i> colonizing companion dogs in Sao Paulo I.B. Moses* (Sao Paulo, Brazil), L. Sartori, D.A. Henriques, M.M. Marini, F.M. Lima, R.X. Espinosa, I. Orlandino Da Silva, F.F. Santos, L. Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales		
O0004	Recent progress towards integrated surveillance of antimicrobial resistance in France L. Collineau* (Lyon, France), S. Bareille, G. Birgand, L. Lacmago, B. Lange, O. Lemenand, C. Chauvin		
O0005	Exploring the plasmidome of 3rd generation cephalosporin-resistant Enterobacterales in wild birds: Insights into horizontal gene transfer and AMR dissemination B. Timmer* (Debrecen, Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-Kiss, L. Laczkó, G. Kardos		
O0006	Emergence of mobile colistin resistance in <i>Klebsiella</i> at human-animal-environment interface in Bangladesh S. Rahman* (Oxford, United Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R. Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T. Walsh, R. Farzana		
O0007	Unveiling the invisible: antimicrobial resistance genes and pathogenic microbial diversity in sewage of North India's largest industrial hub, A metagenomic perspective I. Singh* (Chandigarh, India), R. Sharma, A. Arora, B. Mohan, N. Taneja		
O0008	Culturomics as a tool for ONE HEALTH approach: Unveiling the role of unknown microorganisms as antibiotic resistance carriers in wastewater samples E. Ouranou* (Heraklion, Greece), A. Psaroulaki, D. Chochlakis, M. Malliarou, K. Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos		
O0009	One Health intervention impacts on antibiotic resistance in Denmark, England and Senegal: A mathematical model comparison G. Knight* (London, United Kingdom), R. Booton, J.V. Robotham, K. Aluzaite, D. Belay, J. Guitian, M. Dione, E. Emes		
O0010	Clinically important sequence types and resistance genes in <i>Enterobacteriaceae</i> from coastal environments and gulls V. Silva* (Lisbon, Portugal), M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G. Igrejas		
SY032	08:30 – 10:30		Hall 7
	2-hour Symposium		
	TRN		
New insights into <i>Candida</i> pathogenesis			
Chairs	Aleksandra Barac (Belgrade, Serbia) Joshua Nosanchuk (Bronx, United States)		
S0089	08:30	Insights into the evolution of <i>Candida</i> under antifungal pressure Attila Gacser (Szeged, Hungary)	
S0090	09:00	How do <i>Candida</i> extracellular vesicles modify virulence during disease? Leonardo Nimrichter (Rio De Janeiro, Brazil)	
S0091	09:30	The commensal to pathogen transition: kind to killer Ilse D. Jacobsen (Jena, Germany)	
S0092	10:00	Fungal-bacterial interactions: who wins? Rebecca Hall (Canterbury, United Kingdom)	



ESCMID Global 2025 - Programme

SY033

08:30 – 10:30

Hall 8

2-hour Symposium

Single-cell approaches to dissect cellular phenotypic heterogeneity of bacterial pathogen populations.

Chairs

Christian Stephan Lentz (Tromsø, Norway)  
Annelies Zinkernagel (Zurich, Switzerland)

- S0093

08:30

Adaptive evolution and phenotypic heterogeneity of bacterial pathogens during infectionsChristoph Ernst (Cologne, Germany)
- S0094

09:00

Single-cell imaging and heterogeneity in antimicrobial resistanceStefano Pagliara (Exeter, United Kingdom)
- S0095

09:30

Single-cell RNAseq and heterogeneity in bacterial transcriptionAnna Kuchina (Seattle, United States)
- S0096

10:00

Dissecting the function of individual bacteria in their spatial contextKnut Drescher (Basel, Switzerland)

SY043

09:30 – 10:30

Hall 1

1-hour Symposium

Year in infection control

Chairs

Nico Tom Mutters (Bonn, Germany)  
Ermira Tartari (Msida, Malta)

- S0134

09:30

Andrew James Stewardson (Melbourne, Victoria, Australia)
- S0135

10:00

Kalisvar Marimuthu (Singapore, Singapore)

EF005

09:30 – 10:30

Arena 2

ePoster Flash Session

It's all in the blood

Chair

Colin R. Mackenzie (Neuss, Germany)

- E0039

Limited delayed incubation of blood culture bottles has limited effect on yield and time-to-positivityL. Hardy\* (Antwerp, Belgium), A.S. Heroes, E. Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E. Corsmit, B. De Smet
- E0040

Unnecessary clinical interventions due to blood culture contamination in a large Canadian hospital networkC. Hall\* (Hamilton, Canada), C. Fuller, S. Ramondino, C. Main
- E0041

Utility of sigmoidal growth curve when no organisms are seen on Gram stain in positive blood culturesD. Crilly\* (London, United Kingdom), A. Bapat, J. Youngs, G. Maloney, E. Drakes
- E0042

Clinical microbiology laboratory consultancy to optimize blood culture workflow: Analysis of resultsC. Magri\* (Rome, Italy), C. Magri, G. Menchinelli, D. Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti
- E0043

Comparison of Syndromic Sepsis Panel and Standard Blood Culture Results: Contribution to Patient ManagementS. Buyukberber\* (Ankara, Türkiye), S. Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H. Dal, T. Kayan
- E0044

Predicting blood culture positivity using machine learning with complete blood and differential counts in a tertiary care hospital of TürkiyeÖ. Türkmen Recen\* (Izmir, Türkiye), M. Kıplapınar, H. Özdemir, S. Kurutepe, H. Gazi
- E0045

Performance of direct pathogen and  $\beta$ -lactamase detection workflow using MALDI-TOF MS from positive blood culture specimensK. Kosai\* (Nagasaki, Japan), Y. Kawamoto, K. Yanagihara
- E0046

Waiting for follow-up blood cultures is not always necessary for diagnosis of central line-associated bloodstream infectionsL. Van Balen\* (Maastricht, Netherlands), R. Koeck

E0047

Economic and health gains associated with the adoption of the 2-hour phenotypic antimicrobial susceptibility testing in patients with bloodstream infection in EuropeC. Pina-Vaz\* (Oporto, Portugal), F. Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro, J.A. Paiva

EF006

09:30 – 10:30

Arena 4

ePoster Flash Session

Emerging developments in antifungal pharmacology

Chair

Roger Brüggemann (Nijmegen, Netherlands)

- E0048

NATURE-US: the natural history of antifungal failure in invasive candidiasisL. Ostrosky-Zeichner\* (Houston, United States), P.G. Pappas, M.H. Miceli, A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E. McKie, M. Middle, M. Kordalewska, D.S. Perlin, D.P. Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo
- E0049

The antidepressant vortioxetine enhances resistance toward multiple azolesS. Rizzo\* (Rome, Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B. Posteraro, M. Sanguinetti, F. Bugli, R. Torelli
- E0050

Enhancing Isavuconazole Pharmacokinetics: A Comprehensive Population (PPK) Model from Three Phase 3 Trials and Covariate ExplorationA. Desai\* (Northbrook, United States), L. Kovanda
- E0051

Identification of efflux inhibitors for *Candida albicans* through a drug repurposing strategyD. Marques\* (Lisbon, Portugal), S. Santos Costa, L. Rodrigues
- E0052

Clinical outcomes of micafungin 100 mg vs. 150 mg daily for the treatment of *Candida auris* fungemiaJ. Hou\* (Chicago, IL, United States), Y. Wang, R. Burgos, L. Danziger, E. Drwiega
- E0053

Resolution of clinical signs in adults with invasive candidiasis and/or candidaemia treated with rezafungin or caspofungin: ReSTORE and STRIVE trial pooled analysisG.R. Thompson\* (Davis, California, United States), A. Soriano, M. Bassetti, P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely
- E0054

Ibrexafungerp is effective in treatment of patients with candidiasis, including candidaemia, caused by *Candida auris*: a multicentre, open-label study (CARES)M.H. Miceli\* (Ann Arbor, United States), T.F. Patterson, D. Juneja, G.R. Thompson III, P. Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breed, N. Yaddanapudi, R.S. Siebert, E. McKie, F. Lewis, M. Middle, M. Hoenigl
- E0055

High-dose isavuconazole therapy is well-tolerated and significantly improves survival in a fruit fly model of invasive mucormycosisS. Wurster\* (Houston, United States), N.D. Albert, N.P. Wiederhold, R.E. Lewis, D.P. Kontoyiannis
- E0056

Pharmacokinetics, pharmacodynamics, safety, and efficacy of innovative dosing schedules of liposomal amphotericin B for treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbitsR. Petraitiene\* (New York, United States), E. Naing, A. Garcia, V. Zigmantaite, R. Grigaleviciute, A. Pocekevicius, M. Zimmerman, A.H. Groll, T.J. Walsh, V. Petraitis

FO050

11:00 – 12:00

Arena 1

Open Forum

HIV: a global ethical Conundrum

Chair

Seif Al-Abri (Muscat, Oman)

- F0147

11:00

HIV, from key population to general population: a Pandora's Box.Syed Faisal Mahmood (Karachi, Pakistan)
- F0148

11:10

Ethical considerations in preventing mother-to-child HIV transmission Glory Alexander (Bangalore, India)
- F0149

11:20

HIV drug trials in Africa: ethical concernsShah Reena

ESCMID Global 2025 - Programme

F0150	11:30	HIV-related stigma and discrimination in the healthcare setting Teymur Noori (Stockholm, Sweden)
Co-organised with: ESCMID Ethics Advisory Committee (EEAC)		
EF014	11:00 – 12:00	Arena 2
ePoster Flash Session		
IPC PHEI		
Infection control and prevention around the World		
Chair	Divyashree Shanthamurthy (Mumbai, India)	
E0092	WHO Global Survey on Infection Prevention and Control Minimum Requirements: Laying the Foundation for 2030 Global Targets P. Bischoff* (Geneva, Switzerland), S. Tomczyk, G. Satta, E. Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R. Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh, B. Allegranzi	
E0093	Healthcare-associated infections in african intensive care units: A multicentre prospective cohort study B. Gaye* (Dakar, Senegal), N. Madani, J. Ben Khlii, A. Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M. Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T. Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. Elombila, W. Najja, M. Kahloul, R. Herch, R. Toumi, E. Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. Badis, L. Messaoud, A. Bouzid, S. Feki, H. Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. Faye, L. Ouanes Besbes, Z. Hammouda, M.S. Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy, M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B. Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N. Ben Slimane, F. Kaaniche Medhioub, R. Allala, C. Kaddour, N. Baffoun, R. Hammami, H. Allouche, H. Ghadhoune, S. Soui, H. Hmouda, R. Ben Dabebiss, A. Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O. Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj, H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, R. Abouqal, Y. Coulibaly	
E0094	Epidemiology of community-acquired versus hospital-acquired sepsis in acute hospitals in Ireland - 2016-2022. E. Liddy* (Dublin, Ireland), A. Vellinga, D. Amin	
E0095	Epidemiology of Central Line-Associated Bloodstream Infections (CLABSI) in a Network of Ten Hospitals across Greece: A 30-Month Surveillance Study – GRIPP-SNF Network I. Kopsidas* (Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Karaïskou, D. Kaitelidou, T. Zautis, A. Koutsoukou	
E0096	Characterisation of plasmids disseminating antibiotic resistance in Klebsiella pneumoniae isolates from Pretoria, South Africa T. Govender* (Pretoria, South Africa), A. Moultrie, M. Moodley, J. Featherston, M. Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Liknaitzky, K. Salvador-Oke, A. Smith, I. Arshad, M. Said, M. Ehlers, M. Kock	
E0097	Transmission dynamics of carbapenemase-producing bacteria between hospital and household settings in Benin K. Sintondji* (Abomey-Calavi, Benin), V. Dougnon, B. Legba, B.G. Hougbenou, K. Fabyi, H. Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou	
E0098	Evaluating the impact of a rapid screening test for carbapenem-resistant organisms in Brazilian intensive care units. M. Salomão* (Sao Paulo Sp, Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, G. Mahon, M. Westercamp, M. Chiarastelli Salomao	
E0099	Genomic Insights into the Rapid Rise of Pseudomonas aeruginosa ST463: A High-Risk Clone's Adaptive Strategy in China X. Dong*	

		(Hangzhou, China)
E0100	Nanopore long-read only genome assembly for public health surveillance of Enterobacterales bloodstream infections and plasmid epidemiology in England: A pilot study <i>D. Nagy* (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pennetta, G. Rodger, K. Hopkins, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown</i>	
EF015	11:00 – 12:00	Arena 3
	ePoster Flash Session	
	ANT CLN DX	
Advances in the diagnosis and treatment of skin, bone, and joint infections		
Chair	Norma Jung (Köln, Germany)	
E0101	Potential benefits of PET-CT in the management of bone and joint infections in infective endocarditis: a retrospective analysis from the Mayo Clinic <i>F. Petri* (Milan, Italy), F. Borghonovo, O.K. Mahmoud, R. Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone, A. Gori, E. Berbari</i>	
E0102	Synovial fluid microRNA biomarkers enable accurate diagnosis of periprosthetic joint infection <i>B.J.H. Frank* (Vienna, Austria), T. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A. Diendorfer, M. Hackl, J. Hofstaetter</i>	
E0103	Diagnostic accuracy of 16S rDNA PCR, multiplex PCR and metagenomic Next-Generation Sequencing in periprosthetic joint infections: a systematic review and meta-analysis <i>F. Olearo* (Hamburg, Germany), S. El Zein, E. Portillo M, A. Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker</i>	
E0104	Comparison of microbiology, management and outcome between patients with native and with post-surgical vertebral osteomyelitis: a 7-year retrospective study <i>G. Franceschi* (Modena, Italy), M. Pellegrino, M. Del Monte, A. Bedini, L. Benassi, A. Soffritti, A. Tili, E. Dema, M. Palmisani, A. Veroni, G. Pavesi, M. Cristina</i>	
E0105	Cefiderocol real-life use in bone and joint infection: a retrospective French multicenter study <i>A. Diarra* (Tourcoing, France), V. Delastours, A. Bleibtreu, H. Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B. Valentin, M. Bermejo, P. Gazeau, A. Baldolli, B. Lefevre, A. Asquier, J. Courjon, R. Larcher, L. Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry, I. Eberl, M. Degrendel, P. Patoz, P.Y. Tortai, O. Robineau, E. Senneville</i>	
E0106	Real-Life Experience with Dalbavancin as Suppressive Antibiotic Treatment in orthopaedic implant-related infections. <i>R. Escudero-Sánchez* (Madrid, Spain), S. De La Villa Martínez, A. Rico Nieto, M. Sanchez-Somolinos, M. Tacias Pitarch, M. Salaver Lletí, M. Correa Ballester, R. Blanez Hernández, E. Calabuig Muñoz, M. Montero Alonso, L. Guio Carrion, J. Gomez Junyent, M.L. Sorli, F. Braojos Sanchez, A. Muñoz Gomez, M.J. Nuñez Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J. Perez-Somarribas Moreno, J.M. Barbero Allende, M.J. Garcia Pais, F.J. Martínez Marco, A. Galeote Rivas, B. De La Torre Escuredo, J. Cobo</i>	
E0107	Short or Long Antibiotic Regimes in Orthopaedics: the SOLARIO multicentre randomised controlled trial <i>M. Dudareva* (Oxford, United Kingdom), M. Scarborough, M. McNally, M. Kumin, C. Scarborough, W. Vach, J. Ferguson</i>	
E0108	Clinical and Antibacterial Diversity of <i>Staphylococcal</i> Phenotypes in Skin and Soft Tissue Infections: A Resource-Limited Country Perspective. <i>F. Zeeshan* (Karachi, Pakistan), A. Naeem, F. Uddin</i>	
E0109	Discrepancy between clinical-radiological diagnosis and surgical confirmation in 62 patients undergoing fasciotomy for suspected necrotizing fasciitis: a 11-year retrospective study. <i>F. Romani* (Modena, Italy), A. Bedini, A. Spadoni, G. Manzini, G. Franceschi, B. Fontana, M. Sarti, C. Mussini</i>	

ESCMID Global 2025 - Programme

EF016	11:00 – 12:00	Arena 4
ePoster Flash Session		
AMRCLNPHEI		
Rising threats: antimicrobial resistance in STIs		
Chair	Marcos Rust (Feldkirch, Austria)	
E0110	Important rise of antibiotic resistance of <i>Mycoplasma genitalium</i> , a sexually transmitted pathogen, in a French University hospitalF. Doucet Populaire* (Clamart, France), W. Ben Nejma, C. Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. Guillet-Caruba, N. Bourgeois-Nicolaos	
E0111	Molecular characterization of antimicrobial resistance and genotyping of <i>Mycoplasma genitalium</i> positive samples of the Lisbon area, PortugalM. Barros* (Lisbon, Portugal), F. Pereira, L. Rodrigues	
E0112	Antimicrobial Resistance in <i>Mycoplasma genitalium</i> : Surveillance and Management in São Paulo, Brazil V. Passarelli* (São Paulo, Brazil), F. Goldemberg, A. Freitas, C. Picone, C. Lazari, G. Carnevale, M. Thomazella, S. Chamarelli, D. Gennari, C. Pedrozo, G. Hughes, S. Costa	
E0113	Impact of genotypic substitutions on treatment failure for <i>Mycoplasma genitalium</i> infectionN.B. Bana* (Milan, Italy), A. Nava, D. Fanti, C. Vismara, G. Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. Mulè, L. Denti, M. Puoti, R. Rossotti	
E0114	Macrolide-resistant <i>Mycoplasma genitalium</i> : an emerging threat to public health?J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Valentin-Martín, A. Hernández-Cabezas, J.L. Lopez-Hontangas	
E0115	Comparison of carbapenem MIC in wild-type, MDR and XDR <i>Neisseria gonorrhoeae</i> isolatesJ. Brousseau* (Paris, France), A. Braille, M. Mainardis, F. Meunier, M. MÉRIMÈCHE, F. Caméléna, B. Berçot	
E0116	Unsettling surge in antimicrobial resistance patterns of <i>Neisseria gonorrhoeae</i> - A study from national reference centre in India.D. Sharma* (Delhi, India), S. Muralidhar, N. Joshi	
E0117	Surveillance of <i>Neisseria gonorrhoeae</i> antimicrobial resistance rate and treatment regimes in Singapore from 2014 to 2024M. Giovanni* (Singapore, Singapore), A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S. Goh, S.T. Koh, Y.E. Tan	
E0118	Molecular surveillance results of <i>N. gonorrhoeae</i> in KoreaK.H. Roh* (Goyang, Korea, Republic of), C. Liu, Y.H. Suh, H. Lee, K. Lee	
KN044	11:00 – 12:00	Hall 1
Keynote Lecture		
AMRPHEI		
Asia: an AMR Hot Zone		
Chairs	Giulia De Angelis (Rome, Italy) Robert Leo Skov (Copenhagen, Denmark)	
K0136	11:00	David L. Paterson (Singapore, Singapore)
OS010	11:00 – 12:00	Hall 10
1-hour Case Session		
CLN		
Antimicrobial drugs in action		
Chairs	Katy Jeannot (Besançon, France) Timothy R. Walsh (Oxford, United Kingdom)	
O0072	In vivo cefiderocol resistance due to <i>cirA</i> modification during treatmentE. Carretto* (Reggio Emilia, Italy), P. Pini, R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, M. Bardaro, N.C. Facciolongo, S. Mezzadri, T. Walsh	
O0073	Long-term outcomes in dalbavancin-treated patients with vascular graft infection.A. Specklin* (Reims,	

		France), T. Noë, M. Bonnet, A. Duprey, M. Hentzien
O0074	Aztreonam, ceftazidime/avibactam, and tigecycline combination for the management of multi-drug resistant <i>E.coli</i> on peritonitis in a pediatric liver transplant recipientR. Morales Junior* (Cincinnati, United States), V. Juodinis, C. Donini, J. Sampaio	
O0075	Early oral antibiotic treatment in patients with post-neurosurgical brain abscesses caused by <i>Cutibacterium acnes</i> – a case seriesM. Karolyi* (Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A. Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fiscoeder, M. Ortler, C. Wenisch	
O0076	Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant <i>K. pneumoniae</i> shunt-related ventriculitis: two case reports.G. Giuliano* (Siena, Italy), M. Sambo, P. Castellani, S. Benedetti, F. Tarantino, M. Tumbarello	
SY047	11:00 – 12:00	Hall 11
1-hour Symposium		
IPC		
How long should contact isolation precautions be continued?		
Chairs	Cansu Cimen (Oldenburg, Germany) Kyriaki Tryfinopoulou (Heraklion, Greece)	
S0141	11:00	Contact isolation in patients with MDR organisms: Why, when, where? Gabriel Birgand (Nantes, France)
S0142	11:30	Is discontinuation of contact precautions associated with an increase in infections? Daniel Diekema (Harpswell, United States)
Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee, Multidisciplinary Joint Committee Infection Control UEMS		
ME048	11:00 – 12:00	Hall 12
Meet-the-Expert		
DX		
Cut a long story short: choosing NGS platforms		
M0143	11:00	Etienne Ruppe (Paris, France)
M0144	11:12	Stefan Green (Chicago, United States)
OS011	11:00 – 12:00	Hall 13
1-hour Oral Session		
ANTTRN		
Around the lab in 80 ways: a journey through innovative therapeutics		
Chairs	Zuzanna Drulis-Kawa (Wroclaw, Poland) Helena Zemlickova (Prague, Czech Republic)	
O0077	In vivo expression of an mRNA encoded multi-mechanistic mAb combination against <i>Staphylococcus aureus</i> and protection in a disease modelC. Tkaczyk* (Gaithersburg, United States), N. Michael, P. Mun Mun, T. George, S. Martin, G. Adam, M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark, L. Ashley, D. Antonio, S. Bret	
O0078	Hijacking intrinsic resistance in <i>Mycobacterium abscessus</i> G. Phelps* (Memphis, United States), S. Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E. Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L. Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O. Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A. Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S. Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander, R. Lee	
O0079	Tripartite bacteriophage-based strategy to combat human clinical pathogensP. Kalatzis* (Copenhagen, Denmark), R. Ibarra-Chávez, H. Sampson, S. Michniewski, A. Shen, M. Ford, B. Petersen, P. Worning, P. Klement, H.P. Calum, U.M. Singh, A. Millard, M. Clokie, T. Sicheritz-Pontén	



ESCMID Global 2025 - Programme

00080	Eosin Y and Ceragenin combinations for enhanced antimicrobial photodynamic therapy	Y. Tekintas* (Cigli, Türkiye), P.B. Savage, M. Ucuncu
00081	Identification of compounds capable of removing established bacterial biofilms	T. Inzana* (Brookville, United States), A. Gates, W. Weng, J. Cusumano, Y.J. Lee, N. Vogelaar

ME049	11:00 – 12:00	Hall 14
	Meet-the-Expert	
	PRO	
How to perform clinical trials in mycoses?		

M0145	11:00	Monica Slavin (Melbourne, Australia)
M0146	11:12	Nkechi Azie (Barrington, United States)
Co-organised with: ESCMID Fungal Infection Study Group (EFISG)		

OS012	11:00 – 12:00	Hall 15
	1-hour Oral Session	
	PHEI	
Climate Impact and One Health Approaches Against Infectious Diseases		
Chair	Chadia Wannous (Paris, France)	

00082	Airborne Threats: Pollution, Climate, and Respiratory Infections in a Pyrenean setting: The Andorran hospital based respiratory perspective	C. Royo-Cebrecos* (Andorra, Andorra), N. Duran Torralbo, D. Vilanova Gonzalez, M. Clusas Antolin, L. Trapero
00083	Effects of climate change on Aedes aegypti abundance and dengue transmission	L. Geng* (Singapore, Singapore)
00084	Impact of climate variables on Crimean-Congo hemorrhagic fever in Iran, Iraq, Kazakhstan, and Russia	M. Fereidouni* (Jahrom, Iran, Islamic Republic of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. Alhilfi, M. Keshtkar-Jahromi
00085	Successful public health and one health response to a high pathogenicity avian influenza outbreak in poultry farms in Victoria, Australia: implications for future planning	E. Athan* (Geelong, Australia), A. Hussain, K. Blaney, L. Cardamone, N. Clarke, M. Hayes, M. Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. O'brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear
00086	Turning disease surveillance into reality: Using metagenomic sequencing with piggyery wastewater	M. Muralidhar* (St Lucia, Australia), L. Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni

OS013	11:00 – 12:00	Hall 16
	1-hour Oral Session	
	CLN DX	
Viral challenges in organ transplantation		
Chairs	Ghady Haidar (Pittsburgh, United States) Cristiana Oprea (Bucharest, Romania)	

00087	Evaluation of an individualized CMV prevention strategy guided by post-transplant CMV-specific cell-mediated immunity in intermediate-risk kidney transplant recipients	I. Rodríguez-Goncer* (Madrid, Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan, L.M. Allende, E. Paz-Artal, A. Andrés, F. López-Medrano, J.M. Aguado, I. Rodríguez-Góncer
00088	Real-world Use of Letermovir Prophylaxis for Cytomegalovirus (CMV) Prevention in Non-kidney Transplant Recipients	A. Mughrabi* (Rochester, Minnesota, United States), B. Bisono-Garcia, S. Chesdachai, N. Ranganath, R. Razonable
00089	Real-world administration of maribavir beyond the eight weeks established in the clinical trial	D.

		Martínez-Simón* (Barcelona, Spain), C. Ribera-Puig, M. Bodro, D. Company, J. Esperalba, I. Los Arcos, P. Clèries-Rovira, A. Padullés, N. Sabé Fernández, M. Tuset, O. Len
00090	Prediction of BK Polyomavirus nephropathy in kidney transplantation by measuring neutralizing responses in a large cohort of donor and recipients	M. Solis* (Strasbourg, France), W. Fardi, I. Benotmane, F. Gallais, S. Caillard, S. Fafi-Kremer
00091	Dengue in solid organ transplant recipients	S.I. Galian* (Buenos Aires, Argentina), N. Pujato, N.S. Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustin, G. Werber

SY045	11:00 – 12:00	Hall 2
	1-hour Symposium	
	CLN	
What happens following TB infection?		
Chairs	Catherine Ong (Singapore, Singapore) Sean Wasserman (London, United Kingdom)	

S0137	11:00	Post-TB disease: burden and treatment strategies	Deborah Chong (London, United Kingdom)
S0138	11:30	TB sequelae and fungal infection	Helmut Salzer (Linz, Austria)
Co-organised with: ESCMID Study Group for Mycobacterial Infections (ESGMYC), CPAnet			

YIA	11:00 – 12:00	Hall 3
	Awards	
	PRO	
Young Investigator Award Session		

A001	11:00	Deciphering the pathogenic traits and epidemiological identities of <i>Staphylococcus pseudintermedius</i> : an emerging and underestimated zoonotic pathogen	kechukwu Benjamin Moses (Abakaliki, Nigeria)
A002	11:12	Drugs for Vector-borne Infections: Facts and Fibrillations	Xin Hui Chan (Oxford, United Kingdom)
A003	11:24	Duke criteria for the diagnosis of infective endocarditis in clinical practice: are we there yet?	Matthaios Papadimitriou Oliveris (Sion, Switzerland)
A004	11:36	Finding a place for observational studies in infectious diseases research	Anthony Bai (Kingston, Canada)
A005	11:48	Clearing fungal fog in viral storms: deciphering influenza- and COVID-19-associated pulmonary aspergillosis	Simon Feys (Leuven, Belgium)

SY046	11:00 – 12:00	Hall 5
	1-hour Symposium	
	TRN VAX	
New frontiers in bacterial pathogenesis		
Chairs	Silvio Daniel Brugger (Zurich, Switzerland) Abdou Hachani (Melbourne, Australia)	

S0139	11:00	Bacterial infections and cellular immunity	Charlotte Odendall (London, United Kingdom)
S0140	11:20	Immuno-metabolism in bacterial diseases	Tania Wong (New York, United States)

OS007	11:00 – 12:00	Hall 6
	1-hour Oral Session	
	ANT CLN VAX	
New developments in prophylaxis and treatment of COVID-19		
Chairs	Gölsen Özkaya Sahin (Lund, Sweden) Snjezana Zidovec Lepej (Zagreb, Croatia)	

ESCMID Global 2025 - Programme

00057	<b>Ensirelvir for the prevention of COVID-19 among household contacts: key subgroup analyses of a randomized, double-blinded, placebo controlled post-exposure prophylaxis study, SCORPIO-PEP.</b> <i>Hayden* (Virginia, United States), N. Ohmagari, T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S. Lacey, G. Ichihashi, T. Uehara</i>	
00058	<b>Efficacy of nirmatrelvir/ritonavir on overall COVID-19 related symptoms in immunocompromised adult participants from the EPIC-IC trial</b> <i>R. Mokgokong* (Tadworth, United Kingdom), P. Cislo, E. Tudone, E. Weinstein, J.C. Cappelleri</i>	
00059	<b>COVID-19 patients benefitting from remdesivir for improved survival: a neural network-based approach.</b> <i>T.F. Aiello* (Barcelona, Spain), C. Teijón-Lumbreras, C. García-Vidal, M. Chumbita, M. Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó-Gallo, A. Gallardo-Pizarro, A. Martínez-Urrea, R. Méndez, E. Calbo, M. Ballesterio-Tellez, G. Cuesta-Chasco, M. Marcos, A. Soriano</i>	
00060	<b>Efficacy and safety of sotrovimab vs oral antivirals in omicron waves: a retrospective analysis</b> <i>C. Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N. Coppola</i>	
00061	<b>Pharmacokinetics and immunogenicity of AZD7442 (Tixagevimab/Cilgavimab) in hospitalised COVID-19 patients: results from the DisCoVeRy trial</b> <i>C. Massonnaud* (Paris, France), M. Hites, N. Peiffer-Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader</i>	

OS008	11:00 – 12:00	Hall 7
	1-hour Oral Session	
Advancing Malaria Research: From Molecular Insights to Clinical Challenges		
Chairs	Kamruddin Ahmed (Kota Kinabalu, Malaysia) Giri Shan Rajahram (Kota Kinabalu, Malaysia)	
00062	<b>Influence of second blood meals on <i>Plasmodium vivax</i> development and infectivity in mosquitoes.</b> <i>Bantuchai* (Bangkok, Thailand), W. Nguitragool, J. Sattabongkot, C. Kumpitak</i>	
00064	<b>Severe imported <i>Plasmodium falciparum</i> malaria with hyperparasitaemia: evaluation of predictors for critical disease</b> <i>T. Lingscheid* (Berlin, Germany), J. Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E. Sander, M. Ramharter, F. Kurth</i>	
00065	<b>The current status of <i>Plasmodium falciparum</i> chloroquine resistance transporter gene (K76T) and <i>Plasmodium falciparum</i> multi-drug resistance gene 1 (N86Y) in Cameroon</b> <i>M. Fru* (Buea, Cameroon)</i>	
00066	<b>SOFA score vs WHO severity criteria to guide antimalarial treatment - 10 years of imported malaria cases in a UK tertiary centre reviewed.</b> <i>E. Savory* (Cambridge, United Kingdom), M. Routledge, B. Warne, E. Moore, D. Sparkes</i>	

OS009	11:00 – 12:00	Hall 8
	1-hour Case Session	
Osteoarticular uninvited guests		
Chairs	Tiziana Ascione (Naples, Italy) Jaime Esteban (Madrid, Spain)	
00067	<b>Antibiotic-refractory oligoarthritis in an adolescent caused by <i>Borrelia bavarlensis</i> in Croatia</b> <i>N. Krajcar* (Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak Pažur, S. Roglić, R. Beck, G. Tešović</i>	
00068	<b>Progression of vertebral echinococcosis despite radiotherapy treatment</b> <i>M. González-Sanz* (Madrid, Spain), O. Martín, A. Romero-Alegría, M. Belhassen, S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman, B. Monge Maillo, C. Crespillo-Andújar, M.D.</i>	

00069	<b>Two cases of septic osteoarthritis of <i>Cutibacterium acnes</i> detected by 16S rRNA gene sequencing in immunocompetent adolescents</b> <i>H. Okuno* (Osaka, Japan), K. Shiota, K. Arno</i>	
00070	<b>A UK case of Melioidosis with osteomyelitis two years after geographical exposure</b> <i>C. Darlow* (Liverpool, United Kingdom), L. Swithenbank, R. Taggart, V. Owen, N. Wong, S. Woolley, W.D. Harrison, L. Ratcliffe, J. Lewis</i>	
00071	<b>When Infection Masquerades as Malignancy: A Case of Disseminated <i>Mycobacterium fortuitum</i> complex infection with Mixed Osteoblastic and Osteolytic Lesions and Lymphadenopathy in Anti-IFN-<math>\gamma</math> Immunodeficiency Syndrome</b> <i>N. Hiranburana* (Bangkok, Thailand), S. Khahakaew, K. Meesilpavikkai, M. Satja, G. Suwanpimolkul</i>	

LB001	11:00 – 12:00	Hall 9
	1-hour Oral Session	
Advances in vaccine effectiveness for viral respiratory infections		
Chair	Jean Paul Stahl (Corenc, France)	
L0001	<b>Immunogenicity of JN.1- and KP.2-encoding mRNA COVID-19 vaccines against JN.1 SARS-CoV-2 sublineages in adult participants</b> <i>A. Figueroa* (Cambridge, United States), D. Edwards, K. Johnson, D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt</i>	
L0002	<b>JN.1-adapted vaccine effectiveness against COVID-19 hospitalisation in Europe: a test-negative case-control study using id.DRIVE</b> <i>H.R. Volkman* (New York, United States), L. De Munter, J.L. Nguyen, T.M.P. Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite, S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E. Martro, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M. Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S. Otero-Romero, A. Riva, A. Torres, F. Martinon Torres, L. Jodar, J.M. McLaughlin, K. Bollaerts</i>	
L0003	<b>Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults <math>\geq 65</math> years of age in the United States</b> <i>A. Miles* (New York, United States), J.T. Vietri, S. Rosenstock, H. Li, J. Vojcic, L.R. Grant, A. Randall, B.D. Gessner, P. Balmer, A. Cane, P. Peyrani</i>	
L0004	<b>Safety and immunogenicity of the MERS vaccine, ChAdOx1 MERS, in older adults with and without prior ChAdOx1 exposure</b> <i>D. Jenkin* (Oxford, United Kingdom), E. Sheehan, R. Huq, T. Lambe, S. Gilbert, A.M. Collins, M.N. Ramasamy, A. Mujati, R. Kenneil, N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi, S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O. Mazur, H.T. Belhade, B. Stoilova, D. Pulido-Gomez, H. Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L. Mclellan, O. Hamilton, V. Simpson, J. Court, N. Murphy, M. Farrar, P. Saunderson</i>	
L0005	<b>Vaccination in pregnancy with RSVpreF elicits IgG, IgA and total secretory antibody responses in milk of lactating individuals</b> <i>J. Atwell* (New York, United States), R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan, S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B. Gessner</i>	

SY051	13:30 – 14:30	Hall 1
	1-hour Symposium	
Year in infectious diseases		
Chairs	Nur Benzonana (Istanbul, Türkiye) Evelina Tacconelli (Verona, Italy)	
S0151	13:30	Yoav Keynan (Winnipeg, Canada)
S0152	14:00	Elisa Cordero Matia (Seville, Spain)

ESCMID Global 2025 - Programme

SY053 13:30 – 14:30 Hall 16  
1-hour Symposium

Developing guidelines with AI tools: are they ready for prime time?

Chairs Miranda Langendam (Amsterdam, Netherlands)  
Blin Nagavci (Gjakove, Kosovo)

S0155 13:30 The PROs and CONS of using AI tools for developing guidelinesHolger Schuenemann (Milano, Italy)  
S0156 14:00 AI in action: validated tools for speeding up your systematic reviews and how to use themSara Fernandez (Oslo, Norway)

Co-organised with: ESCMID Guidelines Subcommittee

SY052 13:30 – 14:30 Hall 2  
1-hour Symposium

Exploring children's role in infection spread

Chairs Angelika Berger  
Sanjay Patel (Winchester, United Kingdom)

S0153 13:30 Are children really super-spreaders of respiratory viruses?Emmanuel André (Leuven, Belgium)  
S0154 14:00 Should schools be closed at the start of the next pandemic?Vittoria Colizza (Paris, France)

Co-organised with: European Society of Paediatric Infectious Diseases (ESPID)

EF021 13:30 – 14:30 Arena 1  
ePoster Flash Session

Infections in hemato-oncological hosts: from bacterial to viral

Chair Genovefa Papanicolaou (New York, United States)

E0139 Vancomycin-resistant *Enterococcus faecium* bloodstream infection in patients with hematological malignancy and stem cell transplant: a case-control studyJ. Fung\* (Vancouver, Canada), K. Aldhaheri, C. Nishi, J. Lau, A. Mah, A. Wright, R. Stubbins, M. Charles, S. Belga

E0140 Bacteremia secondary to urinary tract infection in oncology patients: risk factors and impact of multidrug-resistant Gram-negative bacilli.I. Grafia\* (Barcelona, Spain), A. Moll, S.J. Santillá, C. Rodrigo, E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, M. Espasa, D. Marco, S. Fernández, J. Marco-Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Viladot, A. Tuca, P. Puerta-Alcalde

E0141 Rectal carriage of multidrug-resistant organisms and subsequent bloodstream infections in hematologic patients undergoing hematopoietic stem cell transplantation or chimeric antigen receptor T-cell therapyC. Charalampidis\* (Athens, Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. Lazana, C. Chatzidimitriou, A. Zormpa, E. Mastrostamati, I. Grigoropoulos, D. Kavatha, S. Tsiodras, P. Tsigotis, K. Thomas

E0143 The RUSTIC Study: Respiratory Virus Infection in a Contemporary Longitudinal Cohort of Patients with Haematological MalignancyB. Teh\* (Melbourne, Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, P. Kinsella, N. Laundry, J. Wolfe, L. Cooley, M.K. Yong, M.A. Slavin

E0144 Viral respiratory infections in patients with hematological diseases over 10 years: epidemiology and impact on disease severityP. Bono\* (Milan, Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N. Hejazifar, C. Biassoni, G. Giacomel, A. Valzano, M.R. Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti, A. Callegaro, C. Alteri

E0145 Safety and tolerability of SYN-004 in allogeneic

hematopoietic cell transplant (HCT) recipients receiving meropenem (MER) or piperacillin/tazobactam (P/T)E. Dubberke\* (Saint Louis, United States), M. Schroeder, H. Sappington, G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E. Jeremy, M. Keller, A. Bristol, C. Le, S. Connelly, M. Moenk, V. Wacher, M. Kaleko, J. Kuti, M. Olsen

E0146 Standardized gastrointestinal cytomegalovirus (CMV) tissue quantitative-nucleic-acid testing (QNAT) compared to immunohistochemistry in allogeneic hematopoietic cell transplant (HCT) recipientsS. De Aragón De La Cruz\* (Basel, Switzerland), C.S. Walti, N. Khanna, K. Leuzinger, J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J. Vosbeck

E0147 Real-life experience with maribavir for the treatment of cytomegalovirus infection in hematological patients.J. Boan Perez\* (Madrid, Spain), J.M. Sánchez-Pina, C. Aizpurúa, I. Rodríguez-Goncer, F. López-Medrano, R. San-Juan, M. Fernández-Ruiz, E. Aparicio, M. Lizasoain, J.M. Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado

EF022 13:30 – 14:30 Arena 2  
ePoster Flash Session

Syndromic testing is still coming of age

Chair Tommaso Giani (Florence, Italy)

E0148 Bacterial infections of the central nervous system: addressing the diagnostic gap in non- community-acquired meningitisG. Menchinelli\* (Rome, Italy), M. Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis, B. Posteraro, M. Sanguinetti

E0149 Epidemiological surveillance of central nervous system infections through a rapid syndromic testing platformM. Rey\* (Barcelona, Spain), L. Pau, C. Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona

E0150 Impact of Syndromic Panel Implementation on Meningitis/Encephalitis Diagnosis, Antimicrobial Use, Costs, and Hospital Stay in a Regional Australian HospitalS. Subedi\* (Brisbane, Australia), P. Harris, D. Paterson

E0151 Performance evaluation of the NxTAG® GPP Panel for the detection of gastrointestinal pathogens by comparison with current routine methods in Nantes University Hospital.S. Gibaud\* (Nantes, France), L. Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P. Lepape, S. Corvec

E0152 Correct discrimination of Monkeypox virus clades by fast syndromic testingS. Reister\* (Hilden, Germany), L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S. Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla-Cámara, J. Michel, A. Puyskens, F. Van Deursen, D. Lueerssen

E0153 Managing a *Mycoplasma pneumoniae* Outbreak: Impact of Syndromic Panels on Antimicrobial Prescriptions in Pediatric EmergenciesL. Brusca\* (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés-Borrás, G. Santillana-Cernuda, M. Ballester-Tellez, A. Boronat, J. Perez

E0154 Performance of BIOFIRE® FILMARRAY® Pneumonia plus in general population, solid organ transplant recipients and patients with hematologic malignancies – Interim analysisR. Riccardi\* (Bologna, Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P. Viale, M. Giannella

E0155 Impact of the molecular rapid diagnostic panel testing in adjustment of antimicrobial therapy in febrile neutropenic patients with bacteremiaS. Chantharasut\* (Bangkok, Thailand), M. Chayakulkeeree, W. Kamolvit, A. Jitmuang, I. Thaipisuttikul

E0156 BacteREVEAL: Analytical performance and contribution of BioFire® BCID2 and Vitek® REVEAL™ in intensive care patients with Gram-negative bloodstream infectionsC. Roger\* (Nîmes, France), L. Oudiane, M. Benyahia, F. Salipante, A.



ESCMID Global 2025 - Programme

Dubois, L. Muller, J.P. Lavigne, A. Pantel		
EF023	13:30 – 14:30	Arena 3
ePoster Flash Session		
Effective microbiology for the management of sepsis		
Chair Maurizio Sanguinetti (Rome, Italy)		
E0157	Molecular epidemiology of Klebsiella bloodstream infection-causing isolates across England using Nanopore longread-only sequencing: An interim analysis of the NEKSUS studyD. Nagy* (Oxford, United Kingdom), N. Stoesser, S. Lipworth, V. Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones, T. Neksus Study Group, S. Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L. Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown	
E0158	Investigating seasonality of antibiotic resistance associated with <i>E. coli</i> and <i>Klebsiella pneumoniae</i> bloodstream infectionsS. Lipworth* (Oxford, United Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, K. Turner	
E0159	Sensitivity of a host-protein test for microbiologically confirmed bacterial infectionsR. Navon* (Tirat Carmel, Israel), E. Reiner, O. Shaham, A. Neuberger, S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P. Aufderheide	
E0160	Comparative genomics of <i>Klebsiella pneumoniae</i> from gut colonisation and bloodstream infections reveal novel genetic associationsM. Hetland* (Stavanger, Norway), K.L. Wyres, H.B. Cooper, A. Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger, A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr	
E0161	Conventional microbiology vs. conventional microbiology + nucleic acid-based multiplex real-time polymerase chain reaction (MPCR) test kit in septic shock: results of a matched cohort studyG. Sanlidag Isbilen* (Izmir, Türkiye), G. Şanlıdağ İşbilen, B. Akkul, C. Tol, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli, B. Arda, O.R. Sipahi	
E0162	Contribution of <i>Escherichia coli</i> microbiological factors to the presentation as sepsis/septic shock in patients with bacteraemia: a matched case-control studyN. Maldonado* (Seville, Spain), I. López-Hernández, L.E. López-Cortes, P.M. Martínez Pérez-Crespo, A. García-Montaner, M. Alcade-Rico, A. Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á. Pulido-Navazo, C. Labayru Echeverría, A.I. Aller-García, L. Boix-Palop, A. Del Arco-Jiménez, A. Smithson-Amat, J.M. Sánchez-Calvo, C. Natera-Kindelán, J.M. Reguera Iglesias, C. Armíñanzas-Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea-Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T. Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual-Hernández, J. Rodríguez-Baño	
E0163	Simplified and rapid bacterial identification by antimicrobial resistance detection in bacteremia by on-chip multiplexed LAMP.C. Treille* (Saclay, France), K. Perez-Toralla, H. Boutal, X. Garcia Velasquez, L. Pommies, S. Simon, H. Volland	
E0164	Community-onset bloodstream infection among people with oploid use disorders: A twenty-year population-based cohort study in Queensland, Australia.K. Laupland* (Herston, Australia), A. Stewart, F. Edwards, P. Harris, S. Coulter	
E0165	Microbiological diagnosis tools for primary and secondary abdominal aortic infections requiring surgeryS. Soueges* (Lyon, France), A. Blanco, A. Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della-Schiava, U. Huvelle, A. Millon, F. Valour	
EF024	13:30 – 14:30	Arena 4
ePoster Flash Session		
A never-ending evolution of antimicrobial resistance		
Chair Antonio Oliver (Palma De Mallorca, Spain)		

E0166	Gfa, a novel integron-born fosfomycin resistance mechanismN. Kieffer* (Madrid, Spain), L. Ortiz-Miravalles, A. Hipolito, J.A. Escudero	
E0167	Regulons of RamA, RarA and SoxS mediated tigecycline resistance and oxidative stress among <i>in vitro</i> tigecycline resistant evolution trajectory of <i>Klebsiella pneumoniae</i> .X. Wang* (Beijing, China), J. Kuai, Y. Zhao	
E0168	Assessing the impact of altered penicillin binding proteins on susceptibility to novel antimicrobials among clinical isolates of carbapenemase-producing <i>Escherichia coli</i> .C. Tellapragada* (Stockholm, Sweden), P. Jonsson, C. Giske	
E0170	<i>Enterococcus faecalis</i> penicillin-binding protein-4 sequence differences based on penicillin minimum inhibitory concentrationO. Funk* (Brooklyn, United States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S. Brown, J. Cusumano	
E0171	Uncommon genomic rearrangements drive vancomycin resistance in <i>vanB</i> -positive <i>Enterococcus faecium</i> K. Xanthopoulou* (Cologne, Germany), J. Mellüh, R. Arazo Del Pino, L. Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L. Maus, A. Klimka, P.G. Higgins	
E0172	Heteroresistance in <i>Enterococcus faecalis</i> : prevalence and mechanistic insights across clinically relevant antibioticsS. Heidarian* (Uppsala, Sweden), S. Lohsen, A. Gulliaev, K. Hjort, S. Satola, D. I. Andersson	
E0173	Side effects of rifampicin resistance: transcriptome modulation by <i>rpoB</i> mutations in <i>Staphylococcus aureus</i> M. Roch* (Geneva, Switzerland), R. Sierra, C. Colomer Winter, F. Bezrukov, O. Panasenko, A. Guisolon, U. Von Ah, M. Villanueva, P. Redder, K. Kline, J. Prados, W.L. Kelley	
E0174	Novel continuous experimental evolution methodology revealing rapid resistance development and cross-resistanceT. Echelmeyer* (Greifswald, Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H. Fickenschner, G. Maschkowitz, D. Nurjadi, R. Podschun, K. Schaufli, E. Eger	
OS018	13:30 – 14:30	Hall 11
1-hour Oral Session		
Battling the Spore: <i>C. difficile</i> epidemiology and management		
Chairs Nicolas Benech (Lyon, France) Fidelma Fitzpatrick (Dublin, Ireland)		
OO124	Molecular epidemiology and antimicrobial resistome of <i>Clostridioides difficile</i> from private and public healthcare settings in three provinces in South AfricaH. Shirinda* (Pretoria, South Africa), A.M. Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M. Ehlers	
OO125	Screening for <i>Clostridioides difficile</i> colonization at admission and during hospitalizationN. Khanafer* (Lyon, France), S. Bennia, G. Martin-Gaujard, L. Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin, P. Vanhems	
OO126	Revolutionizing CDI treatment: Are shorter antibiotic regimens the futureM. Duricek* (Prague, Czech Republic), J. Benes, K. Halmova	
OO127	Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of <i>Clostridioides difficile</i> infectionE. Rubio-Martín* (Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez Caballero, A.M. Rodríguez Benavente, S. De La Villa, J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez Gómez, E. Calabuig, M. Tasiás, R. Blanes, M.Á. López Zúñiga, J. Rodríguez Granger, P. Merino Amador, A. Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G. Maestro De La Calle, J. Mateo Flores, J.B. Pérez Gilaberte, R.M. Martínez Álvarez, F. Martínez García, N. Cobos-Trigueros, J. Llenas-García, M. Solivella-Rodríguez, L. Ramos Merino, B. Castelo López, M.M.	

ESCMID Global 2025 - Programme

<div>Montero, D. Echeverría-Esnaí, J. López-Contreras, P. Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, A. Muriel García, S. Moreno Guillén, J. Cobo</div>		
00128	<div>Gut phageome profiling in <i>Clostridioides difficile</i> infection and faecal microbiota transplantationC. Chen* (Lausanne, Switzerland), T. Pillonel, J. Schaer, G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine</div>	
OS019	13:30 – 14:30	Hall 12
<div>1-hour Oral Session</div>		
<div>Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Potential</div>		
<div>ChairsMauricio Farfan (Santiago, Chile)Eija Inkeri Könönen (Turku, Finland)</div>		
00129	<div>Multi-omics integrated analysis revealed the key role of <i>Fusobacterium periodonticum</i> in colorectal tumorigenesis by decanoic acid promoting neutrophil chemotaxis.X. Chu* (Beijing, China), Q. Yang</div>	
00130	<div>Exploring the respiratory microbiome in COPD patients: The role of <i>Haemophilus</i> spp. in disease pathogenesisP. Camps-Massa* (Barcelona, Spain), L. Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara-Núñez, F. Tubau, J. Burgos, M. Lopez, A. González-Díaz, C. Ardanuy, M. Domínguez, S. Santos, S. Martí</div>	
00131	<div>Using the in vitro MiGut system to simulate the ulcerative colitis microbiome and post-antibiotic recovery supported by a pre-defined consortium of microbesI. Moura* (Leeds, United Kingdom), W. Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M. Wilcox, N. Kapur, A. Buckley</div>	
00132	<div>Functional characterization of the Brazilian Yanomami microbiome along an urbanization gradient: Insights into the impacts of Westernization on human healthM. Thorp* (Gent, Belgium), C. Callewaert, B. De Pessemier, D. Good, E. Allen-Vergee, L. Paulino, L. Vereecke</div>	
00133	<div>Colonization resistance of the intestinal microbiota to multidrug-resistant bacteria?K. Villageois-Tran* (Bobigny, France), C. Emavivie, H. Skerdi, E.N. Saad, M. Julie, E. Ruppé</div>	
ME055	13:30 – 14:30	Hall 14
<div>Meet-the-Expert</div>		
<div>Long acting injectables to treat and prevent infections: an example from HIV field</div>		
M0159	13:30	Monica Gandhi (Salt Lake City, United States)
M0160	13:42	Pedro Cahn (Buenos Aires, Argentina)
OS020	13:30 – 14:30	Hall 15
<div>1-hour Oral Session</div>		
<div>How to evaluate AMS programs</div>		
<div>ChairsEsther Calbo (Terrassa, Spain)Sabiha Essack (Durban, South Africa)</div>		
00134	<div>Preference-based instrumental variables for estimating the causal effects of antibiotic prescribing decisions in common infections: Assessing potential validity using CPRD dataN. Nguyen* (Oxford, United Kingdom), K. Pouwels, J.V. Robotham, S. Yu, S. Wordsworth</div>	
00135	<div>Novel antibiotic spectrum metrics to quantify the impact of antimicrobial stewardship: a multicentre studyB. Moshy* (London, United Kingdom), R. Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah, B. Gemma, I. Balakrishnan</div>	

00136	Utilizing a weighted-incidence syndromic antibiogram to evaluate antimicrobial therapies and resistance trends in community-acquired infections in a community teaching hospital V. Huang* (Glendale, United States), T. Pham, A. Vogler, H. Chhen, C. Vandenberg	
00137	Capturing days of therapy per days of service as a stewardship tool to identify outliers in prescribing broad-spectrum antimicrobials in the hospital setting A. Hopkins* (Livingston, United States), A. Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime	
00138	Timing of Novel $\beta$ -Lactams vs. Alternatives in Hospitalized Patients with Gram-Negative Infections: Line of Therapy (LoT) Analysis Preliminary findings E. Yucel* (Rahway, United States), J. Min, Y. Wang, M. Vendetti, Y. Emre, R.K. Shields	
ME054	13:30 – 14:30	Hall 3
<div>AMR</div> <div>TRN</div> Meet-the-Expert		
How antimicrobial tolerance impacts polymicrobial biofilm-associated infections		
M0157	13:30	Hans Steenackers (Leuven, Belgium)
M0158	13:42	Brian Conlon (Chapel Hill, United States)
OS017	13:30 – 14:30	Hall 5
<div>CLN</div> 1-hour Case Session		
Bad bacteria		
Chairs		Maristela P. Freire (Sao Paulo, Brazil) Siegbert Rieg (Freiburg, Germany)
00119	Vancomycin Dependent Enterococci: An evolutionary dead end or the ultimate evolution of a superbug R. Gupta (bagga)* (London, Canada), R. Gupta, A. Cabrera, A. Kanyua, F. Almutawa, J. Delpont, K. Kavanoor Sridhar	
00120	Whipple's disease: one of medicine's great imitators S. Kesavan* (Nottingham, United Kingdom), F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos, R. Thomson	
00121	Phage Therapy as a Rescue Treatment for Recurrent <i>Pseudomonas aeruginosa</i> Bontall Infection V. Eiferman* (Paris, France), P.A. Vion, B. Rached, C. Granger, N. Hammoudi, A. Bleibtreu	
00122	A clinical case of <i>Legionella longbeachae</i> pneumonia featuring unique epidemiological features in a major Italian hospital S. Guerriero* (Rome, Italy), M. La Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti, C. Torti	
00123	<i>Francisella tularensis</i> – First autochthonous case in the UK G. Vanstone* (Truro, United Kingdom), A. Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam, A. Ainarozidou	
ME061	14:45 – 15:45	Hall 3
<div>PHEI</div> <div>TRN</div> Meet-the-Expert		
How to use large language models and machine learning for improving One Health		
M0170	14:45	Javier Fernández (Oviedo, Spain)
M0171	14:57	Nicolas Radomski (Teramo, Italy)
Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM), Portuguese Society of Microbiology (SPM)		

ESCMID Global 2025 - Programme

FO063	14:45 – 15:45	Arena 1
PRO		
Open Forum		
Science communication in a noisy world: podcasting and social media in ID/CM		
Chair	Emily G. Mcdonald (Montreal, Canada)	
F0174	14:45	The ID:IOTS guide to creating a successful CM/ID podcast" Callum Mutch (Edinburgh, United Kingdom)
F0175	14:55	Using social media for CM/ID education.Scott Jake (Oakland, United States)
F0176	15:05	Podcasting and social media for antimicrobial stewardship and pharmacyErin McCreary (Pittsburgh, United States)
Co-organised with: CMI Communications Board of Editors		
EF029	14:45 – 15:45	Arena 2
VAX		
ePoster Flash Session		
Vaccination uptake-challenges and opportunities		
Chair	Joanne M. Langley (Halifax, Canada)	
E0195	Electronic nudges to increase influenza vaccination uptake among patients with heart failure: insights from 3 nationwide randomized trials enrolling >2 million patientsN.D. Johansen* (Hellerup, Denmark), M. Vaduganathan, A.S. Bhatt, D. Modin, B.L. Claggett, K.H. Janstrup, C.S. Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, E.L. Dueger, S. Samson, M.M. Loiacono, R.C. Harris, L. Køber, S.D. Solomon, P. Sivapalan, J.U.S. Jensen, T. Biering-Sørensen	
E0196	Psychological Predictors of Influenza Vaccination Intent Among Healthcare Workers in BulgariaP. Velikov* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva, Y. Tcholakov, V. Borisova-Nenov[], D. Ivanov, A. Zasheva, A. Hori	
E0197	Determinants of COVID-19 vaccine uptake in patients with hematologic malignancies: a nationwide cohort studyQ. Hofsink* (Amsterdam, Netherlands), T. Osmenaj, B.I. Lissenberg-Witte, S. Hahné, J. Heijmans, I.S. Nijhof, A. Goorhuis, M.D. Hazenberg, C.E. Rutten, S. Haggenburg, P. Den Tex, A. Dinmohamed, J. Kemmeren, H. De Melker, S. Van Den Hof	
E0199	Inequality in vaccine uptake among children in Denmark in the national childhood vaccination programmeA.C.M. Breschel* (Copenhagen, Denmark), A.V. Søndergaard, S.K. Nørgaard, B. Søborg, P.H. Andersend	
E0200	Prevalence and associated factors of parental refusal rates for routine immunisation: A cross-sectional study in Peshawar, Khyber Pakhtunkhwa, Pakistan-2024M. Hakim* (Hayat Abad Peshawar Kp Pakistan, Pakistan)	
E0201	Shingles Prevalence, Vaccine Awareness, and Acceptance in People Living with HIVD. Yaman* (Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu, D. Gökengin	
E0202	Tick-borne encephalitis vaccine uptake, effectiveness, and impact in Sweden, 2018–2022A. Palmborg* (Stockholm, Sweden), F. Angulo, P. Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar	
E0203	Monkeypox (mpox) vaccination willingness and determinants among people living with HIV (PLWH) in turkeyC. Boşnak* (Altındağ, Türkiye), T.K. Şahin, E. Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal	

EF030	14:45 – 15:45	Arena 3
CLN DX PHEI		
ePoster Flash Session		
Viruses crossing the blood-brain barrier		

E0204	Clinical characteristics and outcome of Herpes simplex virus type 1 and varicella zoster virus encephalitis: A prospective population-based cohort studyL. Duerlund* (Aarhus, Denmark), L. Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G. Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø. Andersen, H. Nielsen, J. Bodilsen	
E0205	Arbovirus associated neurological disease in adults and children in Brazil: a multicentre case-control studyS. Lant* (Liverpool, United Kingdom), R. Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea Carrera, M. Tullius, P. Brasil, C. Miguelote, A. Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim Rodrigues, R. Braga, L. Pamplona, C. Spitz, F. Militao, A. Rosala Hallas, G. Burnside, R. Vivancos, S. Leonhard, L. Rodrigues De Mendonça-Vieira, B. Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R. Franca, A. Bispo, T. Solomon	
E0206	Challenges in managing Central nervous system infections: Battling the Unknown Enemy, West Nile virus vs unknown etiologyC. Marin* (Bucharest, Romania), A. Paun, E. Nedu, S. Tetrarov, S. Lazar, M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu, S.M. Ruta, C.P. Popescu	
E0207	Spatial and temporal profiling of the immune responses induced by Japanese encephalitis virus in a mouse modelZ. Ou* (Shenzhen, China), Z. Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng	
E0208	Intrathecal immunoglobulin synthesis in tick-borne encephalitisS. Grygorczuk* (Białystok, Poland), P. Czapryna, D. Martonik, J. Dunaj-Małyszko, J. Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A. Moniuszko-Malinowska	
E0209	B and T cell responses to Tick-borne Encephalitis VirusN. Mayola Danes* (Stockholm, Sweden), R. Varnaité, N. Mayola Danés, K. Blom, H.G. Ljunggren, S. Gredmark-Russ	
E0210	Enterovirus infections in pediatric central nervous system (CNS) diseases: molecular epidemiology and neuroimaging insightsD. Sharma* (Chandigarh, India), R. Pathania, P. Bhattacharya, M. Gautam, A. Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh	
E0211	Neuroimaging findings and their correlation with autopsy findings: Prospective study on Rabies encephalitisM. Mohata* (New Delhi, India), V. Suri, P. Singh, G.K. Mohi, A. Bhalla, R. Mohindra, R.K. Soni, K. Gupta	
E0212	Toxoplasma gondii IgG Screening and Central Nervous System Complications among People with HIV in the Combination Antiretroviral Therapy Era T. Ou* (New Taipei City, Taiwan, China), T.Y. Tsai, S.H. Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C. Hung	
EF031	14:45 – 15:45	Arena 4
<div><div>ANT</div><div>CLN</div></div> ePoster Flash Session		
AMS around the world: know your data!		
Chair	Eoghan De Barra (Dublin, Ireland)	
E0213	Duration of antibiotic treatment for respiratory tract infections in primary care.C. Llor* (Barcelona, Spain), M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H. Lindberg, I.K. Rebnord, R. Radzeviciene, L. Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk, C. Lionis	
E0214	Antibiotic prescribing for common acute infections in Pakistan - an analysis using IQVIA prescriber healthcare surveysN. Nguyen* (Oxford, United Kingdom), K. Pouwels, M. Sharland, S. Mangla, A. Cook, M. Thorn, P. Stephens	
E0215	Antibiotic prescribing for common acute infections in Egypt - an analysis using IQVIA prescriber healthcare surveysN. Nguyen* (Oxford, United Kingdom), S. Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels, M. Sharland	
E0216	Population based analysis of the impact of Japan's AMR national action plan and the COVID-19 pandemic on antimicrobial prescriptionR. Koizumi*	



ESCMID Global 2025 - Programme

		(Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N. Ohmagari
E0217		<b>Quality of antibiotic prescribing in Portuguese hospitals: a snapshot of the first National Antimicrobial Prescribing Survey.</b> <i>C. Palos*</i> (Lisbon, Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky, P. Sousa
E0218		<b>Evaluating the Impact on 28-day mortality of different empiric AWARe antibiotic treatment strategies for hospital-acquired infections across different hospital settings.</b> <i>C. Lim*</i> (Oxford, United Kingdom), K.B. Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S. Walker, M. Sharland, B.S. Cooper
E0219		<b>Update on WHO's Global antibiotic use surveillance system (GLASS-AMU)</b> <i>B. Huttner*</i> (Geneva, Switzerland), A. Muller, M. Escher, V. Ivanoska, D. Tong
E0220		<b>Harmonisation trajectory of Global-Point Prevalence Survey (Global-PPS) and WHO-PPSA.</b> <i>Versporten*</i> (Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe
E0221		<b>Implementation of prospective audit and feedback strategy in intensive care units: Analysis of antimicrobial prescription patterns in a Guatemalan tertiary care hospital</b> <i>N. Sandoval*</i> (Guatemala, Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa
KN056	14:45 – 15:45	Hall 1
	Keynote Lecture	
	<div>PHEI</div>	
<b>Defending against dengue: global epidemiology and strategies for prevention and control</b>		
Chairs	<i>Anu Kantele</i> (Helsinki, Finland) <i>Carlos Seas</i> (Lima, Peru)	
K0161	14:45	<i>Fernanda Boulos</i> (São Paulo, Brazil)
OS026	14:45 – 15:45	Hall 11
	1-hour Oral Session	
	<div>AMR</div> <div>ANT</div> <div>CLN</div>	
<b>Carbapenem resistance Gram-negatives, what's new in treatment?</b>		
Chair	<i>Maria Milagro Montero</i> (Barcelona, Spain)	
O0180		<b>Ceftriaxone sulbactam disodium EDTA combination(CSE) as a treatment option for carbapenem resistant gram negative bacilli - to be or not to be?</b> <i>Y. Verma*</i> (Hisar, India), K. Narang, D. Bandlish, C. Sharma
O0181		<b>Sulbactam-durlobactam as an effective alternative option against NDM-producing <i>Escherichia coli</i> including cefiderocol and aztreonam-avibactam-resistant isolates in Switzerland</b> <i>C. Le Terrier*</i> (Fribourg, Switzerland), P. Nordmann, A. Delaval, L. Poirel
O0182		<b>Optimising Difficult-to-treat Gram-negative Bacterial Infection Outcomes with Personalised Fosfomycin-Based Combination Therapy Guided by <i>in vitro</i> Antibiotic Combination Testing</b> <i>T. Lim*</i> (Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa
O0183		<b>Management of infections caused by ST308 New Delhi metallo-<math>\beta</math>-lactamase-producing <i>Pseudomonas aeruginosa</i> with <i>in vitro</i>-guided combination antibiotic therapy</b> <i>J. Teo*</i> (Singapore, Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa
O0184		<b><i>In vitro</i> activity of cefepime/enmetazobactam against clinical isolates of <i>Enterobacterales</i> in Portugal: A multicentre retrospective study</b> <i>H. Cruz*</i> (Porto, Portugal), C. Chaves, L. Carneiro
OS027	14:45 – 15:45	Hall 12

AMR

TRN

1-hour Oral Session

Staphylococcus aureus: colonisation, virulence, and persistence

Chair

Stefano Giulieri (Melbourne, Australia)

O0185

The nasal microbiome redefines and predicts Staphylococcus aureus nasal colonisation status

D. Aggarwal\* (London, United Kingdom), K.L. Bellis, B. Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E. Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry, M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L. Sarkane, J. Brennan, S. Duthie, E. Johnson, M. Juhasz, S. Irvine, A. McMahon, A. Van Tonder, E. Di Angelantonio, A. Butterworth, J.A. Geoghegan, J. Danesh, J. Parkhill, S.J. Peacock, E. Harrison

O0186

Development of a Staphylococcus aureus human nasal colonisation model

A. Hachani\* (Melbourne, Australia), B. Tran, E. Cho, R. Guérillot, B. Howden, T. Stinear, E. Vincan

O0187

Selection-free, virulence gene promoter-controlled CRISPR interference system for in vivo pathogenesis study of Staphylococcus aureus- A proof of concept

R. Miah\* (Tromsø, Norway), M. Johannessen, M. Kjos, C. Lentz

O0188

Placebo-controlled study of competitive exclusion using Lactococcus lactis to reduce transmission of LA-MRSA from pigs to humans

B. Duim\* (Utrecht, Netherlands), A. Vlasblom, A. Rittscher-Fogg, R. Rattigan, L. Wajda, D. Crespo-Piazuelo, M. Broekhuizen-Stins, L. Portengen, G. Van Eijden, C. Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A. Zomer, J. Wagenaar

O0189

Rifampicin-induced Staphylococcus aureus persister formation is driven by CodY and oxidative stress level

N. Pordone\* (Lyon, France), J. Guillemot, K. Rodriguez, N. Personnic, E. Botelho-Nevers, P.O. Verhoeven

SY059

14:45 – 15:45

Hall 13

1-hour Symposium

IPC

Value-based syndromic diagnostics in medical microbiology: Pro / Con debate

Chairs

Hege Vangstein Aamot (Lørenskog, Norway)  
Eric Claas (Leiden, Netherlands)

S0166

14:45

Pro: clinical benefit and potential for improved patient outcomes

Kirstine K. Søgaard (Aalborg, Denmark)

S0167

15:15

Con: limitations, costs, and possible overuse of syndromic panels

Gilbert Greub (Lausanne, Switzerland)

Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française

SY060

14:45 – 15:45

Hall 14

1-hour Symposium

IPC

We need to talk about toilets...

Chairs

Stephanie J. Dancer (Glasgow, United Kingdom)  
Juliette Severin (Rotterdam, Netherlands)

S0168

14:45

Infection risks from sanitation engineering

Davey Jones (Bangor, United Kingdom)

S0169

15:15

Ventilation in toilets: how can we improve it?

Michael Gormley (Edinburgh, United Kingdom)

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)

OS028

14:45 – 15:45

Hall 15

1-hour Oral Session

DX

ESCMID Global 2025 - Programme

Unlocking the potential of the human microbiome for clinical diagnostics

<i>Chairs</i>		<i>John W. A. Rossen (Groningen, Netherlands)</i> <i>Maria Vehreschild (Frankfurt Am Main, Germany)</i>
00190		<b>Deep learning-enhanced wellness scores: Advancing gut microbiome-based health predictions</b> <i>O. Nalbantoglu* (Kayseri, Türkiye), A. Gundogdu, B.H. Ermis</i>
00191		<b>Comparison of Second-Generation and Third-Generation Sequencing technologies for 16S rRNA amplicon-based gut microbiome analysis</b> <i>E. Rubio García* (Barcelona, Spain), E. Rubio-García, A. Pulgarin, R. López-Aladid, L. Martínez-Priego, N. Palau, A. Mendoza, R. Isanta, A. Montalbán, J.L. Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. Reig, C. Casals-Pascual</i>
00192		<b>Donor for fecal microbiota transplantation: a challenging research</b> <i>B.S. Orena* (Milan, Italy), M.F. Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E. Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A. Callegaro, L. Cariani</i>
00193		<b>Antibiotic resistance genes diversity and antimicrobial effects in the vaginal microbiome during pregnancy</b> <i>N. Boutouchent* (Rouen, France), S. Kennedy</i>
00194		<b>Distinct gut microbiota and metabolic profiles in brain tumor patients: Bridging microbial insights to CNS oncology</b> <i>A. Gundogdu* (Kayseri, Türkiye), O.U. Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F. Kelestimur, U. Ture</i>

ME062 14:45 – 15:45 Hall 16

ANT CLN

Meet-the-Expert

Untangling the web: antimicrobial dose adjustments in renal impairment

M0172	14:45	<i>Claire Roger (Nimes, France)</i>
M0173	14:57	<i>Isabel Spriet (Leuven, Belgium)</i>
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Critically Ill Patients (ESGCIP)		

SY057 14:45 – 15:45 Hall 2

ANT CLN

1-hour Symposium

Macrolides in community-acquired pneumonia: therapeutic necessity or path to overuse?

<i>Chairs</i>		<i>Marc J.M. Bonten (Utrecht, Netherlands)</i> <i>Karin Thursky (Carlton, Australia)</i>
---------------	--	---

S0162	14:45	<b>Pro: maximising outcomes with evidence-based use</b> <i>Evangelos Giamarellos-Bourboulis (Athens, Greece)</i>
S0163	15:15	<b>Con: the risks of routine (over)use</b> <i>Aurélien Dinh (Garches, France)</i>

SY058 14:45 – 15:45 Hall 4

VAX

1-hour Symposium

Top papers in transplant ID

<i>Chairs</i>		<i>Nicolas Mueller (Zurich, Switzerland)</i> <i>Alessandra Mularoni (Palermo, Italy)</i>
---------------	--	---

S0164	14:45	<b>Top 10 papers in infections in SOT</b> <i>Patricia Munoz (Madrid, Spain)</i>
S0165	15:15	<b>Top 10 paper in infections in HCT and cellular therapy</b> <i>Joshua Hill (Seattle, United States)</i>

OS025 14:45 – 15:45 Hall 5

1-hour Oral Session

DX IPC

Bacterial battles: a paediatric perspective on infections and interventions

<i>Chairs</i>		<i>Angelika Berger</i> <i>Julie Toubiana (Paris, France)</i>
---------------	--	---

00175		<b>Strong Alignment Between National Standard Treatment Guidelines and WHO AWaRe Book Recommendations for Primary Care Pediatric Infections</b> <i>D. Dona* (Padova, Italy), D. Donà, G. Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S. Mathur, M. Sharland, S.M.R. Esposito</i>
00176		<b>Correlation between antibiotic consumption and digestive colonization with multidrug-resistant <i>Enterobacteriales</i> in a paediatric haematology department</b> <i>S. Frigui Ep Oueslati* (Tunis, Tunisia), N. Fitouri, S. Frigui, Y. Chebbi, I. Fezaa, M. Ouederni, C. Drira, W. Achour</i>
00177		<b>Interleukin-6 as a diagnostic biomarker for sepsis in neonates, children and pregnant women – a real-world cohort study</b> <i>Sean Olann Whelan (Dublin, Ireland)</i>
00178		<b>Impact of rapid diagnostic stewardship interventions to reduce blood culture utilization in a pediatric medical center</b> <i>E. Vaugon* (Los Angeles, United States), C. Costales, T. Barter, L. Posch, E. Orgel, J. Dien Bard</i>
00179		<b>Infective endocarditis: A Decade of Experience at a Tertiary Pediatric Care Centre</b> <i>M. De Luca* (Rome, Italy), R. Iacobelli, S. Samperi, S. Mercadante, L. Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti</i>

EW071 16:15 – 18:15 Hall 15

PRO

Educational Session

The rare art of writing scientific articles: from conception to submission

<i>Chairs</i>		<i>Marlieke De Kraker (Geneva, Switzerland)</i> <i>Mical Paul (Haifa, Israel)</i>
---------------	--	--

W0205	16:15	<b>Expressing yourself correctly: writing tips</b> <i>Angela Huttner (Geneva, Switzerland)</i>
W0206	16:35	<b>Constructing your manuscript for an original article</b> <i>Jesús Rodríguez-Baño (Seville, Spain)</i>
W0207	16:55	<b>The use of artificial intelligence tools for writing articles: what to do and not to do</b> <i>Erlangga Yusuf (Rotterdam, Netherlands)</i>
W0208	17:15	<b>Selecting the best journal for my manuscript</b> <i>Andre Kalil (Omaha, United States)</i>

Co-organised with: CMI Board of Editors

SY069 16:15 – 18:15 Hall 16

TRN

2-hour Symposium

Controlled human infection models

<i>Chairs</i>		<i>Frederick Hayden (Charlottesville, United States)</i> <i>Nikolai Siemens (Greifswald, Germany)</i>
---------------	--	--

S0197	16:15	<b>Updates on the dengue human infection model</b> <i>Kirsten Lyke (Baltimore, United States)</i>
S0198	16:45	<b>CHIM in endemic countries</b> <i>Melissa Kapulu (Kilifi, Kenya)</i>
S0199	17:15	<b>Controlled human infection models of parasitic infections</b> <i>Meta Roestenberg (Leiden, Netherlands)</i>
S0200	17:45	<b>Controlled human infection models of non-typhoidal <i>Salmonella</i></b> <i>Malick Gibani (London, United Kingdom)</i>

Co-organised with: British Infection Association (BIA)

ESCMID Global 2025 - Programme

EF033	16:15 – 17:15	Arena 2
ePoster Flash Session		
AMR ANT CLN		
Current treatment options for invasive fungal infections		
Chair	Andreas H. Groll (Münster, Germany)	
E0232	The paediatric European Confederation of Clinical Mycology (ECMM) Quality (paed-EQUAL) Score for the management of candidaemia in children and neonatesZ.D. Pana* (Nicosia, Cyprus), A.H. Groll, A. Bal, R. Sprute, F. Carlesse, S. Mellinghoff, S. Butzer, D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A. Marek, U. Ristau-Schäfer, O. Cornely	
E0233	Prevalence rate, species distribution and antifungal susceptibility of bloodstream infections caused by rare yeasts of the Saccharomycetales order documented in 28 Brazilian medical centersC. Palamin Buonafine* (São Paulo, Brazil), C.P. Buonafine, A.E. Dos Santos, L.M. Favarello, R.C. Cognialli, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T. Guimarães, T.C. Sukiennik, F. Carlesse, P.T. Castro, C.C. Baqueiro, E.C. Francisco, A.L. Colombo	
E0234	Rezafungin showed high <i>in vitro</i> activity and very low resistance rate against a collection of yeasts causing fungaemia in patients admitted to a tertiary hospital in Madrid from 2014 to 2024J. Guinea* (Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, P. Muñoz	
E0235	Posaconazole Drug-Drug Interaction Potential is Similar Across BodyweightR.E. Wishko* (Rahway, United States), P. Kothare, T.J. Bateman, M.G. Johnson, A. Stoch	
E0236	Phase 2, open-label, non-comparative clinical trial evaluating the safety and efficacy of posaconazole in paediatric patients 2 to <18 years old with invasive aspergillosisH. Kang* (Seoul, Korea, Republic of), A.C. Arrieta, C. Dhooze, A. Kelemen, M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassís, S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H. Waskin, M.G. Johnson	
E0237	Activity of manogepix against a worldwide collection of mould isolates from 2023M. Winkler* (North Liberty, United States), S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira	
E0239	<i>Candida auris</i> displays an inoculum effect with multiple antifungal drug classesR. Ben-Ami* (Tel Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi	
E0240	<i>In vitro</i> oloroform activity against <i>Aspergillus</i> spp clinical isolates collected as part as two national surveys on azole resistance conducted in Spain (ASPEN II and III)J. Guinea* (Madrid, Spain), P. Escribano, J. Moraga, A. Gomez, P. Muñoz	
EF034	16:15 – 17:15	Arena 4
ePoster Flash Session		
AMR IPC		
Surgical site infections: epidemiology, risk factors, and prevention strategies		
Chair	Trisha Peel (Melbourne, Australia)	
E0241	Incidence of Surgical Site Infections (SSIs) from the automated patient-based surveillance system, SPICMI, FranceP. Astagneau* (Paris, France), B. Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat-Trannoy, J. Auraix, K. Lebascle	
E0242	Beta-lactam versus non-beta-lactam antimicrobial prophylaxis and its association with the surgical site infection rate, a nationwide cohort study with 348 793 patientsS. Largiadèr* (Lucerne, Switzerland), D. Berthod, A. Widmer, N. Troillet, C. Perdríeu, S. Harbarth, R. Sommerstein	
E0245	<i>Cutibacterium</i> species in Neurosurgical Infections: Not Such a "Cute" Pathogen After AllJ. Donnelly* (Dublin, Ireland), B. Dinesh, S. O'donnell	
E0246	The polymicrobial nature of wound infections in an emergency orthopaedic ward in Northern Nigeria - implications for treatment and patient outcomeK.	

E0247	Efficacy of Octenidine Dihydrochloride Versus Chlorhexidine Gluconate Solutions in Reducing Surgical-Site Infections in Total Hip and Knee Arthroplasty: A Comparative AnalysisA. Abialeovich* (Beer Sheva, Israel), V. Benkovich, G. Benkovich	
E0249	Impact on rates of surgical site infection of requiring pre-authorization of surgical antibiotic prophylaxis choice and post-operative antibiotic dosesC.M. Villavicencio* (Taguig, Philippines), M.C. Hufano, R.R. Gabunada, Z. Alano	
SY067	16:15 – 18:15	Hall 11
2-hour Symposium		
PHEI		
STIs: an ongoing crisis		
Chairs	Dagmar Heuer (Berlin, Germany) Tomislav Mestrovic (Varazdin, Croatia)	
S0189	16:15	STI treatment options are running out due to AMRMagnus Unemo (Örebro, Sweden)
S0190	16:45	Genomic surveillance of <i>Neisseria gonorrhoeae</i> strainsPetra Wolffs (Maastricht, Netherlands)
S0191	17:15	Evolutionary insights into syphilis and <i>Treponema pallidum</i> Mathew Beale (Hinxton, United Kingdom)
S0192	17:45	Challenges in chlamydial STI infectionsCecile Bebear (Bordeaux, France)
Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie		
SY068	16:15 – 18:15	Hall 12
2-hour Symposium		
CLN DX VAX		
Tick-borne encephalitis: contemporary diagnosis and management		
Chairs	Joanna Maria Zajkowska (Białystok, Poland) Dace Zavadskā (Riga, Latvia)	
S0193	16:15	Tick-borne encephalitis: immune response and clinical experienceSara Gredmark Russ (Stockholm, Sweden)
S0194	16:45	TBE immune responses and vaccine effectivenessKarin Stiasny (Vienna, Austria)
S0195	17:15	NS1 antibodies: diagnostics and screening of seroprevalence of TBE virus infectionGerhard Dobler (Munich, Germany)
S0196	17:45	Treatment for TBE: where do we stand?Daniel Ruzek (Brno, Czech Republic)

LB006	16:15 – 18:15	Hall 13
2-hour Oral Session		
The Trial Run: recent trials on S. aureus bacteraemia management		
Chairs	Julia Anna Bielicki (London, United Kingdom) Vance Fowler (Durham, United States)	
L0031	16:15	Introduction, Julia Anna Bielicki (London, United Kingdom), Vance Fowler (Durham, United States)
L0032	16:20	Description of SNAP trial
L0033	16:30	Benzylenicillin versus (flu)cloxacillin for the treatment of penicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial of the S. aureus network adaptive platform (SNAP)S. Tong* (Melbourne, Australia), S. Aureus Network Adaptive Platform Trial Group
L0034	16:45	Cefazolin versus (flu)cloxacillin for the treatment of penicillin-resistant, methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia: a randomised controlled trial within the S. aureus network adaptive platform (SNAP)J. Davis* (Newcastle, Australia), S. Aureus Network Adaptive Platform Trial Group



ESCMID Global 2025 - Programme

L0035	17:00	<b>Cloxacillin versus cefazolin for methicillin-susceptible <i>Staphylococcus aureus</i> bacteraemia (CloCeBa): a randomised, controlled, non-inferiority trial</b> <i>X. Lescure*</i> (Paris, France), <i>F. Vandenesch, X. Duval, S. Tubiana, C. Burdet, N. Saidani, A. Lemaigien, E. Canoui, L. Surgers, M. Esposito Farese, V. Le Moing, P. Tattevin</i>
L0036	17:15	<b>Trial Discussion</b> <i>Julia Anna Bielicki</i> (London, United Kingdom)
L0037	17:30	<b>Trial Discussion</b> <i>Vance Fowler</i> (Durham, United States)
L0038	17:45	<b>Open Discussion and Q&amp;A</b>

OS032	16:15 – 18:15	Hall 14
	2-hour Oral Session	
	CLN DX PHEI	
Unraveling respiratory viruses, 2025		
Chairs	<i>Eeva Broberg</i> (Solna, Sweden) <i>Florian Krammer</i> (New York, United States)	

O0222		<b>Human metapneumovirus infections in hospitalized adults compared to respiratory syncytial virus and influenza infections over ten years in France</b> <i>P. Loubet*</i> (Nîmes, France), <i>S. Guitton, R. Simon, L. Lefrançois, L.B. Luong Nguyen, P. Vanhems, F. Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. Lagathu, V. Foulogne, N. Houhou-Fidhou, A.S. L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay</i>
O0223		<b>Unveiling animal susceptibility to influenza viruses (H1N1(pdm09) and H5N1 HPAIV) using animal-derived respiratory organoids</b> <i>F. Tarrés-Freixas*</i> (Bellaterra, Spain), <i>G. Ceada, N. Navarro, M. Pérez-Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Moreno, C. López, J. Segalés, N. Majó, K. Kochanowski, J. Vergara-Alert</i>
O0224		<b>Exploring the impact of acute lung hypoxia on CD8 T cell phenotypes following severe influenza infection</b> <i>B. Huckestein*</i> (Memphis, United States), <i>P. Thomas</i>
O0225		<b>Virological characterisation of RSV after Nirsevimab Breakthrough Infections in a Multicentre Observational Real-world Study in France</b> <i>S. Fourati*</i> (Créteil, France), <i>A. Reslan, J. Bourret, Y. Rahou, L. Chollet, S. Pillet, P. Tremieux, N. Candace Dosso, E. Gault, M. Salmona, B.M. Imbert, A. Mirand, S. Larrat, A. Moisan, S. Marot, A. Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, A. Henry, V. Stephan, S. Brichler, V. Avettand-Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Deroche, M.C. Jaffar, L. Mouna, C. François, A. Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C. Rodriguez, G. Dos Santos, J. Buchrieser, O. Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, M.A. Rameix-Welti</i>
O0226		<b>Baseline immunity to highly pathogenic avian influenza viruses in a healthcare worker cohort</b> <i>C. Geurts Van Kessel*</i> (Rotterdam, Netherlands), <i>M. Power, W. Rijnink, L. Gommers, T. Bestebroer, W. Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van Nierop, R. Sikkema, A. Grifoni, A. Sette, M. Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Geurtsvankessel</i>
O0227		<b>Impact of reinfection on post-acute sequelae of COVID-19 over multi-organ systems</b> <i>J. Tan*</i> (Singapore, Singapore), <i>J.T. Lim, L.E. Wee, C. Chiew, B. Ong, D. Lye</i>
O0228		<b>Clinical and economic burden of respiratory syncytial virus in adults with acute respiratory infections – a Danish nationwide cohort study</b> <i>Stanislava Bratkovic</i> (Copenhagen, Denmark)
O0229		<b>The burden of respiratory syncytial virus in children &lt;3 years old presenting to primary, secondary and tertiary care in England: report from the STOP RSV prospective surveillance study</b> <i>E. Carter*</i> (Liverpool, United Kingdom), <i>H. Hill, D. Ferreira, A. Collins, C. Solórzano, L. McEllan, L. Kerruish, F. Fyles, S. Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. Crozier, P. Saunderson, R. Kramer, M. Bangert, N. Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J.</i>

O0230		<b>Targeted metagenomic sequencing of influenza, RSV, and symptomatic respiratory infections from UK healthcare workers</b> <i>M. Knoll*</i> (Hinckley, United Kingdom), <i>L. Findlater, B. Katie, J. Wagner, T. Diego, D. Rajan, S. Frances Field, S. Thurston, A. Wong, B. Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin, B. Blane, Y.L. Huang, K. Howe, M. Forbes, K. Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick-Kretschmer, B. Dave, T. Maddison, S. Hopkins, S. Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison</i>
-------	--	--

SY064	16:15 – 18:15	Hall 2
	2-hour Symposium	
	AMR ANT	
PK/PD to avoid emergence of resistance?		
Chairs	<i>Anne-Grete Märtsen</i> (Leiden, Netherlands) <i>Joseph Meletiadis</i> (Athens, Greece)	

S0177	16:15	<b>PK/PD and antibacterial therapy</b> <i>Dolors Soy-Muner</i> (Barcelona, Spain)
S0178	16:45	<b>PK/PD and antifungal therapy</b> <i>Roger Brüggemann</i> (Nijmegen, Netherlands)
S0179	17:15	<b>PK/PD and antiviral therapy</b> <i>Joe Standing</i> (London, United Kingdom)
S0180	17:45	<b>PK/PD considerations in anthelmintic treatment</b> <i>Jennifer Keiser</i> (Allschwil, Switzerland)

EW070	16:15 – 18:15	Hall 3
	Educational Session	
	AMR CLN DX	
Malaria: when the drugs don't work Management of treatment failure in non-endemic countries		
Chairs	<i>Laura Nabarro</i> (London, United Kingdom) <i>Caroline Rönnerberg</i> (Stockholm, Sweden)	

W0201	16:15	<b>Malaria in the non-endemic setting: who to treat as an outpatient and how to detect treatment failure</b> <i>Emmanuel Bottieau</i> (Antwerp, Belgium)
W0202	16:35	<b>Malaria resistance mutations in the non-endemic setting: role of genomic surveillance</b> <i>Anna Rosanas Urgell</i> (Antwerp, Belgium)
W0203	16:55	<b>How to manage <i>Plasmodium Knowlesi</i> infection</b> <i>Giri Shan Rajahram</i> (Kota Kinabalu, Malaysia)
W0204	17:15	<b>Epidemiology and control of <i>Plasmodium Knowlesi</i></b> <i>Kimberly Fornace</i> (Singapore, Singapore)

Co-organised with: British Infection Association (BIA)

SY065	16:15 – 18:15	Hall 4
	2-hour Symposium	
	AMR	
Gram-positives, are they still going?		
Chairs	<i>Diederik Bathoorn</i> (Groningen, Netherlands) <i>Stefania Stefani</i> (Catania, Italy)	

S0181	16:15	<b>The vanco chronicles: enterococci's global journey</b> <i>Guido Werner</i> (Wernigerode, Germany)
S0182	16:45	<b>Pitfall in susceptibility testing of Gram-positives</b> <i>Helena Zemlickova</i> (Prague, Czech Republic)
S0183	17:15	<b>Drivers for daptomycin and linezolid resistance in Gram-positives</b> <i>Glen Carter</i> (Melbourne, Australia)
S0184	17:45	<b>What is new in treatment against MDR Gram-positives?</b> <i>Alex Soriano</i> (Barcelona, Spain)

SY066	16:15 – 18:15	Hall 5
	2-hour Symposium	
	CLN DX	

ESCMID Global 2025 - Programme

Biomarker testing to manage respiratory infections in primary care in low resource settings

Chairs		Sonia Lewycka (Hanoi, Vietnam) Heiman Wertheim (Nijmegen, Netherlands)
S0185	16:15	The Vietnamese experience with CRP testing in the community settingThi Thuy Nga Do (Ha Noi, Vietnam)
S0186	16:45	The Nigerian experience with CRP testing in the community settingAugustine Onwunduba (Awka, Nigeria)
S0187	17:15	CRP testing in diagnosing tuberculosis in Zambia and South AfricaHelen Ayles (Lusaka, Zambia)
S0188	17:45	The health economics of CRP testing in LMICs Yoel Lubell (Bangkok, Thailand)

EF035	17:15 – 18:15	Arena 1
ePoster Flash Session		

Genomics in pathogen surveillance

Chair		Vitor Borges (Lisbon, Portugal)
E0250		Genomic Surveillance of Invasive Group A Streptococcus in Argentina’s 2023 Epidemic: Unveiling Hypervirulent emm1 Lineages and Pediatric emm12 BurdenL. Cipolla* (Buenos Aires, Argentina), A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto
E0251		Understanding the population structure of Moraxella catarrhalis using core-genome multilocus sequence typingI. Yassine* (Oxford, United Kingdom), K.A. Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel, A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J. Maiden, M.P. Nicol, A.B. Brueggemann
E0252		Impact of the COVID-19 pandemic on the Streptococcus pyogenes clones causing adult invasive infectionsM. Ramirez* (Lisbon, Portugal), A. Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt, M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For The Study Of Streptococcal Infections
E0253		Unveiling the Hidden Complexity of Providencia: Genomic Insights into Species Reclassification and Antibiotic ResistanceX. Dong* (Hangzhou, China)
E0254		Genomic description of outbreak of VIM-1 carrying Enterobacter in Switzerland suggests plasmid transmission between sequence typesH. Seth-Smith* (Zurich, Switzerland), M. Greutmann, C. Beckmann, E. Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin-Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte, L. Poirel, P. Nordmann, A. Egli
E0255		Genomic epidemiology of Klebsiella pneumoniae bloodstream infections in a german tertiary centre: increased virulence in carbapenem-resistant strainsL. Knegendorf* (Hannover, Germany), M. Lindenberg, C. Baier, J. Erdmann, S. Häußler, D. Schlüter
E0256		Phylogenetic mixing and undetected circulation of multiple Candida auris lineages following recognition of imported cases in Italy V. Di Pilato* (Genoa, Italy), E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G. Daniele Roberto, M. Mikulska, B. Matteo, M. Anna
E0257		Using Long-Read Sequencing for Core Plasmid Multilocus Sequence Typing to Investigate Plasmid Relationships Among Bacterial Species in German Hospital WastewaterA.K. Bari* (Groningen, Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, T.T. Severs, M.J. Cardoso, M. Savin
E0258		Screening for rectal colonization with multidrug-resistant pathogens: usage of rapid metagenomic long-read technologyS. Purushothaman* (Zurich, Switzerland), A.M. Rooney, S. Moser, A. Egli

EF036	17:15 – 18:15	Arena 3
ePoster Flash Session		

Heads up! CNS Infections

Chair	Jacob Bodilsen (Aalborg, Denmark)
-------	-----------------------------------

E0259		Central Nervous System Involvement by Mycobacterium avium Complex in Advanced HIV: A Rare and Underdiagnosed ChallengeE. Sienra Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A. Camiro Zuñiga, D.H. Martinez Oliva, A. Llamas Lopez, A.P. Rodriguez Zulueta
E0260		Acute disseminated encephalomyelitis following bacterial meningoencephalitis – Two Case reports & Review of LiteratureM. Priyadarshi* (Delhi, India), M. Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R. Bhatia
E0261		Streptococcus equi Subspecies zooepidemicus Endocarditis and Meningitis in a 62-Year-Old Patient: A Case Report and Literature reviewD. Chemello* (Modena, Italy), G. Franceschi, S. Alessandra, B. Andrea, S. Mario, M. Marianna, M. Cristina
E0262		Breaking barriers: meropenem-vaborbactam as a game-changer for KPC central nervous system infectionsF. Prativiera* (Udine, Italy), S. Giuliano, S. Flammini, J. Angelini, P.G. Cojutti, C. Tascini
E0263		Multidrug-Resistant Klebsiella pneumoniae Meningitis in the Absence of Intracranial Devices: A Case ReportM. Chumbita* (Barcelona, Spain), E. Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A. Soriano
E0264		Triple Threat: Sequential Meningitis Infections in an Immunosuppressed Patient with Morganella morganii, Acinetobacter baumannii, and Vancomycin-resistant Enterococcus faeciumY. Çakır Kıymaz* (Sivas, Türkiye), Y. Çakır Kıymaz, E. Kıymaz, Z. Bulut, S.A. Büyüktuna, N. Elaldi
E0265		Invasive pulmonary Arthrographis kalrae infection with cerebral abscesses in an immunocompromised childB. Winkel* (Utrecht, Netherlands), J. Jans, M. Luesink, R.J. Nievelstein, F. Hagen, J. Buil, T. Wolfs, T. Van Der Bruggen
E0266		Treatment of herpes simplex encephalitis with the helicase–primase inhibitor pritelivir in an immunocompromised patientA. Birkmann* (Wuppertal, Germany), C. Lueck, C. Rautenberg, S. Bonsmann, A. Marini, M. Sumner, T. Schroeder, S. Voigt
E0267		A case of influenza A (H1N1) encephalitis: Rare neurological implication in a healthy adultN.K. Midha* (Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D. Kumar, G.K. Bohra

Sunday, 13 April 2025

SY075	08:30 – 10:30	Hall 15
2-hour Symposium		

Diphtheria: from re-emergence to vaccine strategies

Chairs		Helena Seth-Smith (Zurich, Switzerland) Julie Toubiana (Paris, France)
S0221	08:30	Diphtheria: from clinical picture to medical managementRegina Oladokun (Oyo, Nigeria)
S0222	09:00	The epidemiology of diphtheria worldwide over the last half-century: more than one comebackAndreas Hoefer (Solna, Sweden)
S0223	09:30	There’s more than one toxigenic Corynebacterium: the current genomics landscape of diphtheria-associated strainsSylvain Brisse (Paris, France)
S0224	10:00	Diphtheria vaccination: a reappraisal Gayatri Amirthalingam (London, United Kingdom)

Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Vaccine Study Group (EVASG)

EF039	08:30 – 09:30	Arena 1
ePoster Flash Session		

ESCMID Global 2025 - Programme

Novel approaches to antiviral therapy		
Chair	Pinyo Rattanaumpawan (Bangkok, Thailand)	
E0288	Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infectionJ. Pitts* (Foster City, United States), J.L.R. Zamora, S. Manhas, T. Aeschbacher, J. Chan, V. Cutillas, V. Nair, N. Riola, A. Vijapurapu, M. Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S. Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H. Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V. Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T. Cihlar, S. Fletcher, J. Bilello	
E0289	EDP-323, a first-in-class, oral, RSV L-protein inhibitor reduces disease severity (respiratory mucus production) and accelerates viral clearance in a human viral challenge studyJ. Devincenzo* (Watertown, United States), A. Ahmad, S. Chen, B. Löndt, A. Mann, J. Mori, A. Catchpole, S. Rottinghaus	
E0290	A Combined <i>In Silico</i> and <i>In Vitro</i> Pipeline for Optimizing Nanobodies Targeting Surface Proteins of Pathogens: Applications to SARS-CoV-2, WNV, and Influenza A VirusC.L. Pierri* (Bari, Italy), G.C.M. Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba, V. Scaglione, D.I. De Luca, F. Mastropirro, S. Spadone, L. Guerra, M. Volpicella, A. De Grassi	
E0291	Bemnifosbuvir and Remdesivir exhibit potent antiviral activity against tick-borne encephalitis virus <i>in vitro</i> D. Grandgirard* (Bern, Switzerland), S. Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib	
E0292	Combinations of antiviral drugs demonstrating synergistic inhibition of multiple respiratory RNA virusesS. Ellis* (London, United Kingdom), A.I. Jacobs, M. Woodall, S. Zhang, J.F. Standing, J. Breuer	
E0293	The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: Interim results from a Phase 1a/1b study in healthy participantsA. Gaggar* (South San Francisco, United States), E. Gane, C. Schwabe, G. Wang, J. Liu, S. Knox, K. Kitrinos, K. Zomorodi	
E0294	Efficacy of ganciclovir against CMV infection is dependent on treatment initiation timeL. Sudarsono* (Leiden, Netherlands), X. Liu, J.G.C. Van Hasselt, A.G. Mårtson	
E0295	Efficacy of molnupiravir and baloxavir against influenza A H1N1 infection <i>In vitro</i> and <i>In vivo</i> D. Liu* (Hong Kong, Hong-Kong SAR, China), K.Y. Leung, R. Zhang, Y. Fan, K.H. Chan, F.N.I. Hung	
E0296	Human defensin derived peptide showing broad antiviral activity against human adenovirusesX. Wang* (Hongkong, China), H. Zhao	

EF040	08:30 - 09:30	Arena 3
ePoster Flash Session		

New frontiers in parasitic disease and migrant health research

E0298	Targeting metabolic bioenergetics: the 'Achilles' heel' of <i>Leishmania</i> D. Sarkar* (Kolkata, India)	
E0299	Leishmaniasis in Southern Alicante (Spain): what is the new patient profile?M.D. Hernández Rabadán* (Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez López, D. López Parra, J. Llenas García	
E0300	<i>Schistosoma haematobium</i> infection is associated with oncogenic gene expression in cervical mucosa, with enhanced effects following treatmentAnna Mertelsmann (Zürich, Switzerland)	
E0301	Associations between water and sanitation service, risk of intestinal schistosomiasis, infection intensity, and liver fibrosis in selected households living near Lake Albert: a descriptive cross-sectional study?G. Lam* (London, United Kingdom), D. Dee, A. Edielu, E. Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P.	

Mawa, J. Friedman, A. Bustinduy		
E0302	Schistosomiasis detected by Screening of sub-Saharan African Unaccompanied Minor Refugees in Berlin between 2023 and 2024G. Equihua Martinez* (Berlin, Germany), A.K. Lindner, M.C. Moreno-Del Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T. Geppert, F. Mockenhaupt, B. Kampmann, F. Olgemöller	
E0303	NADPH oxidase of the mosquitoes and the antioxidant genes repertoire of the bacteria coordinate mosquito-bacteria interaction in midgutB. Song* (Kowloon, Hong-Kong SAR, China), J. Zeb, N. Buchon, O. Sparagano, P. Butaye	
E0304	Molecular detection and sequencing of the genes encoding the predicted enzymes; Amidase, NADH ubiquinone oxidoreductase, and sodium neurotransmitter symporter in <i>Onchocerca volvulus</i> A. Acheampong* (Sunyani, Ghana), J. Larbi, P.C. Kudzordzi, P. Nyarko, K.B. Otabil	
E0305	Tuberculosis outcomes among International migrants living in Europe compared to the non-migrant population: a systematic review and meta-analysisG. Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R. Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di Franco, M. Affronti, E. Piccione, G. Gualano, F. Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F. Di Gennaro	

EW079	08:30 - 10:30	Hall 11
Educational Session		

New guidelines for management of brain infections		
Chairs	Jacob Bodilsen (Aalborg, Denmark) Kartika Maharani (Jakarta, Indonesia)	
W0237	08:30	Tuberculous meningitis: what can we learn from the first global guidelines?Joseph Donovan (Ho Chi Minh City, Vietnam)
W0238	08:50	WHO guidelines on bacterial meningitis: change of clinical practice?Matthijs Brouwer (Amsterdam, Netherlands)
W0239	09:10	ESCMID encephalitis guidelines 2024: what's new?Tom Solomon (Liverpool, United Kingdom)
W0240	09:30	WHO guidelines for cryptococcal meningitis: success stories and barriers to implementationNelesh Govender (Johannesburg, South Africa)
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)		

SY073	08:30 - 10:30	Hall 12
2-hour Symposium		

Proxy indicators: bridging the gap between surveillance and antimicrobial stewardship		
Chairs	Bhanu Sinha (Groningen, Netherlands) Annelies Verbon (Bosch En Duin, Netherlands)	

S0213	08:30	A broad spectrum of possibilities: spectrum scores as a unifying metricCéline Pulcini (Nancy, France)
S0214	09:00	Proxy indicators to estimate appropriateness of antibiotic prescriptionsDiane Ashiru-Oredope (London, United Kingdom)
S0215	09:30	How to bridge the gap between surveillance and antimicrobial stewardshipMark G. J. De Boer (Leiden, Netherlands)
S0216	10:00	Health economics, surveillance and antimicrobial stewardshipZhu Nina Jiayue (London, United Kingdom)
Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID Education Subcommittee, International Society for Infectious Diseases (ISID)		

SY074	08:30 - 10:30	Hall 13
-------	---------------	---------



ESCMID Global 2025 - Programme

CLN IPC

2-hour Symposium

Difficile to treat: advanced management strategies in difficult to treat CDI

Chairs

Frédéric Barbut (Paris, France)

Kerrie Davies (Leeds, United Kingdom)

S0217

08:30

Severe CDI: when standard protocols fail

Hynek Bartos (Prague, Czech Republic)

S0218

09:00

Therapies for complicated CDI

Emma Bishop (Clayton Vic, Australia)

S0219

09:30

Recurrent CDI: Breaking the cycle

Andrea Marino (Catania, Italy)

S0220

10:00

Live biotherapeutic products for Clostridioides difficile infection

Simon Goldenberg (London, United Kingdom)

Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)

OS038	08:30 – 10:30	Hall 14
2-hour Oral Session		
AMR DX		
Making fast for making better: AMR rapid diagnostics		
Chairs Giulia De Angelis (Rome, Italy) Onur Karatuna (Växjö, Sweden)		
O0278	Point of care rapid lateral flow antibiotic resistance test to detect carbapenem resistance in lower respiratory tract infectionsJ. Rogers* (Bedford, United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch	
O0279	Evaluation of a new rapid Lateral flow Immunoassay for the detection of DHA-producing Gram-negative bacteriaC. Moguet* (Gulpry, France), S. Oueslati, A. Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas	
O0280	The NitroSpeed Taniborbactam NP test; easy detection of $\beta$ -lactamase sensitivity to taniborbactamO. Raro* (Fribourg, Switzerland), S. Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poirel, P. Nordmann	
O0281	Rapid detection of $\beta$ -lactamase-mediated resistance to aminopenicillins from urines.P. Nordmann* (Fribourg, Switzerland), N. Helsens, C. Duployez, L. Poirel, R. Dessein	
O0282	Rapid detection of antibiotic resistance in direct urine samplesM. Bot* (Arnhem, Netherlands), J. Flipse, S. Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim, M. Van Meer	
O0283	Next-Generation Utilizer Dipsticks for direct-from-sample phenotypic Antibiotic Susceptibility Testing in UTIsE. Iseri* (Stockholm, Sweden), W. Van Der Wijngaart, V. Özenci, R. Santini, A. Nakama, O. Ekelund, A. Van Belkum	
O0284	Screening for ceftriaxone-resistant Neisseria gonorrhoeae with the Urogenital and Resistance kit (AusDiagnostic)A. Braille* (Paris, France), M. Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Condamine, F. Caméléna, B. Berçot	
O0285	Comparative evaluation of rapid antimicrobial susceptibility testing assays for Gram-negative bacteria from positive blood culturesD. Squitieri* (Rome, Italy), G. Menchinelli, C. Magri, T. D'inzeo, M. Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti	
O0286	Rapid detection of Carbapenemases directly from positive blood culture bottle: A tool for early shifting from empirical to targeted therapyK. Chaudhary* (New Delhi, India), H. Gautam, P. Batra, S. Mohapatra, S. Sood, B. Dhawan, B. Das Kumar	

SY076	08:30 – 10:30	Hall 16
2-hour Symposium		
AMR		
AMR Surveillance in low resource countries: Insights into clinical and policy translation		
Chairs Kwame Ohene Buabeng (Ho, Ghana) H. Rogier Van Doorn (Hanoi, Vietnam)		

S0225	08:30	New indicators in national monitoring and evaluation of AMR supported by improved data utilisationDirek Limmathurotsakul (Bangkok, Thailand)
S0226	09:00	Interdisciplinary investigation of the drivers and burden of AMR in urinary tract infectionsStephen Mshana (Mwanza, Tanzania, United republic of)
S0227	09:30	A clinically-oriented AMR surveillance network: case-based surveillance and implementationPaul Turner (Siem Reap, Cambodia)
S0228	10:00	National prescribing guidelines based on AMR surveillance data Vilada Chansamouth (Vientiane, Lao People's democratic republic)
Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)		

EW077	08:30 – 10:30	Hall 2
Educational Session		
CLN DX		
New tools in acute bacterial infections and sepsis: from machine learning to precision medicine		
Chairs Benjamin Mcfadden (Perth, Australia) Rita Murri (Rome, Italy)		

W0229	08:30	Differentiating acute infection, sepsis and sepsis mimics in the ED?Lisa Mellhammar (Lund, Sweden)
W0230	08:50	Machine learning for early recognition of sepsisKarsten Borgwardt (Martinsried, Germany)
W0231	09:10	How to avoid common mistakes in randomised clinical study design Yin Mo (Singapore, Singapore)
W0232	09:30	Improved clinical trials in community-acquired pneumonia using precision medicineLennie Derde (Utrecht, Netherlands)
Co-organised with: ESCMID Scientific Affairs Subcommittee, European Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro		

SY072	08:30 – 10:30	Hall 3
2-hour Symposium		
PHEI VAX		
Tackling the emergence of dengue and other Aedes-borne diseases in Europe		
Chairs Fernanda Boulos (São Paulo, Brazil) Martin P. Grobusch (Amsterdam, Netherlands)		
S0209	08:30	How dengue, chikungunya and Zika virus disease became emerging threats to EuropeCeline Gossner (Solna, Sweden)
S0210	09:00	Surveillance of dengue in urbanised tropical regions Vincent Junxiong Pang (Singapore, Singapore)
S0211	09:30	Mosquito surveillance and control: opportunities and challengesTba
S0212	10:00	Tracking autochthonous arboviral infectionLuisa Barzon (Padua, Italy)
Co-organised with: European Centre for Disease Prevention and Control (ECDC)		

EW078	08:30 – 10:30	Hall 4
Educational Session		
DX		
Implementing metagenomics in my lab and mistakes to avoid		
Chairs Hege Vangstein Aamot (Lørenskog, Norway) Claudio Neidhöfer (Bonn, Germany)		

W0233	08:30	Is metagenomics right for my lab?Paula Mölling (Örebro, Sweden)
-------	-------	---

ESCMID Global 2025 - Programme

W0234	08:50	Understanding the experimental and certification aspects of metagenomics <i>Mads Albertsen (Aalborg, Denmark)</i>
W0235	09:10	Navigating tools, techniques, and procurement <i>Basil Britto Xavier (Groningen, Netherlands)</i>
W0236	09:30	Setting realistic goals and outcomes for metagenomics integration <i>Claire Bertelli (Lausanne, Switzerland)</i>
Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association of ESCMID (TAE) Steering Committee		
OS037	08:30 – 10:30	Hall 5
2-hour Oral Session		
Whole genome sequencing: tracking transmission and reservoirs in outbreaks		
Chairs	<i>Eric Claas (Leiden, Netherlands)</i> <i>Paul G. Higgins (Cologne, Germany)</i>	
O0268	From outbreaks to outcomes: Harnessing WGS for IPC in a high-risk paediatric setting <i>N. Storey* (London, United Kingdom), E. Cloutman-Green, J. Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Hatcher, J. Brown, J. Breuer</i>	
O0269	Why do routine genome-oriented surveillance for <i>Pseudomonas aeruginosa</i> ? <i>A. Rath* (Regensburg, Germany), L. Grancicova, B. Kieninger, A. Caplunik-Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert</i>	
O0270	TreeTime estimation depicts transmission dynamics of clinical and environmental <i>Pseudomonas aeruginosa</i> from common reservoirs in healthcare environment through whole genome sequencing (WGS) <i>Ö. Yetis* (London, United Kingdom), Ö. Yetiş, F. Dyrkell, S. Ali, P. Wilson</i>	
O0271	Understanding <i>Serratia</i> transmission during a neonatal ICU outbreak: A combined genotyping and risk factor analysis <i>K. Jaakkola* (Lyon, France), C. Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. Colomb-Cotinat, S. Haijs, J.P. Rasigade</i>	
O0272	Genomic Insights into the Regional Transmission of KPC-Producing Bacteria: Clonal and Non-Clonal Plasmid Sharing <i>C. Shankar* (Ann Arbor, United States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin</i>	
O0273	Genome-oriented analysis of the first outbreaks involving the novel <i>Serratia sarumanii</i> at a neonatal unit <i>A. Rath* (Regensburg, Germany), B. Kieninger, L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M. Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik-Pratsch, M. Kabesch, J. Kalinowski, W. Schneider-Brachert</i>	
O0274	Evaluating the Utility of Whole-Genome Sequencing to Optimise Infection Prevention and Control in a Hospital Setting: Findings from the GENOTYPE Study <i>J. Price* (Brighton, United Kingdom), I. Sey, A. Yeoh, D. Wlazly, A. Davies, O. Mekanjuola, J. Leach, S. Mookerjee, M. Krutikov</i>	
O0275	Outbreak of Carbapenem-Resistant <i>Acinetobacter</i> <i>selfertii</i> in a Neonatal Intensive Care Unit: Genomic Characterization and Surveillance. <i>D. Pereira* (Porto Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, G. De Oliveira, L. Lutz, M. Mott, C. Constante, C. Wilhelm, L. Antoechevis, R. Paiva, K. Tragnago, A. Barth, A. Martins</i>	
O0276	Unveiling the Clonal Dynamics and transmission mechanism of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in the ICU environment <i>X. Han* (Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu</i>	
O0277	Survey of Infection Prevention staff perception of WGS integration into routine IPC practice <i>D. Ling* (Melbourne, Australia), B. Baral, V. Madigan</i>	
EF041	09:30 – 10:30	Arena 2
ePoster Flash Session		

Contemporary diagnostic approaches for fungal infections		
Chair	<i>Ilse D. Jacobsen (Jena, Germany)</i>	
E0306	Evaluation of persistence of <i>C. auris</i> colonization in a cohort of patients discharged from a <i>C. auris</i> endemic area <i>M. Bavastro* (Genoa, Italy), L. Mezzogori, M. Bonaffini, L. Magnasco, F. Centorrino, V. Di Pilato, E. Willison, F. Portunato, D.R. Giacobbe, A. Vena, A. Marchese, M. Mikulska, M. Bassetti</i>	
E0307	A pilot study of digital retinal photography (DRP) and tele-ophthalmology of patients with candidemia. <i>C. Clancy* (Pittsburgh, United States), C. Hadi, E. Waxman, J.A. Viehman, A. Eller, M. O'donnell, F. Silveira, P. Samantha, B. Smith, S. Padival, V. Nauriyal, M.H.T. Nguyen</i>	
E0308	Epidemiology and diagnosis of Pneumocystis pneumonia : a 11 years-surveillance in France. <i>A. Alanio* (Paris, France), K. Boukris-Sitbon, M. Desnos-Ollivier, D. Garcia-Hermoso, F. Lanternier, O. Lortholary</i>	
E0309	Chronic pulmonary aspergillosis coexisting with pulmonary cystic echinococcosis: a global systematic review <i>A. Adhikari* (Chame, Nepal), F. Bongomin, R. Olum, P. Baral, I. Osaigbovo, W. Kibone, B. Ekeng, L. Atulinda, S. Katwal, B. Morgan, N.V. Rhijn, D. Denning</i>	
E0310	Implementation and performance of a universal Mucorales PCR assay for diagnosis of mucormycosis <i>A. Haas* (Salt Lake City, United States), K. Hanson</i>	
E0311	Blood cultures (BCs) contain populations of genetically diverse <i>Candida</i> strains that may differ in antifungal resistance and tolerance <i>C. Clancy* (Pittsburgh, United States), S. Cheng, H. Badrane, B. Hao, G. Fleres, E. Driscoll, D. Chris, E. Josh, M.H. Nguyen</i>	
E0312	Clinical validation of a urinary antigen test as an aid to diagnose invasive aspergillosis in hematology patients <i>Y. Vanbiervliet* (Leuven, Belgium), R. Aerts, T. Mercier, E. Boon, G. Gyseibert, E. Houben, K. Lagrou, J. Maertens</i>	
E0313	Genomic epidemiology of Greek <i>Candida auris</i> clinical isolates <i>M. Siopi* (Athens, Greece), B. Spruijtenburg, I. Anagnostakis, C. Anthoulaki, A. Argyropoulou, S. Varveraki, C. Vossou, A. Votsi, P. Giannopoulou, K. Gartzonika, M. Damala, I. Daskalakis, I. Dendrinos, V. Dimitriou, E. Dimitroulia, L.P. Drosopoulou, O. Zarkotou, L. Zachariadou, V. Ippa, A. Kampas, P. Karagiannidou, S. Karabela, A. Katsaka, A. Katsiaflaka, E. Kafkoulas, M. Kimouli, I. Lamprou, O. Legga, V. Mamali, M. Martsoukou, G. Mouratis, C. Mparka, T. Biniari, A. Xanthaki, E. Oikonomopoulou, M. Orfanidou, F. Paliogianni, E. Palla, A. Pantazatou, K. Panteli, E. Papadogeorgaki, M. Papadogianni, K. Papaefstathiou, P. Papanikolaou, J. Papaparaskevas, G. Parvouleskou, E. Perivolioti, S. Pournaras, C. Silleli, T. Skalidis, E. Souki, A. Spiliopoulou, C. Stergiou, S. Tsiplakou, P. Tsolakidou, N. Charalampaki, E. Chinou, G.S. Christodoulatos, G. Chronopoulou, E. Chrysou, E. Meijer, A. Tsakris, J. Meletiadiis, G. Vrioni</i>	
EF042	09:30 – 10:30	Arena 4
ePoster Flash Session		
Prosthetic and device-associated infections		
Chair	<i>Marjan Wouthuyzen-Bakker (Groningen, Netherlands)</i>	
E0315	Case series of gluteal Apophysomycosis post intramuscular injection <i>R. Sivasankaran* (Vellore, India), R. Bandyopadhyay</i>	
E0316	MIGRATING mesh - an unusual cause of pyogenic liver abscess <i>M. Caris* (Leiden, Netherlands), J. Rutgers, A. Inderson, S.M. Arend, L.M.F. Kuijpers</i>	
E0317	Ceftaroline salvage monotherapy: successful	

# ESCMID Global 2025 - Programme

**treatment of a cerebrospinal fluid drain infection caused by a multidrug-resistant *Staphylococcus epidermidis* strain** *M.D. Di Trapani\* (Bozen, Italy), T. Kamal Eldin, G. Spoladore, D. Drusiani, B. Ladinser, R. Aschbacher*

**E0318** **Timeline of early infections post porcine xenotransplantation** *H. Neumann\* (New York, United States), M. Ringer, R. Alpizar-Rivas, J. Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A. Griesemer, R. Montgomery, S. Williams, S. Mehta*

**E0319** **Invasive Non-tuberculous mycobacteria Infection in children undergoing Cardiac Surgery at the specialized Cardiology Hospital of Peshawar** *M. Khan\* (Peshawar, Pakistan)*

**E0320** **Use of multiplex PCR assay analysis in patients with suspected Implant-based breast reconstruction infection: a single center experience** *A. Pagotto\* (Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor, A. Colombo, P.C. Parodi, C. Tascini*

**E0321** **PET CT controls and Dalbavancin therapeutic drug monitoring can help guiding Dalbavancin treatment duration of complicated cardiovascular infections** *C. Kujat\* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank, A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewerling, A. Friedrichs*

**E0322** **A complex case of pelvic bone infection caused by carbapenem-resistant *Acinetobacter baumannii* successfully treated with eravacycline** *M. Zagarrigo\* (Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro, A. Pozzi, E. Zamparini, P. Viale*

**E0323** **Oritavancin in a patient with recurrent endocarditis by *Enterococcus faecalis*: a new therapeutic option?** *M. Bongiovanni\* (Lugano, Switzerland), B. Barda, E. Bernasconi*

KN080	09:30 – 10:30	Hall 1
	Keynote Lecture	
	VAX	
Infections after solid organ transplantation: past, present and future		
Chairs	Nina Khanna (Basel, Switzerland) Priscilla Rupali (Vellore, India)	
K0241	09:30	Jay Fishman (Boston, United States)

SY082	11:00 – 12:00	Hall 6
<div> <div>PRO</div> <div>PHEI</div> </div> 1-hour Symposium		
<b>How to address anti-science in our community?</b>		
<i>Chairs</i>		
<i>Tuba Dal (Ankara, Türkiye)</i>		
<i>Tyra Grove Krause (Copenhagen, Denmark)</i>		

S0243	11:00	<b>The rise of anti-science: lessons for the future scientist</b> <i>Marion Koopmans (Rotterdam, Netherlands)</i>
S0244	11:30	<b>Open science for public trust</b> <i>Lisa Hansen (Ottawa, Canada)</i>

FO090	11:00 – 12:00	Arena 1
	Open Forum	
	PRO	
European CM/ID exam: going forward		
Chair	Siri Goepel (Tuebingen, Germany)	

F0259	11:00	<b>View from medical microbiology</b> <i>Maeve Doyle (Waterford, Ireland)</i>
F0260	11:10	<b>view from infectious diseases</b> <i>Eoghan De Barra (Dublin, Ireland)</i>
F0261	11:20	<b>view from trainees (TAE)</b> <i>Christian Kraef (Copenhagen, Denmark)</i>
F0262	11:30	<b>European exam - how to prepare?</b> <i>Annelies Verbon (Bosch En Duin, Netherlands)</i>

**Co-organised with: ESCMID Education Subcommittee, ESCMID Professional Affairs Subcommittee, UEMS Section of Medical Microbiology, UEMS Section of Infectious Diseases**

EF049 11:00 – 12:00 Arena 2  
ePoster Flash Session

## Sometimes it's hard to be a woman

*Chair* *Debora Konopnicki (Brussels, Belgium)*

**E0354 Interleukins 17 and 18: Key players in Cervical Cancer Progression in Indian Population***P. Gupta\** (Bhopal, India), A. Vyas, A. Halder, S. Purwar

**E0355** **Risk evaluation of iatrogenic transmission of Human Papillomavirus (HPV) during gynaecological procedures** *B. Casini\* (Pisa, Italy), F. Chiovelli, Y. Ferchichi, E. Esposito, M. Basile, G. Del Bravo, A. Giannini, T. Simoncini*

**E0357** **Rubella screening in pregnancy – Slovakian one-center retrospective analysis around COVID-19 pandemic** Z. Paraličová\* (Kosice, Slovakia), D. Javorská

**E0358**      **The impact of maternal influenza infection and vaccination during pregnancy on birth outcomes.***B. Goundappa\** (Pittsburgh, United States), *X. Zhang, B. Gk. H.E.A. D'agostino, H. Liu, A.M. Rick*

**E0359**      **Use of valaciclovir therapy during pregnancy for the prevention of congenital cytomegalovirus infection: a monocentric experience.** G. Lorenzetti\* (Rome, Italy), S. Garattini, L. Romani, M. Di Giuseppe, M. De Luca, L. Cursi, S. Bernardi, S. Chiurchiù, S. Mercadante, C. Tripiciano, A. Krzysztofciak, C. Vassallo, I. Fabietti, L. Caforio, L. Lancella, F.I. Calò Carducci

**E0360 Multi-systemic long-term sequelae following SARS-CoV-2 Omicron infection in pregnancy: a population-based cohort study** *Y.Y. Tan\** (Singapore, Singapore), *E.X.H. Loy, A.T. Tay, J.T. Lim, C.J. Chiew, D.C.B. Lye, L.E. Wee*

**E0361**      **The Impact of OAS1 rs4766664 and OAS3 rs10735079 Polymorphisms on the Clinical Course of COVID-19 in Pregnant Women** *S. Kirik Yilmaz\* (Konya, Türkiye), S. Kirik Yilmaz, S. Sumer, N. Demir Aktug, O. Ural, E. Ozdemir Marzioglu, O. Secilmis, T. Cora*

**E0362** **Sex-stratified analysis of T cell activation, exhaustion, proliferation and HIV reservoir among PLWH.** *L. Santinelli\* (Rome, Italy), M. Andreotti, L. Maddaloni, Z. Michelini, G. Bugani, F. Romano, E. Gentili Cacciola, G. Antonelli, C.M. Mastroianni, C. Scaqnolari, G. D'ettore*

EF050	11:00 – 12:00	Arena 3
	ePoster Flash Session	
<div>  </div>		
<b>Expanding MALDI-TOF applications</b>		
<i>Chair</i>	<i>Belen Rodriguez-Sanchez (Madrid, Spain)</i>	

**E0363**      **Application of MALDI-TOF Mass Spectrometry and Machine Learning for the Detection of Vancomycin-Resistant *Enterococcus faecium*** M. Sánchez Cueto\* (Madrid, Spain), M. Sánchez-Cueto, M. Blázquez-Sánchez, M. Marin, E. Cercenado, P. Muñoz, B. Rodríguez-Sánchez, D. Rodríguez-Temporal

**E0364** **Early detection of ampicillin susceptibility in *Enterococcus faecium* with MALDI-TOF MS and machine learning** *(Munich, Germany), L. Miranda, N. Wantia, K. Borawardt, J. Sattler*

**E0365** **Rapid antifungal resistance prediction based on MALDI TOF mass spectrometry** *D. Duroux\** (Zurich, Switzerland), *Y. Yang, J. Sattler, A. Egli*

**E0366** **Rapid prediction of fluconazole resistance by machine-learning analysis of *Candida parapsilosis* MALDI-TOF mass profiles.** C. Magri\* (Rome, Italy), C. Magri, V. Ivaanes, M. Sanvini, E. De Carolis



ESCMID Global 2025 - Programme

E0367	<b>Optimizing pretreatment for MALDI-TOF MS: Evaluating the dispersion method for filamentous fungal identification</b> <i>R. Huang*</i> (Shenzhen, China), <i>Y. Li, Y. He, T. Ma, F. Lu</i>	
E0368	<b>Rapid detection of colistin resistance in <i>Acinetobacter baumannii</i> by a MALDI-TOF MS-based assay</b> <i>E. Kirbaş*</i> (Van, Türkiye), <i>I.D. Nix, K. Sparbier, O. Drews, B. Oberheitmann, M. Kostrzewa, G. Hasçelik, B. Sancak</i>	
E0369	<b>Discrimination of clinical <i>Pseudomonas</i> strains at the species level using a large-scale genomically predicted protein mass database with MALDI-MS</b> <i>K. Teramoto*</i> (Kyoto, Japan), <i>Y. Sekiguchi, L. Sellami, M. Tohya, T. Kirikae</i>	
E0370	<b>Automatic differentiation of <i>Clostridioides difficile</i> ribotypes using MALDI-TOF MS and web-based classification models</b> <i>M. Blazquez Sanchez*</i> (Madrid, Spain), <i>M.C. Blazquez-Sanchez, J.M. Moreno, A. Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P. Muñoz, M. Marín, L. Alcalá, D. Rodríguez-Temporal, B. Rodríguez-Sanchez</i>	
E0371	<b>Identification of sepsis-causing bacteria using shotgun proteomics</b> <i>L. Meekes*</i> (Rotterdam, Netherlands), <i>D. Rustad, C. Güzel, T.K. Jenssen, H. Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider, W. Goessens</i>	
EF051	11:00 – 12:00	Arena 4
	ePoster Flash Session	
E0372	<b>Anti-K2 recombinant phage depolymerases as anti-virulence agents against hypervirulent <i>Klebsiella pneumoniae</i></b> <i>M. Roch*</i> (Geneva, Switzerland), <i>R. Sierra, D. Andrey</i>	
E0373	<b>Jumbo <i>Klebsiella</i> bacteriophage demonstrates efficient multidrug-resistant <i>Klebsiella pneumoniae</i> killing and significant clinical potential</b> <i>Y. Liu*</i> (Singapore, Singapore), <i>Y. Zhong, S. Thong, L.H.A. Kwa</i>	
E0374	<b>A new phage cocktail targeting at <i>Klebsiella pneumoniae</i></b> <i>X. Yin*</i> (Chengdu, China), <i>Y. Feng, H. Luo, Z. Zong</i>	
E0375	<b>Bacteriophages against pulmonary infection and colonization of the gut by multidrug-resistant <i>Klebsiella pneumoniae</i> in murine models</b> <i>A.M. Örmälä-Tiznado*</i> (Stockholm, Sweden), <i>S. Patpatia, J. Bengoechea, C. Frantzen, A. Garcia Navarro, C. Giske</i>	
E0376	<b>A novel broad-spectrum phage cocktail effective for carbapenem resistant <i>Acinetobacter baumannii</i> of capsular type 104/2/7 in vitro</b> <i>L. Wei*</i> (Chengdu, China), <i>Y. Feng, Z. Zong</i>	
E0377	<b>Proteomic and Genomic Characterization of a Novel Bacteriophage of a New Genus Infecting <i>Pseudomonas aeruginosa</i></b> <i>S. Unlu*</i> (Ankara, Türkiye), <i>A. Uskudar Guclu</i>	
E0378	<b>Phages as innovative adjuvants of antibiotics therapy against <i>S. aureus</i> and <i>P. aeruginosa</i> in the context of Cystic Fibrosis</b> <i>A. Glorieux*</i> (Brussels, Belgium), <i>S. De Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van Bambeke</i>	
E0379	<b>Evaluation of bacteriophages against <i>Staphylococcus aureus</i> strains isolated from orthopaedic infections</b> <i>S. Patpatia*</i> (Helsinki, Finland), <i>A. Camporeale, S. Kiljunen, C. Giske, A.M. Örmälä-Tiznado</i>	
E0380	<b>Anti-<i>Staphylococcus aureus</i> phages: assessing the risk of bacterial resistance emergence through selective pressure</b> <i>M. Degreze*</i> (Lyon, France), <i>M. Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent, C. Kolenda</i>	

KN081	11:00 – 12:00	Hall 1
	Keynote Lecture	

The new frontiers in antimicrobial stewardship		
Chairs		<i>Jose Ramon Pano-Pardo</i> (Zaragoza, Spain) <i>Jeroen Schouten</i> (Nijmegen, Netherlands)
K0242	11:00	<i>Karin Thursky</i> (Carlton, Australia)
SY084	11:00 – 12:00	Hall 10
	1-hour Symposium	
Sleeping sickness and Chagas: a tale of the two trypanosomes		
Chairs		<i>Hanne Brekke</i> (Oslo, Norway) <i>Irene Losada Galvan</i> (Barcelona, Spain)
S0247	11:00	<b>Human African Trypanosomiasis: recent diagnostic and medical practices</b> <i>Jean-Mathieu Bart</i> (Conakry, Guinea)
S0248	11:30	<b>American Trypanosomiasis: Diagnosis, screening and management</b> <i>Tba</i>
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)		
OS047	11:00 – 12:00	Hall 11
	1-hour Oral Session	
Clinical studies in UTI		
Chairs		<i>Iva Butic</i> (Zagreb, Croatia) <i>Paul Christoffer Lindemann</i> (Bergen, Norway)
O0344		<b>Short versus long antibiotic treatment for pyelonephritis and complicated UTIs: an updated systematic review and meta-analysis of RCTs</b> <i>I. Zahavi*</i> (Haifa, Israel), <i>D. Kunwar, J. Olchowski, H. Dallahsheh, M. Paul</i>
O0345		<b>Antibiotic treatment duration of complicated urinary tract infection patients in Europe: results from the Ecraid POS-cUTI study</b> <i>C. Kats*</i> (Utrecht, Netherlands), <i>J.M. Bravo-Ferrer, T.T. Doesschate, P.D. Van Der Linden, P. Martinez, O. Awwad, E. Rubio, P. Clevenbergh, A. Barac, A. Cano, E. Merino, P. Andrade, L. Jacquin, B. Koprivica, R. Espindola, P. Muñoz, T. Lafon, M. Mendris, J. Van Laethem, D. Viglino, A. Ternhag, J. Rupp, A. Hernandez-Torres, D. Chadwick, B. Carevic, M. Bonten, E. Tacconelli, J. Rodríguez-Baño</i>
O0346		<b>Prevalence and impact of multidrug resistance in a cohort of patients admitted to emergency department for urinary tract infections: the UTILITY study, a prospective multicentre study</b> <i>L. Onorato*</i> (Naples, Italy), <i>E. Allegorico, M. Macera, C. Monari, B. Migliaccio, F.G. Numis, C. Nasta, M.T. Florio, R. Sciorio, G. Guiotto, M. Giordano, R. Raucci, F. Dello Vicario, R. Nasti, A. Voza, N. Coppola</i>
O0347		<b>Weekly sequential antibioprophyllaxis for UTI in neurogenic bladder</b> <i>R. Calin*</i> (Paris, France), <i>C. Chesnel, C. Hentzen, M. Teng, F. Le Breton, V. Phe, F. Adda, C. Palacios, G. Amarenco, G. Pialoux</i>
O0348		<b>Evidence for the duration of antibiotic therapy for chronic bacterial prostatitis: a systematic review</b> <i>L. Cordes*</i> (Geneva, Switzerland), <i>A. Huttner, R. Calin, K. Gupta, M. Lafaurie, M. Lambregts, V. Lavergne, B. Trautner</i>
OS048	11:00 – 12:00	Hall 12
	1-hour Oral Session	
Complexities of infections in solid organ transplantation		
Chair		<i>Silvia Corcione</i> (Turin, Italy)
O0349		<b>Solid Organ Transplants from donors with positive blood cultures: watch out for carbapenem-resistant Enterobacterales</b> <i>A. Cona*</i> (Palermo, Italy), <i>C.</i>

ESCMID Global 2025 - Programme

		<i>Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F. Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. Coppola, A. Mularoni</i>	
O0350		<b>Risk factors for carbapenem-resistant Enterobacteriaceae infection after orthotopic liver transplant in a large cohort of pre-transplant CRE carriers</b> <i>M. Rinaldi* (Bologna, Italy), B. Miani, M. Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L. Alagna, E. Franceschini, P. Burra, A. Mularoni, M. Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. Caroccia, M. Di Chiara, P. Viale, M. Giannella</i>	
O0351		<b>Serologic follow up of solid organ transplant recipients who receive organs from syphilis seropositive donors.</b> <i>O. Fernandez Garcia* (Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. Doucette</i>	
O0352		<b>Prophylaxis strategies and risk of cytomegalovirus in solid organ transplant recipients</b> <i>A. Dahl* (København V, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup, J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning, J. Lundgren, N. Mueller, M. Helleberg</i>	
O0353		<b>Burden of non-microbiologically confirmed infections in solid organ transplant recipients</b> <i>M. Zou* (Basel, Switzerland), M. Koller, O.J. Manuel, N. Mueller, K. Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van Delden, D. Neofytos</i>	
SY085	11:00 – 12:00		Hall 13
	1-hour Symposium		
		<b>Diagnosing the undiagnosed fraction: the final step towards viral hepatitis elimination</b>	
	<i>Chairs</i>	<i>Mojca Maticic (Ljubljana, Slovenia) Snjezana Zidovec Lepej (Zagreb, Croatia)</i>	
S0249	11:00	<b>Role of reflex testing strategies in identifying patients with chronic viral hepatitis</b> <i>Oana Sandulescu (Bucharest, Romania)</i>	
S0250	11:30	<b>Management and elimination of hepatitis in hard-to-reach persons</b> <i>Suda Tekin (Istanbul, Türkiye)</i>	
		Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), Romanian Society for Infectious Diseases and HIV/AIDS	
SY086	11:00 – 12:00		Hall 14
	1-hour Symposium		
		<b>Impact on including a measure of viability in molecular diagnostic tests</b>	
	<i>Chairs</i>	<i>Fusun Can (Istanbul, Türkiye) Denise O'sullivan (Teddington, United Kingdom)</i>	
S0251	11:00	<b>Viability markers in support of development of <i>Chlamydia</i> screening recommendations</b> <i>Petra Wolffs (Maastricht, Netherlands)</i>	
S0252	11:30	<b>Measuring viability to improve the correlation of AMR markers and clinical outcomes in <i>Neisseria gonorrhoeae</i></b> <i>Tatum Mortimer (Athens, United States)</i>	
		Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC)	
ME089	11:00 – 12:00		Hall 15
	Meet-the-Expert		
		<b>How to teach Medical Mycology</b>	
M0257	11:00	<i>Katrien Lagrou (Leuven, Belgium)</i>	
M0258	11:12	<i>Mihai Mares (Iasi, Romania)</i>	
		Co-organised with: European Confederation of Medical Mycology (ECMM)	

SY087	11:00 – 12:00		Hall 16
	1-hour Symposium		
		<b>Innovating antimicrobial drug discovery and host-pathogen interaction studies using chemical biology</b>	
	<i>Chair</i>	<i>Laurent Poirel (Fribourg, Switzerland)</i>	
S0253	11:00	<b>Bacterial PROTACs: Do proteolysis-targeting degraders represent a viable strategy for new antimicrobials?</b> <i>Morreale Francesca Ester (London, United Kingdom)</i>	
S0254	11:30	<b>Activity-based protein profiling of bacterial pathogens: new enzymes and their functions at the host-microbe interface</b> <i>Christian Stephan Lentz (Tromsø, Norway)</i>	
ME088	11:00 – 12:00		Hall 2
	Meet-the-Expert		
		<b>Global AMR Policy after UNGA: what do we do now!</b>	
M0255	11:00	<i>Gisela Robles Aguilar (Oxford, United Kingdom)</i>	
M0256	11:12	<i>Mike Sharland (London, United Kingdom)</i>	
OS043	11:00 – 12:00		Hall 3
	1-hour Oral Session		
		<b>Navigating disinfection challenges: resistance, outbreaks, and efficacy</b>	
	<i>Chairs</i>	<i>Hillary A. Craddock (Dublin, Ireland) Stephanie J. Dancer (Glasgow, United Kingdom)</i>	
O0324		<b>Prolonged disinfectant exposure impacts the antimicrobial resistance of healthcare-associated microorganisms: a systematic review</b> <i>Â.R. Fernandes* (Porto, Portugal), A. Gonçalves Rodrigues, L. Cobrado</i>	
O0325		<b>Sink-associated outbreak of verona integron-encoded metallo-??-lactamase-producing carbapenem-resistant <i>Pseudomonas aeruginosa</i> in a Dutch intensive care unit</b> <i>M. Van Den Bos Kromhout* (Zwolle, Netherlands), S. Debast, M. Van Den Bos-Kromhout, S. De Vries-Van Rossum, S. Abma-Blatter, B. Immeker, K. Zuur, M. Hijmering, J.W.A. Rossen</i>	
O0326		<b>Carbapenemase-producing Enterobacterales outbreak control by replacement of toilets or long-term disinfection? A real-life experience.</b> <i>A.L. Engsbros* (Slagelse, Denmark), K.H. Hansen, M.F.J. Larsen, N. Kling, H.T. Larsen, R. Kjølsten, B. Hansen, L.K. Vejrum, A.L. Laugesen, M. Kemp</i>	
O0327		<b>Tolerance of <i>Klebsiella pneumoniae</i> biofilms to disinfection with peracetic acid</b> <i>M. Arvand* (Berlin, Germany), A.M. Richter, D. Csértő, K. Konrat</i>	
O0328		<b>Bringing balance to the formulation: disinfection efficacy and material compatibility</b> <i>J. Jennings* (Halifax, United Kingdom), T. Langford, H. Mansbridge, E. Fraser, I. Poles, J. Clarke</i>	
LB002	11:00 – 12:00		Hall 4
	1-hour Oral Session		
		<b>Investigation of intriguing outbreaks</b>	
L0006		<b>Molecular surveillance of artemisinin and sulfadoxine-pyrimethamine resistance in <i>Plasmodium falciparum</i> isolates from Uganda: results of ERASE study</b> <i>M. L'episcopia* (Rome, Italy), F.V. Segala, J. Ictho, R. Papagni, I. Obua, E. De Vita, N. Olang, R. Novara, V. Totaro, L. Olal, G. Patti, C. Bignom, C. Agaro, G. Dall'oglio, B. Ngole, S. Okori, P. Lochoro, G.</i>	

ESCMID Global 2025 - Programme

		<i>Putoto, F. Di Gennaro, C. Severini, A. Saracino</i>
L0007		<b>Investigation of an international pseudo-outbreak involving <i>Paraburkholderia fungorum</i> blood culture contamination.</b> <i>J. Moran-Gilad* (Jerusalem, Israel), J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Palavecino, P. Snippes Vagnone</i>
L0008		<b>Evolving cluster of severe infective endocarditis with non-toxigenic <i>C. diphtheriae</i> amongst people experiencing homelessness and substance misuse in the UK.</b> <i>R. Cordery* (London, United Kingdom), T. Patel, T. Anwar, N. Utjesanovic, A. Aryee, E. Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Primus, S. Das, K. Paranthaman, G. Amirthalingham</i>
L0009		<b>AI-driven live cough rate tracking for public health surveillance.</b> <i>M. Kågebäck* (Göteborg, Sweden), E. Carlsson</i>

OS044	11:00 – 12:00	Hall 5
	1-hour Case Session	
	CLN	
Unusual presentations of unusual parasites		
Chairs	<i>Emmanuel Bottieau (Antwerp, Belgium)</i> <i>Marcelo Victor Radisic (Buenos Aires, Argentina)</i>	

O0329		<b>Atypical neonatal cutaneous myiasis: a diagnostic challenge mimicking pustular rash in a resource-limited setting.</b> <i>D. Ekwem Amarachi* (Gulu, Uganda), E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi, R. Olum</i>
O0330		<b>An itchy awakening due to <i>Dermanyssus</i> infestation.</b> <i>J. Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales, J.M. Bérenegr, S. Ranque</i>
O0331		<b>Uterine Myiasis: A Rare Case of External Genitourinary Myiasis.</b> <i>R.L. Johnson* (Birmingham, United States), J.C.F. Nakazaki, P. Legua</i>
O0332		<b>Neurognathostomiasis Presenting with Cerebral Venous Sinus Thrombosis: A case report of rare clinical manifestation.</b> <i>C. Norsungnorn* (Bangkok, Thailand), J. Vinichanan, L. Paitoonpong</i>
O0333		<b>If at first, you don't succeed... Treatment-resistant Fascioliasis: case report.</b> <i>W. Garr* (Leeds, United Kingdom), K. Woods, L. Nabarro</i>

SY083	11:00 – 12:00	Hall 7
	1-hour Symposium	
	CLN DX	
Lyme neuroborreliosis: challenges in diagnosis and treatment		
Chairs	<i>Alexandra Mailles (Paris, France)</i> <i>Joanna Maria Zajkowska (Białystok, Poland)</i>	

S0245	11:00	<b>Challenges in diagnosis of Lyme neuroborreliosis.</b> <i>Rick Dersch (Freiburg, Germany)</i>
S0246	11:30	<b>Challenges in treatment of Lyme neuroborreliosis.</b> <i>Anne Marit Solheim (Kristiansand, Norway)</i>
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR)		

OS045	11:00 – 12:00	Hall 8
	1-hour Oral Session	
	AMR	
Social behavioural dynamics of antibiotic use and AMR		
Chairs	<i>Sonia Lewycka (Hanoi, Vietnam)</i> <i>Filippo Medioli (Milan, Italy)</i>	

O0334		<b>Investigating the Knowledge, Attitudes, and Practices around Antimicrobial Resistance and Stewardship Among Syrian Healthcare Professionals: A Cross-Sectional Survey.</b> <i>A. Abbara* (London, United</i>
-------	--	---

O0335		<b>Gamified Intervention to Enhance Antimicrobial Stewardship: Improving Knowledge and Practices on the Rational Use of Antimicrobials Among Medicines and Therapeutics Committee Members ???.</b> <i>S. Mahadevaiah* (Mysore, India), C. Es, K. Anil, Y. Maheshwarappa, S.S. Sc, S. Srinivas, V. Swamy Gs, K. Gautam</i>
O0336		<b>Healthcare providers' perspectives on antibiotic use and resistance in pregnancy, childbirth, and children under five years of age across four levels of hospitals in Lao PDR, 2024.</b> <i>S. Vantava* (Vientiane Capital, Lao People's democratic republic), K. Thilakoun, D. Sypaseuth, C. Khamla, I. Bounxou, P. Vanpheng, B. Phetsamone, S. Bangthong, K. Sengchanh, S. Latsamy, S. Vanphanom, L. Annick, S. Somphou</i>
O0337		<b>High gender gap in female labour force participation and reduced gender inequality linked to high antibiotic consumption: Evidence from a global analysis.</b> <i>D. Samria* (Bangalore, India), D. Batheja, A. Nandi</i>
O0338		<b>Gender gaps in knowledge of antibiotics and antimicrobial resistance: Evidence from India.</b> <i>D. Batheja* (Delhi, India), S.R. Umenthala, S. Goel, D. Samria, R. Bhagawati, B. Deepshikha</i>

OS046	11:00 – 12:00	Hall 9
	1-hour Oral Session	
	PHEI VAX	
Vaccines and prophylaxis against respiratory viral infections		
Chairs	<i>Ana Atti (London, United Kingdom)</i> <i>Sophie Schneitler (Homburg, Germany)</i>	

O0339		<b>Public health impact of universal prophylaxis with nirsevimab for prevention of infant hospitalizations due to respiratory syncytial virus. Full 2023-24 season analysis of the NIRSE-GAL study (<a href="http://www.nirsegal.es/en">www.nirsegal.es/en</a>).</b> <i>F. Martínón-Torres* (Santiago De Compostela, Spain), N. Mallah, J. Pardo-Seco, O. Pérez-Martínez, M.I. Santiago-Pérez, M.T. Otero-Barrós, N. Suárez-Gaiche, R. Kramer, J. Jing, L. Platero-Alonso, R.M. Álvarez-Gil, O.M. Ces-Ozores, V. Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo, J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez, I. Rivero-Calle, A. Manzanares-Casteleiro</i>
O0340		<b>Relative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trial.</b> <i>K. Feldballe Bernholm* (Copenhagen, Denmark), N. Dyrby Johansen, C. Espersen, D. Modin, K. Hyldekær Janstrup, J. Nealon, S. Samson, M.M. Loiacono, R. Harris, C. Schade Larsen, A.M. Reimer Jensen, N.E. Landler, S. Tellerup Nielsen, L. Russell, T. Skovsgaard Itenov, B.L. Claggett, S.D. Solomon, M.J. Landray, G.H. Gislason, L. Køber, P. Sivapalan, J.U. Staehr Jensen, T. Biering-Sørensen</i>

O0341		<b>Relative vaccine efficacy of a SARS-CoV-2 spike receptor-binding and N-terminal domain COVID-19 vaccine versus mRNA-1273: subgroup analyses.</b> <i>C. Grassi* (Cambridge, United States), S. Chalkias, P. Dennis, D. Petersen, K. Radhakrishnan, L. Vaughan, R. Handforth, N. Vivic, A. Rossi, R. Wahid, D. Edwards, J. Feng, W. Deng, H. Zhou, E. De Windt, V. Urdaneta, B. Girard, S. Faust, S. Walsh, C. Cosgrove, R. Das</i>
-------	--	--

O0342		<b>Effectiveness of RSV vaccine in lung transplant recipients: neutralizing antibody response against reference and seasonal strains.</b> <i>N. Shirin* (Ramat Gan, Israel), L. Levy, D. Yahav, M. Benzmira, Y. Bezalel, T. Hoffman, T. Sinai, M. Jurkowicz, O. Deri, N. Matalon, M. Saute, Y. Lustig, E. Nachum, M. Peled, I. Nemet, M. Mandelboim</i>
-------	--	---

O0343		<b>Novavax investigational COVID-19 Influenza Combination nanoparticle vaccine phase 2 study safety evaluation.</b> <i>C. Bennett* (Gaithersburg, United States), V. Shinde, S. Neal, J.S. Plested, T. Vincent, M. Zhu, S. Cloney-Clark, Z. Cai, B. Riviers, A. Ahmed, F. Mahkhou, A.M. Marchese, I. Cho, L. Fries, W. Woo</i>
-------	--	--



ESCMID Global 2025 - Programme

SY093	13:30 – 14:30	Hall 11
	1-hour Symposium	
	TRN VAX	
Immunosenescence and immune response to vaccination		
Chairs	Petar Velikov (Sofia, Bulgaria) Dafna Yahav (Ramat-Gan, Israel)	
S0267	13:30	How immunosenescence impacts vaccine responseAndrea Cossarizza (Modena, Italy)
S0268	14:00	Strategies to tackle immunosenescence and improve immune response to vaccination in the elderlyInna Ovsyannikova (Rochester, United States)
Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Vaccine Study Group (EVASG)		
EW096	13:30 – 15:30	Hall 15
	Educational Session	
	PRO	
Tools for successful development as a medical educator		
Chairs	Giorgia Caruana (Sion, Switzerland) Yoav Keynan (Winnipeg, Canada)	
W0273	13:30	Developing your educator professional identityTodd Cassese (Bronx, United States)
W0274	13:50	What do IPC doctors need to learn to be preparedSimone Scheithauer (Göttingen, Germany)
W0275	14:10	Communities of practice: successful experience of a transformative collaboration and roadmapErin Bonura (Portland, United States)
W0276	14:30	The critical need for ongoing innovations in medical educationClémentine Schilte (Paris, France)
Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE) Steering Committee, British Infection Association (BIA), Young Leader Circle of the American Society of Microbiology		
FO097	13:30 – 14:30	Arena 1
	Open Forum	
	DX	
Essential diagnostics in Low-Resource Settings: why are we still talking?		
Chair	Truls Michael Leegaard (Lørenskog, Norway)	
F0277	13:30	Training skilled personnel in LMIC and brain drain: Is the solution the problem?Sipho Kenneth Dlamini (Observatory, South Africa)
F0278	13:40	Leveraging surveillance networks to strengthen basic bacteriologyDissou Affolabi (Cotonou, Benin)
F0279	13:50	Clinical bacteriology laboratories in low-resource settings: considerations for sustainabilityMakeda Semret (Montreal, Canada)
Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch Society for Medical Microbiology (NVMM), ESCMID Parity Commission, Federation of European Microbiological Societies (FEMS), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge d'Infectiolo		
FO098	13:30 – 14:30	Arena 2
	Open Forum	
	PRO	
Best of ID Week		
Chair	Tina Tan (Chicago, United States)	
F0280	, Seth Cohen (Seattle, United States), Erin McCreary (Pittsburgh, United States), Ilan Youngster (Beer Yaakov, Israel)	

EF054	13:30 – 14:30	Arena 3
	ePoster Flash Session	
	AMR IPC PHEI	
Beware the sink! Pathogen reservoirs in drains and waste water		
Chair	Stephan Juergen Harbarth (Geneva, Switzerland)	
E0391	Genomic Epidemiology to Investigate Healthcare Environment as Reservoir for Carbapenem-Resistant Organisms in an Academic Hospital in Miami, Florida.A. Jimenez* (Miami, United States), S. Hawken, S. Arenas, K. Mokoban, D. Pronty, O. Martinez, J. Colson, A. Richardson, T. Ferreira, B. Shukla	
E0392	Two clusters of carbapenemase-producing Enterobacterales linked to hospital wastewater drainage in utility rooms – an outbreak investigationI. Vock* (Basel, Switzerland), G. Capoferri, P. Urwyler, P. Domene, D. Roy, S. Kuster, N. Gürtler, B. Ivan, P.M. Keller, S. Tschudin-Sutter	
E0393	Assessing the burden of carbapenemase and colistin antimicrobial resistance genes in hospital wastewaterE. Au* (Calgary, Canada), N. Acosta, B. Waddell, J. Lee, K. Du, R.B. Weyant, B. Dalton, M. Bautista, J. Mccalder, R. Clark, J. Pitout, J. Kim, B. Missaghi, O. Larios, J. Vayalumkal, J. Leal, E. Rennert-May, J. Kanji, P. Westlund, B. Lee, X.L. Pang, K. Frankowski, C. O'grady, J.M. Conly, C.R. Hubert, M. Parkins	
E0394	Hospital wastewater as a reservoir for carbapenemase-producing organismsA. Anantharajah* (Brussels, Belgium), C. Altintas, T. Lavalleye, A. Delaunoy, I. Meyts, E. Dumitreasa, A. Bennert, C. Schirvel, A. Verroken, H. Rodriguez-Villalobos	
E0396	Reversing and controlling microbial proliferation in the water system of a high-risk hospital ward after extended closure and reconstructionD. Chaput* (Glasgow, United Kingdom), K. Clarkson, L. Bagrade, A. Marek, D. Kelly, D. Watson, A. Leanord, T. Steele	
E0397	Whole-genome sequencing as part of the tracking and managing Carbapenemase producing Enterobacterales transmission in an acute hospital settingD. Coffey* (Cork, Ireland), R. Waldron, D. Neshev, M. Cormican, C. Clarke, L. Hayes	
E0398	Is there a solution for hospital acquired infections due to the aquatic reservoir in the near patient environment?H. Zayyad* (Poriya, Israel), R. Khouri, N. Saleh, A. Peretz	
E0399	Reducing Antimicrobial Resistance (AMR) across the One Health Landscape: Diverse Perspectives on AMR risks and their mitigation in sinks, drains, and wastewaterH.A. Craddock* (Dublin, Ireland), A. Kearney, F. Fitzpatrick, C. Finn, M.T. Pryce, D. Fitzgerald-Hughes	

EF055	13:30 – 14:30	Arena 4
	ePoster Flash Session	
	ANT CLN PHEI	
The cutting edge in tuberculosis		
Chair	Graeme Ayton Meintjes (Observatory, South Africa)	
E0400	Personalised risk predictions for incident TB and preventive treatment uptake.R. Rose-Key* (London, United Kingdom), R. Gupta, M. Noursadeghi	
E0401	Programmatic migrant screening for tuberculosis identifies a spectrum of clinical phenotypes and outcomes: cohort data from a national migrant screening programmeM. Gohar* (Leicester, United Kingdom), C. Martin, A. Ayobami, H. Patel, M. Patel, L. Ahyow, B. Srinj, G. Rishi, P. Mark, S. Nilesch, C. Trevithick, K. Pierun, M. Wiselka, L. Gray, I. Abubakar, R. Baggaaley, A. Cooper, P. Haldar, M. Pareek	
E0402	An investigation into the relationship between human and animal <i>Mycobacterium bovis</i> isolates	

ESCMID Global 2025 - Programme

		using whole genome analysis. <i>M. Mansfield* (Dublin, Ireland), E. Roycroft, S. Mok, P. Flanagan, M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V. Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers</i>
E0403		<b>Distinguishing relapse from reinfection in tuberculosis patients from Lithuania</b> <i>L. Vasiliauskaite* (Vilnius, Lithuania), L. Vasiliauskaite, A. Zinola, F. Di Marco, V.E. Davidaviciene, B. Nakceriene, A. Vaitulionyte, D.M. Cirillo, T. Kačergius</i>
E0404		<b>Rapid Resistance Profiling of Mycobacterium tuberculosis from Clinical Specimens using Targeted Next-Generation Sequencing: A Pilot Validation Study</b> <i>P. Chheda* (Mumbai, India), S. Shivaprakash, T. Dama, G. Thandassery</i>
E0405		<b>Inflammation precedes early respiratory worsening in HIV-negative tuberculosis patients during antituberculosis treatment</b> <i>A. Van Laarhoven* (Nijmegen, Netherlands), L. Kurver, E. Klein Teeselink, A. Lemson, C. Bosteels, N. Carpaaj, J. Van Ingen, E. Ardiansyah, C. Van Arkel, R. Vullingsh, C. Magis Escurra, W. Hoefsloot, R. Van Crevel</i>
E0406		<b>Impact of fluoroquinolone resistance on the cost-effectiveness of empiric treatment for multidrug- or rifampicin-resistant tuberculosis</b> <i>C. Kim* (London, United Kingdom), S. Sweeney, H. Sohn, G.M. Knight, C.F. Mcquaid</i>
E0407		<b>A longitudinal study on the evolution of drug resistance during tuberculosis treatment</b> <i>E. Danso* (Accra, Ghana), P. Asare, P. Tetteh, A. Tetteh, A.A. Boadu, S. Osei-Wusu, A. Asante-Poku, Y. Klinogo, A. Sylverken, J. Afriyie-Mensah, A. Adjei, D. Yeboah-Manu</i>
E0408		<b>Phase 1, randomized, double-blind, parallel-group, dose-escalation safety and tolerability of PLGA encapsulated first line antitubercular drugs nanoparticles in healthy volunteers</b> <i>A.K. Pandey* (Chandigarh, India), N. Shafiq, S. Malhotra, C. Mothsara, G. Khuller, J. Verma, L. Verma</i>

SEL	13:30 – 15:30	Hall 1
	Special Session	
	PRO	
Selective Pressure		
Chairs	<i>Jacob Moran-Gilad (Beer Sheva, Israel) Joshua Nosanchuk (Bronx, United States) Jose Ramon Pano-Pardo (Zaragoza, Spain) Jesús Rodríguez-Baño (Seville, Spain) Anja Sterbenc (Ljubljana, Slovenia) Suzanne Van Asten (Nijmegen, Netherlands) David Van Duin (Chapel Hill, Nc, United States)</i>	

JS1	13:30 – 14:30	Hall 12
	Journal Session	
Late-breaker research from CMI and CMI Communications		
J001	13:30	<b>Measuring the impact of hospitalization for infectious diseases on the quality of life of older patients in four European countries: the AEQUI longitudinal matched cohort study (2020–2023)</b> <i>Gaetan Gavazzi (Grenoble, France)</i>
J002	13:45	<b>Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial</b> <i>Thomas Holland (Durham, United States)</i>
J003	14:00	<b>The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study</b> <i>Elise Mitri (Heidelberg, Australia)</i>
J004	14:15	<b>Efficacy and safety of mechanical thrombectomy in acute ischemic stroke secondary to infective endocarditis</b> <i>Tba</i>

LB003	13:30 – 14:30	Hall 13
	1-hour Oral Session	
New solutions for difficult-to-treat infection		
L0011		<b>Antimicrobial CRISPR-Cas9-based treatment against antibiotic resistant extraintestinal pathogenic <i>E. coli</i> (ExPEC) ST131C</b> <i>Morros-Bernaus* (Penryn, United Kingdom), J. Westley, E. R. Wyrsh, S. P. Djordjevic, A. F.C. Leonard, D. Sünderhauf, S. Van Houte</i>
L0012		<b>Ultra-narrow spectrum antibiotic against multi-drug resistant gonococci with novel mode of action</b> <i>N. Nguyen* (Vienna, Austria), N. Nhung, A.K. Mix</i>
L0013		<b>Multivalent OMV-based vaccine against <i>Klebsiella pneumoniae</i></b> <i>B. Cano Castaño* (Madrid, Spain), B. Cano-Castaño, A. Tajuelo Moreno-Palancas, S. Prieto Martin-Gil, D. Fouteris, L. Del Pozo Acebo, F. Docando Sánchez, E. Gato, A. Pérez, M.J. McConnell</i>
L0014		<b>Epidermicin NI01, a first-in-class peptide antibiotic candidate, has potent efficacy in a robust MRSA wound infection model and low allergic reaction liabilities</b> <i>M. Upton* (Plymouth, United Kingdom), G. Barker, V. Bennett, I. Fotheringham, S. Baxter, H. Curry</i>
L0015		<b>Minimum inhibitory concentrations of quabodepistat in <i>Mycobacterium tuberculosis</i> clinical isolates from patients with drug-susceptible pulmonary tuberculosis</b> <i>I. Kontsevaya* (Munich, Germany), Y. Hayashi, D. Towle, N. Hariguchi, Y. Liu, S. Takuva</i>

SY094	13:30 – 14:30	Hall 14
	1-hour Symposium	
	AMR PHEI	
Farm to fork: food-borne antimicrobial resistance		
Chairs	<i>Beatriz Guerra Román (Parma, Spain) Joel Mossong (Luxembourg, Luxembourg)</i>	
S0269	13:30	<b>Foodborne risk in meat and fishery products and impact on AMR</b> <i>Anders Dalsgaard (Frederiksberg C, Denmark)</i>
S0270	14:00	<b>Control challenges associated with food-borne multidrug resistance</b> <i>Luisa Maria Vieira Peixe (Porto, Portugal)</i>
Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG)		

ME095	13:30 – 14:30	Hall 16
	Meet-the-Expert	
	AMR CLN	
Local antimicrobials for deep infections		
M0271	13:30	<i>Karolina Akinosoglou (Patra, Greece)</i>
M0272	13:42	<i>Pierre Tattevin (Rennes, France)</i>
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG), ESCMID Study Group for Implant-associated Infections (ESGII), ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)		

OS052	13:30 – 14:30	Hall 2
	1-hour Oral Session	
	CLN DX	
AI in infectious diseases: the lab and beyond		
Chair	<i>Miranda Langendam (Amsterdam, Netherlands)</i>	
O0381		<b>Accurate strain typing of key bacterial pathogens through artificial intelligence analysis of MALDI-TOF mass spectra</b> <i>N. Macesic* (Melbourne, Australia), H.A. Nguyen, A. Peleg, J. Song, J.A. Wisniewski, D.L. Dowe</i>

ESCMID Global 2025 - Programme

00382	CarbaDetector: An Artificial Intelligence-Driven Prediction Model for Detecting Carbapenemase-Producing Enterobacterales Using Disk-Diffusion <i>L.K. Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler, O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht</i>	
00383	AI-Driven Early Infectious Disease Detection in Dutch Primary Care: leveraging Bidirectional Encoder Representations from Transformers (BERT) and Early Recognition using Neural Information Encoding (ERNIE) <i>G. Danoe* (Groningen, Netherlands), M. Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A. Hamprecht, M. Brillman, L.L. Peters, M.S. Berends</i>	
00384	Predicting potentially infection-related findings in structured radiology reports <i>J. Xu* (Oxford, United Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P. Langlotz, D. Eyre</i>	
00385	Application of Artificial Intelligence in Assisting X-ray Diagnosis of Pediatric Pulmonary Infections <i>H. Zhang* (Shanghai, China), X. Xu, J. Ai</i>	

OS053	13:30 – 14:30	Hall 3
	1-hour Oral Session	

Immune evasion and intracellular survival strategies		
Chairs	Juliane Bubeck Wardenburg (St. Louis, United States) Giovanni Delogu (Rome, Italy)	

00386	Capsule-Dependent Modulation of Cell Death Pathways and Immune Evasion in <i>Acinetobacter baumannii</i> <i>H. Wang* (Beijing, China), C. Jiang</i>	
00387	Intracellular lifestyle of <i>Acinetobacter baumannii</i> : Role of phospholipase A2 and transcriptional factor EB (TFEB) <i>Y. Smani* (Seville, Spain), C. Atalaya Rey, I. Molina Panadero, A. Lora González, A. Hmadcha</i>	
00388	The role of <i>peg344</i> of hypervirulent <i>Klebsiella pneumoniae</i> on suppressing autophagy responses of macrophages <i>Z.E. Kuloğlu* (Istanbul, Türkiye), Ö. Albayrak, D. Güllü, G. Ekinçi, F. Can</i>	
00389	c-Myc Inhibits Macrophage Antimycobacterial Response in Mycobacterium tuberculosis Infection <i>C. Dollé* (Zurich, Switzerland), E. Sarti, R. Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander, G.S. Olson, J. Nemeth</i>	
00390	Targeting neutrophil extracellular traps (NETs) prevents tuberculosis immunopathology <i>J. Kutschenreuter* (London, United Kingdom), D. Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman, J.S. Friedland, D.L.W. Chong</i>	

SY091	13:30 – 14:30	Hall 4
	1-hour Symposium	

Emerging infectious diseases: staying informed and prepared in a globalised world		
Chairs	Nitin Gupta (Manipal, India) Pikka Jokelainen (Copenhagen, Denmark)	

S0263	13:30	Lessons learnt from previous outbreaks <i>Tba</i>
S0264	14:00	Disease X: preparedness for the next pandemic <i>Yee Sin Leo (Singapore, Singapore)</i>

Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, Reisemedizin und Globale Gesundheit e.V.

SY092	13:30 – 14:30	Hall 5
	1-hour Symposium	

Sex differences in management and outcome of patients with serious bacterial infections		
Chairs	Michele Bartoletti (Milan, Italy) Merel Lambregts (Leiden, Netherlands)	

S0265	13:30	Sex impacts incidence, management, and outcome in bacteraemia <i>Annette Westgeest (Leiden, Netherlands)</i>
-------	-------	--

S0266	14:00	The complex interplay between gender and sepsis <i>Ines Lakbar (Montpellier, France)</i>
-------	-------	--

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES)

ME101	14:45 – 15:45	Hall 14
	Meet-the-Expert	

How to master conflict management and negotiation in healthcare

M0285	14:45	<i>Esther Calbo (Terrassa, Spain)</i>
M0286	14:57	<i>Jan A.J.W. Kluytmans (Utrecht, Netherlands)</i>

FO102	14:45 – 15:45	Arena 1
	Open Forum	

Navigating the future of pandemics across One Health		
Chair	<i>Xavier Lescure (Paris, France)</i>	

F0287	14:45	Status of the One Health Joint Plan of Action by the Quadripartite <i>Chadia Wannous (Paris, France)</i>
F0288	14:55	National surveillance responsibilities under the updated international health regulations <i>Tba</i>
F0289	15:05	Long-term consequences of emerging viral diseases <i>Alfonso J. Rodriguez-Morales (Pereira, Colombia)</i>

Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID Study Group for Public Health Microbiology (ESGPHM), Trainee Association of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases (SBI), Latin American Society for Travel Medicine

EF059	14:45 – 15:45	Arena 2
	ePoster Flash Session	

Bacterial infections in the post pandemic era		
Chair	<i>Özlem Kurt Azap (Ankara, Türkiye)</i>	

E0424	Genomic epidemiology of invasive meningococcal disease in Scotland: The impact of the COVID-19 pandemic <i>N. Ahmad* (London, United Kingdom), C. Rodrigues, A. Smith, C. Cameron, L. Macdonald, R. Ure, M. Maiden</i>	
-------	--	--

E0425	Targeted probe-capture culture-independent sequencing identifies emergence of Macrolide-Resistant <i>Bordetella pertussis</i> in Australia <i>W. Fong* (Westmead, Australia), R. Rockett, K. Tam, T. Nguyen, E. Sim, C. Suster, J. Agius, S. Chandra, A. Watt, D. Speers, M. Graham, T. Tran, C. Lim, M. Wehrhahn, A. Ginn, D. Gray, J. Robson, L. Papanicolas, I. Gardner, A. Howard-Jones, A. Outhred, K. Kennedy, L. Cooley, Q. Wang, N. Jeoffreys, S. Chen, K. Basile, T. Golubchik, J. Kok, V. Sintchenko</i>	
-------	--	--

E0426	Invasive pneumococcal disease in Spanish adults. Multicenter analysis of serotypes and lineages in the post-pandemic period. <i>R. España Bonilla* (Barcelona, Spain), R. España-Bonilla, A. González-Díaz, J.M. Marimón, A. Manzanal, E. Cercenado, S. De La Villa, B. Viñado, M. Bernat-Sole, M. Campos-Ruiz, M.D. Quesada, A. Casabella, M.L. Machado, R. Tejero, M.Á. Galán, S. Calvo-Silveria, D. Berbel, J. Yuste, S. Martí, J. Cámara, C. Ardanuy</i>	
-------	--	--

E0427	Group A streptococcal infections in Germany from 2017 to 2024: a post-pandemic rebound above expected numbers? <i>A. Von Laer* (Berlin, Germany), J. Mutevelli, A. Dörre, S. Haller, M. Feig, S. Buda, A. Hoffmann, I. Noll</i>	
-------	---	--



ESCMID Global 2025 - Programme

E0428	<b>Invasive group A streptococcus infections is often preceded by seasonal influenza.</b> <i>J. Westin* (Gothenburg, Sweden), M. Nygren, U. Snygg-Martin, L. Gustavsson, N. Sundell</i>
E0429	<b>Impact of the COVID-19 Pandemic on Tuberculosis Transmission Rates.</b> <i>A. Cannas* (Rome, Italy), V. Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, E. Girardi, C. Fontana</i>
E0430	<b>Treatment outcomes of bedaquiline-based longer oral regimens in Indian children above 5-years of age.</b> <i>D. Gandhi* (Mumbai, India), I. Shah, R. Ansari, H. Warse, S. Kalawadia, T. Yangchen, D. Shah, V. Puri, S. Mattoo, M. Bodhanwala</i>
E0431	<b>Incidence of Invasive <i>Escherichia coli</i>/Disease in the Northwestern United States (2002–2022): Insights from Electronic Health Records.</b> <i>M. Blum* (Leuven, Belgium), C. Onwuchekwa, M.A. Schmidt, J. Poolman, T. Verstraeten, J. Geurtsen</i>
E0432	<b>A prospective controlled cross-sectional study demonstrates significantly higher IgG seroprevalence of leptospirosis among Munich's Eisbach river surfers.</b> <i>F. Voit* (München, Germany), D. Schult-Hannemann, M.H. Richter, L. Wagner, J. Ostermaier, K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider</i>
EF060	<b>14:45 – 15:45</b> ePoster Flash Session <b>AMR in the community</b> <i>Chair Camilla Wiuff Coia (Copenhagen, Denmark)</i>
E0433	<b>Socio-demographic factors associated with community-acquired extended spectrum <math>\beta</math>-lactamase producing <i>E. coli</i>/urinary tract infections at intermunicipal level in France.</b> <i>M. Prime* (Nantes, France), O. Lemenand, S. Thibaut, T. Coeffic, B. Perrot, J. Caillon, D. Boutoille, E. Batard, G. Birgand</i>
E0434	<b>Prolonged community outbreak of OXA-48-producing <i>Escherichia coli</i>/linked to a food premises: Lower Hutt, New Zealand, 2018–2022.</b> <i>C. Thornley* (Lower Hutt, New Zealand), M. Kelly, M. Bloomfield, A. Nesdale, R. White</i>
E0435	<b>Low rates of macrolide resistance found in <i>Mycoplasma pneumoniae</i> cases in Australia.</b> <i>R. Rockett* (Westmead, Australia), J. Kok, K.G. Tam, T. Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, V. Sintchenko, S.C.A. Chen</i>
E0436	<b>Epidemiology of antibiotic resistance associated with <i>E. coli</i>/Klebsiella pneumoniae bloodstream infections in England 2012–2023.</b> <i>S. Lipworth* (Oxford, United Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. Sanderson, C. Beck, R. Hope, C. Brown, T. Katy</i>
E0437	<b>The effect of long-term fluoroquinolone prophylaxis on carriage of antimicrobial resistant organisms in children.</b> <i>C. Brand* (Cape Town, South Africa), R. Ocloo, D. Wilck, P. Dube, A. Hesseling, J. Seddon, A. Demers, M. Newton-Foot, A. Whitelaw</i>
E0438	<b>Risk factors and prevalence of AntiMicrobial Resistant microbes In the English Community (AMRIC).</b> <i>D. Lecky* (Gloucester, United Kingdom), Z. Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S. Leaver, K. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown</i>
E0439	<b>Risk factors for antimicrobial resistance in community commensal <i>Staphylococcus aureus</i> isolates, a sub-analysis of the AMRIC project.</b> <i>M. Joyce* (Manchester, United Kingdom), Z. Aiken, N. Zhu, A. Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R. Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards, S. Hopkins, C. Brown, D.M. Lecky</i>
E0440	<b>Prevalence and risk factors for antimicrobial resistance in invasive pneumococcal disease in southern Ontario in the late post PCV13 era (2014–2023).</b> <i>A. McGeer* (Toronto, Canada), A. Shigayeva, A. Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W.</i>

E0441	<b>Antimicrobial resistance in <i>Streptococcus pneumoniae</i> in the Netherlands: an 11-year trend analysis of surveillance data.</b> <i>I. Nauta* (Bilthoven, Netherlands), W. Altorf-Van Der Kuil, D.W. Notermans, A.F. Schoffelen</i>
EF061	<b>14:45 – 15:45</b> ePoster Flash Session <b>Infections in the Immunocompromised: a multifaceted overview</b> <i>Chair Effrossyni Gkrania-Klotsas (Cambridge, United Kingdom)</i>
E0442	<b>Impact of Donor Colonization or Infection, or preservation fluid contamination with Multiresistant Bacteria and Fungi in Solid Organ Transplantation. Multicenter registry of Argentina.</b> <i>L. Barcan* (Buenos Aires, Argentina), A. Smud, P. Giorgio, R. Gago, N. Pujato, M. Martinez, S. Villamandos, C. Niveyro, N. Lasserre</i>
E0443	<b>Analysis of viral load kinetics and risk factors for Epstein-Barr virus DNAemia and Post-transplant lymphoproliferative disorders in pediatric liver transplant recipients - a single centre experience.</b> <i>B. Kasztelewicz* (Warsaw, Poland), K. Skrok, I. Jankowska, P. Kaliciński, K. Dzierżanowska-Fangrat</i>
E0444	<b>Impact of pre-transplant infection on post-transplant morbidity and graft survival in liver transplant recipients: a prospective cohort study.</b> <i>L. Mani-Perren* (Bern, Switzerland), S.F. Perrodin, A. Berzigotti, V. Banz, C. Hirzel, L.N. Walti</i>
E0445	<b>Risks of live-attenuated vaccines in children with primary immunodeficiency.</b> <i>S. Frigui Ep Oueslati* (Tunis, Tunisia), S. Ben Jaafar, S. Frigui, Y. Chebbi, M. Ouederni, W. Achour</i>
E0446	<b>Chagas reactivation/ transmission in kidney transplantation.</b> <i>M. Radisic* (Buenos Aires, Argentina), N. Pujato, M.C. Lopez-Albizu, R. Del Grosso</i>
E0447	<b>Clinical presentation and treatment of tuberculosis in solid organ transplant recipients: a multicentric retrospective analysis.</b> <i>J. Moltó* (Barcelona, Spain), I. Los-Arcos, D. Ruiz Cabrera, L. López González, M. Fayos Pérez, R. Rodríguez-Alvarez, M. Murga De La Fuente, V. Pomar, E. García Vázquez, T. Tórtola, J. Espinosa, O. Len, A. Sánchez-Montalva</i>
E0448	<b>Clinical presentation, risk factors and outcome of non-tuberculous mycobacteria infection in hematopoietic stem-cell transplant recipients: a multinational case-control study.</b> <i>M. Fernandez Ruiz* (Madrid, Spain), M. Fernández-Ruiz, J.T. Silva, P.L. Carver, S. Rutjanaweche, L.F. Aranha-Camargo, R. Fernandes, S. Belga, A. Alghamdi, N.J. Mueller, S. Burkhard, N.M. Theodoropoulos, D.F. Postma, P.J. Van Duijn, F. Arnaiz De Las Revillas, C. Pérez Del Molino-Bernal, J. Hand, A. Lowe, M. Bodro, E. Vanino, A. Fernández-Cruz, A. Ramos-Martínez, M.J. Makek, R. Bou Mjahed, O. Manuel, N. Kamar, A. Calvo-Cano, L. Rueda-Carrasco, P. Muñoz, A. Álvarez-Uría, S. Pérez-Recio, N. Sabé, R. Rodríguez-Álvarez, A. Mularoni, E. Vidal, J. Alonso-Titos, T. Del Rosal, A.Y. Classen, C. Mejía-Chew, F. López-Medrano</i>
E0449	<b>Impact of bronchoalveolar lavage results on clinical decision-making among immunocompromised, critically ill patients.</b> <i>C. Fanelli* (Sassari, Italy), R. Mondaca, R. Colima, D. Prado, R.R. Abud, S. Morales, M.M. Vera, E. Kattan</i>
E0450	<b><i>Campylobacter</i> spp. bloodstream infections: preliminary results from a multicenter differential clinical analysis in immunocompromised and immunocompetent patients.</b> <i>M. Paniagua-García* (Seville, Spain), J.M. Bernal-Aznar, S. Herrera-Espejo1, S. Salto-Alejandro, A. Valiente, M.C. Domínguez, M.Á. López-Zúñiga, F. Cobo, L. Alsina-Manrique De Lara, C. Martí-Castellote, M. Monsonis-</i>

ESCMID Global 2025 - Programme

*Cabed, V. García-López, A. Polo, J. Laporte-Amargos, G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. Galán, M. Chávez-Caballero, M.O. Mohamed-Balghata, S. Winderickx, J.M. García De Lomas, F.J. Martínez-Marcos, M. Giannella, M. Garzaro, M. Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. López Cardenas, E. Cendejas, A.V. Halperin Benito, A. Romero Palacios, M. Navarro, C.A. Alonso, A. Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E. Pachón-Ibáñez, E. Cordero-Matía*

SY100	14:45 – 15:45	Hall 12
	1-hour Symposium	

**The challenge of a healthy microbiota in neonates**

*Chairs* Maria Vehreschild (Frankfurt Am Main, Germany)  
Walter Zingg (Zurich, Switzerland)

S0283	14:45	Infant gut microbiome development	Debby Bogaert (Edinburgh, United Kingdom)
S0284	15:15	Metagenomic signatures and antibiotic disruption of the gut microbiome in neonates	Gautam Dantas (Saint Louis, United States)

Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI), European Society of Paediatric Infectious Diseases (ESPID)

OS058	14:45 – 15:45	Hall 16
	1-hour Case Session	

**In the field with fungi**

*Chairs* Beatriz L. Gomez (Bogota, Colombia)  
Leonardo Nimrichter (Rio De Janeiro, Brazil)

00419		Fosmanogepix expanded access in patients with <i>Fusarium</i> infections	S. Dadwal* (Duarte, United States), A. Baluch, J. Dickter, J.R. Newman, M.H. Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner
00420		Voriconazole's hidden toll: unveiling perioritis in a heart transplant recipient and a hematologic patient.	G. Motoa* (Boston, United States), A. Woolley, N. Issa
00421		Unveiling the Uncommon: Managing <i>Geotrichum candidum</i> in Pancreatic Necrosis	L. Kriegl* (Graz, Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Schlager, G. Zollner, K. Dichtl, R. Krause
00422		Detection of siderophores as a superior non-invasive diagnostic tool in unravelling mixed fungal infections	V. Havlicek* (Prague, Czech Republic), R. Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. Stevens
00423		Efficacy of novel antifungal therapies in refractory <i>Candida</i> and <i>Aspergillus</i> infections: insights from compassionate use and clinical trials	S. Sedik* (Graz, Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl, J. Prattes

OS056	14:45 – 15:45	Hall 2
	1-hour Oral Session	

**Emerging trends in viral hepatitis across Europe**

*Chairs* Federico Garcia (Granada, Spain)  
Neven Papic (Zagreb, Croatia)

00409		One of the largest outbreak of hepatitis A in the 21 <sup>st</sup> century in Europe	I. Hockickova* (Košice, Slovakia), I. Hockicková, J. Hockicko, D. Javorská, Š. Zamba, A. Vasilová, M. Ševčík, A. Cehelská, D. Hudáčková, P. Kristian
00410		Higher prevalence of Cytomegalovirus and Epstein–	

**Barr virus in acute-on-chronic liver failure – cause or consequence?**J. Sonnenberg\* (Muenster, Germany), K. Thiagarajah, E. Görgülü, P. Lembeck, M. Glitscher, F. Uschner, M. Brol, W. Gu, R. Schierwagen, S. Klein, M. Schulz, T. Wiedemann, J. Reißing, J. Söhne, N. Kraus, M. Pratinjo, J. Fischer, H.P. Erasmus, J. Vasseur, S. Zeuzem, H. Storf, C. Welsch, J. Trebicka, S. Ciesek, J. Chang, T. Bruns, E. Hildt, K.H. Peiffer

**Delta in Denmark: current prevalence of hepatitis delta virus infection**H. Watson\* (Lyon, France), P. Jepsen, H. Vilstrup, H. Krarup

**RatHEV as an aetiological agent of acute hepatitis in Europe: results from the ESGHV-RHEV Study**A. Rivero-Juarez\* (Córdoba, Spain), M. Casares, B. Becerril, Á. Dencs, G. Gherlan, J. Caballero, L. Rios-Muñoz, A.B. Pérez, A. Fuentes, C. Freyre, F. Franco-Álvarez De Luna, I. Viciano, M.D.C. Domínguez, M. Altindis, G. Özkaya, A. Rivero, A. Rivero-Juárez

**Understanding the incidence and risk factors of low-level viremia in chronic hepatitis B: A propensity-matched comparison of tenofovir and entecavir**I. Hasanoglu\* (Ankara, Türkiye), R. Guner, E. Zerdali, A. Batirel, Y. Onlen, E. Parlak, B. Kurtaran, S. Tosun, I. Yilmaz Nakir, O. Gunal, N. Eser, H. Yaqoobi, O. Tabki, T. Turunc, U. Balci, S. Komur, E.E. Tutuncu, L.N. Altunal, N.D. Sari, D.S. Yildiz, H.D. Ozkaya, I.E. Yildiz, S. Kaya, O. Karabay, S. Alkan, F. Tabak

OS057	14:45 – 15:45	Hall 3
	1-hour Oral Session	

**Precision Medicine: from models to patient care**

*Chairs* Anouk Edwina Muller (The Hague, Netherlands)  
Sebastian Wicha (Hamburg, Germany)

**Pharmacokinetics and pharmacodynamics of BPaLM, BPaLC and BPaL regimens for treatment of RR-TB**F. Klopogge\* (London, United Kingdom), B.T. Nyang'wa, I. Motta, R. Moodliar, V. Solodovnikova, S. Rajaram, M. Rasool, Z. Huang, C. Berry, G. Davies, D. Moore

**Physiologically Based Pharmacokinetic Modeling for Nemonoxacin in Predicting the Respiratory System Pharmacokinetic Profile: Based on Comprehensive Preclinical and Clinical Data**Y. Chen\* (Shanghai, China), J. Zhao, J. Zhang

**Context-specific genome-scale metabolic modelling reveals metabolic alterations in multidrug-resistant *Klebsiella pneumoniae* in response to polymyxin B/zidovudine combination**J. Zhao\* (Melbourne, Australia), Y.W. Lin, J. Tao, Y. Zhu, T. Velkov, J. Li

**Agent-based model predictions of polymyxin B activity on *Acinetobacter baumannii***H. Soeorg\* (London, United Kingdom), Y. Yuan, J. Readman, J.F. Standing

**Monthly dalbavancin dosing for suppressive therapy: a case series and pharmacokinetic estimation analysis**C. Volk\* (Madison, United States), W. Kufel, P. Hutson, R. Mahapatra, W. Rose

SY099	14:45 – 15:45	Hall 4
	1-hour Symposium	

**How innovations of AMR and HAI surveillance systems help the clinical practice**

*Chairs* Pascal Astagneau (Paris, France)  
Mandy Wootton (Cardiff, United Kingdom)

S0281	14:45	The EUCAST system in surveillance of AMR	Sören G. Gatermann (Bochum, Germany)
S0282	15:15	Insights into developments in the surveillance of HAIs	Diamantis Plachouras (Solna, Sweden)

Co-organised with: EUCAST Steering Committee, EUCIC Steering Committee, European Centre for Disease Prevention and Control (ECDC)

ESCMID Global 2025 - Programme

Movie Session		15:00 – 18:30	Hall 5
Special Session			
Behind the scenes: Contagion			
Chairs		William Hanage (Boston, United States) Luigia Scudeller (Pavia, Italy)	
SY107	16:15 – 17:15	Hall 15	
<div>PRO</div> <div>PHEI</div>		1-hour Symposium	
Communicating (your) ID science for policy and societal impact			
Chairs		Leonard Leibovici (Petah-Tiqva, Israel) Ines Steffens (Solna, Sweden)	
S0297	16:15	Communicating to policy makers and for societal impact Balázs Babarczy (Budapest, Hungary)	
S0298	16:45	Influencing behaviour through the media and a multichannel communications strategy Charlotte Hutchinson (London, United Kingdom)	
Co-organised with: CMI Board of Editors			
EW109	16:15 – 18:15	Hall 2	
<div>CLN</div> <div>VAX</div>		Educational Session	
Infections in cancer patients: tips for daily practice			
Chairs		José Molina Gil-Bermejo (Seville, Spain) Stefan Schwartz (Berlin, Germany)	
W0301	16:15	Tailoring pharmacologic prophylaxis in patients with non-haematologic cancer: from viruses to fungi Janne Vehreschild (Frankfurt, Germany)	
W0302	16:35	Pneumonitis or pneumonia? A practical approach to lung infiltrates in patients with solid tumours Tba	
W0303	16:55	The diagnostic dilemmas and treatment challenges of mycobacteria in cancer patients Şiran Keske (Istanbul, Türkiye)	
W0304	17:15	HTLV-1 and T-cell lymphoma - predict & prevent Lucy Cook (London, United Kingdom)	
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), International Immunocompromised Host Society (ICHS)			
EF065	16:15 – 17:15	Arena 1	
<div>ANT</div> <div>TRN</div>		ePoster Flash Session	
The Antibiotic bakery: Novel compounds in the pipeline			
Chair		Susanne Haeussler (Braunschweig, Germany)	
E0471	In vitro activity and In vivo proof-of-efficacy of epimutillin derivatives AR-7732, AR-7731, AR-9842 and AR-10058 against AMR bacterial pathogens S. Paukner* (Vienna, Austria), W.W. Wicha		
E0472	SC5005 and DHA: A Novel, Rapid-Acting Combination Therapy for Biofilm Eradication in Catheter-Associated Infections Y. Hui Hui* (Taipei, Taiwan, China), H.H. Yeo, H.N. Huang, Y.T. Huang, Y.S. Lu, H.C. Chiu		
E0473	In vitro potency of ceftibuten with xeruborbactam against $\beta$ -lactamase-producing Isolates of Enterobacteriales (ENT) from the SENTRY global surveillance programme O. Lomovskaya* (San Diego, California, United States), M. Castanheira, J. Lindley		
E0474	Effect of novel antimicrobial peptides SET-M33L and SET-M33L-PEG on <i>Pseudomonas aeruginosa</i> biofilm formation. A. Fontanot* (Rotterdam, Netherlands), W. Unger, J. Hays, P. Croughs, A. De Bruijn, C. Falciani, A. Pini, R. Ecker, I. Ellinger		

E0475	Broad spectrum coverage of serine $\beta$ -lactamase and high <i>in vitro</i> potency against KPC- and OXA-48-like-producing Enterobacteriales of meropenem in combination with the novel diazabicyclooctane $\beta$ -lactamase inhibitor ANT3310L. Sánchez-Peña* (A Coruña, Spain), S. Rodríguez-Pallares, T. Blanco-Martín, L. González-Pinto, M. Outeda-García, P. Aja-Macaya, I. López-Hernández, J.C. Vázquez-Ucha, G. Bou, A. Beceiro, J. Arca-Suárez		
E0476	Antibacterial potential of D-limonene and diallyl disulfide and their interaction with gentamicin against multidrug-resistant <i>Pseudomonas aeruginosa</i> in rat pneumonia model Y. Almuhanha* (Shaqra, Saudi Arabia), M. Asad		
E0477	<i>In vivo</i> pharmacokinetic/pharmacodynamic targets of a novel macrolide antibiotic naffithromycin, determined in neutropenic murine lung infection model of <i>Streptococcus pneumoniae</i> A. Muller* (The Hague, Netherlands), R. Chavan, S. Takalkar, V. Zope, K. Umarkar, P. Tayde, M. Tellis, S. Bhagwat, M. Patel, B. Veeraraghavan		
E0478	NiPharmins: novel low resistance-inducing antimicrobials with antibiofilm activity against <i>Staphylococcus aureus</i> A. Nunes* (Lisbon, Portugal), B. Alves, J.P. Carrilho, N.R. Candeias		
EF066	16:15 – 17:15	Arena 2	
	ePoster Flash Session		
VAX			
Modelling infectious disease burden and impact of vaccination			
Chair	David Fisman (Toronto, Canada)		
E0480	Evaluating the Impact of Re-vaccination on Pneumococcal Disease in Individuals Previously Vaccinated with PPSV23 in Germany: Comparative Approach O. Sharomi* (Mt Carmel, United States), S. Oluwaseun, M. De Lepper, S. Mihm, T.C. Reuter, C. Solleder, G. Meleleo, T. Malik, K. Bakker, R. Oidtman		
E0481	Modeling the public health impact of a 21-valent PCV in the Canadian adult population O. Sharomi* (Rahway, United States), R. Oidtman, M.C. Meilleur, S. Weinrich, K. Bakker		
E0482	Estimating the health and economic burden of pneumococcal diseases attributable to PCV21 (V116) vs. PCV20 or PPSV23 serotypes among adults in Norway Z. Yi* (Rahway, United States), A.A. Tajik, S.T. Klitkou, E. Tsoumani, K. Owusu-Edusei		
E0483	Shifting from risk-based to age-based approach for pneumococcal vaccination in adults in France: a comprehensive evaluation O. Sharomi* (Mt Carmel, United States), S. Oluwaseun, M. Breau-Brunel, F. Gaëlle, B. Lionel, C. Jérémy, M. Giulio, N. Robert, O. Rachel, M. Tufail, B. Kevin		
E0484	The socio-economic value of adult respiratory immunisation programmes in the United Kingdom – Are we measuring what matters to society? C. Harrison* (Tadworth, United Kingdom), T. Hu, J. Yang, J. Vietri, D. Mendes, S. Chowdhury, C. Theakston, S. Brassel, L. Steuten		
E0485	Improving Danish all-cause mortality monitoring by nowcasting weekly deaths A. Kalnæs* (Copenhagen, Denmark), J. Nielsen, L. Vestergaard, S. Nørgaard		
E0486	Modelling to identify an optimal ring vaccination strategy to mitigate a smallpox outbreak V. Costantino* (Sydney, Australia), M. Kunasekaran, T. Leroyd, K. Yeo, R.C. Macintyre		
E0487	The impact of introducing meningococcal C/ACWY booster vaccination among adolescents in Germany: a dynamic transmission modelling study F. Günther* (Berlin, Germany), U. Reinacher, S. Chisholm, M. Griskaitis, M. Höhle, S. Scholz, V. Schönfeld, O. Wichmann, T. Harder, F.G. Sandmann		
E0488	Potential public health impacts of gonorrhoea vaccination programmes under declining incidences: a modelling analysis L. Geng* (Singapore, Singapore)		
EF067	16:15 – 17:15	Arena 3	



ESCMID Global 2025 - Programme

CLN		ePoster Flash Session
Blood parasitology at its best		
Chair Miriam José Álvarez-Martínez (Barcelona, Spain)		
E0489	Unexepected P.malariae diagnosis in Italian woman with no history of travel to endemic areasA. Busni* (Milan, Italy), L. Tartaglione, S. Torri, A. Longhi, E.M. Zavaroni, F. Crippa, C.S. Vismara	
E0490	A blue-hued mystery: Primaquine-induced methemoglobinemia in mixed infection with Plasmodium vivax and Plasmodium falciparumU.A. Zainulabid* (Pahang, Malaysia), X.K. Cheong, P. Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W. Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris	
E0491	Trick or Treat? An unrelenting malaria caseC. Uhomoibhi* (Dublin, Ireland), E. De Barra, C. Leddy, A. Brown	
E0492	"64% Parasitaemia in Falciparum Malaria: Challenges in Managing Severe Infection and Delayed Haemolysis" F. Murphy* (Dublin, Ireland), A. Albadí, P. Coakley, C. McNally	
E0493	Benznidazole treatment in Chagas Disease: a case series in Luigi Sacco Hospital, Milan (Italy) F. Sabaini* (Milan, Italy), A. Giacomelli, M. Beltrami, L.R. Galimberti, S. Antinori	
E0494	The Challenge of Managing Visceral Leishmaniasis in Immunocompromised Patients S. Vita* (Rome, Italy), A. D'abramo, A. Corpolongo, M.V. Tomassi, F. Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G. Maffongelli, E. Nicastrì	
E0495	Diagnosis and management of visceral leishmaniasis in children in France : a national retrospective study J. De Larminat* (Paris, France), N. Dahane, N. Argy, M. Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Pineau, P. Picherit Steinbrucker, S. Azohana, S. Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye	
E0496	Chronic cutaneous leishmaniasis following visceral leishmaniasis in a pediatric patient: a rare report of extensive facial involvement A. Mohita* (Bikaner, India)	
E0497	Therapeutic challenges in the management of Disseminated leishmaniasis in a patient with HIV co-infection N. T R* (Jodhpur, India), T. Kanagiri, S. Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit, G.K. Bohra	

EF068	16:15 - 17:15	Arena 4
ePoster Flash Session		

AMR PHEI		A global perspective on antimicrobial resistance surveillance
Chair Mirfin Mpundu (Lusaka, Zambia)		
E0498	Global, regional and country-level prevalence of antimicrobial resistance in human bacterial infections under surveillance in WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS) E. Van Kleef* (Geneva, Switzerland), O. Tosas Auguet, S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S. Cooper, A.S. Dean, S. Bertagnolio	
E0499	Comparative analysis of antimicrobial resistance (AMR) burden across European countries A. Dörre* (Berlin, Germany), A. Meinen, S. Haller, G. Robles Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns	
E0500	Setting up a regional AMR surveillance network in the Netherlands: challenges and opportunities C. Van Rossum* (Nijmegen, Netherlands), C. Meijer, P. Koopman, D. Van Der Vegt, T. De Groot, M. Nabuurs-Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E. Bowles, A. Tostmann, C. Van Der Veer, S. Pas	
E0501	Bridging gaps in antimicrobial resistance surveillance: the CAESAR network's first decade R. Janssen* (Bilthoven, Netherlands), S. Woudt, D. Boudville, C. Ruesen, W. Van Den Reek, J. Monen, O. Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M.	

Gelormini		
E0502	Global, regional, and national temporal trends in mortality for carbapenem-resistant bacteria from 1990 to 2021: An age-period-cohort analysis C. Zhihui* (Shanghai, China), Z. Mingchen, W. Jing, Y. Xiangru, J. Jialin, Z. Wenhong	
E0503	Global Trends and Impact of Antimicrobial Resistance in Paediatric Populations: An Analysis Using WHO AWaRe Classification and Priority Pathogens Joseph Harwell (North Melbourne, Australia)	
E0504	Antibiotic resistance profile and comparative evaluation of WHO AWaRe Guidelines at the Emergency's Children's Surgical Hospital in Uganda L. Barcellini* (Milan, Italy), F. Riccaboni, V. Fabiano, F. Forlanini, A. Banfi, E. Crivellaro, A. La Mendola, A. Mohammed Zain, G.V. Zuccotti, L. Folgori, L. Napolitano	
E0505	Initiatives in antimicrobial resistance surveillance: Using automated bacteraemia surveillance for hospital-wide multidrug resistance monitoring F.D. Ruether* (Berlin, Germany), L.A. Peña Díaz, M. Behnke, C. Geffers, S.J.S. Aghdassi	
E0506	Global and regional prevalence of antimicrobial resistance in GLASS target bacterial pathogens for bloodstream, urinary tract and gastrointestinal infections: a systematic review of the global literature (2019-2024) B. Caddey* (Calgary, Canada), G. Lazarus, S. Bertagnolio, D.B. Nobrega, R.L. Hamers, A. Dean, V.K. Wangsaputra, F. Febrina, J.M. Conly, H.W. Barkema, E. Van Kleef, O. Tosas-Auguet	

KN103	16:15 - 17:15	Hall 1
CLN		
Keynote Lecture		

Tuberculosis: where are we now and where should we be		
Chairs Jon S. Friedland (London, United Kingdom) Delia Goletti (Rome, Italy)		

K0290	16:15	Guy Thwaites (Ho Chi Minh City, Vietnam)
-------	-------	--

OS063	16:15 - 17:15	Hall 11
DX		
1-hour Oral Session		

Improving blood culture diagnostics: rethinking the basics		
Chairs Direk Limmathurotsakul (Bangkok, Thailand) Pilar Retamar Gentil (Seville, Spain)		

O0461	Blood culture volume, guideline adherence and pathogen yield of 35,433 paediatric blood cultures in Germany J. Forster* (Würzburg, Germany), A.L. Sieg, V. Rücker, H. Haefner, T. Bähr, S. Rössler, J. Held, V. Le Saout - Chapot, M. Hogardt, B. Spielberger, E.A. Idelevich, M. Christner, S. Zimmermann, S. Schneitler, M. Mauritz, C.S. Stingu, M. Gerlach, U. Von Both, S. Schoeler, L. Marr, J. Zens, E. Komini, M. Krone	
O0462	Changing the paradigm: are two sets of blood cultures always needed? R. Rosa* (Miami, United States), J. Somani, K. Manzanillo, H. Dinh, G. Rosello, L. Abbo	
O0463	Evaluating clinical and economic impact of reducing blood culture incubation timings: Time to shift the paradigm? R. Gupta (bagga)* (London, Canada), R. Gupta, J. Delpoit, T. Mazzulli	
O0464	Revolutionizing hospital workflows with blood culture-free ultra-rapid antimicrobial susceptibility testing: A clinical pilot study S. Kwon* (Seoul, Korea, Republic of), K. Sunghoon, K. Dong Young, J. Jisung, K. Tae Hyun, K. Junwon, J. Hyelyn, L. Gi Yoon, P. Wan Beom	
O0465	Human <i>In vivo</i> footprints from blood plasma for improved diagnostics in sepsis M. Sonntag* (Stuttgart, Germany), J. Mueller, A. Von Haeseler, Y. Vainshtein, S.O. Decker, T. Brenner, K. Sohn	

ESCMID Global 2025 - Programme

ME108	16:15 – 17:15	Hall 12
	Meet-the-Expert	
	CLN	
Navigating travel medicine: expert tips for safe international travel		
M0299	16:15	Sophie Schneitler (Homburg, Germany)
M0300	16:27	Andreas Neumayr (Basel, Switzerland)
OS062	16:15 – 18:15	Hall 13
	2-hour Oral Session	
	CLN DX TRN	
Heterogeneity and complexity of sepsis		
Chairs	Despoina Koulenti (London, United Kingdom) Sylvain Meylan (Lausanne, Switzerland)	
O0451	<b>A consensus immune dysregulation framework for sepsis: results of the SUBSPACE consortium.</b> A. Moore* (Emerald Hills, United States), T. Sweeney, A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin-Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B. Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I. Martin-Loeches, A. Garduno, J. Sevransky, D. Wright, R. Rothman, M. Atreya, L. Moldawer, P. Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. Meyer	
O0452	<b>BLOODICU: Bloodstream infections and their outcomes in ICU patients - Insights from the PROSAFE Study</b> C. Genovese* (Milan, Italy), M. Offer, G. Tricella, G. Scaglione, E. Palomba, G. Montrucchio, F. Agostini, F. Dore, G. Monti, B. Viaggi, A. Gori, S. Finazzi, M. Colaneri	
O0453	<b>Deciphering the Dynamics of <i>Klebsiella pneumoniae</i> Colonization and Infection: Genomic Insights and Microbiome Interactions in ICU Patients</b> W. Yu* (Beijing, China)	
O0454	<b>Antibiotics with anti-anaerobe activity promote enteric pathobionts in ICU patients</b> S. Taylor* (Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Papanicolas	
O0455	<b>Association between blood culture time to positivity and 30-day bacteremia mortality differs for bacterial groups</b> M.H. Øvre* (Herlev And Gentofte, Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. Hansen, T.S. Itenov, B.J. Holzknecht	
O0456	<b>Treatment patterns of patients with sepsis/SIRS/septic shock treated with ceftolozane/tazobactam - results from SPECTRA.E</b> Yucel* (Rahway, United States), A. Soriano, F. Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich, J. Levy, H. Yang, S. Kaul	
O0457	<b>Risk of myocardial infarction and stroke following bloodstream infection: a population-based self-controlled case series</b> J. Underwood* (Cardiff, United Kingdom), N. Reeve, V. Best, A. Akbari, H. Ahmed	
O0458	<b>Is transthoracic echocardiography required in all patients with <i>Staphylococcus aureus</i> bacteremia? Validating the VIRSTA and VIRSTA+ scores to define the population at low risk of endocarditis</b> M. Verdejo Gómez* (Barcelona, Spain), D. Malano-Barletta, M.Á. Verdejo, G. Cuervo, C. Pitart, M. Hernández-Meneses, M. Bodro, S. Herrera, C. García-Vidal, P. Puerta, A. Del Río, M. Espasa, J.A. Martínez, L. Morata, A. Soriano	
O0459	<b>DNA methylation changes in Sepsis: Potential use as biomarkers</b> I. López-Cruz* (Valencia, Spain), J.L. García-Giménez, L. Piles, M. Madrazo, G. Judit, M. López-Torres, A. Artero	
O0460	<b>Host response plasma biomarkers and transcriptomic alterations in critically ill patients with suspected aspiration pneumonia</b> S. Doeleman* (Amsterdam, Netherlands), D. Susanne, E. Michels, J. Butler, F. Uhel, O. Cremer, T. Van Der Poll	

SY106	16:15 – 17:15	Hall 14
	1-hour Symposium	
	AMR TRN	
Strain dynamics in determining gut microbial colonisation resistance		
Chairs	Silvio Daniel Brugger (Zurich, Switzerland) Li Yang Hsu (Singapore, Singapore)	
S0295	16:15	<b>Strain dynamics in serious bacterial infections in infants</b> Drew Schwartz (Saint Louis, United States)
S0296	16:45	<b>Long-term colonisation dynamics of carbapenemase-producing Enterobacterales</b> Niranjan Nagarajan (Singapore, Singapore)
OS064	16:15 – 17:15	Hall 16
	1-hour Oral Session	
	DX PHEI VAX	
Viral immune response - nature or nurture? Exploring the limits of immune response		
Chairs	Malin Flodström-Tullberg (Stockholm, Sweden) Florian Krammer (New York, United States)	
O0466	<b>Orthopoxvirus-specific antibody dynamics up to two years after monkeypoxvirus infection or vaccination</b> C. Van Dijk* (Antwerp, Belgium), N. Berens-Riha, L. Zaech, I. Brosius, R. De Vries, J. Marien, L. Liesenborghs	
O0467	<b>DENG-VAC study: preliminary data on immunogenicity and reactogenicity of Qdenga vaccine versus natural infection</b> A. D'abramo* (Rome, Italy), S. Vita, F. Colavita, E. Cimini, P. De Marco, E. Lalle, G. Maffongelli, L. Rosa, S. Cammisa, G. Delia, M. Fabrizio, N. Emanuele	
O0468	<b>Long-Lasting Immunity Followed by Natural CCHFV Infection</b> H. Karakoc* (Trabzon, Türkiye), H.N. Karakoç Parlayan, A. Aslanabadi, D. Yapar, Q. Murphy, G. Kaplan, O. Akdoğan, A. Çelikbaş, A. Koroglu, F. Aksoy, E. Karaaslan, A. Abbasi, M. Karimi, M. Hojabri, G. Yilmaz, S.M. Ciupe, S.D. Pegan, É. Bergeron, G. Lewis, N. Baykam, M.M. Sajadi	
O0469	<b>Why does rabies virus not induce an anti-viral immune response : insights from experimental models and a human cohort</b> C. Geurts Van Kessel* (Rotterdam, Netherlands), C. Embregts, A. Gohar, B. Verstrepen, J. Aijaz, N. Salahuddin, C. Geurtsvankessel	
O0470	<b>Establishing a human challenge model for human metapneumovirus: disease characteristics and immune responses</b> N. Noulin* (London, United Kingdom), A. Mann, N. Veselinski, J. Mori, B. Löndt, K. Bradley, M. Kalinova, S. Ascough, G. Boivin, C. Chiu, A. Catchpole	
SY104	16:15 – 17:15	Hall 3
	1-hour Symposium	
	IPC	
Targeted vs. standard perioperative prophylaxis in Solid Organ Transplant with MDR Gram-negative colonisation		
Chairs	Elda Righi (London, United Kingdom) David Van Duin (Chapel Hill, Nc, United States)	
S0291	16:15	<b>Standard prophylaxis</b> Maddalena Giannella (Bologna, Italy)
S0292	16:45	<b>Targeted approaches</b> Maristela P. Freire (Sao Paulo, Brazil)
Co-organised with: European Association for the study of the liver (EASL)		
SY105	16:15 – 17:15	Hall 4
	1-hour Symposium	

ESCMID Global 2025 - Programme

Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and therapeutic approach

Chairs Robert A. Bonomo (Cleveland, United States)  
Arjana Tambic Andrasevic (Zagreb, Croatia)

S0293 16:15 Novel beta-lactams and beta-lactamase inhibitors: challenges for laboratory diagnosticsAnna Sramkova (Pilsen, Czech Republic)

S0294 16:45 Clinical perspectives of novel beta-lactams and beta-lactamase inhibitorsParikshit Prayag (Pune, India)

Co-organised with: EUCAST Steering Committee

LB004 16:15 – 18:15 Hall 9  
2-hour Oral Session

Trials in severe infections

Chair Steven Tong (Melbourne, Australia)

L0016 16:15 Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): a randomised, pragmatic trialF. Cogliati Dezza\* (Seville, Spain), L. Barrera Pulido, I. Borreguero Borreguero, F. Docobo Pérez, V. Palomo Jiménez, S. De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. Horcajada, E. Merino, M. Parra, J. López-Contreras, A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. Lopez Cardenas, M.C. Gómez Sanchez, I. Pérez Camacho, S.M. Martin Ramos, E. Leon Jimenez, A.I. Aller García, M.T. Pérez-Rodríguez, A. Sousa, M.C. Fariñas, A.D.L.R.A. Fracisco, L. Gisbert Pérez, J. Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, M.J. García País, R. Escudero Sanchez, S. De La Villa, J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz-Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez-Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño Álvarez, Z.R. Palacios Baena, L. López Cerero, J. Rodríguez-Baño

L0017 16:27 HRS-8427 versus imipenem-cilastatin for complicated urinary tract infections: a randomised, double-blind phase 2 studyM. Ju\* (Shanghai, China), M. Wang, J. Yuan, H. Huang, G. Bi, J. Lyv, X. Lyv, L. Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q. Zhang

L0018 16:39 Efficacy and safety in a Phase 2 study of intravenous BV100 combined with polymyxin B versus best available therapy in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to carbapenem resistant *Acinetobacter baumannii*G. Dale\* (Basel, Switzerland), F. Fratreskaki, I. Tsagkaris, A. Armaganidis, M. Katsiashvili, D. Kazaishvili, T. Gaphrindashvili, K. Japaridze, E. Mouloudi, M. Kapanadze, T. Kachibaia, A. Sarkany, E. Zakynthinos, P. Delique, M. Davila, L. Husband, P. Timofeev, F. Jung, C. Kemmer

L0019 16:51 Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trialM. Canetti\* (Tel Aviv, Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Magiel, N. Baharav, A. Belkin, I. Margalit, V. Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G. Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S. Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A. Wieder-Finesod, N. Maggio, D. Yahav

L0020 17:03 Randomised placebo controlled trial of faecal microbiota transplantation to tackle antimicrobial resistance: inducing bacteriophage network remodelling and enteric pathogen reductionL.A. Edwards\* (London, United Kingdom), B. Auch, T. Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T. Tranah, J.M. Blanco, L. Meoli, A. Clavé Llavall, V.T. Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I. Liachko, S. Goldenberg, D.L. Shawcross

L0021 17:15 Double-dose dolutegravir and lamivudine versus efavirenz-based antiretroviral therapy for patients

coinfected with HIV and tuberculosis: a multicentre, open-label, randomised trialY. Shen\* (Shanghai, China), X. Le

L0022 17:27 Initial vancomycin taper for the prevention of recurrent *Clostridioides difficile* infection: the TAPER-V randomised controlled trialE.G. McDonald\* (Montreal, Canada), Y. Chen, B. Coburn, N. Daneman, S. Hota, C. Frenette, C.E. Kandel, L. Kong, Y. Longtin, V.G. Loo, D. Macfadden, M. Muller, T.S. Steiner, L. Valiquette, T.C. Lee

L0023 17:39 Beneficial effects of a clinical metagenomics intervention on clinical outcomes, healthcare economics, and quality of life in patients with sepsis/septic shock: results of the DigiSep-trial T. Brenner\* (Essen, Germany), A. Skarabis, S.J. Schaller, T. Von Grootte, C. Putensen, U. Günther, M. Sauer, S.O. Decker, F. Dusse, M. Weiss, K. Suchodolski, T.P. Simon, P. Rosenberger, O. Moerer, M. Unterberg, J.C. Schewe, H. Bracht, S. Hutzl, M. Feißt, U. Marschall, P. Brandenburg, J. Englisch, P. Stevens, J. Schmidt, M.W. Pletz, J. Brands, A. Antinoro, L.O. Warner, M.A. Weigand, D.M. Hart, G. Marx, J. Mossanen, T. Breuer, H. Häberle, K. Nitzsche, P. Thalmann, J. Brezinski, J. Saam, T. Schwerhoff, S. Grumaz, M. Steinmann, M. Gaasch, B. Pasioka, U. Jaekel, T. Brandenburger, F. Bach, H. Mutlak, S. Utzolino, M.M. Berger

L0024 17:51 Shortened antibiotic treatment for 5 days in patients hospitalised with community-acquired pneumonia (CAP5): a multicentre randomised controlled noninferiority trialS. Bastrup Israelsen\* (Hvidovre, Denmark), L. Hagens Mygind, F. Al-Zergani, B. Lindegaard, A. Knudsen, S. Tingsgård, L. Thorlacius-Ussing, I. S. Johansen, H. Nielsen, P. Ravn, T. Benfield

L0025 18:03 High-dose rifampicin in the treatment of tuberculous meningitis: results of the HARVEST phase III multi-country randomised clinical trialR. Van Crevel\* (Nijmegen, Netherlands), D. Meya, R. Rovina, D. Boulware, B. Dai, N. Engen, F. Cresswell, K. Naidoo, A. Rizal, D. Imran, R. Lessels, L. Tugume, R. Hamers, M. Kabahubya, S. Marais, Y. Moosa, N. Bahr, E. Svensson, L. Te Brake, R. Aarnoutse

EF074 17:30 – 18:30 Arena 1

ePoster Flash Session

New methods for rapid pathogen detection and typing

Chair Sylvain Brisse (Paris, France)

E0532 Rapid detection of Shiga toxin-producing *Escherichia coli* (*stx2a* and *stx2d*) in Korean diarrheal stool samples: a performance evaluationL. Hyeonji\* (Seoul, Korea, Republic of), H.J. Lee, H.J. Kim, S.S. Choi, H.J. Choo, H.J. Huh, E.J. Won

E0533 Global prevalence of O-serotypes and antibiotic resistance among extraintestinal pathogenic *Escherichia coli*/isolated from older adult patients with bacteraemia (2011–2021)J. Geurtsen\* (Leiden, Netherlands), M. De Been, O. Go, M. Aitabi, C. Willame, E. Weerdenburg

E0534 Strategy for the rapid typing of *Salmonella* spp using infrared spectroscopy: a one health perspectiveJ. Jiménez\* (Santiago, Chile), D. Fredes, A. Piña, I. Mercado, J. Miranda, S. Henriquez, T. González, A. Adell, A. Moreno-Switt, A. Wozniak, P. García

E0535 WGS-based surveillance as a paradigm shift in outbreak detection, AMR monitoring and source attribution in *Campylobacter*A. Nunes\* (Lisbon, Portugal), M.L. Lemos, S. Ortiz, I. Santos, S. Ramos, M. Oleastro

E0536 Prevalence of *Staphylococcus aureus* clonal complex 97 amongst BORSA isolates in a large UK hospitalH. Gareth\* (Birmingham, United Kingdom)

E0537 The effectiveness of clinical laboratory tools in the surveillance of nontuberculous mycobacterium isolations within different counties in TaiwanH.W. Chu\* (Taipei, Taiwan, China), T.F. Lee, C.C. Shu, Y.T. Huang

E0538 Rapid detection of oxazolidinone-resistance-related



ESCMID Global 2025 - Programme

	mutations in <i>Enterococcus</i> spp. by using High Resolution Melting-qPCR-typing analysis <i>R. Musumeci*</i> (Monza, Italy), <i>E. Giordano, M. Martinelli, M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P. Congedo, C.E. Cocuzza</i>
E0539	An automated pipeline to genotype bacteriophages using third generation sequencing <i>Z. Halász*</i> (Debrecen, Hungary), <i>E. Szoták, L. Dr. Laczkó, G. Dr. Kardos</i>
E0540	Novel approach for fast, automated strain typing and source tracking by Fourier-transform infrared spectroscopy <i>N. Mauder*</i> (Bremen, Germany), <i>M. Cordovana, M. Kostrzewa</i>

EF075	17:30 – 18:30	Arena 2
	ePoster Flash Session	

Healthcare (workers') safety revisited	
Chair	<i>Daniel Diekema (Harpwell, United States)</i>

E0541	Preparedness and cooperation throughout the chain of care during regional-level outbreaks with multidrug resistant organisms: a network analysis and interview study <i>B. Beishuizen*</i> (Bilthoven, Netherlands), <i>M. Stein, A. Tostmann, C. Rovers, A. Timen</i>
E0542	Preparing First-Line health care workers for 'Virus X' through targeted training (FILI-VI-X) <i>A. Mondelaers*</i> (Antwerp, Belgium), <i>Y. Somers, K. Vanden Driessche, I. Brosius, L. Liesenborghs, C. Rovers, L. Zweers, M. Wieland, E. Vlieghe</i>
E0543	Analysis of the current situation of hospital inspection practices by German health authorities <i>A. Schwabe*</i> (Bonn, Germany), <i>J. Dannenberg, A.D. Wolkopf, F. Droop, S. Engelhart, N.T. Mutters</i>
E0544	A nationwide survey on the status and implementation of infection prevention and control practice on behalf of INSIEME Project (Italian National project for contrast antibiotic resistance a cooperation between Simit (Italian society of infectious diseases) E (&) Ministry of hEalth) <i>M. Meschiari*</i> (Modena, Italy), <i>F.V. Segala, E. Ricchizzi, A. Gallerani, V. Scaglione, R. Castoldi, F. Almerigogna, I. Spalliera, A. Parente, S. Coladonato, P. Grimaldi, C. Camaioni, M. Abbott, A. Carretta, S. Audagnotto, A. Pan, C. Fanelli, S. Cicalini, P. Tanzili, E. Ponatali, I. Gentile, R.F. Del Vecchio, A. Oliva, A. Mularoni, M. Lichtner, F. Di Gennaro, A. Marino, R. Murri, C. Mussini</i>
E0545	High level of measles immunity among Dutch healthcare workers with self-reported "unknown" measles immunity status. <i>C. Meijer*</i> (Nijmegen, Netherlands), <i>J. Leijser, M. Mccall, C. Rovers, E. Bowles, N. Van Der Geest, A. Tostmann</i>
E0546	Factors associated with positive latent TB screening results in healthcare workers at two tertiary referral hospitals in Ireland <i>C. Anderson*</i> (Dublin, Ireland), <i>D. Mcgee, M. Coleman, A. Hehir, L. Dolan, N. Noonan, V. Tormey, C. Bergin, C. Fleming, L. Townsend</i>
E0547	Systematic review of determinants of vaccine hesitancy among healthcare workers <i>V. Gabellone*</i> (Lecce, Italy), <i>F. Nuccetelli, R. Prato, E. Gabrielli, P.L. Lopalco</i>
E0548	Post-pandemic questions on vaccine usage: Two qualitative analyses of open-ended responses comparing hypothetical and novel vaccines <i>P. Shamsrizi*</i> (Hamburg, Germany), <i>S. Eitze, D. Heinemeier, A. Tänzer, M.A. Jenny</i>
E0549	Do healthcare professionals working in acute healthcare settings identify infection prevention and control related knowledge deficits? <i>A. Kearney*</i> (Dublin, Ireland), <i>H. Humphreys, D. Fitzgerald Hughes</i>

EF076	17:30 – 18:30	Arena 3
-------	---------------	---------

	ANT CLN	ePoster Flash Session
Knowing me, knowing you: behaviour influencing AMS		
Chair	<i>Elena Carrara (Verona, Italy)</i>	

E0550	Exploring determinants in deciding the optimal antimicrobial dose in patients relieving CRRT: a mixed method study <i>T. Yanik Yalçın*</i> (Ankara, Türkiye), <i>A. Pehlivanlı, İ. Yeşiler, H. Şahintürk, Ö. Azap, H. Arslan, B. Başgut, P. Zeyneloğlu</i>
E0551	Behaviour change vs policy change: Key drivers of inappropriate antibiotic use among health care professionals in LMICs – insights from Indian community setting <i>N. P Mathew*</i> (Manipal, India), <i>U. B. M. Varma, V. K E, R. Ruiter, G. Thunga, C. Mukhopadhyay</i>
E0552	Contextual determinants to antimicrobial stewardship implementation in 16 hospitals: a four-country analysis in Asia <i>H. Vu Thi Lan*</i> (Ha Noi, Vietnam), <i>R. Limato, H.Y. Duong, S. Manandhar, D. Limmathurotsakul, A. Apisarnthanarak, N.T. Pham, V.C. Nguyen, R.L. Hamers, E.J. Nelwan, S. Sakinah, A. Karkey, M.K. Upadhyaya, E. Dodds Ashley, D. Anderson, H.R. Van Doorn, H. Vu</i>
E0553	SpeakAB, a pilot study to encourage nurses to speak up about antibiotic care <i>M. Bos*</i> (Nijmegen, Netherlands), <i>J. Schouten, H. Vermeulen, M. Hulscher, C. De Bot</i>
E0554	Understanding what matters to patients in antimicrobial stewardship in hospitals. PERSPECT study update <i>B. Jacob*</i> (Dublin, Ireland), <i>E. De Barra</i>
E0555	Determinants of antibiotic prescribing in hospitals from low, middle and high-income countries in Asia <i>S. Chhabra*</i> (Singapore, Singapore), <i>S. Nair, A. Bramley, J.Y. Chee, K. Vignesvaran, R.E.D. See, L.J. Sun, A.H. Ching, B.S. Cooper, E. Charani, Y. Mo</i>
E0556	Riding "the antimicrobial rollercoaster": The behavioural and phenomenological science of antimicrobial use in haemato-oncology. <i>C. Eades*</i> (London, United Kingdom), <i>L. Byrne-Davis, R. Rautemaa-Richardson, T. Felton</i>
E0557	Addressing Antimicrobial Resistance: Expert Insights and Policy Recommendations for Effective Interventions <i>B. Madran*</i> (Istanbul, Türkiye), <i>F. Almeida, E. Carrara, D. Kofteridis, N. Rocha-Pereira, G. Pieve, N. Tziolos, İ. Kayı, Ş. Keske, E. Önder, S. Sakarya</i>
E0558	Implementation of hospital antimicrobial stewardship in Europe using a data-driven behaviour change approach: insights from the drive-AMS EU project/. <i>Pauwels*</i> (Antwerp, Belgium), <i>R. Janssen, E. Iosifidis, N. Milevska-Kostova, M. Lupş, J.A. Paiva, E. Roilides, T. Schoffelen, R. Valinteliene, A. Versporten, E. Vlieghe, J. Schouten</i>

EF077	17:30 – 18:30	Arena 4
	ePoster Flash Session	

Viral aphroditis	
Chair	<i>Rémi Charrel (Marseille, France)</i>

E0559	Potential for international spread of Oropouche virus via commercial air travel <i>M. Torres Portillo*</i> (Toronto, Canada), <i>A. Marwah, M. Kraemer, A. Thomas, K. Khan, I. Bogoch</i>
E0560	Estimating mpox Clade Ib outbreak size in the Democratic Republic of the Congo to attenuate surveillance gaps during the early stages of the 2024 outbreak <i>M. Torres Portillo*</i> (English, Canada), <i>A. Marwah, A. Thomas-Bachli, I. Bogoch, K. Khan</i>
E0561	Disparate epitope recognition between MPXV-infected and Smallpox-vaccinated individuals. <i>A. Otter*</i> (Salisbury, United Kingdom), <i>S. Jones, B. Hicks, B. Hallis, C. Rowe</i>
E0562	Diverse residual and late-onset symptoms of severe fever with thrombocytopenia syndrome: Insights

ESCMID Global 2025 - Programme

			from a multicenter questionnaire study in Western Japan <i>R.M. Sada*</i> (Osaka, Japan), <i>S. Yamamoto, T. Toyokawa, T. Takahashi, A. Yamanaka, M. Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Tanizaki, K. Iwata, S. Kutsuna</i>
E0563			<b>Post-Acute Sequelae and Excess Healthcare Utilization Following Dengue Infection: A Population-Based Cohort Study</b> <i>J.T. Lim*</i> (Singapore, Singapore), <i>I. Wee, W.Z. Tan</i>
E0564			<b>Challenges of dengue in haematological malignancy patients: Analysis from the DANGO registry during the 2023-2024 outbreak in Argentina</b> <i>G.A. Méndez*</i> (Posadas, Argentina), <i>J. Salmanton-García, C. Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Bernard, C.P.L. Fernández, M.F. Tosin, M.F. Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely</i>
E0565			<b>Key predictors of critical illness and mortality in Crimean-Congo haemorrhagic fever</b> <i>D. Yigci*</i> (Istanbul, Türkiye), <i>D. Güllü, N. Baykam, A. Kocagül Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan Sarıkaya, İ. Hasanoglu, H.R. Güner, E. Doğan, F. Karakeçili, H. Alay, Z. Türe Yüce, E. Eryilmaz Eren, A. Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. Yetişgen, M. Özgüler, A. Şenol, Ö. Gündag, M. Çağlar Özer, F. Soyak, B. Tanır, I.D. Alıracı, G. Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkuç, Ö. Ergönül</i>
E0566			<b>Kyasanur Forest Disease in 2024: A Retrospective Cohort Study from a tertiary care centre in South India</b> <i>P. Venkata Swathi Kiran*</i> (Udupi, India), <i>P.K. Tirlangi, N. Gupta, R. Bhat, P. Ravindra, S.K. Pothumarthay</i>
E0567			<b>Unravelling the aetiology of summer flu-like illness in Czechia</b> <i>M.F. Kříha*</i> (Ceske Budejovice, Czech Republic), <i>V. Hönig, J. Kamiš, M. Dvořáková, L. Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek</i>

SY112	17:30 – 18:30	Hall 1
	1-hour Symposium	
Year in public health		
Chairs	<i>Ziad A. Memish (Riyadh, Saudi Arabia)</i> <i>Catherine Moore (Cardiff, United Kingdom)</i>	
S0309	17:30	<i>Li Yang Hsu (Singapore, Singapore)</i>
S0310	18:00	<i>Rita Oladele (Lagos, Nigeria)</i>

SY111	17:30 – 18:30	Hall 11
	1-hour Symposium	
PK/PD in drug development: what's in it for me?		
Chairs	<i>Sandrine Marchand (Poitiers, France)</i> <i>Sebastian Wicha (Hamburg, Germany)</i>	
S0307	17:30	<b>PK/PD from the EUCAST/regulatory perspective: what tools do we need?</b> <i>Joseph Meletiadis (Athens, Greece)</i>
S0308	18:00	<b>PK/PD for new anti-TB drugs</b> <i>Elin Svensson (Uppsala, Sweden)</i>
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)		

OS070	17:30 – 18:30	Hall 12
	1-hour Oral Session	
What's new in antifungal guidelines and management		
Chairs	<i>Sharon Chen (Sydney, Australia)</i> <i>Helmut Salzer (Linz, Austria)</i>	
O0512		<b>Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in</b>

O0513		<b>Impact of achieving early mycological eradication with rezafungin on all-cause mortality and ICU length of stay</b> <i>M. Bassetti*</i> (Genoa, Italy), <i>G.R. Thompson, A. Soriano, S. Dickerson, I. Bielicka, O.A. Cornely</i>
O0514		<b>An open-label study of ibrexafungerp in patients with refractory fungal infections (FURI)</b> <i>O.A. Cornely*</i> (Cologne, Germany), <i>B.D. Alexander, P.G. Pappas, T.F. Patterson, M. Hoenigl, M.H. Miceli, P. Vergidis, A. Spec, G.R. Thompson, L. Ostrosky-Zeichner, R.S. Siebert, M. Middle, E. McKie, F. Lewis, D. Angulo</i>
O0515		<b>Novel immunotherapy approach using pan-<i>Candida</i> monoclonal antibodies to treat life-threatening invasive candidiasis and tackle global AMR</b> <i>Y. Zhao*</i> (Aberdeen, United Kingdom), <i>C.A. Munro, S. Palliyil</i>
O0516		<b>Relative contribution of pharmacokinetics and immune signatures to clinical outcomes in patients with HIV-associated cryptococcal meningitis.</b> <i>K. Stott*</i> (Liverpool, United Kingdom), <i>D. Tembo, C. Kajanga, A. Ahmadu, K.D. Ruwanthi, M. Moyo, D. Lawrence, T. Harrison, J. Jarvis, D. Namakhwa, D. Laloo, W. Hope, H. Mwandumba</i>

OS071	17:30 – 18:30	Hall 14
	1-hour Oral Session	
Intestinal parasitic uncovered: epidemiology and treatment success		
Chairs	<i>Kurt Hanevik (Bergen, Norway)</i> <i>Pavla Tůmová (Praha, Czech Republic)</i>	

O0517		<b>Giardia- Does the treatment work? The experience from a national tertiary referral centre</b> <i>A. Boté Casamitjana*</i> (London, United Kingdom), <i>A. Boté-Casamitjana, S. Eisen, L. Nabarro, N. Longley, G. Godbole</i>
O0518		<b>Giardiasis: Who gets it? Experience from a Central London Teaching Hospital.</b> <i>A. Boté Casamitjana*</i> (London, United Kingdom), <i>A. Boté-Casamitjana, S. Eisen, L. Nabarro, N. Longley, G. Godbole</i>
O0519		<b>Assessing the Effect of Antimicrobial Treatment on the Accuracy of Serial Serum and Urine Testing for Detecting <i>E. histolytica</i> cfDNA</b> <i>P. Datta*</i> (Chandigarh, India), <i>D. Rattan, A. Duseja, N. Sharma, N. Kalra, S. Khurana</i>
O0520		<b>Longitudinal observation of <i>Blasotocysts</i> sp. and <i>Dientamoeba fragilis</i> in children: a very rare occurrence in chronic diseases with gut dysbiosis.</b> <i>J. Hurych*</i> (Prague, Czech Republic), <i>J. Havlova, V. Neuman, K. Litsova, K. Hubackova, L. Hlinakova, M. Kubat, O. Hradsky, J. Bronsky, K.L. Kolho, P. Saavalainen, H. Malcova, D. Cebeceauerova, P. Dřevínek, Z. Sumnik, O. Cinek</i>
O0521		<b>High prevalence of the zoonotic <i>Angiostrongylus cantonensis</i> in rats in Spain</b> <i>J. Caballero Gómez*</i> (Córdoba, Spain), <i>T. Fajardo-Alonso, I. García-Bocanegra, M. González, A. Beato-Benítez, R. Cuadrado-Matías, M.Á. Quevedo, R. Guerra, R. Martínez, A. Rivero-Juárez, J. Martínez, E. Martínez-Nevado, P. Soriano, D. Crailsheim, J. Lazpita, A. González, P. Foronda, J. Caballero-Gómez</i>

OS072	17:30 – 18:30	Hall 15
	1-hour Oral Session	
Training models - a new model for training		
Chairs	<i>Erin Bonura (Portland, United States)</i> <i>Casandra Bulescu (Bucharest, Romania)</i>	

O0522		<b>Can ChatGPT4o help build Objective Structured Clinical Examination (OSCE) stations in infectious diseases ?</b> <i>S. Villard*</i> (Paris, France), <i>Y. Guedj, L.</i>
-------	--	--

ESCMID Global 2025 - Programme

			<i>Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid, M. Thy, N. Peiffer-Smadja</i>
O0523			<b>Large language model in real-world clinical infectious diseases: are we there yet?</b> <i>G. Carra* (Switzerland, Switzerland), M. Van Singer, A. Cancela Costa, P.A. Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. Fougère, T. Galpérine, E. Gauthiez, B. Guery, M. Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Papadimitriou-Oliveris, M. Plebani, V. Suttels, P. Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann, N. Boillat-Blanco</i>
O0524			<b>Artificial Intelligence-Powered Transformation: Enhancing Public Health Education at Tampere University Towards Sustainable Development Goal 3</b> <i>S. Ahmad* (Tampere, Finland)</i>
O0525			<b>A Survey on Perceived Priorities for the Implementation of Artificial Intelligence in Developing ESCMID Guidelines</b> <i>J. Molina Gil-Bermejo* (Seville, Spain), J. Molina, J.R. Paño-Pardo, B. Nagavci, M. Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. Tacconelli, S. Tschudin-Sutter, M. Zervos, L. Scudeller</i>
O0526			<b>Expect the unexpected: Longitudinally extensive transverse myelitis in a healthy young adult - a rare manifestation of tuberculosis</b> <i>S. Angirekula* (Jodhpur, India), R. Modi, R. Bora, R. Lohiya, S.K. Shrivastava, S. Jagannath, D. Kumar, S. Tiwari, G.K. Bohra</i>

OS073	17:30 – 18:30	Hall 16
	1-hour Case Session	
	CLN	
Still going viral		
Chairs	<i>Ursula Hofer (London, United Kingdom) Yee Sin Leo (Singapore, Singapore)</i>	

O0527			<b>Clinical outcomes of adoptive cell therapy for EBV reactivation and EBV-PTLD in primary immunodeficiencies: prophylactic and therapeutic applications of post-allo-HSCT memory T cell infusions</b> <i>A. Tessitore* (Trieste, Italy), N. Maximova, S. Braidotti, M. Granzotto, R. Simeone</i>
O0528			<b>Histopathological proof of herpes simplex pneumonitis in a patient with severe COVID-19 pneumonia</b> <i>J. Heylen* (Leuven, Belgium), B. Lopuhaa, L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K. Lagrou, G. Hermans, M. Peetermans, E. Van Wijngaerden, P. Meersseman, A. Wilmer, G. De Hertogh, G. Verjans, J. Von Der Thüsen, J. Van Kampen, J. Wauters</i>
O0529			<b>Transmission of dengue virus from donors to recipient after solid organ transplantation. Case series in Argentina</b> <i>L. Barcan* (Buenos Aires, Argentina), S. Villamandos, R. Gago, M. Aguirre, A. Martinola, A. Patterer, M. Uranga, C. Sarkis, E. Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. Nyveyro, M. Martinez, A. Smud, P. Giorgio, L. Barcán</i>
O0530			<b>Rash without borders: waning immunity in a travelling physician</b> <i>R. Ville Benavides* (Mexico City, Mexico), R. Ville-Benavides, I. Avendaño-Gutiérrez</i>
O0531			<b>A handful of Orf: a case of successful management with cidofovir in a renal transplant recipient</b> <i>A. Kaya* (Izmir, Türkiye), G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I. Karaaslan, M. Taşbakan</i>

SY110	17:30 – 18:30	Hall 3
	1-hour Symposium	
	VAX	
Immune reconstitution syndrome in infectious diseases: Who. Are. You?		
Chairs	<i>Elisa Borghi (Milan, Italy) Justyna Kowalska (Warsaw, Poland)</i>	

S0305	17:30	IRIS in HIV Immunocompromised hosts: a failure of
-------	-------	---

			<b>success</b> <i>Paola Maria Cinque (Milan, Italy)</i>
S0306	18:00		<b>Dysregulated host responses to infection</b> <i>Michal Holub (Praha, Czech Republic)</i>

OS069	17:30 – 18:30	Hall 4
	1-hour Oral Session	
	AMR ANT	
Determining new and revising old breakpoints		
Chairs	<i>Jaroslav Hrabak (Plzen, Czech Republic) Erika Matuschek (Växjö, Sweden)</i>	

O0507			<b>EUCAST disk diffusion testing of ten additional species of anaerobic bacteria</b> <i>J. Ahman* (Växjö, Sweden), J. Åhman, E. Matuschek, B.J. Holzknecht, P.C. Lindemann, H. Marchandin, S. Copsey-Mawer, T. Morris, G. Kahlmeter</i>
O0508			<b>Standardised antimicrobial susceptibility testing protocol for <i>Legionella pneumophila</i> validated across ten European reference laboratories</b> <i>M. Sewell* (Cardiff, United Kingdom), C. Farley, A.V. Krævel, M. Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B. Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M. González-Rubio, F. González-Camacho, M. Petzold, M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L. Jones, O.B. Spiller</i>
O0509			<b>Antimicrobial susceptibility testing of the combination of aztreonam and avibactam in carbapenem-resistant Enterobacterales: a practical evaluation using the CLSI and EUCAST methods</b> <i>L. Chan* (Kennedy Town, Hong-Kong SAR, China), D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung, V.C.Y. Chow</i>
O0510			<b>Determination of optimal disk diffusion mass for zosurabalpin</b> <i>M. Castanheira* (North Liberty, United States), J. Maher, Y. Edah, A. Trauner</i>
O0511			<b>The clinical significance of aminoglycoside susceptibility breakpoints modification</b> <i>O. Henig* (Tel Aviv, Israel), M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben-Ami</i>

Monday, 14 April 2025

SY116	08:30 – 10:30	Hall 15
	2-hour Symposium	
	PHEI	
Climate Change: changing risks and adaptation strategies for a world on the move		
Chairs	<i>Rachel Lowe (Barcelona, Spain) Giacomo Stroffolini (Lausanne, Switzerland)</i>	

S0323	08:30	<b>Vector-borne diseases in Europe and clinical consequences</b> <i>Tuba Dal (Ankara, Türkiye)</i>
S0324	09:00	<b>Rising temperatures and risks of fungal disease</b> <i>Anuradha Chowdhary (New Delhi, India)</i>
S0325	09:30	<b>Strategies for climate prevention and adaptation in a moving world</b> <i>Kristie Ebi (Seattle, United States)</i>
S0326	10:00	<b>AMR in climate change-affected countries</b> <i>Esmiita Charani (London, South Africa)</i>

Co-organised with: ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)

EF079	08:30 – 09:30	Arena 1
	ePoster Flash Session	
	CLN	
AMS around the world: what we can learn from each other		
Chair	<i>Benedikt Huttner (Geneva, Switzerland)</i>	

E0578		<b>Battlefield Stewardship: Implementing Antimicrobial Management in the Ukrainian Trauma Pathway</b> <i>H.</i>
-------	--	---



ESCMID Global 2025 - Programme

		<i>Uren*</i> (Lviv, Ukraine), <i>N. Aliieva, O. Voitovych</i>
E0579		<b>Evaluating a Tailored Antimicrobial Stewardship Strategy to Optimise IV to Oral Conversion: A Pre and Post-intervention Study</b> <i>M. Alyazji*</i> (Abudhabi, United Arab Emirates), <i>A. Sadeq, J. Shamseddine, Z.O.E. Babiker, A. Almansoori, M. Alhindasi, A. Abadi, S. Alhebsi, S. Alawlaqi, F. Aljasmí, A. Aitamimi, S. Shaabani, A. Alhosani, S. Shawish, R. Ali</i>
E0580		<b>Antimicrobial stewardship program for antibiotic use in the community: Impact of multidisciplinary local guidelines during the 2023-2024 influenza a H1N1 season in northern Italy</b> <i>R. Corsini*</i> (Reggio Emilia, Italy), <i>P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, S. Mezzadri</i>
E0581		<b>Effectiveness of Clinical Algorithms combined with Point-of-Care testing to improve Antibiotic Prescribing practices of physicians in outpatient setting of low middle-income country</b> <i>S. Qureshi*</i> (Karachi, Pakistan), <i>S. Ahmed, N. Nasir, F.N. Qamar</i>
E0582		<b>Antibiotic prescribing behaviour in a public Bangladeshi hospital: a snapshot from BALANCE study</b> <i>M.S. Kabir*</i> (Dhaka, Bangladesh), <i>R. Farzana, S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Humayra, M. Sultana, M.N. Haque, T.R. Walsh</i>
E0583		<b>Tailored response to antimicrobial resistance emergence: remote-created stewardship program in a low/middle-income country pediatric hospital</b> <i>P. Favier*</i> (Valencia, Spain), <i>M.A. Aguilera, G. Rapetti Salik, M. Quipildor, M.M. Maresca, I.A. Falco</i>
E0584		<b>Weekly interdisciplinary antimicrobial stewardship rounds at two surgical wards show notable potential in optimising antimicrobial treatment</b> <i>M. Krauss*</i> (Vienna, Austria), <i>C. Labut, G. Brunhofer-Bolzer, G. Laml-Wallner, B. Unterkoefler, M. Andtisch, E. Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. Starzengruber, F. Loetsch, H. Lagler</i>
E0585		<b>Antimicrobial stewardship programmes may improve patients' outcome and hospitalization: a sub-analysis of the CASAS (CARbapenem Sparing Antimicrobial Stewardship) Project</b> <i>M. Bongiovanni*</i> (Lugano, Switzerland), <i>B. Barda, L. Elzi, P. Bellini, C. Di Benedetto, N. Ramponi, M. Mombelli, N. Centemero, A. Colombo, D. Destefani, M. Bissig, E. Bernasconi</i>
E0586		<b>"Prescribing antibiotics is a gamble...": A mixed-methods approach to current practices and implementation challenges of antimicrobial stewardship in a Ugandan tertiary care hospital</b> <i>L. Jung*</i> (Leipzig, Germany), <i>L. Atikoro, D. Owachi, A. Schneider, S. Schönherr, A. Von Braun, C. Kabugo</i>

E080	08:30 - 09:30	Arena 3
	ePoster Flash Session	

<b>Acinetobacter baumannii, still a strong knight to be knocked</b>	
Chair	<i>Parikshit Prayag</i> (Pune, India)

E0587		<b>Evaluation of the Antibacterial Activity of New Dermaseptin Derivatives against Acinetobacter baumannii</b> <i>H. Haddad*</i> (Sousse, Tunisia)
E0588		<b>Clonal dissemination of highly resistant Acinetobacter baumannii ST2: Insights from the BALANCE study</b> <i>C. Abdellaoui*</i> (Oxford, United Kingdom), <i>R. Farzana, M.N. Haque, M. Sultana, A. Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S. Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh</i>
E0589		<b>Prevalence and genomic characterization of Sulbactam-Durlobactam-resistant and Carbapenem-resistant Acinetobacter baumannii in ICU Patients in a tertiary hospital in Hanoi, Northern Vietnam</b> <i>D. Nurjadi*</i> (Luebeck, Germany), <i>S. Boutin, Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K. Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P.</i>

		<i>Velavan</i>
E0590		<b>In vitro activity of nitrooxoline among Acinetobacter baumannii and Stenotrophomonas maltophilia clinical isolates</b> <i>E. Wohlfarth*</i> (Cologne, Germany), <i>P.G. Higgins, M. Kresken</i>
E0591		<b>Assessing biocide resistance genes and susceptibility to biocides in carbapenem-resistant Acinetobacter baumannii isolates from Thai hospitals</b> <i>M.R.D. Wiradiputra*</i> (Bangkok, Thailand), <i>K. Thirapanmethee, P. Khuntayaporn, M.T. Chomnawang</i>
E0592		<b>Epidemiological and Genomic Characteristics of Acinetobacter baumannii in a Hospital in Zhejiang, China: A Study from 2015 to 2020</b> <i>Y. Zhang*</i> (Hangzhou, China), <i>X. Hua</i>
E0593		<b>Evaluation of the susceptibility of Carbapenem-resistant Acinetobacter baumannii to sulbactam-durlobactam</b> <i>J. Caierão*</i> (Porto Alegre, Brazil), <i>L. Silva Dornelles, G. Da Silva Collar, M. Preussler Mott, A. Luís Barth</i>
E0594		<b>Clonal dissemination of Acinetobacter baumannii International Clone 2 Carrying ArmA and emergence of OXA-23-NDM1 co-producers in India</b> <i>G. Nagaraj*</i> (Bangalore, India), <i>N. Geetha, S. Varun, K. Ravikumar</i>
E0595		<b>Insight into Acinetobacter baumannii's phenotypic and genotypic traits in oncological patients</b> <i>F. Sivori*</i> (Rome, Italy), <i>I. Cavallo, M. Truglio, G. Fabrizio, M. Francalancia, F. Fraticelli, E. Abril, E.G. Di Domenico, F. Pimpinelli</i>

EW119	08:30 - 10:30	Hall 11
	Educational Session	

<b>This bacterium might harbour AmpC, what should I do?!</b>		
Chairs	<i>Sören G. Gatermann</i> (Bochum, Germany) <i>Pranita Tamma</i> (Ellicott City, United States)	

W0335	08:30	<b>Laboratory identification of AmpC and its impact on /l&gt;in vitro resistance</b> <i>Ana Gales</i> (Sao Paulo, Brazil)
W0336	08:50	<b>Divergent levels of AmpC expression in Gram-negative pathogens</b> <i>Antonio Oliver</i> (Palma De Mallorca, Spain)
W0337	09:10	<b>Rational choice of antimicrobial therapy against AmpC-producing pathogens</b> <i>Patrick Harris</i> (Herston, Australia)
W0338	09:30	<b>Novel antimicrobials active against AmpC: what RCTs tell us in support of their use?</b> <i>Amy Mathers</i> (Charlottesville, United States)

SY114	08:30 - 10:30	Hall 13
	2-hour Symposium	

<b>Sepsis Global 2025</b>		
Chairs	<i>Brigitte Lamy</i> (Bobigny, France) <i>Willem Joost Wiersinga</i> (Amsterdam, Netherlands)	

S0315	08:30	<b>The ESCMID-ISF Sepsis Award Lecture</b> <i>Andrew Moore</i> (Emerald Hills, United States)
S0316	08:45	<b>The WHO Global Maternal Sepsis Study</b> <i>Carolina Carvalho Ribeiro Do Valle</i> (Sao Paulo, Brazil)
S0317	09:15	<b>Sepsis: year in review</b> <i>Sylvain Meylan</i> (Lausanne, Switzerland)
S0318	09:45	<b>How to design and implement a Sepsis National Action Plan (SNAP)</b> <i>Erika Vlieghe</i> (Edegem, Belgium)

Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)

SY115	08:30 - 10:30	Hall 14
	2-hour Symposium	

<b>Challenges in infection management, prevention and antimicrobial</b>		
---	--	--

ESCMID Global 2025 - Programme

stewardship in long-term care facilities			
Chairs		Gaetan Gavazzi (Grenoble, France) Giusy Tiseo (Pisa, Italy)	
S0319	08:30	The burden of nosocomial infections in long-term facilities Virginie Prendki (Genève-Thônex, Switzerland)	
S0320	09:00	Pneumonia in the elderly: management and prevention Marcos Restrepo (San Antonio, United States)	
S0321	09:30	Challenges in the clinical diagnosis of infection in the elderly Maheen Abidi (Denver, United States)	
S0322	10:00	Challenges in implementing antimicrobial stewardship in long-term care facilities Elena Carrara (Verona, Italy)	
Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering Committee			
SY117		08:30 – 10:30	Hall 16
		2-hour Symposium	
		<div>AMR</div> <div>CLN</div>	
Survival of the parasites: Is treatment failure due to antimicrobial resistance?			
Chairs		Hanne Brekke (Oslo, Norway) Jaco J. Verweij (Tilburg, Netherlands)	
S0327	08:30	Nitroimidazole refractory <i>Giardia Intestinalis</i> infection Pavla Tůmová (Praha, Czech Republic)	
S0328	09:00	Treatment failure in scabies Francisco Bravo (Lima, Peru)	
S0329	09:30	Recurrent <i>Enterobius</i> infections Sarah Eisen (London, United Kingdom)	
S0330	10:00	Recent advances in the treatment of Visceral Leishmaniasis and PKDL Shyam Sundar (Varanasi, India)	
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)			
EW118		08:30 – 10:30	Hall 2
		Educational Session	
		<div>DX</div> <div>IPC</div>	
How can we infer and track plasmid outbreaks?			
Chairs		Alessandra Carattoli (Rome, Italy) Jacob Moran-Gilad (Beer Sheva, Israel)	
W0331	08:30	Evolutionary modelling of plasmids Manuel Ares Arroyo (Paris, France)	
W0332	08:50	How plasmids shape the emergence of nosocomial pathogens Jukka Corander (Oslo, Norway)	
W0333	09:10	Understanding the complexity of plasmid outbreaks using bioinformatics Torsten Seemann (Melbourne (VIC), Australia)	
W0334	09:30	Plasmid transmission at the One Health interface Nicole Stoesser (Oxford, United Kingdom)	
Co-organised with: ESCMID Study Group for Epidemiological Markers (ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM)			
SY113		08:30 – 10:30	Hall 3
		2-hour Symposium	
		<div>PHEI</div>	
Haemorrhagic viral infections			
Chairs		Önder Ergönül (Istanbul, Türkiye) Catherine Houlihan (Porton Down, United Kingdom)	
S0311	08:30	Filovirus disease: evolving therapeutic strategies Ian Crozier (Frederick, United States)	
S0312	09:00	Jack in the box: Re-emergence of Kyasanur Forest Disease in India Kavitha Saravu (Manipal, India)	

S0313	09:30	Crimean Congo Haemorrhagic Fever: Newer insights into pathogenesis leading to new vaccines and therapeuticsAli Mirazimi (Stockholm, Sweden)	
S0314	10:00	Venezuelan Equine Encephalitis: Impact of newer strategies for vector controlCarlos Seas (Lima, Peru)	
OS078	08:30 – 10:30	Hall 5	
		2-hour Oral Session	
		CLN DX TRN	
Trending topics in tuberculosis			
Chairs		Delia Goletti (Rome, Italy) Sean Wasserman (London, United Kingdom)	
O0568		Lineage-specific Immune responses to <i>Mycobacterium tuberculosis</i> : Insights into L4 and L6 pathogenesisM. Silva* (Porto, Portugal), J. Couto, M. Cardoso, B. Cá, M. Saraiva	
O0569		Deciphering the functional role of distinctive <i>Mycobacterium tuberculosis</i> peptidoglycan modifications in modulating antibiotic resistance and the immune responseC. Silveiro* (Lisbon, Portugal), F. Oliveira, M. Mandal, D. Pires, E. Anes, M.J. Catalão	
O0570		Increased Innate Immune and neutrophil blood transcriptomic signatures associate with poor outcome in HIV-1 tuberculous meningitisJ. Barnacle* (London, United Kingdom), A. Davis, R.J. Wilkinson, K. Wilkinson, C. Stek, M. Maxebengula, N. Bangani, G. Kelly, M. Rodriguez-Lopez, R. Lai, S. Wasserman, G. Meintjes, A. O' Garra	
O0571		Subpopulations in clinical samples of <i>Mycobacterium tuberculosis</i> can give rise to rifampicin resistance and shed light on how resistance is acquiredV. Brunner* (Oxford, United Kingdom), P. Fowler	
O0572		A systematic comparison of automated <i>Mycobacterium tuberculosis</i> complex whole genome sequencing analysis pipelinesR. Spies* (Ho Chi Minh City, Vietnam), D. Crook, T. Peto, P. Fowler, R. Turner, H. Thai, J. Watson, T. Walker	
O0573		Lung ultrasound for the detection of pulmonary tuberculosis using expert and AI-guided interpretationVeronique Suttels (Lausanne, Switzerland)	
O0574		Nanomotion Technology for Rapid Antimicrobial Susceptibility Testing of <i>Mycobacterium tuberculosis</i> : Evaluating Novel Benzothiazinone DerivativesA. Vocat* (Lausanne, Switzerland), A. Luraschi-Eggemann, C. Antoni, G. Cathomen, D. Cichocka, G. Greub, O. Riabova, V. Makarov, O. Opota, A. Mendoza, S. Cole, A. Sturm	
O0575		Rapid drug susceptibility testing of <i>Mycobacterium tuberculosis</i> directly from clinical samples using targeted next-generation sequencingE. Rosendal* (Lisbon, Portugal), J. Isidro, S. Carneiro, R. Macedo	
O0576		Enhancing cerebral tuberculosis therapy with an innovative particulate nose-to-Brain drug delivery system: Insights from pharmacokinetic and pharmacodynamic studiesK. Jadhav* (Sas Nagar, India), K. Sudhakar Jadhav, A.K. Singh, R.K. Verma	
O0577		Multi-drug resistant tuberculosis among migrants in EuropeS. Hayward* (London, United Kingdom), K. Rustage, L.B. Nellums, J.S. Friedland, S. Hargreaves	
SY120	09:30 – 10:30	Hall 1	
		1-hour Symposium	
		DX	
Year in clinical microbiology			
Chairs		Fidelma Fitzpatrick (Dublin, Ireland) Maurizio Sanguinetti (Rome, Italy)	
S0339	09:30	Mario Ramirez (Lisbon, Portugal)	
S0340	10:00	Anna Papa-Konidari (Thessaloniki, Greece)	

ESCMID Global 2025 - Programme

EF081		09:30 – 10:30	Arena 2	FO129		11:00 – 12:00	Arena 1	
		ePoster Flash Session		PRO		Open Forum		
Clinical features and outcome of invasive fungal infections				Predatory journals in CM/ID: from symptoms to cure				
Chair		Marcus De Melo Teixeira (Brasília, Brazil)		Chair		Emily G. McDonald (Montreal, Canada)		
E0596		Management, outcomes and predictors of mortality of <i>Cryptococcus</i> infection in patients without HIV: a multicentre study in 46 hospitals from Australia and New Zealand. J. Coussemment* (Melbourne, Australia), C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. Crawford, S.J. Crawford, B.J. Smith, A.P. Gador-Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B. Walls, G.M. O'kane, M.T. Broom, C.L. Keighley, O. Bupha-Intr, L. Cooley, J.A. O'hern, J.D. Jackson, A.J. Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade, V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A. Slavin, S.C.A. Chen		F0356		11:00	The genesis of predatory journals: symptoms and root problems. Leonard Leibovici (Petah-Tiqva, Israel)	
				F0357		11:10	The role of editors and publishers of 'reputable journals': what can they do to stop predatory journals? Till Bärnighausen (Heidelberg, Germany)	
				F0358		11:20	The roles of authors and academic institutions: towards governance and regulation. Luigia Scudeller (Pavia, Italy)	
				F0359		11:30	Bibliometric literacy in scientific publication. Lauren Maggio (Chicago, United States)	
				Co-organised with: CMI Communications Board of Editors				
EF089		11:00 – 12:00	Arena 2	PHEI		ePoster Flash Session		
				Emerging Infectious Diseases, Zoonoses and Outbreaks				
E0640		Seasonality of Influenza and Respiratory Syncytial Virus related hospital contacts in Denmark (1999–2021). O. Reza Hosseini* (Hillerød, Denmark), C.L. Burrett, M.F. Eiberg, M.P. Andersen, M.F. Howitz, C. Roed, J.G. Holler, B. Lindegaard Madsen, D.M. Weinberger, T.K. Fischer, C. Torp-Pedersen, Z.B. Harboe						
E0641		Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us? I. Sanz-Muñoz* (Valladolid, Spain), J. Sánchez-Martínez, C. Rodríguez-Crespo, I. Arroyo-Hernández, C.S. Concha-Santos, M.L. De Dlego, S. Rojo-Rello, M. Domínguez-Gil, M. Hernández-Pérez, A. Martín-Toribio, A. Mostafa, L. Martínez-Sobrido, J.M. Eiros, A. Nogales						
E0642		The UK Imported Fever Service (IFS): National VHF testing 2023–2024. A. Belfield* (Salisbury, United Kingdom), A. Thompson, H. Umpleby, B. Hack, S. Poole, J. Furneaux, J. Owen, J. Osborne, C. Petridou, T. Brooks, N.C. Gordon, T. Rampling, C. Houlihan, C.E. Warrel						
E0643		Reemergence of Poliovirus in Pakistan: Challenges and Implications for Global Health Security. S. Ahmad* (Tampere, Finland)						
E0644		Preparing an emerging infectious diseases unit for high-consequence infectious diseases. A. Silva-Pinto* (Porto, Portugal), C. Silva, A.S. Santos, M. Teixeira, L. Santos						
E0645		Correlation between clinical and wastewater measles positivity rate in three towns of Karachi, Pakistan. F. Naz Qamar* (Karachi, Pakistan), F.N. Qamar, S. Qureshi, M. Larik, F. Kabir, J. Iqbal, K. Begum, J. Gauld, S. Kroiss, J. Giles						
E0646		Salmonella serovars in wild European hedgehogs (Erinaceus europaeus): an over 12-year monitoring in the Ferrara Province, Italy. E. Massella* (Piacenza, Italy), M. Munari, S. Russo, L. Cirasella, C. Torreggiani, R. Taddei, A. Luppi, S. Rubini						
E0647		Clinico-epidemiological and Microbiological Investigation of Diphtheria Outbreak in Odisha, India, 2024. I. Praharaj* (Bhubaneswar, India), S. Panda, S. Subhadra, J. Sabat, S. Mallik, S. Xalxo, N. Manisha, S. Priyadarshini, S. Nayak, N. Ray, S. Mallick, S. Pati						
E0648		Seroprevalence of nine causes of acute febrile illness in rural Cambodia and Thailand using a multiplex assay. M. Zhang* (Bangkok, Thailand), R. Tripura, L. Dysoley, C. Perrone, E. M. Batty, J. Wongsantichon, S. D. Blacksell, S. S. Y. Kang, N. P. J. Day, R. J. Maude, S. J. Lee, Y. Lubell, T. J. Peto						



ESCMID Global 2025 - Programme

EF090	11:00 – 12:00	Arena 3
	ePoster Flash Session	
	<div>DX</div>	
Addressing the need for speed: advances in point-of-care testing		
Chair	Jennifer Dien Bard (Los Angeles, United States)	
E0649	Rapid respiratory microbiological POCTs and antibiotic use in primary care: the RAPID-TEST RCT.E. Brown* (Bristol, United Kingdom), A.D. Hay, S. Abbs, M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G. Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke, M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P. Mitchell, L. Zhu, L. Yardley, C. Metcalfe	
E0650	Evaluation of the prototype BIOFIRE® nasal HR panel (nHRP) in children with acute respiratory illness, a nasal swab-based rapid hoSt gene expression test.G. Storch* (Saint Louis, Missouri, United States), M. Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin	
E0651	Evaluation of the analytical performance of the Biosynex AMPLIQUICK Fecal Bacteriology kit in the diagnosis of bacterial intestinal infections.P. Lehours* (Bordeaux, France), Q. Beaufils, L. Benejat, A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain	
E0652	Development and Validation of a Novel Rapid Antigen Test for Norovirus Detection: A Comparative Performance AnalysisN. Younes* (Doha, Qatar), G. Nasrallah	
E0653	A Rapid Molecular POCT System for Detection of Carbapenem-Resistant Enterobacterales (CRE)S.Y. Choi* (Daejeon, Korea, Republic of), C. Lee, H.O. Park	
E0654	Validation of an ultra-rapid, point-of-care, antibiotic susceptibility testing deviceA. Van Der Linden* (Eindhoven, Netherlands), Y. Deurloo, N. Doomen, D. Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko	
E0655	Development of a frugal multiplexed paper sensor for rapid detection of sepsis-causing pathogensC. Singhal* (Faridabad, India), S. Chatterjee, S. Gupta, M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, A. Tyagi, N. Kumar, S. Chaudhuri	
E0656	Multianalyte POCT device for a sample-to-result detection of nucleic acid and proteinL. Pommiers* (Gif Sur Yvette, France), H. Boutal, D. Fras, H. Volland	
E0657	A smartphone app for point-of-care quantification of lateral flow assaysR. Armiger* (London, United Kingdom), R. Reid, P. Georgiou, A. Holmes, J. Herberg	

KN121	11:00 – 12:00	Hall 1
	Keynote Lecture	
	<div>PHEI</div>	
HIV: from needle parks to injectables		
Chairs	Mary Horgan (Dublin, Ireland) Gölsen Özkaya Sahin (Lund, Sweden)	
K0341	11:00	Huldrych Günthard (Zürich, Switzerland)

OS085	11:00 – 12:00	Hall 10
	1-hour Oral Session	
	<div>CLN</div> <div>PHEI</div>	
Planes, Pains, and Pathogens: The Perils of Travel Medicine		
Chairs	Anu Kantele (Helsinki, Finland) Carlos Seas (Lima, Peru)	
O0620	Fever in returning travelers from tropical regions: what not to miss in an evolving epidemiologyS. Caronni* (Milan, Italy), M. Pieruzzi, A. Rizzo, A.H. Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, A. Mancon, D. Mileto, S. Antinori	
O0621	Tracing the itch: A spatiotemporal analysis of scabies rates and its risk factors using the Global Burden of Disease dataS. Gupta* (Auckland, New Zealand), S. Thornley, G. Sundborn, C. Grant	

O0622	Molecular epidemiological characterization of enterotoxigenic and enteroaggregative <i>Escherichia coli</i> causing traveller's diarrhoea and their relationship with clinical featuresP. Oliveras Julia* (Barcelona, Spain), P. Oliveras, E. Riera, L. Horvath, R.M. Albarracin, M.E. Valls, M.J. Álvarez-Martínez, M. Alguacil, E. Guiral, M. Espasa, D. Camprubi-Ferrer, J. Vila	
O0623	Bites and bytes – can digital surveillance of travellers' illness predict outbreaks?N. Hedrich* (Zürich, Switzerland), T. Lovey, P. Schlagenhauf	
O0624	Travel-associated infections and diseases: a retrospective cross-sectional studyM. Trojanek* (Prague, Czech Republic), M. Trojanek, V. Grebenyuk, V. Jegorova, P. Hubacek, A. Briksi, J. Havlova, K. Dundrova, L. Kolarik, I. Zicklerova, L. Richterova, O. Beranek, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, B. Pisova, R. Šindlerová, M. Tulach, Z. Uhříková, M. Vidlička, M. Štefan, F. Stejskal	

OS086	11:00 – 12:00	Hall 11
	1-hour Oral Session	
	<div>DX</div> <div>TRN</div>	
Marker based diagnostics: forget the pathogen		
Chairs	Virginie Prendki (Genève-Thônex, Switzerland) Suzanne Van Asten (Nijmegen, Netherlands)	
O0625	A 29-mRNA molecular host response test demonstrates enhanced accuracy compared to a protein-based host response test for the diagnosis of bacterial and viral infectionsN. Whitfield* (Sunnyvale, United States), C. Lu, O. Liesenfeld	
O0626	Diagnostic accuracy of a bacterial versus viral host-protein test for pediatric inpatients with acute infectionT. Gottlieb* (Tirat Carmel, Israel), L. Bont, A. Klein, M. Stein, M. Mor, I. Srugo, R. Navon, E. Eden, B.P. Muller	
O0627	Diagnostic accuracy of combined urine lipocalin 2 and copper test in acute pyelonephritis or cystitis V. Havlicek* (Prague, Czech Republic), J. Hrbacek, T. Pluhacek, J. Houst, A. Palyzova, D. Luptakova, D.A. Stevens, J. Novak, R. Dobias, R. Zachoval	
O0628	Diagnostic Performance of Whole-Blood RNA Signatures for Tuberculosis Diagnosis in a Cohort of Patients with Non-Tuberculous Mycobacterial Lung DiseaseP. Escalante* (Rochester, Mn, United States), B. Piatkowski, B. Pathakumari, V. Van Keulen, N. Fadra, P. Arias-Sanchez, L. Gutierrez, S. Karnakoti, T. Peikert	
O0629	Diagnostic utility of MxA and MxA/CRP ratio in differentiating viral and bacterial infections: a prospective cohort studyO. Beránek* (Prague, Czech Republic), R. Prusa, M. Trójanek, O. Beranek, Z. Uhříková, J. Illner, P. Lehnert, P. Bukovska, M. Štefan, V. Jegorova, T. Ernestova, L. Kohout, G. Meseznikov, A. Nycova, R. Šindlerová, M. Tulach, M. Vidlička, V. Grebenyuk	

PM2	11:00 – 12:00	Hall 12
	Panel Discussion	
AMR and vaccines		
Chairs	Charlotte Vernhes (Brussels, Belgium) Ghada Zoubiane (London, United Kingdom)	
L005	11:00	Overview of the current evidence of the impact of vaccines on AMRAdam Cunningham (Birmingham, United Kingdom)
L006	11:20	Panel discussion: gaps, needs, and opportunities to leverage vaccines against AMR, Adam Cunningham (Birmingham, United Kingdom), Sipho Kenneth Dlamini (Observatory, South Africa), Erin Duffy (Boston, United States), Mateusz Hasso-Agopsowicz (Geneva, Switzerland)

ESCMID Global 2025 - Programme

SY126	11:00 – 12:00	Hall 13
	1-hour Symposium	

Why is the concept of complicated UTI so complicated?

Chairs	Gernot Bonkat (Basel, Switzerland) Maeve Doyle (Waterford, Ireland)
--------	--

S0350	11:00	The concept of complicated UTI: underlying conditions matterSuzanne Geerlings (Amsterdam, Netherlands)
S0351	11:30	The concept of complicated UTI: the site of infection matters mostJesús Rodríguez-Baño (Seville, Spain)

Co-organised with: ESCMID Education Subcommittee

ME128	11:00 – 12:00	Hall 14
	Meet-the-Expert	

How to apply organoid models to study infectious disease

M0354	11:00	Jennifer Rohn (London, United Kingdom)
M0355	11:12	Nathalie Sauvonnnet (Paris, France)

OS087	11:00 – 12:00	Hall 15
	1-hour Oral Session	

Antimicrobial resistance around birth

Chairs	Julia Anna Bielicki (London, United Kingdom) Surbhi Malhotra-Kumar (Antwerp, Belgium)
--------	--

O0630	Prevalence and risk factors of antibiotic resistance genes in breastmilk and neonatal oral cavity of preterm mother-infant pairsA. Sharma* (Chandigarh, India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Ray
O0631	Effect of maternal peripartum antibiotic exposure on the microbial diversity, relative abundance of taxa, and resistome in breastmilkA. Chakraborty* (Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. Kumar, P. Kumar, A. Pal, A. Arora
O0632	Dynamics of gastrointestinal colonisation by antibiotic-resistant bacteria in high-risk infants in Swiss and Greek neonatal intensive care unitsA. Braspenning* (Antwerp, Belgium), L. Timbermont, L. Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar
O0633	Harnessing functional omics to decipher how probiotics reduce antibiotic resistance gene carriage in infants' gutV. Pettersen* (Tromsø, Norway), A. Bargheet, G.H. Bø, C. Klingenberg
O0634	Dynamics of gut resistome and mobilome in early life: A meta-analysis V. Pettersen* (Tromsø, Norway), A. Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K. Korpela, M. Valles-Colomer, J. Debelius, A. Kurilshikov

OS088	11:00 – 12:00	Hall 16
	1-hour Oral Session	

Advancing diagnostics and preventive measures in hemato-oncological patients

Chairs	Dina Averbuch (Jerusalem, Israel) Malgorzata Mikulska (Genoa, Italy)
--------	---

O0635	Prediction of bacterial and fungal bloodstream infections using machine learning in patients undergoing chemotherapyM. Freire* (Sao Paulo, Brazil), A. Villani, Jr, M. P. Freire, F. Lazzar Neto, L.A. De Padua Covas Lages, M. Salaroli De Oliveira, E. Abdala, F. L.S. Nunes, A.S. S. Levin
-------	---

O0636	Viral metagenomics in patients with persistent unexplained neutropenic fever- some clues to the cause of fever?A. Douglas* (Melbourne, Australia), L. Caly, M.A. Slavin, I. Savic, J. Moselen, A. Aziz, G. Papadakis, G. Ng, J. Druce, K. Thursky
-------	---

O0637	Results of Optifill study: 18F-FDG-PET/CT guided antifungal stewardship in invasive pulmonary aspergillosisF. Lanternier* (Paris, France), C. Maunoury, F. Montravers, F. Marquant, S. Poirée, C. Elie, C. Robin, A. Thiebaut, F. Ader, F. Suarez, E. Blanchard, O. Lortholary
-------	--

O0638	Long-term immunogenicity and boostability of the 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation: a prospective cohort studyS. Haggenburg* (Amsterdam, Netherlands), J. Schnyder, H. Garcia Garrido, M. Schoordijk, A. Reiners, B. Meek, M. Hazenberg, A. Goorhuis
-------	--

O0639	Humoral and cellular immune response to adjuvanted respiratory syncytial virus vaccine RSVPreF3 in adults after allogeneic hematopoietic cell transplantationJ. Lötscher* (Basel, Switzerland), C.S. Walti, J. Halter, N. Khanna, S. Heller, S. Schmid, K. Leuzinger
-------	--

OS082	11:00 – 12:00	Hall 2
	1-hour Oral Session	

New insights in bloodstream infections and endocarditis

Chairs	Barbara Hasse (Zurich, Switzerland) José M. Miro (Barcelona, Spain)
--------	--

O0605	Different from the start – Sex differences in Staphylococcus aureus bacteremia mortalityA. Westgeest* (Leiden, Netherlands), M. Lambregts, F. Ruffin, V.G. Fowler, J.T. Thaden
-------	--

O0606	Tracking evolution in action during invasive Staphylococcus aureus infections: the BARISTA studyS. Giulieri* (Melbourne, Australia), D. Daniel, M. Duarte Aguilera, D. Velasquez-Reyes, R. Guérillot, A. Gador-Whyte, F. James, E. Goodall, P. Fuge-Larsen, M. Henri, J. Trubiano, M. Leroi, K. Bond, T. Stinear, S. Tong, J. Kwong, B. Howden
-------	--

O0607	Identifying heterogeneity of treatment effect for antibiotic duration in bloodstream infection – an exploratory post-hoc analysis of the BALANCE randomized clinical trialS. Ong* (Melbourne, Australia), R. Pinto, A. Rishu, S. Tong, R. Commons, J.M. Conly, G. Evans, M. Fralick, C. Kandel, P. Lagacé-Wiens, T. Lee, S. Lothar, D. Macfadden, J. Marshall, V. Martel-Laferrrière, M. Mayette, E. Mcdonald, J. Neary, J. Prazak, E. Raby, A. Regli, B.A. Rogers, S. Smith, L. Taggart, H.T. Wang, T. Wuerz, D. Yahav, P. Young, R.A. Fowler, N. Daneman
-------	--

O0608	Bloodstream infection pathogen diversity and clinical impact revealed through unbiased whole genome sequencing: a prospective genomic epidemiology studyN. Macesic* (Melbourne, Australia), J. Hawkey, J.A. Wisniewski, A. Peleg
-------	--

O0609	Risk of infection of intracardiac devices in patients with valvular infective endocarditis who carry cardiovascular implanted electronic devices. Analysis on a national cohortA. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, E. Calbo, P. Muñoz, D. Monzón, M. Valerio, M. Hernandez Meneses, J.M. Miró, M. Cobo Belastegui, A. De Alarcón, R. Rodríguez, I. Villanueva Benito, J.C. Lopez-Azor, L. García-Alvarez, L. Boix
-------	---

SY122	11:00 – 12:00	Hall 3
	1-hour Symposium	

Chronic infections in the era of CFTR modulators: what is going on in cystic fibrosis lungs these days?

Chairs	Pavel Drevinek (Prague, Czech Republic) Helle Krogh Johansen (Copenhagen, Denmark)
--------	---

ESCMID Global 2025 - Programme

S0342	11:00	The lung microbiome of people with cystic fibrosis receiving modulator therapy <i>Sebastien Boutin (Lübeck, Germany)</i>
S0343	11:30	Tackling chronic infections in people with cystic fibrosis receiving modulator therapy: is it still necessary? <i>Alessandra Bragonzi (Milano, Italy)</i>
Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society for Medical Microbiology		

SY123	11:00 – 12:00	Hall 4
1-hour Symposium		
Infection prevention and control and intensive care: challenges and solutions		
<i>Chairs</i> Antonios Katsounas (Bochum, Germany) Claire Roger (Nimes, France)		
S0344	11:00	Intensive care unit (ICU) and infection: two sides of a coin <i>Reto Schuepbach (Zurich, Switzerland)</i>
S0345	11:20	Ventilator- associated pneumonia (VAP) and ICU environment: how can we improve practices? <i>Despoina Koulenti (London, United Kingdom)</i>
Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP), EUCIC Steering Committee		

OS083	11:00 – 12:00	Hall 5
1-hour Oral Session		
Don't 'rash' it		
<i>Chairs</i> Heli Harvala (Turku, Finland) Catherine Moore (Cardiff, United Kingdom)		
O0610	Current Prevalence of Parvovirus B 19 Infections: Ankara Bilkent City Hospital Experience 2019-2024 <i>B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kirca, A. Toyran, S. Aydoğan, B. Dinç</i>	
O0611	Managing an outbreak of parvovirus B19 infection in pregnancy: clinical outcomes from a single-centre study <i>M. Melchio* (Genoa, Italy), E. Ricci, E. Cristina, E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. Mesini, M. Mariani, C. Russo Artimagnella, C. Saffioti</i>	
O0612	The dark side of the „fifth disease” endemic: human parvovirus B19 infections transmitted through blood transfusions in adults with malignant hematological diseases <i>B.G. Szabo* (Budapest, Hungary), D. Korozs, P. Remenyi, J. Sinko</i>	
O0613	Key learnings from a measles outbreak with multiple hospital exposures in Ireland, May-July 2024 <i>A.M. Murray* (Dublin, Ireland), G. Larkin, D. Hickey</i>	
O0614	Measles virus in the context of subacute sclerosing panencephalitis (SSPE) <i>J. Dina* (Caen, France), S. Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous</i>	

SY124	11:00 – 12:00	Hall 6
1-hour Symposium		
Antimicrobial prescribing: myths or pearls?		
<i>Chairs</i> Massimo Fantoni (Roma, Italy) Spyros Pournaras (Athens, Greece)		
S0346	11:00	Why treat IV when PO is possible? <i>Bradley Spellberg (Los Angeles, United States)</i>
S0347	11:30	De-escalation of antibiotic therapy to narrow-spectrum IV drugs <i>Flaminia Olearo (Hamburg, Germany)</i>
Co-organised with: CMI Communications Board of Editors, ESCMID AMR Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship (ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID Scientific Affairs Subcommittee		

SY125	11:00 – 12:00	Hall 7
1-hour Symposium		
Cutting edge methods in mycology		
<i>Chairs</i> Katrien Lagrou (Leuven, Belgium) Antonio Vena (Genova, Italy)		

S0348	11:00	Imaging for diagnosing mycoses: focus on 18F-FDG PET/CT <i>Ana Fernández-Cruz (Majadahonda (Madrid), Spain)</i>
S0349	11:30	Exploring the intersection of fungal metagenomics and medical mycology <i>Marcus De Melo Teixeira (Brasília, Brazil)</i>
Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID Education Subcommittee, Medical Mycology Study Group (GEMICOMED) within the SEIMC (Spanish Society of Infectious Diseases and Clinical Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIP), Società Italiana per la Terapia Antinfett		

OS084	11:00 – 12:00	Hall 8
1-hour Case Session		
Weird and unusual infections		
<i>Chairs</i> Murat Akova (Ankara, Türkiye) Muge Cevik (St Andrews, United Kingdom)		

O0615	Vertical Transmission of Clade Ib monkeypoxvirus during Pregnancy: Clinical and Histopathological description of 3 cases <i>E. Hasivirwe Vakaniaki* (Kinshasa, Congo, the Democratic Republic of the), N.R. Swar Kuispond, H. Yuichiro, S. Tadaki, R. Bulakali Chirimwami, L. Liesenborghs, P. Mbala-Kingebeni, E. Bangwen, I. Brosius, T. Wawina-Bokalanga, S. Sabiti Nundu</i>	
O0616	First case of Oropouche fever in the South of Spain <i>I. Pérez Hernández* (Málaga, Spain), I.A. Pérez-Hernández, E. Basallote Leal, M.A. Sempere Alcocer, B. O'donnell Cortés</i>	
O0617	Wild hippopotamus bite and <i>Aeromonas</i> spp. infection: a treatment challenge. First case report. <i>J. Alza Arcila* (Medellín, Colombia), N.M. Daza Alarcon, M.V. Montoya Garcia, A. Múnera-Echeverri, F.F. Jiménez Quiroz, J. Alza-Arcila</i>	
O0618	From the sea to the land: an emerging species <i>K. Rodríguez Martínez* (Santo Domingo, Dominican Republic), K. Rodríguez, A. Fernández, K. Espallat, J. Cruz, X. Rodríguez, T. Flores</i>	
O0619	The first findings of <i>Wohlfahrtiimonas chitiniclastica</i> and <i>Ignatzschineria</i> species bacteremia in two cases with maggots infested wounds in Scandinavia <i>A.L. Engsbros* (Slagelse, Denmark), C. Mortensen, R. Jul, W. Cebula, A.L. Laugesen, J.T. Møller, M. Kemp</i>	

ME127	11:00 – 12:00	Hall 9
Meet-the-Expert		
EUCAST: What's new in susceptibility testing		

M0352	11:00	Erika Matuschek (Växjö, Sweden)
M0353	11:12	Rafael Canton (Madrid, Spain)
Co-organised with: EUCAST Steering Committee		

ME134	13:30 – 14:30	Hall 16
Meet-the-Expert		
The older solid organ transplant recipient: between frailty, immunosenescence and infection		



ESCMID Global 2025 - Programme

M0367 13:30 Maheen Abidi (Denver, United States)  
M0368 13:42 Alaa Atamna (Petah-Tikva, Israel)  
Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE)

SY131	13:30 – 14:30	Hall 2
1-hour Symposium		
AMR PHEI VAX		
Vaccines and antimicrobial resistance		
Chairs	Iva Butic (Zagreb, Croatia) Zitta Barrella Harboe (Hillerød, Denmark)	
S0361	13:30	The impact of current and future vaccines on AMR: from pneumococcal to COVID-19Mateusz Hasso-Agopsowicz (Geneva, Switzerland)
S0362	14:00	Can vaccines against AMR be translated into policy?William Hausdorff (Washington DC, United States)
Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG)		

EW135	13:30 – 15:30	Hall 3
Educational Session		
PRO		
Transforming your research idea into an appropriate study design		
Chairs	Casandra Bulescu (Bucharest, Romania) Mary Horgan (Dublin, Ireland)	
W0369	13:30	Designing high-quality research studies: methodological skills and knowledgeMical Paul (Haifa, Israel)
W0370	13:50	How to design and run scientific studies using AI agents as research assistantsAlyssa Bilinski (Cambridge, United States)
W0371	14:10	Designing your first study: how to construct a workable project when your work environment may not helpThomas Tängdén (Uppsala, Sweden)
W0372	14:30	Bridging early-career professionals with partners and seniorsGiorgia Caruana (Sion, Switzerland)
Co-organised with: CMI Board of Editors, CMI Communications Board of Editors, Trainee Association of ESCMID (TAE) Steering Committee		

FO136	13:30 – 14:30	Arena 1
Open Forum		
PRO		
Diversity in CM and ID: gender gaps and policy traps		
Chair	Andre Fuchs (Augsburg, Germany)	
F0373	13:30	How to avoid parity traps in ID/CM research?Muge Cevik (St Andrews, United Kingdom)
F0374	13:40	Gender gaps in visibility at scientific conferencesSarah Delliére (Paris, France)
F0375	13:50	Psychological determinants of empowerment at individual and societal levelTba
Co-organised with: ESCMID Education Subcommittee, ESCMID Parity Commission		

EF093	13:30 – 14:30	Arena 2
ePoster Flash Session		
CLN DX		
Real world experience with modern HIV treatment: the art of ART		
E0668	Use of long-acting cabotegravir/rilpivirine in HIV-viraemic individuals: a metanalysisM. Bongiovanni* (Lugano, Switzerland), B. Barda, G. Barilaro, E.	

E0669	Assessment of HIV-DNA, immune activation and senescence biomarkers during injectable cabotegravir/rilpivirine treatmentM. Mazzitelli* (Padua, Italy), M.R. Petrara, C. Cozzolino, L. Sasset, D. Leoni, S. Gardin, E. Ruffoni, A. De Rossi, A. Cattelan	
E0670	Impact of Cabotegravir plus Rilpivirine Long-Acting on Body Composition: Results from a Prospective StudyA. De Vito* (Sassari, Italy), A. Marongiu, A. Cano, M. Puci, A. Colpani, A. Mura, M.G. Catte, M.A. Deledda, S. Uzzau, S. Babudieri, G. Sotgiu, F. Deriu, A. Spanu, G. Madeddu	
E0671	Real-World Efficacy and Tolerability of Long-Acting Cabotegravir/Rilpivirine in Older Woman with Polypharmacy and ComorbiditiesM. Rosas Cancio-Suárez* (Madrid, Spain), A. Moreno, S. Del Campo Terrón, M.J. Vivancos, A. G. García De Morales, J. Martínez-Sanz, M.D. Corbacho, M. Suárez, C. Cano, R. Ron, M.J. Cárdenas-Isasi, M. Vélez-Díaz-Pallarés, S. Moreno, M.J. Pérez-Elías	
E0672	Two-year comparative analysis of lipid profile changes between INSTI-based single tablet regimens in treatment-naïve people living with HIV: real-world evidence from South KoreaS.Y. Lim* (Seoul, Korea, Republic of), B. Chin, M.K. Kim, Y. Kim, G. Kim, J. Bang	
E0673	Long-acting antiretroviral therapy in PLWH with prior HBV exposureJ. Mateo Gonzalez* (Valencia, Spain), J.I. Mateo-Gonzalez, M. Plaza-De-La-Torre, D. Martinez-Perez, J. Martinez-Andres, V. Abril-Lopez-De-Medrano, E. Ballester-Belda, M. Garcia-Rodriguez, C. Ricart-Olmos, M. Garcia-Deltoro	
E0674	Protease Inhibitors in today's antiretroviral landscape: are we tracking resistance?J. Ciscar Soriano* (València, Spain), J. Ciscar-Soriano, M.D. Gómez-Ruiz, A. Hernández-Cabezas, A. Valentín-Martín, M. Montero-Alonso, J.L. López-Hontangas	
E0675	Effect after Switching from Efavirenz to Rilpivirine on Liver Steatosis Among People Living with HIV with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled TrialL. Srikham* (Sakon Nakhon, Thailand), S. Sriphoosanaphan, O. Putcharoen	
E0676	Impact of maternal dolutegravir on growth outcomes of HIV-exposed uninfected children: A prospective studyE. Yoram* (Morongoro, Tanzania, United republic of), E. Luoga, S. Glanzman, F. Vanobberghen, M. Weisser, E. Dotto, G.J. Mollel, G. Sigalla, E. Nyenza, L. Moshi, L. Wilson, J. Okuma, D. Paris	

EF094	13:30 – 14:30	Arena 3
ePoster Flash Session		
CLN DX PHEI		
Speed, convenience and performance of virus diagnostic methods		
Chair	Hans H. Hirsch (Basel, Switzerland)	

E0677	Prospective evaluation of a rapid diagnostic test in a tertiary hospital and prospects for reinforced dengue surveillance in Catalonia (Northeastern Spain)L. Horvath* (Barcelona, Spain), L. Horvath Ruiz, J. Naverro, M. Navarro, M. Pujada, A. Navarro, M. Garrido, B. Herreras, P. Rodriguez, N. Zancada, B. Escudero-Perez, M.J. Martinez	
E0678	Sequence-Independent Single-Primer Amplification (SISPA) followed by Next-Generation Sequencing for Diagnosing Viral Respiratory Tract InfectionsP. Trindade* (Santa Maria, Brazil), B.C. Casarin, T.R. Y Castro, B.C. Piccoli, V.T. Santos, L.F. Tessele, A. V. Schwarzbold	
E0679	Seasonal trends and co-infection dynamics of respiratory pathogens: insights from a yearlong studyZ. Tsinaris* (Thessaloniki, Greece), A. Tychala, G. Meletis, A. Greco, T. Chatziantoniou, R. Dimitriadou, C. Chantzi, E. Georgiadou, G. Kagkalou, O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou	
E0680	Speed meets reliability in respiratory infections diagnosis with a new nucleic acid extraction workflowL. Pastor-Bernad* (San Mateo De Gállego, Spain), B. Santos Da Silveira, E. Lucia, M.C. Gil-Rodríguez, H. Alonoso, C. Giménez-Rota	

ESCMID Global 2025 - Programme

E0681		<b>Pathobiome characterization and role in disease severity in children under 5-years with respiratory infection symptoms</b> <i>L. Terranova* (Milan, Italy), L. Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna, M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchi, M. Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A. Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri</i>
E0682		<b>Viral viability markers of SARS-CoV-2: A Comparison of cell culture genomic RNA RT-PCR and subgenomic RNA RT-PCR</b> <i>C. Cuesta Chasco* (Barcelona, Spain), S. Alex, M. M<sup>a</sup> Ángeles, C.C. Genoveva, A. Francesco, R. Cristina, V. Anna, H. Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N. Mireia, G. Ignacio, B. Marta, G.V. Carolina</i>
E0683		<b>Diagnostic performance of Hepatitis B virus surface antigens in the Netherlands using type-specific external quality assessment</b> <i>E. Vanhulle* (Bilthoven, Netherlands), M. Simões, H. Ten Bruin, G. Boland, A. Brandenburg, K. Benschop</i>
E0684		<b>Low utility of parallel testing by multiplex and individual real-time PCR assays for the diagnosis of viral meningitis and encephalitis at a large public hospital in the United States</b> <i>A. Cuber* (Los Angeles, United States), S. Butler-Wu</i>
E0685		<b>Plasma Separation Card as an alternative sampling method for quantitative HCV RNA testing with high comparability to EDTA plasma</b> <i>F. García* (Granada, Spain), A. Fuentes López, A. Rando Segura, R. Carracedo, A. Kessler, A. De Salazar González, S.Z. Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, A. Carrasco Durán, A. Aguilera, F. García, M. Buti Ferret</i>

KN130	13:30 – 14:30	Hall 1
	Keynote Lecture	
Infectious disease challenges in an ever-changing environment		
Chairs	Jacob Moran-Gilad (Beer Sheva, Israel) Annelies Zinkernagel (Zurich, Switzerland)	
K0360	13:30	Pamela Rendi Wagner (Stockholm, Sweden)

PM3	13:30 - 14:30	Hall 12
Meet-the-Innovators		
Future prospects of electronic clinical decision support systems in stewardship programs		

L007	13:30	<b>Opportunities for clinical decision support systems in infectious disease management</b> <i>Nathan Peiffer-Smadja (Paris, France)</i>
L008	14:00	<b>CDSS and AMS programs: the Lumed example</b> <i>Valiquette Louis (Sherbrooke, Canada)</i>

SY132	13:30 – 14:30	Hall 13
1-hour Symposium		
<div>AMR</div> <div>DX</div>		
<b>Predicting antibiotic susceptibility profiles from whole genome sequences: state-of-the-art</b>		
<i>Chairs</i>	<i>Werner Ruppitsch (Vienna, Austria)</i> <i>Balaji Veeraraghavan (Vellore, India)</i>	

S0363	13:30	<b>Impact of the WHO's developed catalogue of mutations on rapid TB diagnosis and treatment</b> <i>Thomas Schön (Kalmar, Sweden)</i>
S0364	14:00	<b>Antimicrobial resistance prediction using whole genome sequencing</b> <i>Patricia Simner (Rochester, United States)</i>

**Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers (ESGEM), EUCAST Steering Committee**

OS092	13:30 – 14:30	Hall 14
	1-hour Case Session	
CLN		
Mycobacterial mayhem		
Chairs	Seif Al-Abri (Muscat, Oman) Linda Aulin (Leiden, Netherlands)	
O0663	<b>Limitations of the Xpert® MTB/RIF assay: A series of four clinical cases</b> <i>A. Haas* (Salt Lake City, United States), A. Ma, J. Pham, P. Verma, U. Malhotra, E.C. Church, M. Narita, V. Escuyer, S. Shakir</i>	
O0664	<b>Pharmacokinetic analysis of blood and cerebrospinal fluid contezolid concentrations in a patient with tuberculous meningoencephalitis</b> <i>W. Nie* (Beijing, China), N. Chu</i>	
O0665	<b>Is this the first case of Mycobacterium stephanolepidis infection in humans?</b> <i>S. Pérez-Recio* (Barcelona, Spain), M.D. Grijota-Camino, A. Lérida, A. Bauer, L. Fernández-Delgado, M.J. Luque, N. Sabé Fernández, F. Alcaide, M. Santin</i>	
O0666	<b>Diagnostic Aspects of a Bacillus Calmette-Guérin Infection Following Intravesical Treatment for Bladder Cancer</b> <i>K.J. Kim* (Seoul, Korea, Republic of), J.H. Cha, S.G. Yoon, M.H. Nam, G.I. Lee, Y. Cho</i>	
O0667	<b>Mycobacterium abscessus: Is Shorter Antibiotic Therapy Combined with Surgery Sufficient?</b> <i>M.J. Lopes* (Amadora, Portugal), C. Paulo, D. Trigo, M. Caixeiro, M. Alves, R. Macedo, P. Pacheco</i>	

SY133	13:30 – 14:30	Hall 15
1-hour Symposium		
ANT		
Probiotics in infectious diseases: current state-of-play		
Chairs	Nicolas Benezet (Lyon, France) Silvia Corcione (Turin, Italy)	
S0365	13:30	Probiotics in infectious diseases: the perfect complement to antimicrobial therapies? Lena Biehl (Cologne, Germany)
S0366	14:00	The horizon of next generation probiotics for infectious diseases Cormac Gahan (Cork, Ireland)
Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI)		

OS091	13:30 – 14:30	Hall 5
1-hour Oral Session		
AMR TRN		
Genomic and molecular drivers of bacterial virulence and resistance		
Chairs	Ecaterina Noroc (Chisinau, Moldova, Republic of) Guido Werner (Wernigerode, Germany)	
O0658	Characterization of the virulence shaping and adaptability in the methicillin-resistant <i>Staphylococcus aureus</i> ST9 lineage. Y. Chen* (Hangzhou, China), L. Sun	
O0659	Elucidating molecular mechanisms of bacterial conjugation: towards an improved understanding of plasmid evolution and epidemiology S. David* (Oxford, United Kingdom), C. Seddon, J. Wong, N. Ishimoto, S. He, J. Bradshaw, W.W. Low, D. Aanensen, G. Frankel, K. Beis	
O0660	Clinical carbapenem-resistant <i>Klebsiella pneumoniae</i> (CRKP) strains carrying a muthH mutation are hypermutators that have heightened virulence and readily develop $\beta$ -lactam/ $\beta$ -lactamase resistance. S. Cheng* (Pittsburgh, United States), C. Clancy, M.H. Nguyen, B. Hao, G. Liu	
O0661	Genomic insights into the new prophages of MDR <i>Pseudomonas aeruginosa</i> : an example of phage-host-phage interaction A. Uskudar Guclu* (Ankara,	

ESCMID Global 2025 - Programme

Türkiye), S. Unlu		
O0662	Genome-wide association study (GWAS) reveals importance of vaginal epithelium associated genes in case of recurrent vaginitisR. Mändar* (Tartu, Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk	
EF099	14:45 – 15:45	Arena 1
ePoster Flash Session		
Infection Prevention in Action: Innovations, Insights, and Global Intervention		
Chair Allison Mcgeer (Toronto, Canada)		
E0706	A <i>Candida auris</i> cgMLST Scheme for Enhanced Outbreak Surveillance and Global Epidemiological TrackingC. Harless* (Silver Spring, United States), J. Stam, B. Corey, E. Horishny, A. Ong, Y. Kwak, J. Bennett, P. Mcgann, F. Lebreton	
E0707	Machine Learning-Augmented Clinical Scoring System for Predicting KPC Infections in Healthcare Crisis ScenariosA. Rearte* (Buenos Aires, Argentina), F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi	
E0708	Incident infections with respiratory syncytial virus in a hospital-based healthcare worker cohort, 2023-2024 winter seasonC. Savulescu* (Paris, France), M. Rojas, K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. Hrisca, M. Cisneros, M. Latorre-Millán, J. McGrath, L. Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Nardone	
E0709	Evaluation of the efficiency of reusable terminal filters for showers for nosocomial legionellosis prevention in a French university hospitalN. Khanafer* (Lyon, France), A. Regard, L. Beraud, R. Sintes-Tissot, Q. Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Chaboud	
E0711	Emerging uncommon non-fermenters and their decreasing antibiotic susceptibility in patients with prolonged hospital stayV. Khillan* (New Delhi, India), V.G. Nag P, P. Kale, A. Paul, A. Saran	
E0712	Air and surface sampling around mpox Clade 1b in hospitals in the UKS. Gould* (Liverpool, United Kingdom), B. Atkinson, B. Hack, T. Williams, J. Otter, Y. Ceesay, A. Alsonso, G. Nebbia, S. Blundell, W. Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. Dunning	
E0713	Utilization of a healthcare facilities rapid assessment tool to define infection prevention and control and Water, Sanitation and Hygiene baseline criterion met during Democratic Republic of Congo mpox outbreak from August to November 2024A. Baller* (Geneva, Switzerland), N.R. Okum, G. Nsambi, K. Kabamba, Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton Hurwitz, M. Moon	
E0714	The REACT study: Exploring the BSI Potential of KPC, NDM, VRE, and CRAB rectal colonizationM. Colaneri* (Milano, Italy), P. Giordani, S. Lerta, A. Sangani, V.A. Villano, A. Gori, M. Rettani, S. Milanese, G. De Nicolao, R. Bruno	
EF100	14:45 – 15:45	Arena 2
ePoster Flash Session		
Cefiderocol: an efficient Trojan horse?		
Chair Anna Sramkova (Pilsen, Czech Republic)		
E0715	Acceleration of Emergence of Cefiderocol Resistance in Microfluidic Evolution SystemB. Li* (Beijing, China), S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang	
E0716	The hidden link between cefiderocol resistance and increased virulence in <i>Klebsiella pneumoniae</i> . Insights from a TraDIS-based investigationE. Eger*	

E0717	Resistance profiles of Carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?I. Baltas* (London, United Kingdom), T. Patel, A.L. Soares	
E0718	Impact of cefiderocol therapy on patient survival across different multi-drug resistant Gram-negative bacilli infections: insights from the SUSANA cohort.N. Corti* (Monza, Italy), M. Faltoni, L. Mezzadri, E. Ricci, M. Fois, A. De Vito, A. Bandera, P. Maggi, D. Bavaro, S. Rusconi, A. Mastroianni, M.A. Carleo, G. Cenderello, L. Bisi, G. Madeddu, P. Bonfanti	
E0719	Decoding resistance: investigating cefiderocol's battle against carbapenem-resistant <i>Acinetobacter baumannii</i> Y. T. Lee* (Taipei, Taiwan, China)	
E0720	Long-read sequencing reveals novel genetic factors in cefiderocol resistance in <i>Pseudomonas aeruginosa</i> ATCC 27853: A stepwise adaptive evolution studyM. Cardoso* (Groningen, Netherlands), B.B. Xavier, B. Sinha, J. W. A. Rossen, A. Kumar Bari, T. T. Severs	
E0721	Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales clinical isolates causing infection in hospitals in Europe and adjacent regionsR. Mendes* (North Liberty, United States), A. Scullin, D. Beekman, Z. Kockler, J.M. Maher, H.S. Sader, M. Castanheira	
E0722	Cefiderocol activity against planktonic and biofilm forms of $\beta$ -lactamase-producing <i>Pseudomonas aeruginosa</i> from people with cystic fibrosisG. Fabrizio* (Rome, Italy), M. Truglio, I. Cavallo, F. Sivorì, M. Francalancia, R. Riveros Cabral J, S. Petrolo, L. Pamparau, M. Comar, D. Compagnino, M. Trancassini, G. Antonelli, F. Ascenzioni, G. Cimino, F. Pimpinelli, E.G. Di Domenico	
E0723	Activity of cefiderocol against clinical isolates of <i>Pseudomonas aeruginosa</i> collected from five European countries as part of SENTRY antimicrobial surveillance program 2020-2023C. Longshaw* (London, United Kingdom), J. Maher, R. Mendes, H. Yamashiro, Y. Yamano	

EF101	14:45 – 15:45	Arena 3
ePoster Flash Session		
Immunology of bacterial pathogens		
E0724	Serotype 38 <i>Streptococcus pneumoniae</i> emerges as one of the dominant serotypes causing invasive pneumococcal disease in Germany and Poland, but not in the NetherlandsK. Hajji* (Bilthoven, Netherlands), I. Wróbel-Pawelczyk, J. Van Veldhuizen, K. Maruhn, W. Miellet, M. Rob, A. Steens, N. Van Sorge, K. Trzciński, M. Van Der Linden, A. Skoczyska, L. Visser	
E0725	Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116: a secondary analysis of five phase 3 studiesM. Esteves Jaramillo* (Rahway, United States), J. Li, H. Platt, W. Hu, W. Xu, T. Chapman, K. Nolan, J. Hartzel, U. Buchwald	
E0726	Baseline serotype-specific IgG responses to pneumococcal vaccines in type 2 diabetes: implications for vaccine strategy in vulnerable populationsS. Mettingal Ramakrishnan* (Bsk 2nd Stage,Bangalore, India), V. Govindan, M.M. Akhila, N. Geetha, K.L. Ravikumar	
E0727	Protection against invasive meningococcal disease and gonorrhoea, 5 years post introduction of a 4CMenB immunisation program in infants and adolescents in South AustraliaH. Marshall* (Adelaide, Australia), B. Wang, L. Giles, P. Andraweera, M. Mcmillan, S. Almond, R. Beazley, J. Mitchell, J. Sinsnowski, C. Bell, L. Flood, J. Ward	
E0728	Molecular epidemiology and correlates of protection among group B <i>Streptococcus</i> from carriage and disease: assessing vaccine coverage in Brazil T. Pinto* (Rio De Janeiro, Brazil), L. Oliveira, N. Costa, E. Bressan, A. Rio Tinto, S. Fracalanza, L. Teixeira	



ESCMID Global 2025 - Programme

E0729		Impact of BCG vaccination on adaptive immune responses to mycobacterial and non-mycobacterial antigens in HIV-exposed, uninfected infants. <i>R. Namakula*</i> (Bergen, Norway), <i>V. Nankabirwa, S. Cose, O. Namugga, M.G. Netea, H. Steinsland, H. Sommerfelt, K. Hanevik</i>
E0730		Immune signature against <i>Klebsiella pneumoniae</i> proteins in a mother-baby cohort from Blantyre, Malawi. <i>E. Heinz*</i> (Glasgow, United Kingdom), <i>J. Campo, O. Pearce, A. Zuza, A. Teng, J. Pablo, A. Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey</i>
E0731		A comprehensive computational mapping of B-cell epitopes in the <i>Klebsiella pneumoniae</i> porinome. <i>S. Prieto Martin Gil*</i> (Madrid, Spain), <i>S. Prieto Martin Gil, E. Gato, A. Pérez, M.J. McConnell, A.J. Martin Galiano</i>
E0732		Chronic infection induces a broadly neutralizing antibody response to Elastase B of <i>Pseudomonas aeruginosa</i> . <i>A. Albus*</i> (Cologne, Germany), <i>D. Kolling, K. Rox, D. Holzmann, K. Mundry, M. Sánchez Agut, C. Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Klein, J. Koehnke, J. Rybniker, A. Simonis</i>

KN137	14:45 – 15:45	Hall 1
	Keynote Lecture	
		TRN
Staphylococcus aureus host-microbe interaction: ecology, disease, and vaccine development		
Chairs	Werner Ruppitsch (Vienna, Austria) Annelies Zinkernagel (Zurich, Switzerland)	

K0376	14:45	Juliane Bubeck Wardenburg (St. Louis, United States)
-------	-------	--

ME140	14:45 – 15:45	Hall 11
	Meet-the-Expert	
		DX TRN
Bioinformatic tools from start to finish		

M0381	14:45	Vitor Borges (Lisbon, Portugal)
M0382	14:57	Clare Sloggett (Melbourne, Australia)

ME141	14:45 – 15:45	Hall 13
	Meet-the-Expert	
		AMR CLN
AI use in antimicrobial stewardship		

M0383	14:45	Shruti Gohil (Irvine, United States)
M0384	14:57	Jose Ramon Pano-Pardo (Zaragoza, Spain)

OS097	14:45 – 15:45	Hall 14
	1-hour Oral Session	
		PHEI
Update on zoonotic and enteric infections		
Chairs	Steen Ethelberg Kavitha Saravu (Manipal, India)	

O0696		A large-scale epidemiological study of <i>Campylobacter</i> employing whole genome analysis reveals the evolution of highly virulent and multidrug-resistant clones in the UK. <i>B. Lopes*</i> (Middlesbrough, United Kingdom), <i>A.S. Boaitay-Biko</i>
O0697		Population dynamics and evolution of multidrug resistant clones of <i>Shigella sonnei</i> in Metropolitan France. <i>C. Silva Nodari*</i> (Paris, France), <i>I. Carle, M. Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M. Pardos De La Gandara, F.X. Weill</i>

O0698		Shiga toxin-producing <i>Escherichia coli</i> /O26 as an increasingly common cause of haemolytic uraemic syndrome in England: A fifteen-year analysis of national enhanced surveillance data. <i>L. Mcgeoch*</i> (London, United Kingdom), <i>O. Quinn, C. Sawyer, A. Douglas, C. Jenkins, S. Balasegaram</i>
O0699		Incidence, clinical presentation, and outcomes of <i>Pasteurella</i> infections: a population-based Danish study. <i>L. Øbo Larsen*</i> (8200, Denmark), <i>L.Ø. Larsen, H.L. Nielsen, K.K. Søgaard</i>
O0700		Natural history of latent brucellosis and efficacy evaluation of B-spot in active and latent cases: A 12-month prospective cohort study. <i>H. Wang*</i> (Shanghai, China), <i>G. Yuan, D. Li, H. Liu, J. Ai, W. Zhang</i>

OS098	14:45 – 15:45	Hall 15
	1-hour Case Session	
		CLN
Opportunistic infections in the immunocompromised		
Chairs	Aleksandra Barac (Belgrade, Serbia) Olivier Lortholary (Paris, France)	

O0701		Dog scratch disease? A case of <i>Vibrio vulnificus</i> in a liver transplant patient. <i>E. Kim*</i> (Galveston, United States), <i>A. Covington</i>
O0702		Mpx infection among solid organ transplant recipients: a single center experience at a U.S. Tertiary Care Facility. <i>J. Bini Viotti*</i> (Miami, United States), <i>J. Bini</i>
O0703		Histoplasmosis in Hansen’s Disease: Thalidomide for TNF-alpha inhibition in ENL with a Risk of Opportunistic Infections. <i>K.K. Vaitheeswaran*</i> (Delhi, India), <i>M. Soneja, N. Bhari, R. M., G. K. V., S. Agarwal, R. Kumar, Y. Dharmashaktu</i>
O0704		Nocardiosis in a kidney transplant recipient: pros & cons of tedizolid. <i>M. Pellegrino*</i> (Modena, Italy), <i>V. Todisco, S. Generoso, L. Benassi, E. Franceschini, F. Damiano, G. Donati, C. Mussini, A. Cervo</i>
O0705		Mycobacterium genavense-Associated IRIS with Macrophage Activation Syndrome: A Case Report Highlighting Diagnostic Challenges. <i>M. Meroi*</i> (Verona, Italy), <i>M. Morra, M.E. De Rui, E. Tacconelli, F. Soldani</i>

SY139	14:45 – 15:45	Hall 16
	1-hour Symposium	
		CLN DX
How to manage bacterial meningitis in low resource settings		
Chairs	Joseph Donovan (Ho Chi Minh City, Vietnam) Christina Obiero (Kilifi, Kenya)	

S0379	14:45	Bacterial meningitis diagnosis and surveillance. <i>Divya Deodhar</i> (Muscat, Oman)
S0380	15:05	Clinical presentation and management of CNS infections. <i>Kartika Maharani</i> (Jakarta, Indonesia)
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)		

OS095	14:45 – 15:45	Hall 2
	1-hour Oral Session	
		CLN PHEI
Community respiratory tract infections: latest trends and approaches		
Chairs	Catia Cilloniz (Barcelona, Spain) Aurélien Dinh (Garches, France)	

O0686		<i>Mycoplasma pneumoniae</i> increase in 2023/24 causes disease in adults in Europe. <i>B.M.M. Streng*</i> (Utrecht, Netherlands), <i>C. Prat Aymerich, L. Bont, P. Meyer Sauteur, M. Bonten, A. Van Rossum</i>
O0687		Serotype distribution of pneumococcal community-

ESCMID Global 2025 - Programme

		<b>acquired pneumonia in hospitalized adults in Germany</b> <i>D. Karssen* (Utrecht, Netherlands), L. Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T. Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U. Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten, C. Prat-Aymerich</i>	
00688		<b>Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: a Bayesian latent class analysis</b> <i>J. Wei* (Oxford, United Kingdom), K. Yuan, A. Luk, S. Walker, D. Eyre</i>	
00689		<b>Causes of death and risk factors for 90-day mortality and readmission in community-acquired pneumonia</b> <i>F. Al-Zergani* (Hvidovre, Denmark), C. Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard, L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. Benfield</i>	
00690		<b>Oropharyngeal carriage of gut-derived Enterobacteriales increases RTI risk in long-term aged care residents</b> <i>S. Miller* (Adelaide, Australia), F. Zhang, S. Taylor, A. Shoubbridge, E. Vasil, R. Woodman, L. Papanicolas, G. Rogers</i>	
SY138	14:45 – 15:45	1-hour Symposium	Hall 4
		AMR	
		<b>Global clones and evolving resistance mechanisms towards newer beta-lactams: Where are we heading?</b>	
		<i>Chairs</i>	<i>Yesim Besli (Istanbul, Türkiye) Spyros Pournaras (Athens, Greece)</i>
S0377	14:45	<b>Carbapenemase-producing Enterobacteriales: the not so good, the bad and the ugly</b> <i>Arjana Tambic Andrasevic (Zagreb, Croatia)</i>	
S0378	15:15	<b>The <i>P. aeruginosa</i> frightening cocktail: high-risk clones, horizontally-acquired resistance and evolving mutational resistome</b> <i>Katy Jeannot (Besançon, France)</i>	
		Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)	
OS096	14:45 – 15:45	1-hour Oral Session	Hall 5
		AMR	
		<b>Trends in antifungal resistance</b>	
		<i>Chairs</i>	<i>Alexandre Alanio (Paris, France) Ana Alastruey-Izquierdo (Madrid, Spain)</i>
00691		<b>Turning resistance into vulnerability: leveraging genetic insights to predict collateral sensitivity and synergism for effective multidrug therapies</b> <i>K. Schmidlin* (Tempe, United States), K. Geiler-Samerotte</i>	
00692		<b>Role of the C2585G substitution in the <i>MRR1</i> gene in the development of azole resistance in <i>Candida parapsilosis sensu strictu</i></b> <i>I. Franconi* (Pisa, Italy), P. Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, M. Falcone</i>	
00693		<b>Fungaemia in a tertiary Madrid hospital from 2007 to 2024: changes in species epidemiology, increase in echinocandin resistance and low patient-to-patient transmission in recent years</b> <i>J. Guinea* (Madrid, Spain), P. Escribano, G. Jesús, M. Machado, A. Burillo, P. Muñoz</i>	
00694		<b>A multicentre study for determination of epidemiological cutoff values for rezafungin and four comparators against <i>Candida auris</i> with EUCAST broth microdilution reference methodology</b> <i>J. Meletiadis* (Haidari, Greece), J. Guinea, S. Arikant-Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup</i>	
00695		<b>Decoding <i>Candida auris</i> Resistance in Latin America: <i>Candida.app</i> vs. Pathogenwatch</b> <i>J. Acosta España* (Quiro, Ecuador), P. Eduarda, J.D. Acosta-España, A.</i>	

			Herrera-Yela
SY144	16:15 – 17:15	1-hour Symposium	Hall 14
		PHEI VAX	
		<b>What's the role of infant and maternal immunisation for paediatric RSV prevention?</b>	
		<i>Chairs</i>	<i>Joanne M. Langley (Halifax, Canada) Peter Openshaw (London, United Kingdom)</i>
S0391	16:15	<b>Pros and cons of passive infant immunisation with mAb before their first RSV season</b> <i>Federico Martínón-Torres (Santiago De Compostela, Spain)</i>	
S0392	16:45	<b>Pros and cons of maternal vaccination in preventing severe RSV infections in infants</b> <i>Anne Vergison (Luxembourg, Luxembourg)</i>	
EF104	16:15 – 17:15	ePoster Flash Session	Arena 1
		DX PHEI	
		<b>Cutting-edge technologies to improve viral diagnostics</b>	
		<i>Chair</i>	<i>Patrícia Alvarez (Rio De Janeiro, Brazil)</i>
E0743		<b>How straightforward is the switch from qPCR to dPCR in a routine lab setting for quantification of Varicella-zoster virus in CSF samples</b> <i>A. Baumhögger* (Bochum, Germany), T. Bähr, G. Geis, S. Gatermann</i>	
E0744		<b>A novel biosensor for the detection of RSV infection</b> <i>C. Zannella* (Naples, Italy), F. Passeggio, F. Napolitano, A. De Filippis, F. Arcadio, C. Marzano, I. Tavoletta, L. Zeni, M. Galdiero, G. Portella, N. Cennamo</i>	
E0745		<b>Insufficient sexual health bloods don't always need throwing away!</b> <i>S. Hutchings* (Bristol, United Kingdom), R. Hopes, P. North, W. Stoate, M. Murphy, G. Beckley, J. Gabb</i>	
E0746		<b>A comparison of 4 HAV serology assays: the value of consensus results as a reference standard</b> <i>T. Chin* (Ghent, Belgium), E. Padalko</i>	
E0747		<b>Advancing herpesvirus diagnostics: clinical evaluation of a high-performance real-time PCR assay</b> <i>H. Alonso-Ezcurra* (Zaragoza, Spain), S. Lucea, C. Escolar, H. Alonso</i>	
E0748		<b>Evaluation of microbiological techniques for the diagnosis of West Nile Virus in the Virgen del Rocío hospital area (Sevilla, Spain)</b> <i>M. Aznar Fernandez* (Seville, Spain), M. Aznar, C. Lozano, L. Merino, M.J. Pérez, J.L. García, C. Cintora, J.A. Lepe</i>	
E0749		<b>Development of Non-Cross-Reactive Monoclonal Antibodies Against West Nile Virus and Usutu Virus Non-Structural Protein 1 to Improve Early Diagnosis</b> <i>M. Ceconi* (Antwerp, Belgium), K. Ariën, P. Delputte</i>	
E0750		<b>Enhancing Diagnostics and Global Standards through the QCMD Viral Metagenomics EQA</b> <i>G. Sutton* (Glasgow, United Kingdom), D. Montgomery, E. McCulloch, A. Ricketts</i>	
E0751		<b>Analysis of HIV-1 drug-resistance in newly diagnosed subjects using Next Generation Sequencing</b> <i>V. Micheli* (Milan, Italy), F. Bracchitta, L. Morelli, A. Cavallo, S. Giubileo, A. Tamoni, A. Lombardi, A. Dolci</i>	
EF105	16:15 – 17:15	ePoster Flash Session	Arena 2
		ANT CLN TRN	
		<b>New data in non-tuberculous mycobacterial disease</b>	
		<i>Chair</i>	<i>Lorenzo Guglielmetti (Paris, France)</i>
E0752		<b>Deciphering genotypic resistance to amikacin in <i>Mycobacterium abscessus</i> using whole genome sequencing and a specific pipeline (GenoMAB)</b> <i>C.</i>	

# ESCMID Global 2025 - Programme

	<i>Allam* (Paris, France), S. Agsous, P. Baylac, K. La, N. Godron, F. Mougari, Z. Awad, E. Cambau</i>
E0753	<b><i>Pseudomonas aeruginosa</i> rapidly kills <i>Mycobacterium abscessus</i> in dual-species biofilms in vitro</b> <i>M. Mcdaniel* (Nijmegen, Netherlands), J. Scofield, J. Van Ingen</i>
E0754	<b>Distribution of cotrimoxazole in different tissues of mice and human patients infected with <i>Mycobacterium abscessus</i></b> <i>W. Nie* (Beijing, China), N. Chu</i>
E0755	<b>Exploration of clofazimine and bedaquiline activity against clinical strains of <i>Mycobacterium abscessus</i> to advance innovative therapeutic strategies</b> <i>C. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, J.J. Aguilera-Correa, M.C. Muñoz-Egea</i>
E0756	<b>Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria</b> <i>S. Sarkar* (Parkville, Australia), K. Strumila, S. Yu, R. Werder, T. Johansson, A. Hidalgo Gonzalez, E. Stanley, S. Ranganathan</i>
E0757	<b>Recovery of Non-Tuberculous Mycobacteria and Detection of Dominant Circulating Clones in Indoor Water Samples from Germany</b> <i>N. Wetzstein* (Frankfurt, Germany), M. Diricks, D. Frank, I. Friesen, S. Niemann, T. Wichelhaus</i>
E0758	<b>Deciphering the Epidemiology of <i>Mycobacterium chimaera</i>: Genetic Lineages, Environmental Sources, and Infection Prevention Insights</b> <i>G. Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. Casadei, C. Scarparo</i>
E0759	<b>Evaluation of a novel media for susceptibility testing of <i>Mycobacterium avium-intracellulare</i> complex isolates</b> <i>T. Grams* (Salt Lake City, United States), S. Shakir</i>
E0760	<b>Emerging cases of <i>Mycobacterium chelonae</i> endocarditis associated with <i>BioIntegral</i> bioprostheses</b> <i>J. Kikhney* (Berlin, Germany), F. Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, A. Moter</i>

EF106	16:15 – 17:15	Arena 3
-------	---------------	---------

ANT CLN

ePoster Flash Session

## The ABC (allergy, bloodstream infections and clinical decision support) in AMS

Chair Céline Pulcini (Nancy, France)

E0761	<b>Evaluation of the allergy fact checker, a clinical decision support system to promote non-invasive delabeling of incorrect penicillin allergy labels: a mixed-methods study</b> <i>D. Wets* (Leuven, Belgium), R. Schrijvers, I. Spriet, G. Van De Sijpe, L. Gilissen, C. Breynaert, T. Ieven, P. De Munter</i>
E0762	<b>Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trial</b> <i>J. Sandoe* (Leeds, United Kingdom), S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P. Howard, D. Howdon, S. Mort, R. Mujica-Mota, A. Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, L.M. Yu, S. Pavitt</i>
E0763	<b>Stewardship interventions reduced blood culture utilization by 40% during BD BACTEC™ Blood Culture media shortage</b> <i>X. Li* (Toronto, Canada), K. Katz, A. Ceantavida, R. Kozak, C. Vermeiren, P. Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R. Lovinsky</i>
E0764	<b>Prescriptive Impact of Rapid Microbiological Diagnostics in Bloodstream Infections Caused by <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Staphylococcus aureus</i> (PRIMEKA): A Retrospective Single-Center Cohort Study</b> <i>F. Salvati* (Rome, Italy), F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo, R. Murri, C. Torti</i>

E0765	<b>The inappropriate use of antibiotics for blood culture contamination and colonisation by multidrug-resistant microorganisms: the role of counselling on antibiotic prescription</b> <i>R.R. Peña-Zalbidea* (Palma (balearic Islands), Spain), L. Martin, H. Vilchez, L. Periañez, E. Rojo, M. Peñaranda, M. Garcia, M. Riera, X. Mulet, A. Oliver, J. Murillas</i>
E0766	<b>Factors influencing meropenem prescription following the 2020 EUCAST « I » definition update : a multicentric observational study in Belgian hospitals</b> <i>L. Catteau* (Brussels, Belgium), L. Bonacini</i>
E0767	<b>Impact of an Antimicrobial Stewardship Mobile Application on Antimicrobial Prescribing, Length of Hospital Stay, and Cost Savings</b> <i>Z.O.E. Babiker* (Abu Dhabi, United Arab Emirates), L. Bukasa, A. Sadeq, J. Shamseddine, R. Ali</i>
E0768	<b>Evaluation of a model-based clinical decision support system for empirical antimicrobial therapy</b> <i>M.L. Mogensen* (Aalborg, Denmark), S.N. Søgaard, L. Ward, H. Skjot-Arkil</i>
E0769	<b>A rapid systematic review of criteria to facilitate prompt intravenous-to-oral antimicrobial switch in children and young people in England</b> <i>R. Oettle* (London, United Kingdom), S. Patel, A. Demirjian, M. McLeod, C. Jamieson, G. Damant, K. Hand, D. Ashiru-Oredope</i>

EA	16:15 – 17:30	Hall 1
----	---------------	--------

Awards

PRO

## Excellence Award Lectures

Chairs Jon S. Friedland (London, United Kingdom)  
Robert Leo Skov (Copenhagen, Denmark)

A006	16:15	<b>Towards pandemic prevention, moonshot or utopia?</b> <i>Marion Koopmans (Rotterdam, Netherlands)</i>
A007	16:50	<b>Can global warming bring new infectious diseases?</b> <i>Arturo Casadevall (Baltimore, United States)</i>

SY143	16:15 – 17:15	Hall 11
-------	---------------	---------

1-hour Symposium

VAX

## ESCMID guidelines for the vaccination of immunocompromised individuals: solid organ transplant recipients

Chairs Elisa Cordero Matia (Seville, Spain)  
Zitta Barrella Harboe (Hillerød, Denmark)

S0389	16:15	<b>Vaccination against respiratory pathogens</b> <i>Albert Vollaard (Bilthoven, Netherlands)</i>
S0390	16:45	<b>Other vaccines</b> <i>Olivier Epaulard (Grenoble, France)</i>

Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), ESCMID Vaccine Study Group (EVASG)

EW146	16:15 – 18:15	Hall 13
-------	---------------	---------

Educational Session

## How to detect, manage and communicate hospital outbreaks

Chairs Margaret Ip (Shatin, Hong-Kong SAR, China)  
Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)

W0395	16:15	<b>How to detect hospital outbreaks</b> <i>David Fisman (Toronto, Canada)</i>
W0396	16:35	<b>How to confirm hospital outbreaks using genomics</b> <i>John W. A. Rossen (Groningen, Netherlands)</i>
W0397	16:55	<b>How to rapidly respond to an ongoing hospital outbreak</b> <i>Ermira Tartari (Msida, Malta)</i>
W0398	17:15	<b>How to communicate hospital outbreaks via scientific publication</b> <i>Ines Steffens (Solna, Sweden)</i>



ESCMID Global 2025 - Programme

ME145	16:15 – 17:15	Hall 15
CLN DX Meet-the-Expert		
Fungal meningitis: recognition and current status of management		
M0393	16:15	Olivier Lortholary (Paris, France)
M0394	16:27	Janis Blair (Phoenix, United States)
JS2	16:15 – 17:15	Hall 16
PRO Journal Session		
Late-breaker research from the Lancet group: new interventions for familial and new infectious diseases		
Chairs	Syeda Saleha Hassan (London, United Kingdom) Ursula Hofer (London, United Kingdom)	
J011	16:15	TBA
J012	16:30	The spatio-temporal ecology of Oropouche virus: a laboratory-based modelling study across Latin AmericaJan Felix Drexler (Berlin, Germany)
J013	16:45	The WHO Bacterial Priority Pathogens List: guiding research and development, and informing innovative public health strategies to address antimicrobial resistanceHatim Sati (Geneva, Switzerland)
J014	17:00	Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three RSV seasons: a randomized trialAlberto Papi (Ferrara, Italy)
Co-organised with: The Lancet group		
OS102	16:15 – 17:15	Hall 2
AMR DX 1-hour Oral Session		
AI tools empowering AMR prediction in WGS and MALDI-TOF		
Chairs	Oliver Nolte (Zürich, Switzerland) Patricia Simner (Rochester, United States)	
O0733	A scalable machine learning approach to predict antimicrobial susceptibility from whole genome sequencing dataY. Zhong* (Liverpool, United Kingdom), A. Gerada, A. Howard, P. Green, W. Hope	
O0734	Machine Learning-Based Antimicrobial Resistance Prediction of 11 antibiotics for <i>Klebsiella pneumoniae</i> from Clinical NGS DataJ. Xinmiao* (Beijing, China), X. Jia, J. Zhang, J. Chen, Q. Yang	
O0735	AI-Powered Real-Time Plasmid Prediction Using Nanopore SequencingE. Sauerborn* (Munich, Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. Foster-Nyarko, L. Urban	
O0736	MALDI-TOF Prediction model based on machine learning algorithm for the detection of ST23 high-virulence <i>K. pneumoniae</i> L. Dortet* (Le Kremlin-Bicêtre, France), L. Mancera Pascual, M.J. Arroyo	
O0737	Predicting rifampicin resistance in <i>Mycobacterium tuberculosis complex</i> with a machine learning based MALDI-TOF MS approachY.W. Sun* (Taichung, Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W. Lu, C.C. Chen, J. Yu	
LB005	16:15 – 17:15	Hall 3
1-hour Oral Session		
Emerging pathogens in humans, animals and vectors		
L0026	Genome-wide association study identifies <i>ABCG1</i> as a susceptibility locus for tick-borne encephalitisP. Gampawar* (Graz, Austria), M. Sagmeister, D. Ruzek,	

N. Schweintzger, E. Hofer, B. Kohlmaier, V. Švendová, P. Bogovic*, J. Zajkowska, L. Krbková, V. Štruncová, A. Mickiene, D. Kohlfürst, A. Sonnleitner, A. Fořtová, M. Berankova, M. Pychova, D. Zavadska, N. Sallah, A. Pichler, D. Sedláček, A. Chrdle, C. Haudum, B. Obermayer-Pietsch, P. Hoffmann, M. Nöthen, M.L. Tammesoo, A. Metspalu, P. Husa, K. Stiasny, A. Binder, A. Berghold, F. Strle, M. Hibberd, W. Zenz		
L0027	First detection of tick-borne encephalitis virus in Belgian ticks, May 2024E. Portell-Buj* (Stockholm, Sweden), C. Philippe, S. Van Gucht, F. Dufrasne	
L0028	Spread of a fusidic acid and methicillin-resistant <i>Staphylococcus aureus</i> clone causing impetigo in EuropeA.R. Larsen* (Copenhagen, Denmark), A. Petersen, L. Roer, K. Vendrik, R. Zwittink, D. Notermans, N. Yin, M. Perrin, K. Khonyongwa, A. Tristan, B. Youenou, F. Layer-Nicolaou, G. Werner, H. Enger, E.C.H. Eikrem, J. Darenberg, B. Mäkitalo, M. Paulsson, H. Fang, E. Tång Hallbäck, L. Lindholm, K. Moganeradj, B.J. Holzknecht, H.B. Eriksen, M. Hoppe, M.D. Bartels, J.A. Samaniego Castruita	
L0029	Increase of PVL-positive livestock-associated MRSA in the Netherlands: a growing concern beyond livestock settingsK. Vendrik* (Bilthoven, Netherlands), S. Witteveen, D.W. Notermans, S.C. De Greeff, C.C. Wielders, E. Van Duijkeren, A.S. Schoffelen, A.P. Hendrickx, R.D. Zwittink	
L0030	H5N1 human infection in the United Kingdom: a One-Health approachR. Puleston* (London, United Kingdom), N. Hamzaoui, S. Hayward, W. Proto, E. Booth, C. Beck, A. Lackenby, K. Spence, M. Beadsworth, N. Wong, M. Samuel, A. Singanayagam, K. Hoschler, N. Groves, D. Kumar, O. Olufon, W. Cook, N. Watkins, D. Ready, S. Makki, K. Marston, S. Collins, C. Arevalo, D. Blackman, L. Guinness, C. Chatt, M. McGivern, A. Edwards, A. Banyard, R. Jorquera, K. Saville, R. Benee, S. Van Helvoort, E. Brown, L. Leighton Mctague, M. Chand, S. Rokadiya, S. Hopkins, H.I.M. Team, N. National Response Center Team	

SY142	16:15 – 18:15	Hall 4
<div><div>DX</div><div>TRN</div></div> 2-hour Symposium		
Precision genomics to improve infectious diseases management		
ChairJacob Moran-Gilad (Beer Sheva, Israel)		
S0385	16:15	Human genomics approaches to infection immunityFergus Hamilton (Bristol, United Kingdom)
S0386	16:45	Applying bacterial GWAS to uncover new mechanisms of antibiotic resistanceMarco Galardini (Hannover, Germany)
S0387	17:15	Evolution in action: large-scale within-host evolution analyses of persistent bacterial infectionsStefano Giuliani (Melbourne, Australia)
S0388	17:45	Machine learning in bacterial genomics and metagenomicsFrancesco Asnicar (Trento, Italy)

OS103	16:15 – 17:15	Hall 5
<div><div>AMR</div><div>TRN</div></div> 1-hour Oral Session		
Polymicrobial interactions and competition		
ChairsAlessandra Bragonzi (Milano, Italy) Kimberly Kline (Genève, Switzerland)		
O0738	The <i>Klebsiella pneumoniae</i> type VI secretion system effector Tie4 facilitates adaptation survival by damaging the cell membrane of competing bacteriaW. Li* (Shanghai, China), J. Zhang	
O0739	<i>Candida albicans</i> promotes TSST-1 production in <i>Staphylococcus aureus</i> by depleting glucose and lifting carbon catabolite repressionM. Carriou* (Lyon, France), C. Badiou, A. Soulard, K. Chikh, O. Vitalis, A. Frugier, K. Dufresne, G. Lina	
O0740	Understanding polymicrobial biofilm dynamics: focus	

ESCMID Global 2025 - Programme

	on <i>Pseudomonas aeruginosa</i> and its molecular interactions.S. Kansal* (Chandigarh, India), U. Dutta, A. Angrup, P. Ray
O0741	Intra- and interspecific antagonism inhibits growth of <i>Staphylococcus aureus</i> in human nasal microbial communitiesL. Brülisauer* (Zurich, Switzerland), M. Boumasmoud, S. Brugger, A.R. Hall
O0742	Combination therapy against drug resistance biomimetic dual-species biofilm model of <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> P. Mojarrad* (Helsinki, Finland), P. Tammela, T. Laaksonen, Z. Gounani

EF110	17:30 – 18:30	Arena 1
	ANTCLNDX	ePoster Flash Session

Advancing diagnostics and treatment of endocarditis	
Chair	Benoît Guery (Lausanne, Switzerland)

E0785	18F-FDG-PET/CT improves source control of extra-cardiac complications in infective endocarditisJ.M. Prins* (Amsterdam, Netherlands), S. Douiyeb, W. Van Gameren, D. Buis, T. Van Der Vaart, M. Boekholdt, J. Selder, D. Robbers-Visser, H. Verberne, H. Van Werkhoven, K. Sigaloff
E0786	Comparing Duke criteria updates: Advancing IE diagnosis in patients with prosthetic intracardiac materialsM. Papadimitriou Olivgeris* (Sion, Switzerland), M. Papadimitriou-Olivgeris, B. Ledergerber, N. Fourné, V. Zimmermann, N. Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, O. Dzemali, J. Epprecht, B. Guery, B. Hasse
E0787	<i>In vivo</i> Dalbavancin efficacy against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and high-level aminoglycoside resistant (HLAR) <i>Enterococcus faecalis</i> (EFAE) experimental endocarditis model.C. García De La María* (Barcelona, Spain), C. García De La Mária, M.A. Cañas, M. Brunet, J. García-González, G. Cuervo, M. Espasa, M. Hernandez-Meneses, C. Falces, A. Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. Llopis, A. Moreno, J.M. Miro
E0788	Identification and validation of clinical phenotypes in <i>Staphylococcus aureus</i> blood stream infection and their association with mortality (FEN-AUREUS study)J. Rodríguez-Baño* (Seville, Spain), B. Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M. Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita-Santos, Á. Cano, R. Palacios, S. López-Cárdenas, M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E. Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata-Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez, L. Romero-Calderón, A. Alemán-Rodríguez, E. Recacha, J. Torre-Cisneros, N. Merchante, Á. Pascual, L.E. López-Cortés
E0789	Enterococcal Infective Endocarditis: demographics, comorbidities, diagnostic evaluation and mortality outcomesM. Singh* (London, United Kingdom), C. Watkins, H. Bristowe, M. Gunning, J. Galloway, R. Dworakowski, M. Arias
E0790	Health related quality of life of patients with infective endocarditis – preliminary data of the DERIVE cohortC. Meyer-Schwickerath* (Cologne, Germany), K. Schmidt-Hellerau, J. Camp, K. Last, I. Joost, S. Rieg, N. Jung
E0791	The optimal management of <i>Enterococcus faecium</i> catheter-related bloodstream infections: a gap to bridgeI. Rancan* (Florence, Italy), M. Rinaldi, F. Malerba, B. Profiti, L. Ancillotti, M. Tumbarello, P. Viale, M. Giannella
E0792	Ceftibiprole alone versus in combination with ampicillin against borderline penicillin-resistant, vancomycin-resistant <i>Enterococcus faecalis</i> O. Funk* (Brooklyn, United States), I. Khan, J. Li, J. Cusumano
E0793	Risk factors for in- hospital mortality in 500 cases of infective endocarditisC. Lamas* (Rio De Janeiro, Brazil), G. Pompeo, T. De Almeida, M. De Carvalho,

N. Feijó, R. Garrido, G. Barbosa, B. Zappa, C. Weksler, M. Correia, W. Golebiovski
--

EF111	17:30 – 18:30	Arena 2
	CLN	ePoster Flash Session

Don't blink: STIs are everywhere	
Chair	Mathew Beale (Hinxtton, United Kingdom)

E0794	Neurosyphilis and Mpox co-infection mimic HIV encephalitisL. Mejdoubi* (Vienna, Austria), A. Nader, L. Mautner, A. Bahrami, F. Hofer
E0796	An unusual cause of transverse myelitisJ. Koleri* (Doha, Qatar), M. Samawi, M. Maslamani
E0798	Ocular Syphilis, an uncommon presentation form of syphilis: two casesR. Kardashi* (Dresden, Germany), A. Frenz, K. De With
E0799	Case report of a severe skin infection in a young man on PREP and DoxyPEP M. Zlámá* (Prague, Czech Republic), Z. Bartovská, B. Lacmanová, M. Holub
E0800	Serowaffling In PREP Users: The Difficulty of HIV Diagnosis – A Case Report.P. Pillado Alonso* (Badalona, Spain), G. Fernández Rivas, A. Rivero Calaf, Á. Hernández-Rodríguez, R. Peña, J. Prado, J. Martínez-Picado
E0801	Severe disseminated mpox in a patient with advanced HIV: A case reportM.A. Quadros Flores* (Lisbon, Portugal), R. Diogo, F. Gonçalves, T. Marques, S. Paulo, F. Cota Medeiros, D. Mendes Pedro
E0802	Sensorimotor polyneuropathy in a patient affected by HIV-1: an atypical presentation of neurosyphilis associated to anti-SOX-1 antibodiesA. Lippi* (Siena, Italy), L. Ancillotti, M. Fabbiani, L. Migliorini, S. Bartalini, F. Ginanneschi, M. Tumbarello, F. Pippi, C. Puttini, F. Montagnani

EF112	17:30 – 18:30	Arena 3
	AMRANTCLN	ePoster Flash Session

Clinical considerations in resistant organisms	
Chair	Divya Deodhar (Muscat, Oman)

E0803	Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicenter clinical experienceF. Serapide* (Catanzaro, Italy), R. Serraino, L. Spadafora, M. Bernardi, G. Brucci, G. Cattardico, S. Corcione, I. De Benedetto, M. Del Monte, A. Limongelli, D.R. Giacobbe, E. Graziano, M. Meschiari, S. Mornese Pinna, M. Peghin, G. Tiseo, A. Vena, F. Romeo, G. Sarto, M. Bassetti, G. Biondi-Zoccai, F.G. De Rosa, M. Falcone, P.A. Grossi, C. Mussini, A. Russo
E0804	Clinical outcomes of MSSA bacteremia exhibiting the cefazolin inoculum effect and development of a novel diagnostic methodS. Yoshizawa* (Ota-Ku, Japan), T. Sato, K. Komori, K. Yamada, T. Yamaguchi, K. Tateda
E0805	Third- and fourth-generation cephalosporins for the treatment of infections due to OXA48 carbapenemase-producing EnterobacteralesA. Blanco Arévalo* (Barcelona, Spain), A. Blanco-Arevalo, E. Sastre-Escolá, J. Camara Mas, F. Tubau Quintano, R. Costa, A. Padulles, E. Shaw, C. Gudiol, M. Puig-Asensio
E0806	Are meropenem or Imipenem-cilastatin effective therapies for patients with invasive ertapenem-resistant infections?A. Peters* (Santiago, Chile), S. Fiawoo, L. Diaz, J.R. Martínez, M. Spencer-Sandino, L. Rivas, M.P. Riquelme, P. Rojas, L. Rojas, M.L. Rioseco, J. Moreno, R. Araos, P. García, P.D. Tamma, J.M. Munita
E0807	Oral Fosfomycin after Carbapenems as de-escalating therapy In Complicated Urinary Tract

ESCMID Global 2025 - Programme

		<b>Infection: A randomized controlled trial</b> <i>K. Angkanavisan* (Bangkok, Thailand), B. Sakboonyarat, C. Ungthammakhun</i>	
E0808		<b>Oral switch vs. intravenous antibiotics treatment for serious carbapenem-resistant Enterobacterales and <i>Pseudomonas aeruginosa</i> infections on hospital discharge: the next frontier for oral switch?</b> <i>C. Arena* (Detroit, United States), A. Abed, R. Kenney, G. Suleyman, A. Shallal, S. Davis, M. Veve</i>	
E0809		<b>Metallo-<math>\beta</math>-lactamase colonization and subsequent risk of infection: a retrospective study</b> <i>C. Lee Luna Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato, S. Castelbuono, G. Di Martino, F. Cardinale, F. Monaco, A. Cona, A. Mularoni</i>	
E0810		<b>Polymyxin including therapy versus colistin including therapy in the therapy of carbapenem-resistant Gram-negative infections: A retrospective matched cohort study</b> <i>M. Mert Vahabi* (Van, Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yeniyoğlu, G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkara, M. Ceylan, C. Bulut Avcı, U. Önal, S. Ketentzi, A. Uyan Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Vatansever, C. Tol, Ş. Aydemir, D. Akdağ, H.A. Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi</i>	
E0811		<b>Prognostic factors and role of clinical management in carbapenem-resistant <i>Acinetobacter baumannii</i> bacteraemia: results from a prospective, international, multicentre cohort (EURECA)</b> <i>F. Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, S. Benea, D. Tomescu, A. Meda Vasiesiu, L. Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H. Goossens, M.J.M. Bonten, J. Rodríguez-Baño</i>	

SY147	17:30 – 18:30	Hall 11
	1-hour Symposium	
<b>Avian influenza in mammals: jumps under the radar</b>		
Chairs	<i>Patricia Antunes (Porto, Portugal)</i> <i>Ana Vale (Dublin, Ireland)</i>	

S0399	17:30	<b>Threat of highly pathogenic avian influenza to non-traditional hosts, including humans</b> <i>Thijs Kuiken (Rotterdam, Netherlands)</i>
S0400	18:00	<b>Recent changes in the epidemiology of avian influenza in relation to human health risks</b> <i>Ron Fouchier (Rotterdam, Netherlands)</i>

Co-organised with: ESCMID Food- and Water-borne Infections Study Group (EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM), ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific Working group on Influenza (ESWI)

SY148	17:30 – 18:30	Hall 15
	1-hour Symposium	
<b>Echinococcosis: neglected but expanding</b>		
Chairs	<i>Daniel Grupel (Jerusalem, Israel)</i> <i>Francesca Tamarozzi (Negrar-Verona, Italy)</i>	

S0401	17:30	<b>Expansion and diversity of cystic echinococcosis</b> <i>Pedro Legua (Lima, Peru)</i>
S0402	18:00	<b>Management of echinococcosis: evidence, eminence and new developments</b> <i>Beate Grüner (Ulm, Germany)</i>

Co-organised with: Österreichische Gesellschaft für Antimikrobielle Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group for Infections In Travellers and Migrants (ESGITM)

OS109	17:30 – 18:30	Hall 16
	1-hour Oral Session	
<b>Training CM/ID - a global view</b>		
Chairs	<i>Mihai Mares (Iasi, Romania)</i> <i>Priya Nori (New York, United States)</i>	

O0780		<b>Specialist training in infectious diseases in Europe</b> <i>J. Salmanton-García* (Cologne, Germany), J. Salmanton-García, A. Guerra Maio, J.P. Stahl, E. De Barra, S. Jensen-Fangel, C. Torti, C. Kraef, J.M. Miró, A. Verbon, O.A. Cornely, N. Beeching</i>
O0781		<b>Infectious Diseases Residency Training over the World</b> <i>P. Irkören* (Zeytinburnu/Istanbul, Türkiye), P. Irkoren, C. Cimen, S. Keske, Ö. Ergönül</i>
O0782		<b>Five years of experience with the virtual International Postgraduate Diploma in Infection Prevention and Control from the Infection Control Africa Network</b> <i>A. Tostmann* (Nijmegen, Netherlands), E. Schoeman, B. Du Toit Ludick, E. Ruizendaal, Y. Gouws, J. Hopman, C. Azzouz, S. Mehtar</i>
O0783		<b>Combatting challenges in laboratory capacity through an innovative, longitudinal Gram stain training programme for blood culture specimens in Zimbabwe</b> <i>T. Mwaturura* (Harare, Zimbabwe), D. Hettle, F. Makoga, A. Mudungwe, B. Sado, K. Kranzer</i>
O0784		<b>Benefit of the implementation of Entrustable Professional Activities (EPA) as an assessment tool in the Laboratory of clinical bacteriology: a study focused on the improvement of residents' skills and feelings</b> <i>H. Pailhoriès* (Angers, France), H. Pailhories, C. Zins, R. Chenouard, M. Kempf, M. Eveillard</i>

ME149	17:30 – 18:30	Hall 2
	Meet-the-Expert	
<b>How to perform molecular surveillance of multidrug resistant bacteria</b>		
M0403	17:30	<i>Martina Lengerova (Brno, Czech Republic)</i>
M0404	17:42	<i>Henrik Hasman (Copenhagen, Denmark)</i>

OS107	17:30 – 18:30	Hall 3
	1-hour Oral Session	
<b>Novel vaccines in clinical development</b>		
Chairs	<i>Mateusz Hasso-Agopsowicz (Geneva, Switzerland)</i> <i>Hanna M. Nohynek (Helsinki, Finland)</i>	

O0770		<b>Safety and immunogenicity of a seasonal booster dose of the 6-valent, OspA-based Lyme borreliosis vaccine candidate VLA15 in a healthy population aged 5-65 years</b> <i>M. Messier* (Vienna, France), L. Wagner, R. Hochreiter, J. Larcher-Senn, E. Lamberth, R. Simon, C. Clarkin, J. Stark, S. Eder-Lingelbach</i>
O0771		<b>Safety and immunogenicity of mRNA mpox vaccine candidate mRNA-1769: Interim analysis results from a Phase 1/2 Trial</b> <i>H. Hiruy* (Cambridge, United States), R. Lazarus, K. McCafferty, K. Cohen, R. Dhar, T. Rizk, A. Adeniji, X. Chang, L. Siquel, H. Bennett, B. Leav</i>
O0772		<b>Development of a Rapid-Acting Oral Cholera Vaccine: Phase I Clinical Trial</b> <i>A. Hannaford* (Boston, United States), D. Leitner, M. Waldor, L. Baden, M. Desjardins, M. Suzuki, L. Carr, D. Slater, H. Levine, H. Kaul, J.B. Park Chang, A. Piermatti, N. Puri, B. Piantadosi, J. Harris, S. Piantadosi, A. Sherman, S. Walsh</i>
O0773		<b>Safety and immunogenicity of a Group B Streptococcus vaccine in participants aged 55-75 years</b> <i>L. Oostvogels* (Frederiksberg, Denmark), A. Alhatemi, S. De Gussem, E. Englev, B. Jacobs, B. Johansson-Lindbom, G. Kitson, G. Waerlop, I. Leroux-Roels</i>



ESCMID Global 2025 - Programme

O0774		<b>Aggregated summary of immunogenicity and safety for the chikungunya virus virus-like particle (VLP) vaccine development programme</b> <i>L. Tindale* (Toronto, Canada), J. Richardson, D. Anderson, J. Mendy, S. Muhammad, T. Loreth, V. Jenkins, P. Ajiboye, L. Bedell</i>
OS108	17:30 – 18:30	Hall 5
	1-hour Oral Session	
<b>Novel approaches to preventing device-related infections</b>		
<i>Chairs</i>	<i>Natividad Benito (Barcelona, Spain)</i> <i>Preeti Malani (Ann Arbor, United States)</i>	
O0775		<b>Clinical and microbiological impact of antibiotic-impregnated catheters in ventriculoperitoneal shunt infections in adults.</b> <i>M. Sanz De Mena* (Barcelona, Spain), I. Pelegrín Senent, J. Gómez Junyent, J. Poblet Florentin, C. Iglesias, A. Siverio Parés, S. Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Horcajada</i>
O0776		<b>Reducing drainage-associated meningitis by using an antiseptic dressing: A randomized controlled trial</b> <i>AntiRedMen.S. Scheithauer* (Goettingen, Germany), O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K. Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich, A. Beste, N. Kucheryava, M. Baehr</i>
O0777		<b>Efficacy of antimicrobial envelopes in preventing cardiac implantable electronic device infections – systematic review and meta-analysis</b> <i>A. Mahajan* (Melbourne, Australia), C. Robson</i>
O0778		<b>A bundled approach to reducing central line associated blood stream infections (CLABSI) in hemodialysis (HD) patients</b> <i>J. Guerrero* (Scarborough, Canada), A. Garga, S. Paramalingam, R. Lovinsky, F. Go</i>
O0779		<b>Increased long-term mortality in patients with prosthetic joint infection after primary total hip arthroplasty – a cohort study with 89’709 patients</b> <i>N. Imhasly* (Lucerne, Switzerland), A. Widmer, C. Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M. Wicki, M. Beck, R. Sommerstein</i>

Tuesday, 15 April 2025

SY152	08:30 – 10:30	Hall 12
	2-hour Symposium	
<b>Out of the spotlight or out of reach? Vaccination of hard-to-reach groups</b>		
<i>Chairs</i>	<i>Olivier Epaulard (Grenoble, France)</i> <i>Justyna Kowalska (Warsaw, Poland)</i>	
S0413	08:30	<b>Ukrainian war refugees and vaccination attitudes: experience from Poland</b> <i>Maria Ganczak (Zielona Gora, Poland)</i>
S0414	09:00	<b>Vaccination in migrants in Latin America: The challenges of transit through Darien, Panama</b> <i>Alfonso J. Rodriguez-Morales (Pereira, Colombia)</i>
S0415	09:30	<b>Are penitentiary systems ready for introducing vaccination programmes?</b> <i>Lara Tavoschi (Pisa, Italy)</i>
S0416	10:00	<b>HPV and other essential vaccinations for sex workers</b> <i>Debora Konopnicki (Brussels, Belgium)</i>
Co-organised with: ESCMID Vaccine Study Group (EVASG)		
SY153	08:30 – 10:30	Hall 13
	2-hour Symposium	
<b>Breaking new ground in febrile neutropaenia management</b>		
<i>Chairs</i>	<i>Murat Akova (Ankara, Türkiye)</i> <i>Stefan Schwartz (Berlin, Germany)</i>	

S0417	08:30	<b>Do we need to redefine the concept of febrile neutropaenia in the era of immunotherapy?</b> <i>Manuela Aguilar-Guisado (Seville, Spain)</i>
S0418	09:00	<b>Should some patients be empirically treated with combination therapy?</b> <i>Dina Averbuch (Jerusalem, Israel)</i>
S0419	09:30	<b>Role of new antibiotics in febrile neutropaenia</b> <i>Malgorzata Mikulska (Genoa, Italy)</i>
S0420	10:00	<b>Can treatment strategies be personalised using AI or new diagnostic tools?</b> <i>Carolina Garcia Vidal (Barcelona, Spain)</i>
Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH), European Conference on Infections in Leukemia (ECIL)		

EW156	08:30 – 10:30	Hall 5
	Educational Session	
<b>The rules of the game: how to tackle the peer-review and publication process</b>		
<i>Chairs</i>	<i>Christian Kraef (Copenhagen, Denmark)</i> <i>Oana Sandulescu (Bucharest, Romania)</i>	
W0429	08:30	<b>Communicating with journals, editors and reviewers</b> <i>Angela Huttner (Geneva, Switzerland)</i>
W0430	08:50	<b>The Wild West of predatory journals</b> <i>Ursula Hofer (London, United Kingdom)</i>
W0431	09:10	<b>Communicating your publications on social media</b> <i>Neil Stone (London, United Kingdom)</i>
W0432	09:30	<b>Re-imagining peer review</b> <i>Amelia Joseph (Nottingham, United Kingdom)</i>
Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie, CMI Communications Board of Editors, ESCMID Parity Commission, CMI Board of Editors		

EF114	08:30 – 09:30	Arena 1
	ePoster Flash Session	
<b>Innovations and insights in diagnosing parasitic infections</b>		
<i>Chair</i>	<i>Pikka Jokelainen (Copenhagen, Denmark)</i>	

E0822		<b>Evaluation of a multiplex beads assay for the simultaneous detection of serum antibodies in neurocysticercosis patients.</b> <i>A. Lopez Alva* (Lima, Peru), P.D.S. Nakazaki Aza, L.M. Toribio Salazar, H.H. García Lescano</i>
E0823		<b>Development and evaluation of real-time loop mediated isothermal amplification assay for rapid detection of hookworm (Ancylostoma duodenale) in human fecal samples</b> <i>M. Thakur* (Chandigarh, India), S. Khurana, A. Mewara, L. Pvm</i>
E0824		<b>Exploring Genotypic Prevalence and Transmission of Cryptosporidium and Giardia in Immunocompromised Patients: A Dual Approach with Modern Molecular Methods: MLST &amp; nested real-time HRMP</b> <i>P. Rani* (Chandigarh, India), P. Datta, S.L. Bhasin, P. Malhotra, S.S. Rana, R. Sehgal</i>
E0825		<b>Prevalence and diagnostic accuracy of different diagnostic tests for Chagas disease in the Paraguayan Chaco</b> <i>S. Ardiles Ruesjas* (Saarbruecken, Germany), S. Ardiles-Ruesjas, V. Lesmo, V. González-Romero, Z. Cubilla, L. Chena, C. Huber, M.J. Rivas, P. Saldaña, A. Carrascosa, S. Méndez, S. Sanz, S.L. Becker, J. Alonso-Padilla, I. Losada</i>
E0826		<b>Development and validation of an artificial intelligence model for detection of gastrointestinal parasites from concentrated wet-mount stool examinations</b> <i>M.R. Couturier* (Salt Lake City, Ut, United States), B. Mathison, K.A. Knight, J.R. Potts, F. Markow, A.E. Wood, K.W. Dixon, J.F. Walker, D.L. Bess, W. Hymas</i>
E0827		<b>Evaluation of KU-F40 automated microscope for diagnosis of intestinal parasitic infections : will AI</b>

ESCMID Global 2025 - Programme

	<b>rescue old-time microscopy ?</b> A. Aupaix* (Hornu, Belgium), L. Filippin, I. Mansoor, M. Chemaïs, D. Martiny, V.Y. Miendje Deyi, M. Deffontaine, C. Deckers, V. Verbelen, J. Brauner
E0828	<b>Improving vector surveillance: evaluating a real-time PCR assay for <i>Leishmania</i> DNA detection in sandflies</b> H. Alonso-Ezcurra* (Zaragoza, Spain), M.P. Peris, I. Ruiz-Arondo, J.A. Castillo, D. Martínez-Durán, S. Delacour, I. Ruiz-Zarzuela, I. De Blas, C. Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H. Alonso
E0829	<b>Assessment of a new immunochromatographic assay for serological diagnosis of amoebic liver abscess</b> R. Fleury* (Besançon, France), M.P. Brenier-Pinchart, P. Tírad-Collet, F. Gabriel, E. Pretot, F. Touafek, A. Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont, A. Moreno-Sabater, F. Grenouillet
E0830	<b>Human piroplasmiasis: diagnostic lessons from a national parasitology reference laboratory in South Africa</b> C. Sriruttan-Nel* (Johannesburg, South Africa), J. Freen

EF115	08:30 – 09:30	Arena 3
	ePoster Flash Session	

New genomic methods in clinical microbiology	
Chair	Natacha Couto (Oxford, United Kingdom)

E0831	<b>Prediction of antimicrobial minimum inhibitory concentration from <i>Escherichia coli</i> whole genome sequence data using machine learning</b> A. Gerada* (Liverpool, United Kingdom), N. Harper, Y. Zhong, A. Howard, P.L. Green, W. Hope
E0832	<b>Dynamically Optimized Reference Adaptive Sampling (DORAS) to streamline bacterial Multi-Locus Sequence Typing</b> A. Ramette* (Bern, Switzerland), L. Borcard, M.A. Terrazos Miani, S. Gempeler, S. Neuenschwander
E0833	<b>Prediction of antibiotic resistance in <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> from genomic data using machine learning and deep learning approaches</b> E. Denakpo* (Gif-Sur-Yvette, France), N. Dias, F. Jay, B. Iorga
E0834	<b>Machine learning pipeline accelerates identification of diagnostic targets for <i>Neisseria gonorrhoeae</i></b> A. Verich* (Sydney, Australia), T. Applegate, D. Bauer, P. Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany
E0835	<b>Reliable bacterial genomic genotyping from Oxford Nanopore Technologies data – the ONT cgMLST Polisher</b> N. Scherff* (Muenster, Germany), J. Rothgänger, D. Harmsen
E0836	<b>Developing a core genome MLST (cgMLST) for <i>Mycoplasma pneumoniae</i></b> C. Dixon* (Cardiff, United Kingdom), R. Mamede, M. Ramirez, H. Milton, P.M. Meyer Sauteur, G. Greub, N. Couto, M.L. Beeton
E0837	<b>Voyager: real-time taxonomic characterization of long-read mixed-species sequencing samples in sorted motif distance space</b> S. Branders* (Hamar, Norway), M. Grabherr, R. Ahmad
E0838	<b>VCP: a signature protein-based tool for accurate and rapid profiling of human gut virome</b> J. Li* (Shenzhen, China), F. Yang, L. Xiong, X. Feng, H. Zhong
E0839	<b>Genomic Data-Driven Machine Learning for Predicting Antimicrobial Resistance in ESCAPEE Pathogens</b> A. Skoulakis* (Lamia, Greece), K. Daniilidis, S. Digenis, A. Hatzigeorgiou

CGR	08:30 – 10:30	Hall 1
	Special Session	

Clinical Grand Round	
Experts	Nina Khanna (Basel, Switzerland) Dimitrios P. Kontoyiannis (Houston, Tx, United States) Lior Nesher (Beersheba, Israel) David L. Paterson (Singapore, Singapore)

	Priscilla Rupali (Vellore, India) Monica Slavin (Melbourne, Australia)
CGR01	<b>Case 1</b> Kruthi Malur Kumaraswamy (Mumbai, India)
CGR02	<b>Case 2</b> Christopher Wong (Victoria, Australia)
CGR03	<b>Case 3</b> Filipa Ferreira (Porto, Portugal)
CGR04	<b>Case 4</b> Jia Arng Lee (Zhongzheng Dist, Taipei City, Taiwan, Taiwan, China)
CGR05	<b>Case 5</b> Lorenzo Bertolino (Naples, Italy)
CGR06	<b>Case 6</b> Armani Hawes (Baltimore, United States)
CGR07	<b>Case 7</b> Sima Sharara (Baltimore, United States)
Co-organised with: Infectious Diseases Society of America (IDSA)	

OS113	08:30 – 10:30	Hall 11
2-hour Oral Session		
<div>AMR ANT TRN</div>		
Knockin' on Science's Door: New Antimicrobial Solutions		
Chairs		
Sandrine Marchand (Poitiers, France) Ursula Theuretzbacher (Vienna, Austria)		

O0812	<b>Chimerbactin: a hybrid antibiotic for persistent Gram-positive infections that overcomes resistance development</b> R. Lee* (Memphis, United States), Y. Zhao, A. Arya, M. Lafleur, R. Conlin, G. Phelps, C. Dunn, E. Griffith, J. Portelinha, N. Chumbler, V. Loudon, I. Lister, S. Zia, K. Urish, K. Lewis
O0813	<b>A Novel Klebicin Cocktail to Treat Lung Infection Caused by <i>Klebsiella pneumoniae</i></b> V.D. Paul* (Bangalore, India), A. Ambady, U. Chopra
O0814	<b>Thiophene derivatives: A promising solution against MDR Gram-negative bacilli</b> Y. Smani* (Seville, Spain), I. Molina Panadero, Á. Rey Hidalgo, M. Morales-Tenorio, A. García-Rubia, T. Samernate, P. Nonejuie, A. Martínez, A. Hmadcha, A. De Alarcón, C. Gil
O0815	<b>Molecular insight into non-lytic polyproline peptide disruption of <i>Klebsiella pneumoniae</i> biofilms</b> R. Fleeman* (Orlando, United States), R. Beckman Iv, B. Victoria, L. Suits, P. Eswara
O0816	<b>Reverting cefotaxime resistance in CTX-M-15-producing <i>Escherichia coli</i> using Targeted-Antibacterial-Plasmids (TAPs): a CRISPR-Cas9 approach</b> N. Roson Calero* (Barcelona, Spain), N. Roson-Calero, E. Derollez, P. Rouze, A. Dedieu-Berne, S. Bigot, C. Ballesté-Delpierre, J. Vila, P. Bogaerts, C. Lesterlin
O0817	<b>Structural and functional characterization of LysSM5: An innovative endolysin from <i>Salmonella</i> Phage vB_SenA_SM5K</b> Sharma* (Chandigarh, India), H. Kaur, N. Chaudhary, S. Prajapati, B. Mohan, N. Taneja
O0818	<b>Rational step-by-step design of a two-phage cocktail against a contemporary <i>A. baumannii</i> strain recovered from a burned patient at CHUV</b> G. Resch* (Lausanne, Switzerland), H. De Villiers De La Noue, G. Golliard, X. Vuattoux
O0819	<b>A novel antibiotic class targeting the enolase of <i>Acinetobacter baumannii</i></b> Molina Panadero* (Seville, Spain), A. Moreno Rodriguez, Á. Rey Hidalgo, L. Tomás Gallardo, M. De La Cruz, P. Sánchez, T. Samernate, A.J. Pérez Pulido, S. Glisic, O. Genilloud, P. Nonejuie, A. Hmadcha, Y. Smani
O0820	<b>Reviving antibiotic potency: Pharmacological Assessment of JS238 a newly designed potentiator against <i>P. aeruginosa</i></b> P. Rasouli* (Brussels, Belgium), J.M. Brunel, J.H. Lorent, F. Van Bambeke
O0821	<b>Advancements in combating tularemia: Novel therapeutic strategies targeting <i>Francisella tularensis</i></b> S. Guillier* (Brétigny-Sur-Orge, France), M. Gâchon, C. Lemoigne, C. Rougeaux, V. Lourde, C. Demeure, J. Pizarro Cerda, G. Guichard, G. Compain, D. Burnouf, O. Gorgé, J. Wagner

SY154	08:30 – 10:30	Hall 14
-------	---------------	---------

ESCMID Global 2025 - Programme

		2-hour Symposium	
		<div>AMR</div> <div>PHEI</div>	
Using mathematical and epidemiological models to identify the drivers of AMR			
Chairs		Marc J.M. Bonten (Utrecht, Netherlands) Sarah Tschudin Sutter (Basel, Switzerland)	
S0421	08:30	Quantifying the drivers of antiviral resistance: what does it take to prevent resistance evolution?Roger Kouyos (Zürich, Switzerland)	
S0422	09:00	Inferring the determinants of AMR dynamics across bacterial pathogensLulla Opatowski (Paris, France)	
S0423	09:30	Modelling the evolution of resistanceErida Gjini (Lisbon, Portugal)	
S0424	10:00	Assessing the associations of microbiome and socio-demographic dynamics on AMRKatariina Pärnänen (Helsinki, Finland)	
EW157		08:30 – 10:30	Hall 15
		Educational Session	
		<div>DX</div> <div>PHEI</div>	
Endemic mycoses and mycetoma: underdiagnosed and underreported fungal diseases			
Chairs		Ana Alastruey-Izquierdo (Madrid, Spain) Rita Oladele (Lagos, Nigeria)	
W0433	08:30	Advances and gaps in the diagnosis and treatment of histoplasmosisDiego Rodrigues Falci (Porto Alegre, Brazil)	
W0434	08:50	Paracoccidioidomycosis: an update on diagnostic challengesBeatriz L. Gomez (Bogota, Colombia)	
W0435	09:10	What is new in TalaromycosisBrown Lottie (London, United Kingdom)	
W0436	09:30	Mycetoma: treatment challenges of a unique neglected tropical diseaseBorna Nyaoke-Anoke (Nairobi, Kenya)	
EW155		08:30 – 10:30	Hall 2
		Educational Session	
		<div>DX</div> <div>PHEI</div>	
An update on arboviral disease challenges			
Chairs		Misa Korva (Ljubljana, Slovenia) Anna Papa-Konidari (Thessaloniki, Greece)	
W0425	08:30	The global epidemiology of arboviral diseasesChantal B.E.M. Reusken (Bilthoven, Netherlands)	
W0426	08:50	Arboviral diseases transmitted by mosquitoesLuisa Barzon (Padua, Italy)	
W0427	09:10	Arboviral diseases transmitted by ticksJoanna Maria Zajkowska (Białystok, Poland)	
W0428	09:30	Arboviral diseases transmitted by sandfliesRémi Charrel (Marseille, France)	
Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Infectiologists			
SY150		08:30 – 10:30	Hall 3
		2-hour Symposium	
		<div>ANT</div>	
Faecal microbiota transplantation and live biotherapeutic products: scientific and regulatory challenges			
Chairs		Lindsey Ann Edwards (London, United Kingdom) Ed J. Kuijper (Leiden, Netherlands)	
S0405	08:30	How can we recognise and deal with adverse events of Faecal Microbiota Transplantation?Serena Porcari (Roma, Italy)	
S0406	09:00	What to check? – An attempt at evidence-based donor screeningElisabeth Terveer (Leiden,	

		Netherlands)	
S0407	09:30	What are the right bugs – Developing LBPs out of FMTs <i>Lena Biehl (Cologne, Germany)</i>	
S0408	10:00	What's up next? – Hot LBP candidates <i>Ilan Youngster (Beer Yaakov, Israel)</i>	
Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAM), The European Faecal Microbiota Transplantation Network of academics (EurFMT), European Helicobacter & Microbiota Study Group (EHMSG)			
SY151		08:30 – 10:30	Hall 4
		2-hour Symposium	
	CLN		
News in endocarditis care			
Chairs		<i>Michele Bartoletti (Milan, Italy)</i> <i>Pilar Retamar Gentil (Seville, Spain)</i>	
S0409	08:30	Endocarditis guidelines: what is new? <i>Siegbert Rieg (Freiburg, Germany)</i>	
S0410	09:00	Oral therapy and outpatient care <i>Laura Escolà-Vergé (Barcelona, Spain)</i>	
S0411	09:30	PK/PD aspects of endocarditis antibiotic therapy <i>Fekade Bruck Sime (Brisbane, Australia)</i>	
S0412	10:00	The Endocarditis Team: there is no way to work alone <i>Barbara Hasse (Zurich, Switzerland)</i>	
Co-organised with: ESCMID Study Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares (SEICAV)			
EF116		09:30 – 10:30	Arena 2
		ePoster Flash Session	
	CLN	DX	TRN
Sepsis revolutions: from machines to molecules			
Chair		<i>Pierluigi Del Vecchio (Roma, Italy)</i>	
E0840		Machine learning enabled prediction of blood stream infection in emergency department attendees. <i>C. Rosato* (Liverpool, United Kingdom), S. Aston, A. Velluva, A. Howard, W. Hope</i>	
E0841		Utilizing Automation to Streamline the Blood Culture Process: Enhancing Efficiency and Patient Outcomes. <i>J. Qin* (Shanghai, China), M. Li, Z. Shen</i>	
E0842		Implementation of a bundle for Gram-negative bloodstream infection: impact on mortality and MDT/DTT carriage. <i>C. Bonazzetti* (Bologna, Italy), A. Grechi, D. Gibertoni, L. Mangione, F. Todisco, N. Caroccia, M. Rinaldi, R. Pascale, B. Tazza, A. Toschi, A. Amicucci, C. Campoli, Z. Pasquini, F. Calo', P. Viale, M. Giannella</i>	
E0843		A matter of time: Impact of time to first follow-up blood cultures in patients with candidemia and <i>Staphylococcus aureus</i> bacteremia from a retrospective cohort. <i>P. Valsecchi* (Pavia, Italy), E. Bono, A. Valeretto, S. Resuli, M. Corbella, P. Cambieri, E. Seminari, R. Bruno</i>	
E0844		Characteristics of infections and outcomes in patients with left ventricular assist devices. <i>N. Sarı* (Ankara, Türkiye), E. Ateş, Ç. Sarıkaş, Ö. Kurt Azap, Ç. Erol, A. Sezgin</i>	
E0845		Nb <sub>2</sub> (Sn <sub>0.7</sub> Cu <sub>0.3</sub> )C MAX phase for anti-infection therapy via hyperthermia-mediated bacterial metabolic interference. <i>M. Yang* (Chengdu, China)</i>	
E0846		Age-Dependent Plasma Lipidomic Alterations and Immune Correlations in Sepsis: Insights Into Disease Severity and Biomarker Potential. <i>Y. Sun* (Shanghai, China), K. Lin, L. Wang, J. Ai, J. Zhao, X. Cheng, Y. Wan, P. Cui, S. Wang, J. Wu, J. Jin</i>	
E0847		Aberrant Integrin activation causes transmigration defects in S100A9 <sup>-/-</sup> neutrophils during sepsis. <i>S. Mülder* (Münster, Germany), N. Ludwig, J. Rossaint, T. Vogl</i>	



# ESCMID Global 2025 - Programme

E0848

Efficacy of dimercaptosuccinic acid in combination with imipenem in a murine model of experimental sepsis due to metallo- $\beta$ -lactamase-producing *Pseudomonas aeruginosa*. S. Herrera-Espejo\* (Seville, Spain), M. Bouvier, J. Findlay, L. Ceballos-Romero, J. Pachón, J.M. Cisneros, M.E. Pachón-Ibáñez, P. Nordmann

EF117

09:30 – 10:30

Arena 4

CLN

IPC

ePoster Flash Session

C. diff challenges: Insights into treatment, monitoring, and infection prevention

Chair

Kerrie Davies (Leeds, United Kingdom)

E0849

Epidemiology, risk factors, and outcomes of nosocomial *Clostridioides difficile* infections: a cohort study in a tertiary hospital. L. Ruiz Salazar\* (Madrid, Spain), T. Mata Forte

E0850

Long-read or short-read sequencing in *Clostridioides difficile* infection surveillance? M. Brajerová\* (Prague, Czech Republic), M. Brajerova, P. Kinross, P. Drevinek, M. Krutova

E0851

"Beyond C. difficile Colitis": Exploring the Role of Fidaxomicin in preventing concomitant and secondary bloodstream infections in patients with *Clostridioides difficile* colitis. D.F. Bavaro\* (Milan, Italy), D. Schumerni, A. Cilli, L. Diella, D. Barbanotti, D. Mondatore, F. Mediolli, M. Casana, A. Belati, L. Bussini, V. Cento, R. Epis, M. Bartoletti

E0853

Comparison of bezlotoxumab versus no-bezlotoxumab on recurrence in high-risk patients with *Clostridioides difficile* infection C. Arena\* (Detroit, United States), A. Abed, R. Kenney, A. Shallal, S. Davis, M. Veve

E0854

Exploring bacterial contributors to *C. difficile* colonization resistance: comparative effects of vancomycin and fidaxomicin in humanised mice E. Montenegro-Borbolla\* (Lausanne, Switzerland), L. Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery

E0855

An optimised vancomycin dosing regimen is effective against *C. difficile*, reduces gut microbiota impact and prevents recurrent *C. difficile* infection in a human in vitro gut model. J. Freeman\* (Leeds, United Kingdom), C. Normington, E. Clark, K. Bentley, J. Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M. Wilcox, K. Davies

E0856

Cost and resource utilization of fidaxomicin in risk patients with recurrent or refractory *Clostridioides difficile* infection M. Engelhard\* (Cologne, Germany), I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff

E0857

Impact of a cohorting intervention on the incidence of hospital-acquired *Clostridioides difficile* infection (CDI): an interrupted time series analysis C.D. Moschopoulos\* (Athens, Greece), M. Tsakona, S. Grigoropoulou, P. Kazakou, M. Kostoula, I. Kliani, C. Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras, D. Kavatha

ME165

11:00 – 12:00

Hall 12

PHEI

Meet-the-Expert

How to use citizen science for public health

M0450

11:00

Anna Noel-Storr (Leamington Spa, United Kingdom)

M0451

11:12

Jani Sormunen (Turku, Finland)

Co-organised with: European Centre for Disease Prevention and Control (ECDC)

SY164

11:00 – 12:00

Hall 12

1-hour Symposium		
CLN VAX		
dsDNA virus infections in immunocompromised patients		
Chairs Lior Nesher (Beersheba, Israel) Michelle Yong (Melbourne, Australia)		
S0448	11:00	Challenges of diagnosis: do we need to treat all patients with detectable dsDNA virus PCR? Hans H. Hirsch (Basel, Switzerland)
S0449	11:30	The role of CRISPR-Cas9-edited antiviral T cells against dsDNA virus infections Tba
F0167	11:00 – 12:00	Arena 1
PHEI VAX Open Forum		
Vaccine rollout in low resource settings		
Chair Asma Nasim (Karachi, Pakistan)		
F0454	11:00	Typhoid vaccine roll outNginache Nampota (Baltimore, United States)
F0455	11:10	Introduction of malaria vaccines to countries in sub-Saharan Africa: acceptance and barriersBernhards Ogutu Ragama (Nairobi, Kenya)
F0456	11:20	The story of COVID-19 vaccines in LMICPaul Adepoju (Perton, United Kingdom)
Co-organised with: ESCMID Ethics Advisory Committee (EEAC)		
EF123	11:00 – 12:00	Arena 2
ANT CLN ePoster Flash Session		
Advancing antimicrobials: trials and therapies for resistant infections		
Chair Ursula Theuretzbacher (Vienna, Austria)		
E0888	11:00	Efficacy of High Dose Tigecycline-Containing Regimens for the Combination Treatment of Carbapenem Resistance Enterobacteriales Bacteremia: a propensity score-matched study V. Vasikasin* (Bangkok, Thailand), W. Nasomsong, P. Wanloptaree
E0883	11:06	Evaluation of CRS3123 compared to vancomycin for the treatment of Clostridioides difficile infection (CDI) J. Bruss* (Pagosa Springs Co, United States), M.A. Degroote, L. Boccumini, W. Ribble, J. Day, C. Mason, X. Sun, J. Freeman, N. Seema, N. Janjic, T. Jarvis, U. Ochsner, M. Wilcox, T. Louie
E0884	11:12	Phase 2/3, open-label, randomized, active-controlled clinical trial evaluating the safety and efficacy of imipenem/cilastatin/relebactam (IMI/REL) in paediatric patients with gram-negative bacterial infection J. Bradley* (San Diego, United States), C.T. Norice, E. Rollides, A. Shevelev, B. Jurkiewicz, J.A. Piedrahita, S. Koseoglu, I. Masih, P. Nair, K. Young, D.W. Hilbert, G.T. Nieddu, J.A. Huntington, C.J. Bruno
E0885	11:18	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Tolerability of Intravenous Ertapenem (ERT) with Zidebactam (ZID) in Combination (WCK 6777) in Healthy Adult Subjects T. Lodise* (Albany, United States), R. Chavan, A. Patel, R. Yeole, S. Bhagwat, M. Patel, G. Saviolakis, K. Gu, V. Ghazaryan, M. Kankam, A. Jaunaraajs, E. Hammett, H. Howell, R.A. Bonomo
E0886	11:24	Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections – Results from a retrospective multicentre study A. Marino* (Catania, Italy), A.E. Maraolo, M. Mazzitelli, A. Oliva, N. Geremia, A. De Vito, C. Gullotta, V. Scaglione, E. Vania, S. Lo Menzo, P. Navalesi, L. Volpicelli, A. Fiori, P. Prestifilippo, A. Cattelan, C.M. Mastroianni, G. Madeddu, B. Cacopardo, G. Nunnari
E0887	11:30	Phase 3 study of oral gepotidacin for the treatment of uncomplicated urinary tract infection in Japanese

ESCMID Global 2025 - Programme

		<b>female participants (EAGLE-J)</b> <i>Y. Kayama* (Tokyo, Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Mozzicato, S. Ura</i>
E0889	11:36	<b>Efficacy of Ceftolozane/Tazobactam vs. Ceftazidime/Avibactam in the Treatment of Nosocomial Pneumonia Caused by <i>Pseudomonas aeruginosa</i>: a multicentric retrospective study from the SUSANA cohort.</b> <i>A. Bitti* (Sassari, Italy), A. De Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S. Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Socio, P. Morelli, P. Bonfanti, G. Madeddu</i>
E0890	11:42	<b>Experience of dalbavancin use for unliscensed indications in a UK tertiary infectious diseases setting</b> <i>C. Darlow* (Liverpool, United Kingdom), J. Parsons, D. Lucy, N. Wong</i>
E0891	11:48	<b>Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcare-associated and hospital-acquired gram-negative bacterial bloodstream Infections (BSI) : Hierarchical composite endpoint analysis with DOOR and generalised pairwise comparisons</b> <i>M. Hardy* (Maroochydore, Australia), D.L. Paterson, M. Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N. Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, V. Thamlikittkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris</i>

EF124	11:00 – 12:00	<b>Arena 3</b>
	ePoster Flash Session	
	<b>Thinking outside the box in urinary tract infection</b>	
<i>Chair</i>	<i>Özlem Kurt Azap (Ankara, Türkiye)</i>	
E0892		<b>Targeted NGS: a promising approach for pathogen detection of urinary tract infection</b> <i>W. Gao* (Beijing, China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B. Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang</i>
E0893		<b>Turnaround time of just four hours from sample collection to informed decision-making for complicated urinary tract infections in a urology ward, using culture-independent metagenomics</b> <i>A.B. Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. Asadi, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. Wagenlehner, R. Ahmad</i>
E0894		<b>Identification of Microorganism Types in Urinary Tract Infections Using Machine Learning and Flow Cytometry</b> <i>E. Flores* (Alicante, Spain), I. Gutierrez, R. Torreblanca, A. Blasco, R. Carbonell, M. Lopez-Garrigós</i>
E0895		<b>A New Approach In Diagnosis Of Urinary Tract Infections</b> <i>B. Dinc* (Ankara, Türkiye), F. Kırca, S. Kazıcı, Ö. Uslu, N. Çöplü</i>
E0896		<b>Diagnosis of urinary tract infections: from machine learning to clinical practice</b> <i>E. Flores* (Alicante, Spain), R. Torreblanca, I. Gutierrez, R. Carbonell, L.G. Maite, A. Blasco</i>
E0897		<b>Strategic testing optimisation practices for urinary tract infections (STOP-UTI): findings from LMIC hospital setting</b> <i>S. Sarika* (Tamil Nadu, India), B. Rithik Dharan</i>
E0898		<b>Rapid culture-independent mass spectrometry based proteomics methods for improving urinary tract infection diagnostics</b> <i>S. El-Ali* (Gothenburg, Sweden), L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E. Moore</i>
E0899		<b>Unraveling the complexity: Corynebacterium diversity and antimicrobial resistance hub in the urinary tract ecosystem</b> <i>E. Cappelli* (Porto, Portugal), A. Morais, T. Ribeiro, L. Peixe</i>
E0900		<b>Active surveillance in the diagnosis of sexually transmitted infections: performing PCR in negative urine cultures</b> <i>A. Castellano Verdasco* (Lleida, Spain),</i>

		<i>E. Sánchez Bäscones, E. López González, A. Blanquero-Porras, M. Riesgo Magaña, A. Bernet Sánchez, S. Mormeneo Bayo, I. Prats Sánchez, A. Bellés-Bellés, M. García González</i>
EF125	11:00 – 12:00	<b>Arena 4</b>
	ePoster Flash Session	
	<b>Bugs breaking the blood-brain barrier</b>	
<i>Chair</i>	<i>Markus Zeitlinger (Vienna, Austria)</i>	
E0901		<b>Pharmacologic depletion of meningeal macrophages worsens disease in a mouse model of meningitis</b> <i>U. Koedel* (Munich, Germany), S. Dyckhoff-Shen, I. Masouris, H.W. Pfister, M. Klein</i>
E0902		<b><i>Pgm1</i> modulates the inflammatory response of macrophages in experimental pneumococcal meningitis</b> <i>D. Bakker* (Amsterdam, Netherlands), R. Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Van De Beek</i>
E0903		<b>Heparin-binding protein in cerebrospinal fluid as a biomarker for bacterial meningitis: a study of diagnostic accuracy</b> <i>S. Olie* (Amsterdam, Netherlands), S.L. Staal, A.C. Da Cruz Campos, J. Bodilsen, H. Nielsen, D. Van De Beek, M.C. Brouwer</i>
E0904		<b>Efficacy Analysis of Intraventricular/Intrathecal Polymyxin B sulphate Injections in the Treatment of Post-neurosurgical CNS Infections in Neurocritical III Patients:a prospective observational study</b> <i>L. Yang* (Shanghai, China), J. Song, M. Wang, H. Yuan, Q. Yuan, Z. Du, G. Wu, J. Hu, W. Chen</i>
E0905		<b>Ventriculitis characteristics and outcomes (VELCRO): an international retrospective cohort study</b> <i>D. Luque Paz* (Rennes, France), B. Díaz Pollán, M. Boyer-Besseyre, F. Djanikian, A.L. Munier, F. Cunha, L. Escaut, G. Martin-Blondel, B. Sarton, P. Jaquet, F. Arrivé, R. Wolf, V. Legros, M. Willig, O.R. Sipahi, L. Flurin, A. Bianchi, B. Balança, J. Puel, R. Lino, B. Soyer, T. Leveque, A. Salomon, A. Serris, R. Larcher, F. Bruneel, N. Mongardon, A. Mazeraud, M. Wolff, R. Sonnevill, F. Valour, P. Tattevin</i>
E0906		<b>Clinical Features and Outcomes of <i>Staphylococcus aureus</i> Brain Abscess</b> <i>E. Eriksen* (Aalborg, Denmark), M. Bijlsma, S. Olie, L. Larsen, M. Storgaard, H. Mens, L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau, H. Nielsen, M. Brouwer, J. Bodilsen</i>
E0907		<b>Epidemiology of Adult Intracranial Bacterial Abscess in the Republic of Ireland (2010-2021)</b> <i>S. Kilgarriif* (Cork, Ireland), E. Glynn, D. Murray, C. Lim, C. Hickey, S. O'Donnell, B. Dinesh, C. O'Connor, A. Doherty</i>
E0908		<b>Corticospinal tract involvement in Neuromyeloidosis: A Retrospective cohort Study from South India and a Systematic Review of Literature</b> <i>P.K. Tirlangi* (Manipal, India), N. Gupta, V. Muralidhar, C. Mukhopadhyay</i>
E0909		<b>A multicenter prospective study to develop and validate clinical prediction models for diagnosis of scrub typhus and treatment with doxycycline in children with acute encephalitis syndrome in southern India</b> <i>T. Damodar* (Bangalore, India), L. Turtle, R. Kolamunnage-Dona, M. Jose, U. Kinhal, B. Singh, A. L. S. Marate, N. Prabhu, L. A V, F.S. D'souza, S.V. Sajjan, K. Mallesh, R.S. Mani, T. Solomon, V.K. Gowda, R. Vasanthapuram, R. Yadav</i>

KN158	11:00 – 12:00	<b>Hall 1</b>
	Keynote Lecture	
	<b>What genomics brought to the knowledge of tuberculosis, leprosy and buruli ulcer</b>	
<i>Chairs</i>	<i>Emmanuelle Cambau (Paris, France) Kathryn Holt (London, United Kingdom)</i>	
K0437	11:00	<i>Stewart T. Cole (Paris, France)</i>

ESCMID Global 2025 - Programme

SY162	11:00 – 12:00	Hall 11
	1-hour Symposium	
	AMR	
Antimicrobial stewardship across the lifespan from paediatrics to geriatrics		
Chairs	Lucy Catteau (Brussels, Belgium) Priya Nori (New York, United States)	
S0444	11:00	Antimicrobial Stewardship in paediatrics across different settingsTaylor Morrisette (Charleston, United States)
S0445	11:30	Stewardship in geriatrics: an exceedingly important targetDafna Yahav (Ramat-Gan, Israel)
ME166	11:00 – 12:00	Hall 13
	Meet-the-Expert	
	DX	
Implementing AI in microbiological diagnostics: practical steps and quality control		
M0452	11:00	Oliver Nolte (Zürich, Switzerland)
M0453	11:12	Jennifer Dien Bard (Los Angeles, United States)
Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)		
SY163	11:00 – 12:00	Hall 14
	1-hour Symposium	
	AMR	
People-centred approach to strengthening the AMR response at primary care		
Chairs	Benedikt Huttner (Geneva, Switzerland) Mirfin Mpundu (Lusaka, Zambia)	
S0446	11:00	Implementation of WHO's people-centred interventionsNienke Van De sanDe Bruinsma (Geneva, Switzerland)
S0447	11:30	Opportunities for strengthening AMR interventions in primary healthcareSholpan Kaliyeva (Karaganda City, Kazakhstan)
Co-organised with: World Health Organisation (WHO)		
OS122	11:00 – 12:00	Hall 16
	1-hour Oral Session	
	PRO	
Serious games - a serious business		
Chairs	Christian Kraef (Copenhagen, Denmark) Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)	
O0878	The development process, Impact and implementation of an educational VR-module in infection prevention and control for medical students and healthcare workers in The Netherlands.A. Tostmann* (Nijmegen, Netherlands), O. Coenen-Bouwman, B. Schippers, F. Luk, M. Graner, F. Van Hoek, N. Stikkelbroeck, M. Dronkers	
O0879	Impact of Professional Background on Performance in ToREIMC: A Gamified Medical Knowledge PlatformA. Blanco-Di Matteo* (Pamplona, Spain), M. Morante Ruiz, M. Riesgo Magaña, M. Martín García	
O0880	Serious games and storytelling to enhance adolescents' capabilities for decision-making regarding meningococcal vaccination: a monocenter studyT. Morris* (Saint-Etienne, France), S. Essalim, K. Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho-Nevers, A. Gagneux-Brunon	
O0881	'The Sepsis Olympics': Raising awareness of the Sepsis 6 care bundle in an Irish Hospital through a clinical challenge game.C. Uhomoihi* (Dublin, Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra	
O0882	Improvement of learners' confidence in antibiotic	

management by an interdisciplinary annual multi-centred webinarA. Friedrichs* (Kiel, Germany), E. Kramme, T. Koch, J. Jochum, A. Van Der Linde, H. Gerth, F. Jahn, A. Neubert		
SY159	11:00 – 12:00	Hall 2
	1-hour Symposium	
	CLN TRN	
Beat the cancer by beating the infections		
Chairs	Daniela Maric (Novi Sad, Serbia) Mojca Maticic (Ljubljana, Slovenia)	
S0438	11:00	Prevention of infection-associated cancer: learning from each otherCatharina Alberts (Amsterdam, Netherlands)
S0439	11:30	Test and treat early to prevent cancer: hepatitis B and hepatitis CFrancesco Negro (Geneva, Switzerland)
SY160	11:00 – 12:00	Hall 4
	1-hour Symposium	
	CLN IPC	
Personalised patient management and infection prevention: Current evidence and future perspectives		
Chairs	Agnes Hajdu (Budapest, Hungary) Iris K. Minichmayr (Vienna, Austria)	
S0440	11:00	The dosing perspective: towards individualised treatment strategiesThomas Tängdén (Uppsala, Sweden)
S0441	11:30	The infection control perspective: advancing patient-centred approachesAlessia Savoldi (Verona, Italy)
SY161	11:00 – 12:00	Hall 5
	1-hour Symposium	
	CLN	
Emerging fungal diseases in children: Global challenges and approach to management		
Chairs	Andreas H. Groll (Münster, Germany) Adilia Warris (Exeter, United Kingdom)	
S0442	11:00	Emerging fungal infections in immunocompromised and geographically exposed childrenLaura Ferreras-Antolin (London, United Kingdom)
S0443	11:30	Best available treatments and options for children in resource-limited settingsFabianne Carlesse (Sao Paulo, Brazil)
Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-Speaking Mycological Society (DMyKG)		
OS118	11:00 – 12:00	Hall 6
	1-hour Oral Session	
	AMR ANT	
Plasmids as a powerful tool of antibiotic resistance spread		
Chair	Monika Dolejska (Pilsen, Czech Republic)	
O0858	Co-anchorage of antibiotic resistance genes and mobile genetic elements on bacterial plasmids boosts horizontal gene transfer across sewage interfacesM. Shafiq* (Shantou, China)	
O0859	The emergence of tet(X4) and mcr co-harbored on the same plasmid and its clinical significanceN. Rakhi* (Oxford, United Kingdom), A. Lankapalli, T. Lanyon-Hogg, P. Niumsup, K. Thomson, K. Sands, T. Walsh	
O0860	The plasmidome of a global collection of convergent K. pneumoniae and its impact on virulenceF. Lebreton* (Silver Spring, United States), M. Martin, A.P. Sapre, T. Luo, U. Carolino-Macdonald, E. Mills, B.	



ESCMID Global 2025 - Programme

		Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. Russo, P. Mc Gann
O0861	Factors that affect plasmid transfer in multispecies biofilms	H.Y. Liu* (Norwich, United Kingdom), M. Yasir, E. Trampari, G. Langridge, M. Webber
O0862	Identification of the czc metal efflux operon on a new plasmid type in a <i>Pseudomonas aeruginosa</i> clinical isolate belonging to ST357 O11A	Valcek* (Brussels, Belgium), D.I. Costescu Strachinaru, P. Soentjens, A. Stoefs, C. Van Der Henst

OS119	11:00 – 12:00	Hall 7
	1-hour Case Session	

Looking inside endovascular infections

Chairs	Claus Moser (Copenhagen, Denmark) Matthaios Papadimitriou Olivgeris (Sion, Switzerland)
--------	--

O0863	A Case of Persistent <i>Legionella micdadei</i> Aortitis with Endocarditis: Diagnostic and Therapeutic Challenges	V. Zwart* (Breda, Netherlands), E. Kayabasi, H. De Groot, R. Bentvelsen
O0864	Management and Prognosis of Vascular Endograft Infections: Case Series	N. Scarpulla* (Napoli, Italy), F. Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. Gallo, E. Durante-Mangoni
O0865	Fungal frenzy: handling an uncommon etiology in prosthetic valve endocarditis	I. Cafarella* (Naples, Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino, A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante-Mangoni
O0866	Successful Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by <i>Enterococcus</i> spp.: Experience from Seven Cases in a Referral Center	F. Frondizi* (Rome, Italy), G.M. Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. Taddei, G. Scoppettuolo, C. Torti
O0867	Clinical Features and Outcomes of Gram-Negative Bacterial Endocarditis: A Case Series from a University Hospital	G. Oliva* (Rome, Italy), F. Giovannenze, G.M. Leanza, F. Frondizi, M. Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. Scoppettuolo, C. Torti

OS120	11:00 – 12:00	Hall 8
	1-hour Oral Session	

Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial Virulence

Chairs	Giovanni Delogu (Rome, Italy) Simon Foster (Sheffield, United Kingdom)
--------	---

O0868	Bacteria and host responses in both mice and human lung organoid model revealed the role of a novel plasmid pvirh1 in hypervirulent Carbapenem-resistant <i>Klebsiella pneumoniae</i>	Y. Zhang* (Shanghai, China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang
O0869	Presence and role of hypervirulence-associated markers in <i>Klebsiella pneumoniae</i> groups based on LD50 value in mouse septic model	A. Avdeeva* (Saint-Petersburg, Russian Federation), D. Kandina, E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Sopova, V. Lomonosova, V. Galushka, A. Afinogenova, V. Shapovalova, O. Sullian, I. Ageevets, V. Ageevets, S. Sidorenko
O0870	Meta-transcriptomic Insights into Host-Pathogen Interactions in Necrotizing Soft Tissue Infections Using Differential Analysis	T. Vashist* (Chandigarh, India), N. Rana, D. Nair, A. Angrup, V. Sharma, C. Tandup, P. Ray, A. Arora
O0871	Unveiling the hidden virulence of <i>Achromobacter baumannii</i> : how the lipooligosaccharide core modulates immune responses and enhances interferon- $\gamma$ production	Y.T. Lee* (Taipei, Taiwan,

O0872	Platelets drive neutrophil-mediated neuroinflammation in tuberculous meningitis	K. Skolimowska* (London, United Kingdom), R. Wilkinson, J.S. Friedland, D. Kirwan, T. Reid, D. De Swardt, D.L.W. Chong, J. Kutschenreuter, M. Saeed, A. Davis, S. Wasserman, R. Goliath, Q. Kakana, P. Renner, M. Panchoo, C. Stek, R. Johnson, M. Maxebengula
-------	---	--

OS121	11:00 – 12:00	Hall 9
	1-hour Oral Session	

Shaping the future of IPC - digitalisation of surveillance

Chairs	Diamantis Plachouras (Solna, Sweden) Maaik S.M. Van Mourik (Utrecht, Netherlands)
--------	--

O0873	11:00	PRAISE hospital-onset bacteraemia and fungaemia algorithm as novel automated surveillance indicator: results from four European university hospitals	S. Van Der Werff* (Stockholm, Sweden), S.J.S. Aghdassi, M. Behnke, M.S.M. Van Mourik, G. Catho, M. Brekelmans, L.A. Peña Diaz, N. Buetti, F.D. Rüther, D. Dinis Teixeira, D. Sjöholm, P. Naclér
O0874	11:12	Transforming hospital-onset bacteremia and fungemia data to the OMOP common data model	H. Düsseldorf* (Vienna, Austria), G. Duftschmid, E. Presterl
O0876	11:24	Dutch Electronic Health Records in primary care: the Nivel general practitioners database	F.F. Stelma* (Utrecht, Netherlands), J. Van Summeren, M. Hooiveld, C. Baliatsas, V. Sankatsing, J. Schmitz, S. Van Beusekom
O0877	11:36	Local signs at catheter insertion sites: Insights from the multicenter DeepCath cohort study with 4,256 pictures	N. Buetti* (Geneva, Switzerland), S. Ruckly, A. Byczko, L. Gallay, A. Nguyen, H. Slimani, J.R. Zahar, J.F. Timsit
O0875	11:48	Prospective evaluation of a machine learning-based real-time multidrug-resistant organism prediction system	V. Vasikasin* (Bangkok, Thailand), W. Nasomsong, A. Holmes, R.L. Peach, K. Bhangnanda, A. Myall, C.H. Yoon, D. Changpradub, S. Mookerjee, J. Price, B. Mauricio, T.M. Rawson

EF131	13:30 – 14:30	Arena 1
	ePoster Flash Session	

The current landscape of carbapenem resistance: from genotype to phenotype and virulence determinants

Chair	Amy Mathers (Charlottesville, United States)
-------	--

E0940	Molecular Insights into the Growing Threat Carbapenem-Resistant Hypervirulent <i>Klebsiella pneumoniae</i> and the Rising Challenge of Ceftazidime-Avibactam Resistance	C. Vatansever* (Istanbul, Türkiye), A. Akpinar, J. Boral, S. Belge, N. Kardan, B. Tanyolaç, G. Shahrokhi, G. Ekinci, E. Ural, B. İşler, Ö. Ergönül, F. Can
E0941	Global large-scale genomic snapshot on the diversity of carbapenem-resistant and hypervirulent <i>Klebsiella pneumoniae</i> strains	R. Elias* (Lisboa, Portugal), T. Clark, I. Portugal, J. Perdigo
E0942	Carbapenem-resistant <i>Enterobacter cloacae</i> complex: genetic determinants of resistance and molecular epidemiology	D. Pinheiro De Sousa Santos* (Lisbon, Portugal), D. Santos, A. Bruschy-Fonseca, E. Gonçalves, D. Ranhel, C. Conceição, A. Pedrosa, A.C. Silva, A. Duarte, L. Méndez, C. Toscano, J. Melo-Cristino, C. Caneiras
E0943	Molecular epidemiology of carbapenemase-producing <i>Escherichia coli</i> in Hungary	A. Hanczvikkel* (Budapest, Hungary), D. Göbhardt, E. Ungvári, N. Derzsy, A. Darab, L. Jánvári, L. Buzgó, L. Holub, K. Papp, K. Kristóf, L. Majoros, K. Kamotsay, M. Käfer, G.

ESCMID Global 2025 - Programme

	Jakab, Á. Sonnevend, Á. Tóth	
E0944	<b>Genomic multicentre surveillance of VIM-producing <i>Enterobacteriales</i> shows spread driven by bacterial clones and plasmids in Germany from 2015 to 2021A.</b> Wendel* (Cologne, Germany), J. Sattler, B. Bader, J. Müller, A. Hamprecht, S. Peter	
E0945	<b>Three distinct routes of virulence-resistance convergence in ST-395 <i>K. pneumoniae</i> from Eastern Europe over the last decade.</b> A. Sapre* (Silver Spring, United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R. Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M. Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J. Bennett, P. Mc Gann, M. Martin, F. Lebreton	
E0946	<b>Carbapenemases in Germany in 2024: Report of the German National Reference Centre for Multidrug-resistant Gram-negative Bacteria</b> N. Pfennigwerth* (Bochum, Germany), S. Möller, J. Eistfeld, F. Pankok, A. Anders, S. Gatermann	
E0947	<b>Unravelling divergent genomic modes of transmission of Carbapenemase-Producing Organisms in a single hospital in Singapore between 2019 and 2022</b> V. Koh* (Singapore, Singapore), Z.Q. Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakkj, P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, S. Vasoo, K. Marimuthu, O.T. Ng	
E0948	<b>2011-2017 vs 2018-2024: comparison of carbapenem non-susceptibility trends among bloodstream <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i> isolates from Greek hospitals: data from the Electronic System for the AMR surveillance-WHONET-Greece</b> M. Polemis* (Vari, Greece), A. Vatopoulos, K. Tryfinopoulou	
EF132	13:30 – 14:30	Arena 2
	ePoster Flash Session	
	CLN	
Difficult-to-treat cases in the immunocompromised		
Chair	Nicolas Mueller (Zurich, Switzerland)	
E0949	<b>A case of IRIS nocardiosis</b> S.K. Dlamini* (Cape Town, South Africa), P. Namale, P. Arnab	
E0951	<b>Concurrent invasive disseminated Nocardia farcinica and Candida infections in a patient undergoing long-term glucocorticoid therapy for autoimmune thrombocytopenia: A case report</b> N. Zhang* (Bengbu, China)	
E0952	<b>Subcutaneous paeohyphomycosis due to <i>Alternaria infectoria</i> in an immunosuppressed renal transplant recipient: successful multidisciplinary management</b> E. Vetsiou* (London, United Kingdom), E. Rudd, S. Rai, K. Ahmed, S. Rao-Merugumala, A. Wasif, C. Shaw, A. Abdolrasouli, M. Arias	
E0953	<b>Lung nodules in a patient with breast cancer history... Not everything is cancer.</b> E. Muñoa Hernández* (Chiapas, Mexico), E. Muñoa	
E0954	<b>Treatment of fulminant <i>Clostridioides difficile</i> infection using bacteria-free stool supernatant in adult hematological patients during chemotherapy-induced aplasia</b> B.G. Szabo* (Budapest, Hungary), D. Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko	
E0955	<b>Eradication of multidrug resistant <i>Pseudomonas aeruginosa</i> pneumonia in acute lymphoblastic leukemia patient with broad host-range phage</b> P. Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I. Ferrés, A. Galiana, F. Grill, G. Iraola	
E0956	<b>An Emerging fungal pathogen in immunocompromised hosts: A rare case of subcutaneous abscess caused by <i>Chondrostereum purpureum</i></b> P. Kitjachaerachai* (Bangkok, Thailand), A. Thammahong, J. Vanichanan	
E0957	<b>Unveiling a Rare Simultaneous Central Nervous System infection in an Immunocompromised Patient from Mexico</b> E. Sienra Iracheta* (Tlalpan, Mexico), A. Magallanes Lopez, J.P. Venzor Castellanos, M.J. Corredor Nassar, A.P. Rodriguez Zulueta	

EF133	13:30 – 14:30	Arena 3
ePoster Flash Session		
CLN PHEI VAX		
Viral infections in special populations		
Chair	Federico Garcia (Granada, Spain)	
E0958	<b>ORCHESTRA Delphi Consensus: Therapeutic and Diagnostic Management of SARS-CoV-2 Infection in Rheumatological Patients</b> M.G. Caponcello* (Seville, Spain), P. Olivares Navarro, J. Rodríguez Baño, Z.R. Palacios Baena, C. Bonazzetti, C. Campoli, A. Savoldi, E. Gentilotti, G. Marchetti, S. Lo Caputo, L. Otero-Varela, I. Castrejón, E. Tacconelli	
E0959	<b>Immunogenicity, reactogenicity and safety of booster vaccinations with BNT162b2 or full-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED) – final report</b> J. Stemler* (Cologne, Germany), L. Yeghiazaryan, C. Stephan, R. Cox, K. Greve-Isdahl Mohn, A.J. Carcas-Sansuan, E. Romero Rodriguez, J. Moltó, I. Vergara Mitxelorena, T. Welte, B. Zablockienė, M. Akova, U. Bethe, S. Grimm, J. Salmanton-García, J. Jakobs, L. Tischmann, M. Zarrouk, A. Cüppers, L.M. Biehl, J. Grothe, S.C. Mellinghoff, J.A. Nacov, J.M. Neuhaan, R. Sprute, J. Frías-Iniesta, R. Negi, C. Gaillard, G. Saini, A. García León, P.W.G. Mallon, C. Lammens, A. Hotterbeekx, L. Katherine, S. Malhotra-Kumar, H. Goossens, S. Kumar-Singh, F. König, M. Posch, P. Koehler, O.A. Cornely	
E0960	<b>Effectiveness of adjuvanted recombinant zoster vaccine in adults aged ≥50 years in the United States</b> L. Qian* (Pasadena, United States), L.S. Sy, B.K. Ackerson, E. Rayens, J. Wu, Y. Luo, Y. Cheng, J.H. Ku, L.I. Vega Daily, H.S. Takhar, J. Song, R.A. Cohen, H. Yun, D. Oraichi, H. Seifert, H.F. Tseng	
E0961	<b>Differential SARS-CoV-2 RNAemia features and humoral immune response analysis of acute COVID-19 in solid organ transplant recipients and patients with hematological malignancies</b> A. Ruiz-Molina* (Seville, Spain), J. Martín-Escolano, C. Infante-Domínguez, Z.R. Palacios-Baena, I. Tallón-Ruiz, F. Martín-Domínguez, G. Bernal-Blanco, B. Villacorta-Linaza, G. Suárez-Artacho, C. Cepeda-Franco, D. Rangel-Sousa, C. Rodríguez-Urbistondo, B. Gutiérrez-Gutiérrez, M. Carretero-Ledesma, N. Maldonado, S. Salto-Alejandro, B. Gallego, L. Merino, J. Rodríguez-Baño, J.M. Cisneros, J.A. Pérez-Simón, E. Cordero, J. Pachón, M. Aguilar-Guisado, R. Álvarez-Marín, J. Sánchez-Céspedes	
E0962	<b>Prevalence of and risk factors for persisting COVID-19 in patients with B-cell malignancies</b> A. Toschi* (Bologna, Italy), Z. Pasquini, A. Amicucci, N. Caroccia, M. Di Chiara, F. Simone, B. Casadei, C. Pellegrini, A. D'abramo, P. De Marco, L. Bussini, M. Ciccone, A. Visentin, G. Caponcello, M. Bartoletti, E. Nicastri, M. Krampera, P.L. Zinzani, J. Rodriguez Baño, E. Tacconelli, M. Giannella	
E0963	<b>Clinical characteristics and predictors of severe outcome among older adults hospitalized with respiratory syncytial virus (RSV) infection– a retrospective study from Israel</b> M. Jurkowicz* (Tel Aviv, Israel), I. Margalit, I. Harris, D. Mazar, A. Teper, I. Royzman, S. Uppal, C. Liang, E. Begier, I. Ganiel, M. Mandelboim, D. Yahav	
E0964	<b>RSV and bronchiolitis associated primary care and emergency department visit rates in children under 5 years: Estimates for Europe and other high-income countries</b> F.F. Stelma* (Utrecht, Netherlands), S. Heemskerk, L. Van Heuvel, P. Spreeuwenberg, L. Bont, J. Van Summeren	
E0965	<b>Higher incidence of post-transplant EBV infection in pediatric liver transplant recipients compared to pediatric kidney transplants: a retrospective analysis from a tertiary pediatric transplant center</b> S. Mercadante* (Rome, Italy), L. Romani, A. Pietrobattista, I. Guzzo, R. Labbadia, A. Cappoli, A. Mosca, L. Lancella, M. De Luca	
E0966	<b>Insights from a single center's experience in hepatitis C treatment across four prisons in Slovakia</b> I. Hockickova* (Košice, Slovakia), I. Hockicková, J. Hockicko, M. Novotný, Z. Paraličová,	

ESCMID Global 2025 - Programme

P. Kristian		
EF134	13:30 – 14:30	Arena 4
ePoster Flash Session		
Infection Controller's Daily		
Chair Cansu Cimen (Oldenburg, Germany)		
E0967	Mortality and length of stay associated with antimicrobial-susceptible and resistant hospital-onset bloodstream infections at a tertiary referral hospital in Melbourne, AustraliaA. Stewardson* (Melbourne, Victoria, Australia), S.J. Curtis, S.L. Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley, A.C. Cheng, D.W. Spelman, A.Y. Peleg	
E0968	MRSA on the rise in neonatal care departments.E. Herkes* (Amsterdam, Netherlands), A. Schoffelen, R. Zwitterink, J. Kluytmans, D. Notermans	
E0969	Risk factors for OXA-carbapenemase-producing Enterobacteriaceae acquisition in Israel: a retrospective case control studyM. Amar* (Haifa, Israel), R. Najjar-Debbiny, G. Weber, R. Yasin, A. Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked-Mishan, O. Barnett-Griness	
E0970	Experience providing a rapid, reactive nanopore isolate sequencing service for bacterial outbreak investigation for hospitals in London, UK.S. Raharison* (Nice, France), A. Alcolea-Medina, L.B. Snell, M. Tan, G. Humayun, R. Chang, D. Ward, V. Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. Goldenberg, J. Edgeworth, J. Otter	
E0971	Duration of colonization and time to de-isolation in patients with extended-spectrum beta-lactamase producing non-Escherichia coli Enterobacterales.J. Männer* (St.Gallen, Switzerland), V. Steinacher, T. Dörr, M. Schlegel, P. Kohler	
E0972	A tale of three cities: The comparative longitudinal epidemiology of vancomycin-resistant Enterococcus faecium from bloodstream infections at three tertiary care hospitals in Bavaria, GermanyA. Rath* (Regensburg, Germany), B. Neumann, V. Rauschenberger, B. Kieninger, A. Eichner, J. Steinmann, S. Kampmeier, W. Schneider-Brachert	
E0973	Molecular epidemiology and transmission dynamics of vancomycin-resistant Enterococcus faecium in Belgian hospitals (2022-2023)S. De Koster* (Edegem, Belgium), S. Van Kleef-Van Koeveringe, H. Jansens, S. Vandamme, T. Demuyser, M. Vanden Driessche, Y. Glupczynski, S. Malhotra-Kumar, V. Matheussen	
E0974	Increasing Prevalence of Linezolid-resistant Enterococci: Outbreak or Overuse?R. Traynor* (Cork, Ireland), G. Brennan, I. O Callaghan, E. Keily, E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A. Doherty, C. Hickey	
E0975	Continuous 2-year surveillance for airborne fungi at hospitals in the same city: Impact of season, construction, a construction accident and HEPA-filtered/positive pressure roomsM.H. Nguyen* (Pittsburgh, United States), C. Clancy, Z. Wilkins, Y. Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann, A. Ayres, S. Graham	
EW174	13:30 – 15:30	Hall 11
Educational Session		
Best practices and emerging strategies in the management of ventilator- and healthcare-associated pneumonia		
Chairs Fusun Can (Istanbul, Türkiye) Jeroen Schouten (Nijmegen, Netherlands)		
W0481	13:30	Artificial Intelligence to predict VAPMiia Jansson (Oulu, Finland)
W0482	13:50	Metagenomic approach to VAP diagnosisJacques

Schrenzel (Geneva, Switzerland)		
W0483	14:10	Viruses in VAP and HAP: should we worry about them?Catia Cilloniz (Barcelona, Spain)
W0484	14:30	Optimising antibiotic therapy in VAPPinyo Rattanaumpawan (Bangkok, Thailand)
SY170	13:30 – 15:30	Hall 13
2-hour Symposium		
Novel strategies for eliminating the 'worst films ever'		
Chairs Elisa Borghi (Milan, Italy) Markus Zeitlinger (Vienna, Austria)		
S0465	13:30	What answers can biofilm PK/PD modelling provide?Coen Van Hasselt (Leiden, Netherlands)
S0466	14:00	subMIC antibiotic effects to improve biofilm PK/PD parameters – still relevant?Francoise Van Bambeke (Brussels, Belgium)
S0467	14:30	PK/PD-based optimisation of antibiotic treatments to suppress resistance in dynamic biofilm modelsMaria Dolores Macia Romero (Palma De Mallorca, Spain)
S0468	15:00	Giving antibiotics an upper hand in the treatment of biofilm infections – antibiotic augmenting strategiesClaus Moser (Copenhagen, Denmark)
Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Scientific Affairs Subcommittee		
SY171	13:30 – 15:30	Hall 14
2-hour Symposium		
Enhancing efficiency and reducing cost in microbiological diagnostics using pool testing		
Chairs Mauricio Farfan (Santiago, Chile) Chiara Minotti (Basel, Switzerland)		
S0469	13:30	Congenital cytomegalovirus detection by pool testing in salivaGiannina Izquierdo (Santiago, Chile)
S0470	14:00	Detection of blood-corne pathogens in asymptomatic blood donors by pool testingPatricia Alvarez (Rio De Janeiro, Brazil)
S0471	14:30	Large-scale pooled testing to increase rapid molecular diagnostic test coverage for tuberculosisMelissa Sander (Bamenda, Cameroon)
S0472	15:00	Pool testing for screening of bacterial sexually transmitted infectionsTba
OS130	13:30 – 14:30	Hall 16
1-hour Oral Session		
Advances in fungal diagnostics		
Chair Sarah Delliere (Paris, France)		
O0935	BAL galactomannan dynamics predict survival in critically ill patients with virus-associated pulmonary aspergillosisV. Delanote* (Leuven, Belgium), J. Wauters, S. Feys, J. Heylen, H.M. Lauwers, C. Jacobs, L. Maessen, Y. Debaveye, P. Frederiks, G. Hermans, P. Meersseman, M. Peetermans, E. Van Wijngaerden, A. Wilmer, K. Lagrou	
O0936	Retrospective Assessment of a New Chemiluminescence Immunoassay for Serum (1, 3)-[D-Glucan Levels in Patient with Invasive Fungal InfectionsZ. Zhou* (Tianjin, China), K. Yuan, L. Ye, S. Liu, A. Huang, Z. Chen, W. Yan, S. Niu, K. Hua, Q. Wang, G. Zhang, H. Wang, Y. Zhao, G. Li	
O0937	Evaluation of a multiplex PCR assay using barcoded magnetic bead technology for detection of fungal pathogens in bronchoalveolar lavage fluid: a diagnostic aid for invasive fungal infectionsS. Zhang* (Baltimore, United States)	



ESCMID Global 2025 - Programme

O0938		Combined use of (1,3)-[D]-glucan and PCR in oral wash for <i>Pneumocystis jirovecii</i> pneumonia diagnosis in non-HIV populationA. Falcó Roget* (Matardó, Spain), A. Falcó-Roget, A. Albasanz-Puig, A.B. Pérez, S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len, I. Ruiz-Camps, M.T. Martín-Gómez
O0939		Iron levels in bronchoalveolar lavage fluid of hematological patients with suspected invasive pulmonary aspergillosis and their association with 12-week mortality: a retrospective cohort studyH. Lamberink* (Amsterdam, Netherlands), J. Heijmans, A. Wagemakers, K. Van Dijk

SY168	13:30 – 15:30	Hall 2
	2-hour Symposium	

Staphylococcus aureus: its expansion dynamics and interactions with its pals		
Chair	Barbara C. Kahl (Münster, Germany)	

S0457	13:30	S. aureus and its special relationship to S. epidermidis Andreas Peschel (Tübingen, Germany)
S0458	14:00	Computational and in vitro evaluation of probiotic treatments for nasal S. aureus decolonizationSilvio Daniel Brugger (Zurich, Switzerland)
S0459	14:30	Clonal population expansion of S. aureus occurs due to escape from a finite number of intraphagocyte nichesSimon Foster (Sheffield, United Kingdom)
S0460	15:00	How bacteriophages and pathogenicity islands drive the evolution of S. aureus John Chen (Singapore, Singapore)

Co-organised with: ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)

EW172	13:30 – 15:30	Hall 3
	Educational Session	

Beyond the gift of life: viral infection during pregnancy		
Chairs	Gölsen Özkaya Sahin (Lund, Sweden) Simona Ruta (Bucharest, Romania)	

W0473	13:30	Hepatitis B during pregnancy: diagnosis, management and outcome Tba
W0474	13:50	RSV and Influenza during pregnancy: management and outcomeMonika Redlberger-Fritz (Vienna, Austria)
W0475	14:10	Prenatal screening and prevention of congenital CMV: shifting concepts and consensus guidelineMarianne Leruez-Ville (Paris, France)
W0476	14:30	Novel methods of vaccine administration to newborns Tba

Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), European Society for Infectious Diseases in Obstetrics and Gynaecology (ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Hepatology Association of SubSaharan Africa (GHASSA)

SY169	13:30 – 15:30	Hall 4
	2-hour Symposium	

Molecular epidemiology, resistance mechanisms and management of Gram-negative bacteria		
Chairs	Agnes Maria Sonnevend (Pécs, Hungary) Kyriaki Xanthopoulou (Cologne, Germany)	

S0461	13:30	Globally emerging resistance patterns of EnterobacterialesSasheela Ponnampalavanar (Kuala Lumpur, Malaysia)
S0462	14:00	Non-fermenters still important globally: a review of spread and resistanceAnupa Thamby (Vellore, India)
S0463	14:30	Innovative rapid diagnostic methodologies for Gram-negative pathogensLaurent Dortet (Le Kremlin-

		Bicêtre, France)
S0464	15:00	Tailoring treatment to resistant Gram-negative bacteria: newer therapeutic approachesJuan P. Horcajada (Barcelona, Spain)

Co-organised with: ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)

EW173	13:30 – 15:30	Hall 5
	Educational Session	

Tropical dermatology: a case-based approach		
Chairs	Pedro Legua (Lima, Peru) Bobbi Pritt (Rochester, United States)	

W0477	13:30	Parasitic diseases: dermatological manifestations in the tropicsKirti Sabnis (India)
W0478	13:50	Madura foot and other Implantation mycosesM Ramam (New Delhi, India)
W0479	14:10	MycobacteriaFrancisco Bravo (Lima, Peru)
W0480	14:30	Approach to rash in the returning travellerFrank O. D. Pettersen (Oslo, Norway)

OS127	13:30 – 14:30	Hall 6
	1-hour Oral Session	

The good, the bad and the itchy: update on STIs		
Chair	Tatum Mortimer (Athens, United States)	

O0920		High frequency of Nichols-like strains of Treponema pallidum subsp. pallidum circulating in Barcelona, SpainP. Nadal-Baron* (Barcelona, Spain), P. Nadal-Barón, J. Trejo-Zahinos, M. Arando, A. Barberan-Masegosa, M. Bernat-Sole, A. Perez-Ugarte, M. Valverde Espinal, A. Canals Quintana, J.J. González-López, A. Antón, M. Alberny, O. Mitjà, N. Larrosa, Y. Hoyos-Mallecot
-------	--	---

O0921		Doxycycline post-exposure prophylaxis (doxy-PEP) use and outcomes in metropolitan DetroitC. Arena* (Detroit, United States), N. Everson, R. Kenney, I. Brar, S. Gudipati, N. Yared, S. Davis, M. Veve
-------	--	---

O0922		The Gonococcus Bacterial Load Measured by the Cycle Threshold (Ct) in Urinary Samples Correlates with SymptomatologyG. Beraud* (Orleans, France), T. Prazuck, L. Barhoum, H. Meyjonnade, J. Effa, L. Hocqueloux, A. Seve, J. Guinard, K. Kochbatj, E. Carbonelle, C. Guillaume
-------	--	--

O0923		STI pathogen interactions and viability in men who have sex with men (MSM)E. Rayo* (Zurich, Switzerland), D. Onorini, C. Leonard, H. Marti, T. Pesch, B. Hampel, N. Low, N. Borel
-------	--	---

O0924		Epidemiology of bacterial genitourinary infections among women with recurrent vulvovaginal Candidiasis (RVVC) in Nigeria.S. Fayemiwo* (Ibadan, Nigeria), L. Novak-Frazer, I. Adewole, R. Rautemaa-Richardson
-------	--	--

OS129	13:30 – 14:30	Hall 7
	1-hour Oral Session	

Biofilm biology and control		
Chairs	Margherita Cacaci (Rome, Italy) Laura Escolà-Vergé (Barcelona, Spain)	

O0930		Influence of non-coding small RNA00203 in biofilm cells of Acinetobacter baumannii. Transcriptomic and phenotypicD. Gebrelibanos* (Hong Kong, China), P. Leung, A.M. Shenkutie, F. Chow
O0931		Sub-MIC antibiotic effects on Pseudomonas aeruginosa biofilm streamer formationA. Di Claudio* (Pieve Emanuele, Italy), R. Rusconi, E. Secchi, G. Savorana

ESCMID Global 2025 - Programme

O0932	Regulation of Novel Genes and Their Downstream Functions in the AI-2-Mediated Quorum Sensing System of <i>Klebsiella pneumoniae</i> X. Chu* (Beijing, China), Q. Yang
O0933	Exploring structural differences in biofilms of smooth and rough <i>Mycobacterium abscessus</i> clinical strains through confocal laser scanning microscopyC. Maria* (Madrid, Spain), M. Cano-Fernández, J. Esteban, P. López-Roa, A. Ruedas-López, M.C. Muñoz-Egea
O0934	Antibacterial and biofilm eradication of mupirocin-loaded nano-emulsionsZ. Najmi* (Novara, Italy), A.C. Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Rimondini, D. Dupin

OS126	13:30 – 15:30	Hall 8
CLN DX PHEI		
2-hour Oral Session		
Emerging viruses, diverse threats		
Chairs	Luisa Barzon (Padua, Italy) Karin Stiasny (Vienna, Austria)	

O0910	Epidemiological and clinical features of mpox during the clade Ib outbreak in South-Kivu, Democratic Republic of the Congo: a prospective cohort studyI. Brosius* (Antwerp, Belgium), E. Hasivirwe Vakaniaki, S. Sabiti Nundu, L. Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P. Munganga, J.C. Tshomba, E. De Vos, E. Bangwen, Y. Mujula, A. Tsoumanis, C. Van Dijk, A. Alengo, L. Mutimba-Mambo, F. Mweshi Kumbana, J. Babingwa Muunga, D. Mazambi Mambo, J. Wakilongo Zangilwa, S. Bilembo Kitwanda, S. Houben, N. Hoff, J.C. Makangara-Cigolo, E. Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. Kindrachuck, N. Low, P. Katoto, E. Bwenge Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka, S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-Bokalanga, J.J. Muyembe-Tamfum
O0911	Tracing the origin, spread and molecular evolution of Dengue type 1 cases occurred in Northern Italy in 2023G. Romano* (Pavia, Italy), G. Ferrari, A.M.G. Pitrolo, F. Rovida, A. Piralla, F. Baldanti
O0912	Dengue Country Risk Estimation: Vector Suitability and Imported Activity 2024.M. Torres Portillo* (Toronto, Canada), K. Williams, R. Lababidi, A. Thomas, K. Khan
O0913	Rat HEV in humans in Germany: presence but low detection rate, a screening study 2022 - 2023L. Mueller* (Berlin, Germany), M.L. Schmidt, T. Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J. Jansen, J. Melchert, T. Mauno, C. Drosten, R. Johne, V.M. Corman
O0914	Emergence of new enterovirus D68 lineage in Europe in 2023 associated with distinct amino acid substitutions in VP1 proteinA. Hirvonen* (Vantaa, Finland), C.K. Johannesen, P. Simmonds, T.K. Fischer, H. Harvala, K.S.M. Benschop
O0915	Health-economic impacts of chikungunya vaccination in 34 countriesJ. Zhou* (Oxford, United Kingdom), N. Salant, D. Smith, D. Hollingsworth, K. Pouwels, S. Radoykova, J. Lord, K. French
O0916	Clinical importance of a new tick-borne <i>flaviviridae</i> virus, Alongshan Virus: retrospective serologic and molecular study in SwitzerlandF. Tagini* (Lausanne, Switzerland), O. Opota, A. Eggermann, A. Coste, G. Greub
O0917	From Trade Routes to Transmission Routes: Risk Assessment of Japanese Encephalitis Outbreak in Pakistan under China-Pakistan Economic Corridor Using One Health ApproachS. Ahmad* (Tampere, Finland)
O0918	Building a screening protocol for the detection of Orthobunyavirus oropoucheense infectionG. Gagliardi* (Milan, Italy), D. Mileto, A. Mancon, L. Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli, A. Lombardi, A. Dolci

O0919	Substantial viral diversity in bats and rodents from East Africa: insights into conservation, recombination, and co-circulationD. Wang* (Shenzhen, China)
-------	---

OS128	13:30 – 14:30	Hall 9
ANT CLN		
1-hour Oral Session		
AI Aiding AMS		
Chairs	Marlieke De Kraker (Geneva, Switzerland) Bhanu Sinha (Groningen, Netherlands)	

O0925	Using natural language processing to understand free-text antibiotic prescriptionsA. Martin* (Middlesbrough, United Kingdom), L. Christopher
O0926	Enhancing Antimicrobial Stewardship Through Collaboration Between an Intelligent System and Infectious Disease ExpertsH.M. Wei* (Taichung, Taiwan, China), Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P. Hwang
O0927	Augmented Intelligence in Infectious Diseases (AI <sup>2</sup> D) as an antimicrobial stewardship tool for early antibiotic discontinuation in suspected lower respiratory tract infectionsJ.L. Lim* (Singapore, Singapore), P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan, S.Y. Thien, S.L.S. Tang, L.X.T. Lee, Y.C.D. Yii, P.Y. Zhou, Y. Wang, S.J. Chung, L.H.A. Kwa
O0928	Virtual antimicrobial stewardship ward rounds: predicting antibiotic course stopping decisions in hospitals using machine learningK. Yuan* (Oxford, United Kingdom), J. Wei, C.H. Yoon, Q. Gu, W. Walker, T. Zhu, D. Eyre
O0929	Prospective evaluation of a machine learning-based decision support system for intravenous-to-oral antibiotic switching.W. Bolton* (London, United Kingdom), R. Wilson, P. Georgiou, A. Holmes, T.M. Rawson, M. Gilchrist